<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003344.pub2" GROUP_ID="ANAESTH" ID="745000073110492540" MERGED_FROM="" MODIFIED="2014-01-06 14:39:37 +0000" MODIFIED_BY="Jane Cracknell" REVIEW_NO="115" REVMAN_SUB_VERSION="5.2.7 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.2">
<COVER_SHEET MODIFIED="2014-01-06 14:39:37 +0000" MODIFIED_BY="Jane Cracknell">
<TITLE>Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis</TITLE>
<CONTACT MODIFIED="2014-01-06 14:39:37 +0000" MODIFIED_BY="Jane Cracknell"><PERSON ID="12314" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Mical</FIRST_NAME><LAST_NAME>Paul</LAST_NAME><EMAIL_1>paulm@post.tau.ac.il</EMAIL_1><EMAIL_2>mica@zahav.net.il; MichalP2@clalit.org.il; paulm@post.tau.ac.il</EMAIL_2><ADDRESS><DEPARTMENT>Division of Infectious Diseases</DEPARTMENT><ORGANISATION>Rambam Health Care Campus and the Technion-Israel Institute of Technology</ORGANISATION><ADDRESS_1>6 Ha'Aliya Street</ADDRESS_1><CITY>Haifa</CITY><ZIP>31096</ZIP><COUNTRY CODE="IL">Israel</COUNTRY><PHONE_1>+972 50 2062140</PHONE_1><FAX_1>+972 4 854 1720</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2014-01-06 14:39:37 +0000" MODIFIED_BY="Jane Cracknell"><PERSON ID="12314" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Mical</FIRST_NAME><LAST_NAME>Paul</LAST_NAME><EMAIL_1>paulm@post.tau.ac.il</EMAIL_1><EMAIL_2>mica@zahav.net.il; MichalP2@clalit.org.il; paulm@post.tau.ac.il</EMAIL_2><ADDRESS><DEPARTMENT>Division of Infectious Diseases</DEPARTMENT><ORGANISATION>Rambam Health Care Campus and the Technion-Israel Institute of Technology</ORGANISATION><ADDRESS_1>6 Ha'Aliya Street</ADDRESS_1><CITY>Haifa</CITY><ZIP>31096</ZIP><COUNTRY CODE="IL">Israel</COUNTRY><PHONE_1>+972 50 2062140</PHONE_1><FAX_1>+972 4 854 1720</FAX_1></ADDRESS></PERSON><PERSON ID="11752494463348553364101014055606" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Adi</FIRST_NAME><LAST_NAME>Lador</LAST_NAME><EMAIL_1>adilador@gmail.com</EMAIL_1><MOBILE_PHONE>972502076409</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Medicine E</DEPARTMENT><ORGANISATION>Beilinson Hospital, Rabin Medical Center</ORGANISATION><ADDRESS_1>39 Jabotinski Street</ADDRESS_1><CITY>Petah Tikva</CITY><ZIP>49100</ZIP><COUNTRY CODE="IL">Israel</COUNTRY><PHONE_1>+972 050 2076409</PHONE_1></ADDRESS></PERSON><PERSON ID="13694" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Simona</FIRST_NAME><LAST_NAME>Grozinsky-Glasberg</LAST_NAME><EMAIL_1>simonag@hadassah.org.il</EMAIL_1><ADDRESS><DEPARTMENT>Neuroendocrine Tumors Unit, Endocrinology &amp; Metabolism Service</DEPARTMENT><ORGANISATION>Dept of Medicine, Hadassah-Hebrew University Medical Center</ORGANISATION><ADDRESS_1>POB 12000</ADDRESS_1><CITY>Jerusalem</CITY><ZIP>91120</ZIP><COUNTRY CODE="IL">Israel</COUNTRY><PHONE_1>+972 2 677 6788</PHONE_1></ADDRESS></PERSON><PERSON ID="12295" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Leonard</FIRST_NAME><LAST_NAME>Leibovici</LAST_NAME><POSITION>Head</POSITION><EMAIL_1>leibovic@post.tau.ac.il</EMAIL_1><EMAIL_2>leibovici@clalit.org.il</EMAIL_2><ADDRESS><DEPARTMENT>Department of Medicine E</DEPARTMENT><ORGANISATION>Beilinson Hospital, Rabin Medical Center</ORGANISATION><ADDRESS_1>39 Jabotinski Street</ADDRESS_1><CITY>Petah Tikva</CITY><ZIP>49100</ZIP><COUNTRY CODE="IL">Israel</COUNTRY><PHONE_1>+972 3 937 6501</PHONE_1><PHONE_2>+972 3 937 6506</PHONE_2><FAX_1>+972 3 937 6505</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-11-27 18:07:15 +0000" MODIFIED_BY="Karen Hovhannisyan">
<UP_TO_DATE>
<DATE DAY="4" MONTH="11" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="4" MONTH="11" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="3" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2013-12-20 15:47:39 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-12-20 15:47:39 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="12" YEAR="2013"/>
<DESCRIPTION>
<P>This review is an update of the previous Cochrane systematic review (<LINK REF="REF-Paul-2006" TYPE="REFERENCE">Paul 2006</LINK>), which included 64 RCTs.</P>
<P>Five new trials were added in the current update; three were published after the previous review (<LINK REF="STD-Banasal-2006" TYPE="STUDY">Banasal 2006</LINK>; <LINK REF="STD-Damas-2006" TYPE="STUDY">Damas 2006</LINK>; <LINK REF="STD-Hasali-2005" TYPE="STUDY">Hasali 2005</LINK>), one was awaiting assessment in the previous review (<LINK REF="STD-Figueroa_x002d_Damian-1996" TYPE="STUDY">Figueroa-Damian 1996</LINK>) and one was newly identified (<LINK REF="STD-Garc_x00ed_a-Ram_x00ed_rez-1999" TYPE="STUDY">García Ramírez 1999</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-12-20 15:47:29 +0000" MODIFIED_BY="Jane Cracknell">
<DATE DAY="20" MONTH="12" YEAR="2013"/>
<DESCRIPTION>
<P>Our updated review reached the same conclusions as <LINK REF="REF-Paul-2006" TYPE="REFERENCE">Paul 2006</LINK>. The added trials did not change the direction or the magnitude of results. We have added Summary of finding tables to the current update and have graded the quality of evidence for the main outcomes.</P>
<P>Karla Soares-Weiser has left and Adi Lador has joined the review author team.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-08-13 16:09:01 +0100" MODIFIED_BY="Karen Hovhannisyan">
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2013-08-13 16:08:43 +0100" MODIFIED_BY="Jane Cracknell">
<DATE DAY="13" MONTH="8" YEAR="2013"/>
<DESCRIPTION>
<P>Feedback submitted and responded to.</P>
<P>Two Cochrane references updated and typos corrected.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-08-13 16:09:01 +0100" MODIFIED_BY="Jane Cracknell">
<DATE DAY="2" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Rabin Medical Center - Beilison Campus</NAME>
<COUNTRY CODE="IL">Israel</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>EU 5th Framework - TREAT project (grant number: 1999-11459)</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Department for International Development</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-12-20 15:51:16 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-12-20 14:19:12 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2013-12-20 14:19:12 +0000" MODIFIED_BY="[Empty name]">A single beta lactam antibiotic versus a beta lactam-aminoglycoside combination for patients with severe infection</TITLE>
<SUMMARY_BODY MODIFIED="2013-12-20 14:19:12 +0000" MODIFIED_BY="[Empty name]">
<P>Infections caused by bacteria and requiring hospitalization are a leading cause of preventable death. The beta lactam antibiotics (e.g. penicillins, cephalosporins) and the aminoglycosides (e.g. gentamicin) kill bacteria by different means. Combining a beta lactam with an aminoglycoside could, therefore, result in more effective treatment of patients with severe infection but with the side effects of both antibiotics. We reviewed clinical trials that compared intravenous treatment with a beta lactam versus treatment with a beta lactam plus an aminoglycoside.</P>
<P>We searched the literature until November 2013. We included in the review 69 trials that randomly assigned 7863 participants . Participants were hospitalized with urinary tract, intra-abdominal, skin and soft tissue infections, pneumonia and infections of unknown source. One set of studies compared a broad-spectrum beta lactam versus a different, generally narrower-spectrum beta lactam combined with an aminoglycoside (47 studies). No clear difference in all-cause deaths was observed, but treatment failures were fewer with single beta lactam antibiotic treatment. A significant survival advantage was seen with single therapy in studies that involved infections of unknown source. The other studies compared one beta lactam versus the same beta lactam combined with an aminoglycoside antibiotic (22 studies). In these trials, no differences between single and combination antibiotic treatments were seen. Overall, adverse event rates did not differ between the study groups, but renal damage was more frequent with the combination therapy. Combination therapy did not prevent the development of secondary infection.</P>
<P>The review authors concluded that beta lactam-aminoglycoside combination therapy does not provide an advantage over beta lactams alone. Furthermore, combination therapy was associated with an increased risk of renal damage. The limited number of trials comparing the same beta lactam in both study arms and the fact that more than a third of the studies did not report on all-cause deaths may limit these conclusions. The subgroup of <I>Pseudomonas aeruginosa</I> infections was underpowered to examine effects.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-12-20 14:19:13 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-12-20 14:19:13 +0000" MODIFIED_BY="Dolores Matthews">
<P>Optimal antibiotic treatment for sepsis is imperative. Combining a beta lactam antibiotic with an aminoglycoside antibiotic may provide certain advantages over beta lactam monotherapy.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-12-20 14:19:13 +0000" MODIFIED_BY="Jane Cracknell">
<P>Our objectives were to compare beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy in patients with sepsis and to estimate the rate of adverse effects with each treatment regimen, including the development of bacterial resistance to antibiotics.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-12-20 14:19:13 +0000" MODIFIED_BY="[Empty name]">
<P>In this updated review, we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (2013,<I> </I>Issue 11); MEDLINE (1966 to 4 November 2013); EMBASE (1980 to November 2013); LILACS (1982 to November 2013); and conference proceedings of the Interscience Conference of Antimicrobial Agents and Chemotherapy (1995 to 2013). We scanned citations of all identified studies and contacted all corresponding authors. In our previous review, we searched the databases to July 2004.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-12-20 14:19:12 +0000" MODIFIED_BY="[Empty name]">
<P>We included randomized and quasi-randomized trials comparing any beta lactam monotherapy versus any combination of a beta lactam with an aminoglycoside for sepsis.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-12-20 14:19:12 +0000" MODIFIED_BY="[Empty name]">
<P>The primary outcome was all-cause mortality. Secondary outcomes included treatment failure, superinfections and adverse events. Two review authors independently collected data. We pooled risk ratios (RRs) with 95% confidence intervals (CIs) using the fixed-effect model. We extracted outcomes by intention-to-treat analysis whenever possible.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-12-20 14:19:12 +0000" MODIFIED_BY="[Empty name]">
<P>We included 69 trials that randomly assigned 7863 participants. Twenty-two trials compared the same beta lactam in both study arms, while the remaining trials compared different beta lactams using a broader-spectrum beta lactam in the monotherapy arm. In trials comparing the same beta lactam, we observed no difference between study groups with regard to all-cause mortality (RR 0.97, 95% CI 0.73 to 1.30) and clinical failure (RR 1.11, 95% CI 0.95 to 1.29). In studies comparing different beta lactams, we observed a trend for benefit with monotherapy for all-cause mortality (RR 0.85, 95% CI 0.71 to 1.01) and a significant advantage for clinical failure (RR 0.75, 95% CI 0.67 to 0.84). No significant disparities emerged from subgroup and sensitivity analyses, including assessment of participants with Gram-negative infection. The subgroup of <I>Pseudomonas aeruginosa</I> infections was underpowered to examine effects. Results for mortality were classified as low quality of evidence mainly as the result of imprecision. Results for failure were classified as very low quality of evidence because of indirectness of the outcome and possible detection bias in non-blinded trials. We detected no differences in the rate of development of resistance. Nephrotoxicity was significantly less frequent with monotherapy (RR 0.30, 95% CI 0.23 to 0.39). We found no heterogeneity for all these comparisons.</P>
<P>We included a small subset of studies addressing participants with Gram-positive infection, mainly endocarditis. We identified no difference between monotherapy and combination therapy in these studies.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-12-20 14:19:12 +0000" MODIFIED_BY="[Empty name]">
<P>The addition of an aminoglycoside to beta lactams for sepsis should be discouraged. All-cause mortality rates are unchanged. Combination treatment carries a significant risk of nephrotoxicity.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-12-20 15:50:19 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-12-20 14:19:12 +0000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2013-12-20 14:19:12 +0000" MODIFIED_BY="Jane Cracknell">
<P>Sepsis is defined as clinical evidence of infection, accompanied by a systemic inflammatory response such as fever. When associated with organ dysfunction, decreased blood flow in an organ (hypoperfusion) or abnormally low blood pressure (hypotension), sepsis is defined as severe (<LINK REF="REF-Bone-1992" TYPE="REFERENCE">Bone 1992</LINK>; <LINK REF="REF-Mandell-2004" TYPE="REFERENCE">Mandell 2004</LINK>). Sepsis may be a response to direct microbial invasion or may be elicited by microbial signal molecules or toxin production. Bacterial infections may be lethal, with fatality rates ranging from less than 10% to more than 40% for those with severe sepsis (<LINK REF="REF-Moore-2001" TYPE="REFERENCE">Moore 2001</LINK>; <LINK REF="REF-Rangel_x002d_Frausto-1995" TYPE="REFERENCE">Rangel-Frausto 1995</LINK>; <LINK REF="REF-Russell-2000" TYPE="REFERENCE">Russell 2000</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-12-20 14:19:12 +0000" MODIFIED_BY="Jane Cracknell">
<P>Antibiotic treatment for bacterial infection is usually initiated empirically, before the causative bacteria are identified and their susceptibility to antibiotic treatment is ascertained. Appropriate empirical antibiotic treatment, defined as that matching the in vitro susceptibility of subsequently identified bacteria, has been shown to halve the fatality associated with sepsis (<LINK REF="REF-Ibrahim-2000" TYPE="REFERENCE">Ibrahim 2000</LINK>; <LINK REF="REF-Leibovici-1998" TYPE="REFERENCE">Leibovici 1998</LINK>; <LINK REF="REF-Paul-2010" TYPE="REFERENCE">Paul 2010</LINK>). Causative bacteria are identified only in about one-third of patients with sepsis overall (<LINK REF="REF-Paul-2006a" TYPE="REFERENCE">Paul 2006a</LINK>). At this time, treatment is tailored according to the antibiotic susceptibilities of identified bacteria. Both empirically and after bacterial identification, single or combination antibiotic treatment may be given.</P>
</INTERVENTION>
<THEORY MODIFIED="2013-12-20 14:19:12 +0000" MODIFIED_BY="Jane Cracknell">
<P>Combination antibiotic therapy offers several theoretical advantages. First, it can be used to broaden the spectrum of antibiotic coverage when used empirically to increase the chance of covering the causative bacteria. Second, the combination may possess an enhanced potential (synergism) when compared with the additive effect of each of the antibiotics assessed separately. Synergism between specific beta lactam antibiotics and aminoglycoside antibiotics has been shown in vitro for Gram-negative bacteria and specifically for <I>Pseudomonas aeruginosa</I> (<LINK REF="REF-Giamarellou-1986" TYPE="REFERENCE">Giamarellou 1986</LINK>; <LINK REF="REF-Klastersky-1976" TYPE="REFERENCE">Klastersky 1976</LINK>; <LINK REF="REF-Klastersky-1982" TYPE="REFERENCE">Klastersky 1982</LINK>), <I>Staphylococcus aureus</I>, <I>Enterococcus </I>sp. and <I>Streptococcus </I>sp. (<LINK REF="REF-Bach-1980" TYPE="REFERENCE">Bach 1980</LINK>; <LINK REF="REF-Korzeniowski-1978" TYPE="REFERENCE">Korzeniowski 1978</LINK>; <LINK REF="REF-Levy-1979" TYPE="REFERENCE">Levy 1979</LINK>; <LINK REF="REF-Saleh_x002d_Mghir-1992" TYPE="REFERENCE">Saleh-Mghir 1992</LINK>; <LINK REF="REF-Sande-1974" TYPE="REFERENCE">Sande 1974</LINK>; <LINK REF="REF-Torres-1993" TYPE="REFERENCE">Torres 1993</LINK>). Third, combination therapy has been claimed to suppress the emergence of subpopulations of microorganisms resistant to antibiotics (<LINK REF="REF-Allan-1985" TYPE="REFERENCE">Allan 1985</LINK>; <LINK REF="REF-Milatovic-1987" TYPE="REFERENCE">Milatovic 1987</LINK>). Disadvantages of combination therapy may include additional costs, enhanced drug toxicity, possible induction of resistance caused by the broader antibiotic spectrum (<LINK REF="REF-Manian-1996" TYPE="REFERENCE">Manian 1996</LINK>; <LINK REF="REF-Weinstein-1985" TYPE="REFERENCE">Weinstein 1985</LINK>) and possible antagonism between specific drug combinations (<LINK REF="REF-Moellering-1986" TYPE="REFERENCE">Moellering 1986</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-12-20 14:19:12 +0000" MODIFIED_BY="Jane Cracknell">
<P>Several systematic reviews have addressed the clinical effects of beta lactam-aminoglycoside combinations for the treatment of sepsis, bacteraemia or specific types of infection. In previous versions of the current review (<LINK REF="REF-Paul-2003" TYPE="REFERENCE">Paul 2003</LINK>; <LINK REF="REF-Paul-2006" TYPE="REFERENCE">Paul 2006</LINK>), we found no advantage of combination therapy over monotherapy and an increased rate of renal toxicity with combination therapy. In a separate systematic review assessing the same intervention for cancer patients with neutropenia (excluded from the current review), similar results were found, with a small advantage of monotherapy when compared with a narrower-spectrum beta lactam combined with an aminoglycoside (<LINK REF="REF-Paul-2013" TYPE="REFERENCE">Paul 2013</LINK>). To fully examine the implications of in vitro synergism, we pooled all randomized controlled trials comparing one beta lactam antibiotic versus the same beta lactam with an aminoglycoside (<LINK REF="REF-Marcus-2011" TYPE="REFERENCE">Marcus 2011</LINK>). Overall, no advantage emerged for combination therapy; the subgroup of <I>P aeruginosa</I> bacteraemia was too small to allow definitive conclusions. Safdar et al. focused on Gram-negative bacteraemia and compiled randomized trials and observational studies (<LINK REF="REF-Safdar-2004" TYPE="REFERENCE">Safdar 2004</LINK>). In the subgroup of <I>P aeruginosa</I> bacteraemia, an advantage was reported for combination therapy, but aminoglycosides were used as monotherapy in some of the trials (<LINK REF="REF-Paul-2005" TYPE="REFERENCE">Paul 2005</LINK>). Kumar et al. performed a meta-regression analysis showing that an advantage of combination therapy involved mortality rates in randomized and observational studies (<LINK REF="REF-Kumar-2010" TYPE="REFERENCE">Kumar 2010</LINK>), but how much of this was due to the inherent association between odds ratios and event rates and how much to a true clinical effect was unclear (<LINK REF="REF-Paul-2010a" TYPE="REFERENCE">Paul 2010a</LINK>). When restricting the analysis to infective endocarditis (caused by Gram-positive bacteria), Falagas et al. found no advantage of combination therapy (<LINK REF="REF-Falagas-2006" TYPE="REFERENCE">Falagas 2006</LINK>). The same group of authors reported no advantage of combination therapy with regard to emergence of antibiotic resistance following therapy (<LINK REF="REF-Bliziotis-2005" TYPE="REFERENCE">Bliziotis 2005</LINK>).</P>
<P>Despite the large body of evidence pointing against a benefit for combination therapy, most recommendations and guidelines still recommend combination therapy, and combination therapy is frequently used in clinical practice. In the guidelines for the management of severe sepsis of the "Surviving Sepsis Campaign", initial combination therapy is recommended (<LINK REF="REF-Dellinger-2008" TYPE="REFERENCE">Dellinger 2008</LINK>). Narrowing the spectrum of coverage after three to five days is recommended, except for infections caused by <I>P aeruginosa </I>and<I> </I>infections among neutropenic patients, for whom continued combination treatment is advised. Beta lactam-aminoglycoside treatment is recommended for pneumonia caused by <I>P aeruginosa </I>(<LINK REF="REF-Sun-2011" TYPE="REFERENCE">Sun 2011</LINK>). Treatment of infective endocarditis has traditionally consisted of beta lactam-aminoglycoside combinations based on in vitro synergy studies and experimental studies. Although current guidelines, acknowledging the lack of evidence, recommend beta lactam monotherapy as first-line therapy for most pathogens, combination therapy is still suggested as optional treatment and is recommended for resistant bacteria, mainly <I>Enterococcus </I>sp. and <I>S aureus </I>(<LINK REF="REF-Baddour-2005" TYPE="REFERENCE">Baddour 2005</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-12-20 15:50:19 +0000" MODIFIED_BY="Karen Hovhannisyan">
<P>Our objectives were to compare beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy in patients with sepsis and to estimate the rate of adverse effects with each treatment regimen, including the development of bacterial resistance to antibiotics.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-12-20 14:19:12 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-12-20 14:19:12 +0000" MODIFIED_BY="Karen Hovhannisyan">
<CRIT_STUDIES>
<P>We included randomized or quasi-randomized controlled trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-12-20 14:19:12 +0000" MODIFIED_BY="[Empty name]">
<P>We included hospitalized participants with sepsis acquired in the community or in the hospital. We defined sepsis as clinical evidence of infection plus evidence of a systemic response to infection (<LINK REF="REF-Bone-1992" TYPE="REFERENCE">Bone 1992</LINK>). We excluded neonates and preterm babies. We also excluded studies including more than 15% neutropenic patients.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-12-20 14:19:12 +0000" MODIFIED_BY="Karen Hovhannisyan">
<P>We considered studies comparing the antibiotic regimens described below.</P>
<OL>
<LI>Any intravenous beta lactam antibiotic given as monotherapy, including:</LI>
<OL>
<LI>penicillins;</LI>
<LI>beta lactam drugs plus beta lactamase inhibitors (e.g. co-amoxiclav);</LI>
<LI>cephalosporins (e.g. ceftazidime, cefotaxime); or</LI>
<LI>carbapenems (e.g. imipenem, meropenem).</LI>
</OL>
<LI>Combination therapy of a beta lactam antibiotic (as specified) with one of the following aminoglycoside antibiotics:</LI>
<OL>
<LI>gentamicin;</LI>
<LI>tobramycin;</LI>
<LI>amikacin;</LI>
<LI>netilmicin;</LI>
<LI>streptomycin;</LI>
<LI>isepamicin; or</LI>
<LI>sisomicin.</LI>
</OL>
</OL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-12-20 14:19:12 +0000" MODIFIED_BY="Karen Hovhannisyan">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2012-02-09 07:08:52 +0000" MODIFIED_BY="Karen Hovhannisyan">
<P>All-cause mortality by the end of the study follow-up.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-12-20 14:19:12 +0000" MODIFIED_BY="Karen Hovhannisyan">
<OL>
<LI>Treatment failure defined as death and/or one or more serious morbid events (persistence, recurrence or worsening of clinical signs or symptoms of presenting infection; any modification of the assigned empirical antibiotic treatment; or any therapeutic invasive intervention required and not defined in the protocol). If defined differently, the study definitions were documented.</LI>
<LI>Length of hospital stay.</LI>
<LI>Superinfection: recurrent infections, defined as new, persistent or worsening symptoms and/or signs of infection associated with the isolation of a new pathogen (different pathogen or same pathogen with different susceptibilities) or the development of a new site of infection.</LI>
<LI>Colonization by resistant bacteria: the isolation of bacteria resistant to the beta lactam antibiotic, during or following antibiotic therapy, with no signs or symptoms of infection.</LI>
<LI>Adverse effects:</LI>
<OL>
<LI>life-threatening or associated with permanent disability (severe nephrotoxicity; ototoxicity; anaphylaxis; severe skin reactions);</LI>
<LI>serious: requiring discontinuation of therapy (other nephrotoxicity; seizures; pseudomembranous colitis; other allergic reactions); or</LI>
<LI>any other (other gastrointestinal; other allergic reactions).</LI>
</OL>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-12-20 14:19:12 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2013-12-20 14:19:12 +0000" MODIFIED_BY="[Empty name]">
<P>We formulated a comprehensive search strategy in an attempt to identify all relevant studies regardless of language or publication status (published, unpublished, in press and in progress).</P>
<P>We searched the Cochrane Infectious Diseases Group specialized trials register for relevant trials up to September 2011 using the following search terms: ((aminoglycoside* OR netilmicin* OR gentamicin* OR amikacin* OR tobramycin* OR streptomycin* OR isepamicin* OR sisomicin*) AND (pneumonia* OR infection OR infect* OR sepsis OR bacter* OR bacteremia OR septicemia).</P>
<P>In this updated review, we searched the Cochrane Central Register of Controlled Trials (CENTRAL, 2013, Issue 11; see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for a detailed search strategy), PubMed (1966 to November 2013; see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), EMBASE (Ovid SP, 1980 to November 2013; see <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>) and LILACS (via BIREME interface, 1982 to November 2013; see <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>). We combined our PubMed search strategy with the Cochrane highly sensitive search strategy for identifying randomized controlled trials (RCTs), as suggested in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We modified this RCT filter for use in EMBASE and LILACS. In our previous review (<LINK REF="REF-Paul-2006" TYPE="REFERENCE">Paul 2006</LINK>), we searched the databases until July 2004.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-12-20 14:19:12 +0000" MODIFIED_BY="Karen Hovhannisyan">
<P>We searched the Interscience Conference of Antimicrobial Agents and Chemotherapy conference proceedings (1995 to 2012) and the European Congress of Clinical Microbiology and Infectious Diseases (2000 to 2013) for relevant abstracts.</P>
<P>We contacted the first or corresponding author of each included study and researchers active in the field for information regarding unpublished trials or for complementary information on their own trials.</P>
<P>We also checked the citations of major reviews and of all trials identified by the above methods for additional studies.</P>
<P>We did not have a language restriction.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-12-20 14:19:12 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2013-12-20 14:19:12 +0000" MODIFIED_BY="[Empty name]">
<P>One review author (MP for the original review; AL for the 2013 update) inspected the abstract of each reference identified in the search and applied the inclusion criteria. When relevant articles were identified, the full article was obtained and was inspected independently by two review authors (MP, AL, IS or LL).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-12-20 14:19:12 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors (MP, Ishay Silbiger or SG-G) independently extracted data from included trials in the original review, and AL and MP extracted data for the 2012 update. In case of disagreement between the two review authors, a third review author (LL) independently extracted the data. A third review author (LL) also extracted the data in 10% of the studies, selected at random. We discussed data extraction, documented decisions and contacted authors of all studies for clarification. We resolved differences in the data extracted by discussion. We also documented the justification for excluding studies from the review.</P>
<P>We identified the trials by the name of the first author and the year in which the trial was first published, and we listed them in chronological order. We extracted, checked and recorded the following data.</P>
<SUBSECTION>
<HEADING LEVEL="6">Characteristics of trials</HEADING>
<OL>
<LI>Date, location and setting of trial.</LI>
<LI>Publication status.</LI>
<LI>Country of origin.</LI>
<LI>Design (intention-to-treat, method of randomization).</LI>
<LI>Duration of study follow-up.</LI>
<LI>Performance of surveillance cultures (routine cultures for the detection of colonization).</LI>
<LI>Sponsor of trial.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Characteristics of participants</HEADING>
<OL>
<LI>Number of participants in each group.</LI>
<LI>Age (mean and standard deviation, or median and range).</LI>
<LI>Number of participants with renal failure before treatment.</LI>
<LI>Number of participants with shock.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Characteristics of infection</HEADING>
<OL>
<LI>Number of participants with infection caused by bacteria resistant to the administered beta lactam antibiotic.</LI>
<LI>Number of participants with nosocomial infection.</LI>
<LI>Number of participants with bacteraemia.</LI>
<LI>Number of participants with bacteriologically documented infection.</LI>
<LI>Number of participants with infection caused by Gram-negative bacteria.</LI>
<LI>Number of participants with Gram-negative bacteraemia.</LI>
<LI>Number of participants with documented <I>Pseudomonas</I> infection (<I>Pseudomonas</I> isolated in blood or specimen(s) obtained from suspected site(s) of infection).</LI>
<LI>Number of participants with:</LI>
<OL>
<LI>urinary tract infection;</LI>
<LI>pneumonia;</LI>
<LI>intra-abdominal infection;</LI>
<LI>skin and soft tissue infection; and</LI>
<LI>infection of unknown origin.</LI>
</OL>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Characteristics of interventions</HEADING>
<OL>
<LI>Antibiotic type and dose.</LI>
<LI>Duration of therapy (mean).</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Characteristics of outcome measures</HEADING>
<OL>
<LI>Number of deaths at the end of the follow-up period.</LI>
<LI>Number of participants failing treatment (as defined).</LI>
<LI>Adverse reactions (as defined) in each group.</LI>
<LI>Loss of follow-up (dropouts) before the end of the study in each group.</LI>
<LI>Number of participants developing superinfection.</LI>
<LI>Number of participants developing colonization (as defined) with resistant bacteria.</LI>
<LI>Duration of fever and hospital stay.</LI>
</OL>
<P>We collected outcome measures on an intention-to-treat basis whenever possible. When such data were not presented, we sought information from the trial authors, and, if unavailable, per-protocol results were used. For failure outcome, we performed sensitivity analyses comparing these results with a 'presumed all intention to treat', which we achieved by counting all dropouts as failures. We could not make such an assumption in studies that did not specify the number of dropouts per study arm, and we analysed these studies separately.</P>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-12-20 14:19:11 +0000" MODIFIED_BY="[Empty name]">
<P>We assessed the risk of bias of the trials to be included for random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, blinding and incomplete outcome data (for mortality and failure outcomes), selective reporting, intention-to-treat analysis and number of participants excluded from the outcome assessment. Two review authors (MP, AL, Ishay Silbiger and Karla Soares-Weiser ) independently performed the risk of bias assessment by classifying each item separately as low, unclear or high risk of bias according to the criteria suggested by the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-12-20 14:19:11 +0000" MODIFIED_BY="[Empty name]">
<P>We calculated risk ratios for dichotomous outcomes. For length of stay, we extracted the measure reported in the study (mean or median) along with its dispersion measure.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-12-20 14:19:11 +0000" MODIFIED_BY="[Empty name]">
<P>We expected all studies to be individually randomly assigned and to recruit each participant only once into the trial; thus no unit of analysis issues were expected for this review.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-12-20 14:19:11 +0000" MODIFIED_BY="[Empty name]">
<P>We contacted the first or corresponding author of each included study and researchers active in the field to ask for information regarding unpublished trials or complementary information on their own trials.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-12-20 14:19:11 +0000" MODIFIED_BY="[Empty name]">
<P>We initially assessed heterogeneity by visual inspection of the forest plots. Statistical assessment was based on the Chi<SUP>2</SUP> test of heterogeneity (P &lt; 0.1) and the I<SUP>2</SUP> measure of inconsistency (substantial and considerable heterogeneity &gt; 50%) (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-12-20 14:19:11 +0000" MODIFIED_BY="[Empty name]">
<P>We visually examined a funnel plot of standard error (SE) (log(risk ratio)) versus risk ratio of each study to estimate small study effects, including publication bias or other. Statistical testing for funnel plot asymmetry was conducted using Egger's regression (Comprehensive Meta Analysis, version 2.2). The funnel plot was examined for the outcomes of mortality and failure.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-12-20 14:19:11 +0000" MODIFIED_BY="[Empty name]">
<P>We used the Mantel-Haenszel fixed-effect model to pool risk ratios. We did not plan to pool results for length of stay because this variable is not normally distributed.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-12-20 14:19:11 +0000" MODIFIED_BY="[Empty name]">
<P>We explored heterogeneity by subgroup analysis of the different types of infection.</P>
<OL>
<LI>Infections caused by Gram-negative bacteria and <I>P aeruginosa.</I>
</LI>
<LI>Gram-negative bacteraemia.</LI>
<LI>Urinary tract infection and non&#8211;urinary tract infection, assuming that the latter might be more serious and thus might benefit more from combination therapy.</LI>
<LI>Gram-positive infection and endocarditis.</LI>
</OL>
<P>For subgroup analyses, we analysed the outcomes of mortality and failure. For Gram-positive infection, we also analysed microbiological failure.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-12-20 14:19:10 +0000" MODIFIED_BY="[Empty name]">
<P>We analysed separately studies at low risk of bias with regard to allocation concealment, generation, blinding and incomplete outcome data reporting. We based conclusions regarding the effect of risk of bias on results on the evidence of a strong association between poor allocation concealment and overestimation of effect (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>).</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-12-20 14:19:10 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-12-20 14:19:10 +0000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2013-12-20 14:19:10 +0000" MODIFIED_BY="Jane Cracknell">
<P>The search strategy resulted in 6562 references. We filtered double references and screened 3629 different abstracts for inclusion. We did not further evaluate studies in which the comparator antibiotic regimens were clearly incompatible with inclusion criteria. We similarly excluded non-randomized and non-human studies. We retrieved 159 studies for full-text inspection, of which we excluded 72 publications. Eighty-three articles were deemed eligible for inclusion, of which 14 were secondary publications. One is ongoing (<LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>); thus we have included 69 trials in this review (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Five trials are included in the current update that were not included in the original review (<LINK REF="STD-Banasal-2006" TYPE="STUDY">Banasal 2006</LINK>; <LINK REF="STD-Damas-2006" TYPE="STUDY">Damas 2006</LINK>; <LINK REF="STD-Hasali-2005" TYPE="STUDY">Hasali 2005</LINK>; <LINK REF="STD-Figueroa_x002d_Damian-1996" TYPE="STUDY">Figueroa-Damian 1996</LINK>; <LINK REF="STD-Garc_x00ed_a-Ram_x00ed_rez-1999" TYPE="STUDY">García Ramírez 1999</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-12-20 14:19:10 +0000" MODIFIED_BY="Jane Cracknell">
<P>Main study characteristics are detailed in the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. The included studies were performed between the years 1968 and 2006. Twenty-two were multi-centred. Twenty-one were performed in the United States or Canada, 35 in Europe and 14 in other countries. The studies included 7863 participants. The median number of included participants per trial was 80 (range 20 to 580). Four trials (<LINK REF="STD-Banasal-2006" TYPE="STUDY">Banasal 2006</LINK>, <LINK REF="STD-Cardozo-2001" TYPE="STUDY">Cardozo 2001</LINK>; <LINK REF="STD-Hasali-2005" TYPE="STUDY">Hasali 2005</LINK>, <LINK REF="STD-Naime-Libien-1992" TYPE="STUDY">Naime Libien 1992</LINK>) included children, and all other trials were restricted to or included mostly adults.</P>
<P>The studies differed by the type of population and the type of infection targeted (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). Forty-five trials included participants with severe sepsis, suspected Gram-negative infection or pneumonia (designated as 'sepsis'). The adjusted mean fatality rate in these studies was 8.5%.Twelve trials included participants with intra-abdominal infection, related mainly to the biliary tract (designated 'abdominal'). The mean fatality rate in these trials was 1.7%. Seven trials were restricted to participants with urinary tract infection (UTI), all hospitalized, mainly women. Five of these studies reported on mortality, and no deaths occurred in four. Finally, five of the studies included in the review targeted participants with Gram-positive infection. Four studies addressed participants with endocarditis caused by <I>S aureus</I> (<LINK REF="STD-Abrams-1979" TYPE="STUDY">Abrams 1979</LINK>; <LINK REF="STD-Korzeniowski-1982" TYPE="STUDY">Korzeniowski 1982</LINK>; <LINK REF="STD-Ribera-1996" TYPE="STUDY">Ribera 1996</LINK>) or streptococci (<LINK REF="STD-Sexton-1998" TYPE="STUDY">Sexton 1998</LINK>). One study included any staphylococcal infection (<LINK REF="STD-Coppens-1983" TYPE="STUDY">Coppens 1983</LINK>).</P>
<P>Most studies compared beta-lactam monotherapy vs. beta-lactam-aminoglycoside combination therapy as the initial, empirical antibiotic treatment administered to participants. Four studies assessed the empirical and definitive treatment of a specific infection by randomly assigning participants empirically and evaluating only those who subsequently fulfilled criteria for the specific infection. Two such studies randomly assigned participants with suspected endocarditis and evaluated only those with <I>S aureus</I> bacteraemia and proven endocarditis (<LINK REF="STD-Abrams-1979" TYPE="STUDY">Abrams 1979</LINK>; <LINK REF="STD-Korzeniowski-1982" TYPE="STUDY">Korzeniowski 1982</LINK>). The other two randomly assigned participants with suspected biliary tract infection and evaluated only participants with a surgically proven diagnosis (<LINK REF="STD-Gerecht-1989" TYPE="STUDY">Gerecht 1989</LINK>; <LINK REF="STD-Yellin-1993" TYPE="STUDY">Yellin 1993</LINK>). Non-evaluated participants in these studies were not counted as dropouts because the study protocol a priori defined evaluation only for participants fulfilling definitive criteria. Eight studies, focusing on participants with specific infections or pathogens (e.g. cholecystitis, staphylococcal infections), tested the effect of monotherapy versus combination therapy semi-empirically. In these studies (designated 'semi-empirical', see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>), randomization occurred after the specific infection was documented and participants could have received prior antibiotic treatment for this infection. Analysis of empirical and semi-empirical studies was not separated.</P>
<P>The specific antibiotic regimens used are detailed in the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. Forty-seven studies compared a single beta lactam drug versus a different, narrower-spectrum beta lactam combined with an aminoglycoside (designated 'different BL'). Sixteen 'different BL' studies reported baseline susceptibility rates of the pathogens isolated on admission to the beta lactam. The beta lactam used in the combination arm covered fewer pathogens than the monotherapy beta lactam in 13 studies, and the opposite occurred in two studies only. Twenty-two studies compared the same beta lactam in the combination and monotherapy arms (designated 'same BL'). Results obtained from studies comparing same and different beta lactams were kept separated throughout all efficacy analyses. The beta lactam monotherapies used in the studies and their dosing are detailed in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. The aminoglycoside was administered once daily in nine trials (<LINK REF="STD-Cardozo-2001" TYPE="STUDY">Cardozo 2001</LINK>; <LINK REF="STD-Damas-2006" TYPE="STUDY">Damas 2006</LINK>; <LINK REF="STD-Garc_x00ed_a-Ram_x00ed_rez-1999" TYPE="STUDY">García Ramírez 1999</LINK>, <LINK REF="STD-Hasali-2005" TYPE="STUDY">Hasali 2005</LINK>; <LINK REF="STD-Jaspers-1998" TYPE="STUDY">Jaspers 1998</LINK>; <LINK REF="STD-Rubinstein-1995" TYPE="STUDY">Rubinstein 1995</LINK>; <LINK REF="STD-Sandberg-1997" TYPE="STUDY">Sandberg 1997</LINK>; <LINK REF="STD-Sexton-1998" TYPE="STUDY">Sexton 1998</LINK>; <LINK REF="STD-Speich-1998" TYPE="STUDY">Speich 1998</LINK>). Other trials administered the aminoglycosides multiple times daily (49 trials) or did not specify the administration schedule (11 trials). Mean antibiotic treatment duration ranged between three and 17.5 days in the sepsis studies, between 6.8 and 11.9 days in the abdominal studies, between 4.1 and seven days in the UTI studies and between two and four weeks in the endocarditis studies.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-12-20 14:19:10 +0000" MODIFIED_BY="Jane Cracknell">
<P>We excluded 72 publications, representing 69 studies (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). Several studies compared monotherapy versus combination therapy among participants with cystic fibrosis. Participants in these studies typically did not have fever or other signs of sepsis when entering the trial and thus did not fulfil inclusion criteria for this review. These studies are included in a separate review (<LINK REF="REF-Elphick-2005" TYPE="REFERENCE">Elphick 2005</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-12-20 14:19:10 +0000" MODIFIED_BY="[Empty name]">
<P>See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>, Risk of bias tables, <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<ALLOCATION MODIFIED="2013-12-20 14:19:10 +0000" MODIFIED_BY="[Empty name]">
<P>Thirty-two percent of the studies (22/69) reported adequate allocation concealment and thus considered were at low risk of bias. Four studies were graded as high risk of bias (<LINK REF="STD-Duff-1982" TYPE="STUDY">Duff 1982</LINK>; <LINK REF="STD-Garc_x00ed_a-Ram_x00ed_rez-1999" TYPE="STUDY">García Ramírez 1999</LINK>; <LINK REF="STD-Hasali-2005" TYPE="STUDY">Hasali 2005</LINK>; <LINK REF="STD-Landau-1990" TYPE="STUDY">Landau 1990</LINK>). No information was available for the other studies (37 studies), or envelopes were used but were not described as sealed or opaque (six studies).</P>
<P>Allocation generation was considered at low risk of bias in 51% of the studies (35/69). No information was available for 30 studies. Two studies were at high risk of bias, using participant identification numbers (<LINK REF="STD-Duff-1982" TYPE="STUDY">Duff 1982</LINK>; <LINK REF="STD-Landau-1990" TYPE="STUDY">Landau 1990</LINK>). Both allocation generation and concealment were at low risk in 29% of the studies (20/69).</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-12-20 14:19:10 +0000" MODIFIED_BY="[Empty name]">
<P>Most studies were open. Although these were considered at high risk of bias, for mortality assessment the lack of blinding after randomization probably did not introduce bias. Two studies, including 226 participants, were double-blinded (<LINK REF="STD-Sanfilippo-1989" TYPE="STUDY">Sanfilippo 1989</LINK>; <LINK REF="STD-Smith-1984" TYPE="STUDY">Smith 1984</LINK>). Outcome assessors were blinded in four studies (<LINK REF="STD-Brown-1984" TYPE="STUDY">Brown 1984</LINK>; <LINK REF="STD-Dupont-2000" TYPE="STUDY">Dupont 2000</LINK>; <LINK REF="STD-Rubinstein-1995" TYPE="STUDY">Rubinstein 1995</LINK>; <LINK REF="STD-Verzasconi-1995" TYPE="STUDY">Verzasconi 1995</LINK>). Clinicians were blinded to treatment in one study (<LINK REF="STD-Yellin-1993" TYPE="STUDY">Yellin 1993</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-12-20 14:19:10 +0000" MODIFIED_BY="[Empty name]">
<P>We separated included studies into four different study types with relation to outcome reporting.</P>
<OL>
<LI>Full Intention-to-treat analysis (all randomly assigned participants included in the analysis).</LI>
<LI>Per-protocol analysis, in which the number of dropouts was given per study arm.</LI>
<LI>Per-protocol analysis, in which the number of dropouts was known but was not given per study arm.</LI>
<LI>Studies that did not distinguish between the number of randomly assigned participants and the number of evaluated participants. These studies did not refer to dropouts, but the study authors did not define the study explicitly as intention-to-treat.</LI>
</OL>
<P>The distribution of included studies by study type was as follows.</P>
<UL>
<LI>All-cause fatality (reported in 44 studies).</LI>
<UL>
<LI>Type one: 20 studies (45%).</LI>
<LI>Types two and three: 18 studies (41%).</LI>
<LI>Type four: six studies (14%).</LI>
</UL>
<LI>Treatment failure (reported In 66 studies).</LI>
<UL>
<LI>Type one: 15 studies (23%).</LI>
<LI>Type two: 23 studies (375%).</LI>
<LI>Type three: 16 studies (254%).</LI>
<LI>Type four: 12 studies (18%).</LI>
</UL>
</UL>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-12-20 14:19:10 +0000" MODIFIED_BY="[Empty name]">
<P>Protocols were not available for most studies because they were conducted before mandatory trial registry. In general, the primary outcome specified as planned and reported in all trials was "treatment success" ( a variously defined composite outcome including clinical response and the need for antibiotic modifications). All-cause mortality was not specifically defined as an outcome in most trials, and if reported, it was a safety measure reported in the results. Since this was uniformly observed across trials, we have not specified selective reporting for each trial in the Risk of bias tables.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2012-03-20 08:01:22 +0000" MODIFIED_BY="[Empty name]">
<P>No other potential sources of bias were identified.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-12-20 14:19:10 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">All-cause mortality</HEADING>
<P>Forty-four trials including 5577 participants were included in this comparison (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). Thirteen studies including 1431 participants compared the same beta lactam. These studies showed near equivalence (risk ratio (RR) 0.97, 95% confidence interval (CI) 0.73 to 1.30), and studies comparing different beta lactams tended non-significantly in favour of monotherapy (RR 0.85, 95% CI 0.71 to 1.01). No heterogeneity was present for these comparisons (I<SUP>2</SUP>= 0% for the same beta lactam comparison, I<SUP>2</SUP>= 19% for different beta lactams). Analysis was further broken down according to the main study population, excluding Gram-positive infection studies (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). The advantage of the monotherapy was statistically significant in studies comparing different beta lactams addressing 'sepsis' (RR 0.83, 95% CI 0.69 to 0.99), but no significant differences were noted between subgroups in this analysis.</P>
<P>The funnel plot analysis for all-cause mortality showed that small studies favouring combination therapy may be missing (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>; Egger's regression two-sided P value 0.05). Mortality outcome was unavailable from 36% of the trials.</P>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analyses</HEADING>
<P>No significant difference between monotherapy and combination therapy was apparent when analysis was restricted to participants with any Gram-negative infection (eight studies) or Gram-negative bacteraemia (five studies; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>). Only four studies permitted mortality outcome extraction among participants with <I>P aeruginosa</I> infection, and these did not show a difference (total of 60 evaluable participants and 15 deaths; graph not shown). Five UTI studies reported mortality, and mortality was null in three studies. Excluding participants with UTI from the analysis ('non-UTI' subgroup; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>) strengthened the advantage of monotherapy in studies comparing different beta lactams (RR 0.70, 95% CI 0.52 to 0.95).</P>
<P>Three studies addressing Gram-positive infection reported on mortality, all comparing the same antibiotics, with a small sample size and few deaths (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>). No difference was observed between monotherapy and combination therapy, with the point estimate in the direction favouring monotherapy (RR 0.44, 95% CI 0.12 to 1.58).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sensitivity analyses</HEADING>
<P>Low-risk allocation concealment and generation were associated with risk ratios closer to one than studies with unclear methods for studies comparing different beta lactams but without a statistically significant difference between subgroups (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>). Combination therapy was significantly better among studies comparing different beta lactams classified as unclear allocation concealment. Blinding was performed in too few studies to assess its effect on mortality. The combined RR for studies comparing the same beta lactam and reporting mortality by intention-to-treat was 0.57 (95% CI 0.28 to 1.19) compared with 1.09 (95% CI 0.80 to 1.51) for studies reporting mortality per-protocol (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>; P value 0.11 for subgroup difference). Comparison of intention-to-treat versus per-protocol studies for different beta lactams did not reveal a difference. Reanalysis of the mortality comparison by the random-effects model was very similar for same beta lactams (RR 0.99, 95% CI 0.74 to 1.33) and for different beta lactams (RR 0.85, 95% CI 0.69 to 1.05).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Treatment failure</HEADING>
<P>We included 66 trials in the clinical failure analysis, comprising 6803 participants (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). We detected no difference between monotherapy and combination therapy among studies comparing the same beta lactam (RR 1.11, 95% CI 0.95 to 1.29). We found a significant advantage of monotherapy among studies comparing different beta lactams (RR 0.75, 95% CI 0.67 to 0.84). No heterogeneity was present (I<SUP>2</SUP>= 0% for both comparisons). Grouping studies according to study population highlighted an advantage of combination therapy among the 'sepsis' studies that compared the same beta lactam (RR 1.25, 95% CI 1.01 to 1.55). This group of studies also accentuated the opposing advantage of monotherapy among studies comparing different beta lactams (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). Assessment of efficacy for urinary tract infection included reinfection and relapse as outcomes (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). We noted no significant difference between monotherapy and combination therapy, with six trials and 458 participants included in this comparison.</P>
<P>The funnel plot for treatment failure generated a nearly symmetrical 'funnel distribution' (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analyses</HEADING>
<P>We analysed 28 studies including 1835 participants with Gram-negative infection and 18 studies including 426 participants with <I>P aeruginosa</I> infection (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>; <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>). We observed no significant differences between the study groups for studies comparing the same or different beta lactams. For studies comparing the same beta lactam, the RR was 1.23 (95% CI 0.90 to 1.68) for Gram-negative infection and 1.02 (95% CI 0.68 to 1.51) for <I>P aeruginosa</I> infection. We observed no difference between study groups among participants with Gram-negative bacteraemia or any bacteraemia (<LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>; <LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>). The latter comparison mainly comprised participants with Gram-negative bacteraemia but was available from a larger number of studies and showed a large advantage of monotherapy among studies comparing different beta lactams. Both subgroups of participants with UTIs (<LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK>) and participants without UTIs maintained the trends seen previously (<LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>).</P>
<P>All five studies targeting Gram-positive infection reported on clinical failure. All compared the same beta lactam. The combined risk ratio for clinical failure was 0.69 (95% CI 0.40 to 1.19, five studies, 305 participants; <LINK REF="CMP-002.11" TYPE="ANALYSIS">Analysis 2.11</LINK>). Measures of treatment failure in these studies included persistence of bacteraemia or signs of endocarditis, relapse, need for valve replacement, need for surgery in endocarditis and death. The time of outcome determination was predefined in all trials and follow-up was long (one to six months). The need for surgery in endocarditis was reported in all four trials including participants with endocarditis, with no statistically significant difference noted between treatment groups (<LINK REF="CMP-002.12" TYPE="ANALYSIS">Analysis 2.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sensitivity analyses</HEADING>
<P>The quality of allocation concealment and generation did not affect the risk ratios for treatment failure among studies comparing the same or different beta lactams (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>; <LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>). All studies at high risk for bias (quasi-randomized) compared different beta lactams, and their results were highly heterogenous.</P>
<P>Several studies comparing different beta lactams used some type of blinding. The advantage of monotherapy was non-significantly larger among these studies compared with non-blinded studies (<LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>; P value 0.05 for subgroup difference).</P>
<P>Among studies comparing the same beta lactam, we observed an advantage of combination therapy in the presumed intention-to-treat analysis (type two studies), in which we imputed failure for dropouts. Among studies comparing different beta lactams, intention-to-treat, presumed intention-to-treat and per-protocol results were similar, favouring monotherapy (<LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>). Analysis by the random-effects model did not change the results (RR 1.09, 95% CI 0.94 to 1.27 for same beta lactams; RR 0.76, 95% CI 0.67 to 0.87 for different beta lactams).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Bacteriological cure</HEADING>
<P>Bacteriological cure occurred more frequently with monotherapy among studies comparing different beta lactams (RR 0.81, 95% CI 0.69 to 0.94) but did not differ significantly in studies comparing the same beta lactam (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
<P>In an analysis restricted to the studies assessing Gram-positive infection, no difference in microbiological failure rates was reported (<LINK REF="CMP-002.13" TYPE="ANALYSIS">Analysis 2.13</LINK>),</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Length of hospital stay</HEADING>
<P>Eleven studies published data for the comparison of hospital stay. Significant heterogeneity precluded their combination. Duration of hospitalization was longer with monotherapy in three studies (<LINK REF="STD-McCormick-1997" TYPE="STUDY">McCormick 1997</LINK>; <LINK REF="STD-Figueroa_x002d_Damian-1996" TYPE="STUDY">Figueroa-Damian 1996</LINK>; <LINK REF="STD-McCormick-1997" TYPE="STUDY">McCormick 1997</LINK>; 331 participants), shorter in four studies (<LINK REF="STD-Arich-1987" TYPE="STUDY">Arich 1987</LINK>; <LINK REF="STD-Biglino-1991" TYPE="STUDY">Biglino 1991</LINK>; <LINK REF="STD-Damas-2006" TYPE="STUDY">Damas 2006</LINK>; <LINK REF="STD-Sexton-1998" TYPE="STUDY">Sexton 1998</LINK>; 186 participants) and similar in four studies (<LINK REF="STD-Garc_x00ed_a-Ram_x00ed_rez-1999" TYPE="STUDY">García Ramírez 1999</LINK>; <LINK REF="STD-Mouton-1990" TYPE="STUDY">Mouton 1990</LINK>; <LINK REF="STD-Wing-1998" TYPE="STUDY">Wing 1998</LINK>; <LINK REF="STD-Yellin-1993" TYPE="STUDY">Yellin 1993</LINK>; 540 participants).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Development of resistance and adverse events</HEADING>
<P>We merged studies comparing same and different beta lactams for assessment of development of resistance and adverse events. These outcomes are intended to assess the antibiotic class effect of aminoglycoside-beta lactam combinations versus beta lactams alone, whether same or different.</P>
<P>Bacterial superinfections occurred more frequently with combination therapy (RR 0.75, 95% CI 0.57 to 0.99, 28 studies, 3135 participants; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>). We detected no significant difference in the rates of fungal superinfection (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). Bacterial colonization was non-significantly more common with combination therapy in all studies reporting on colonization (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>) and in studies in which surveillance cultures were performed routinely (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>). Few studies monitored development of resistance among pathogens isolated initially (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>). We observed no significant difference between monotherapy and combination therapy.</P>
<P>Any adverse event occurred non-significantly more frequently with combination therapy (RR 0.92, 95% CI 0.83 to 1.01; <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>), and this analysis was slightly heterogenous. No significant difference was reported with regard to adverse events requiring treatment discontinuation, but these were reported in a minority of studies (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>). We found nephrotoxicity to be more common in the combination arm in nearly all studies, with a highly significant combined risk ratio in favour of monotherapy (RR 0.30, 95% CI 0.23 to 0.39 <LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>). A significantly increased rate of nephrotoxicity was seen in studies administering the aminoglycoside once daily and in studies with a multiple-day regimen. Vestibular symptoms and ototoxicity, other known serious side effects of aminoglycoside treatment, were not reported routinely and could not be analysed. Different definitions and detailing of specific adverse events precluded a meaningful meta-analysis of other adverse events, individually or grouped.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-12-20 14:19:10 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2013-12-20 14:19:10 +0000" MODIFIED_BY="Jane Cracknell">
<P>The present review compares beta lactam-aminoglycoside antibiotic combinations versus beta lactam monotherapy among non-neutropenic participants with sepsis. The primary outcome that we assessed was all-cause mortality. Twenty-two of the 69 included studies used the same beta lactam in both study arms. Most studies compared one beta lactam versus a different, narrower-spectrum beta lactam combined with an aminoglycoside. Special emphasis should be placed on studies comparing the same beta lactam. These studies directly test the hypothesis that the addition of an aminoglycoside to the beta lactam is beneficial. Among these studies, all-cause mortality did not differ between study arms (RR 0.97, 95% CI 0.73 to 1.30). Treatment failure occurred more frequently in the monotherapy arm, reaching statistical significance only among the group of 'sepsis' studies. In studies comparing different beta lactams, both failure and mortality were more common in the combination treatment arm. Failure was highly significant, and mortality reached significance only with subgroup analyses. These studies demonstrate an advantage of broad-spectrum beta lactam monotherapy when compared with a narrower-spectrum beta lactam combined with an aminoglycoside, despite equal in vitro coverage of the culprit pathogens in both arms.</P>
<P>Development of resistance was assessed by the occurrence of superinfection and colonization, assuming that bacteria appearing under antibiotic treatment are resistant to the antibiotic administered. Bacterial superinfection occurred significantly more frequently with combination therapy (RR 0.75, 95% CI 0.57 to 0.99). Adverse events occurred more frequently with combination therapy. Specifically, nephrotoxicity occurred significantly more frequently in the combination treatment arm (RR 0.30, 95% CI 0.23 to 0.39). The major adverse event associated with combination therapy was nephrotoxicity. During the past decade, once-daily administration of aminoglycosides has come into use, with similar efficacy but lower nephrotoxicity (<LINK REF="REF-Barza-1996" TYPE="REFERENCE">Barza 1996</LINK>). Most studies in our review used multiple-day administration schedules for the complete duration of antibiotic therapy or until modification. The RR of 0.30 for any nephrotoxicity that we observed may, therefore, be an overestimation. However, the RR among the few studies that did administer the aminoglycoside once daily was also highly significant in favour of monotherapy (RR 0.17, 95% CI 0.06 to 0.53).</P>
<P>A small subset of studies in our review addressed participants with Gram-positive infection, mainly <I>S aureus </I>endocarditis. No study assessed enterococcal infection specifically. In these, also, no outcome was improved by the addition of an aminoglycoside.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-12-20 14:19:10 +0000" MODIFIED_BY="Jane Cracknell">
<P>We defined all-cause mortality as the primary outcome, and most studies assessed and reported treatment failure as a main outcome. Obviously, the most significant outcome for the patient is survival following the infectious episode, and this is the ultimate goal in the treatment of sepsis. Available evidence shows that the addition of an aminoglycoside to a beta lactam does not reduce mortality. Replacing beta lactam monotherapy with a narrower-spectrum beta lactam combined with an aminoglycoside may be associated with increased mortality. Failure was commonly defined as lack of clinical improvement, deterioration, relapse and/or modifications to the antibiotic treatment. These endpoints are highly subjective and do not necessarily translate to detriments experienced by the patient. Detection bias is a concern in open trials that compared the same beta lactam and in trials comparing a 'new' broad-spectrum monotherapy versus a conventional antibiotic regimen. Thus, the advantage of monotherapy in studies comparing different beta lactams, and the opposing advantage of combination therapy in studies comparing the same beta lactam, may be largely biased. Failure was poorly correlated with mortality, despite the fact that the clinical failure definition most commonly included infection-related deaths. In 42 trials reporting both deaths and failures, the Pearson correlation coefficient was 0.36 (RR of 1.0 was assumed for studies with no events in both groups).</P>
<P>The rationale for administering combination therapy arose from in vitro studies showing synergistic bactericidal activity of specific beta lactam-aminoglycoside antibiotic combinations. Synergy has been observed for <I>P aeruginosa</I> (<LINK REF="REF-Giamarellou-1984" TYPE="REFERENCE">Giamarellou 1984</LINK>), other Gram-negative bacteria (<LINK REF="REF-Giamarellou-1986" TYPE="REFERENCE">Giamarellou 1986</LINK>; <LINK REF="REF-Klastersky-1976" TYPE="REFERENCE">Klastersky 1976</LINK>) and staphylococci (<LINK REF="REF-Sande-1975" TYPE="REFERENCE">Sande 1975</LINK>; <LINK REF="REF-Sande-1976" TYPE="REFERENCE">Sande 1976</LINK>). Assessment of antibiotic efficacy against specific infections in randomized trials must be limited to definitive treatment (randomization performed when infection is microbiologically documented) or must be performed as a subgroup analysis to assess empirical treatment (randomly assigning participants empirically and assessing those with documented infection). Eight studies assessed definitive treatment (semi-empirical studies), and most assessed empirical treatment. We did not find an advantage of combination therapy among participants with any Gram-negative infection, Gram-negative bacteraemia or <I>P aeruginosa</I> infection. Lack of data precluded the assessment of <I>P aeruginosa</I> bacteraemia. Why does synergy, observed in vitro, not translate into clinical benefit? Specific growth conditions in vitro, unattainable in vivo, may induce synergism. Pharmacokinetic and pharmacodynamic properties involving specific antibiotics, sites of infection, timing and intervals of administration may prevent synergism in vivo. Adverse events related directly to the aminoglycoside, or to the combination, may interfere with an in vivo benefit, amounting altogether to no benefit.</P>
<P>Combination therapy in endocarditis similarly relies on in vitro and in vivo data. Animal studies have shown that sterilization of cardiac vegetations may be achieved more rapidly with combination therapy (<LINK REF="REF-Sande-1975" TYPE="REFERENCE">Sande 1975</LINK>; <LINK REF="REF-Sande-1976" TYPE="REFERENCE">Sande 1976</LINK>). One clinical study included in our review showed that combination therapy shortened the duration of bacteraemia, but this comparison was performed according to the empirical antibiotic regimen, while randomization occurred empirically or semi-empirically (<LINK REF="STD-Korzeniowski-1982" TYPE="STUDY">Korzeniowski 1982</LINK>). We could not show an advantage of combination therapy by combining all trials in humans. On the contrary, all outcomes tended to favour monotherapy, although statistical significance was not reached.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-12-20 14:19:10 +0000" MODIFIED_BY="Jane Cracknell">
<P>See <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P>
<P>Among studies comparing the same beta lactam, the quality of evidence of mortality was graded as low, mainly because of imprecision. The 95% confidence intervals range from 27% improved survival to 30% higher risk of death with monotherapy. The quality of evidence for failure was graded as very low because of the indirectness of the outcome and the risk of detection bias associated with assessment of a subjective outcome in open trials (<LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>).</P>
<P>In studies using different beta lactams, the quality of evidence for mortality was low because the advantage of monotherapy was derived from studies at unclear risk of bias in relation to allocation concealment and due to suspected publication or reporting bias. The advantage of monotherapy with regard to treatment failure was graded as very low quality of evidence, again because of the indirectness of the failure outcome and the high risk of bias in non-blinded trials.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-12-20 14:19:10 +0000" MODIFIED_BY="Jane Cracknell">
<P>A major limitation of existing studies and thus of the compiled analysis is the lack of data for all-cause mortality from more than a third of included studies. This was probably not due to selective reporting bias in that all-cause mortality was not defined as an outcome in included studies. However, the funnel plot for mortality was asymmetrical. Data for subgroups most likely to benefit from combination therapy were also not available from all studies. In our analysis, we did not correct for the appropriateness of antibiotic treatment, which has been shown conclusively to correlate with survival (<LINK REF="REF-Ibrahim-2000" TYPE="REFERENCE">Ibrahim 2000</LINK>; <LINK REF="REF-Leibovici-1998" TYPE="REFERENCE">Leibovici 1998</LINK>). Data were not fully available to perform such an analysis. However, among studies comparing the same beta lactam, combination therapy by definition broadened the spectrum of coverage without improving outcomes. In studies comparing different beta lactams, an inappropriate beta lactam was used more frequently in the combination arm, which may partially explain the advantage of monotherapy.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-12-20 14:19:10 +0000" MODIFIED_BY="Jane Cracknell">
<P>Observational studies tend to show an advantage of combination therapy for severe infection caused by Gram-negative bacteria or <I>P aeruginosa</I>. Combination therapy was claimed to be superior to monotherapy in a prospective observational study of participants with <I>P aeruginosa</I> bacteraemia, but most participants in the monotherapy group received an aminoglycoside (<LINK REF="REF-Hilf-1989" TYPE="REFERENCE">Hilf 1989</LINK>). Kumar et al. conducted a large multi-centre retrospective study, including 4662 critically ill participants in the intensive care unit (ICU) with culture-positive, bacterial septic shock. In a propensity-matched analysis (1223 propensity-matched pairs), combination therapy was associated with lower mortality than monotherapy, with an overall hazard ratio for 28-day all-cause mortality of 0.77 (95% CI 0.67 to 0.88; <LINK REF="REF-Kumar-2010b" TYPE="REFERENCE">Kumar 2010b</LINK>). This included all infections (Gram-negative and Gram-positive), and any antibiotics of any class could be included in the combination and monotherapy arms. An analysis restricted to beta lactam-aminoglycosides as combination therapy showed an advantage of combination therapy, but an analysis of beta lactam-aminoglycoside versus beta lactam alone (same or different) is not presented. Bliziotis et al. compared combination therapy versus monotherapy for <I>P aeruginosa</I> bacteraemia in a retrospective cohort study and found no significant difference between the regimens, although both mortality and treatment failure were more common with monotherapy (<LINK REF="REF-Bliziotis-2011" TYPE="REFERENCE">Bliziotis 2011</LINK>). In contrast, in a prospective study of bacteraemic participants with Gram-negative bacteraemia, we found no significant difference with regard to in-hospital mortality between appropriate beta lactam monotherapy and appropriate beta lactam aminoglycoside combination therapy, both empirically and semi-empirically. Appropriate single aminoglycoside monotherapy was associated with increased mortality (<LINK REF="REF-Leibovici-1997" TYPE="REFERENCE">Leibovici 1997</LINK>). Participants included in observational studies are different from those included in randomized trials. It is possible that an effect that was not observed in randomized controlled trials exists. However, observational studies to date do not provide clear enough conclusions.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-12-20 14:19:10 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-12-20 14:19:10 +0000" MODIFIED_BY="[Empty name]">
<P>We conclude that the addition of an aminoglycoside to a beta lactam does not improve the clinical efficacy achieved with the beta lactam alone. Substituting a narrow-spectrum beta lactam with an aminoglycoside for a single broad-spectrum beta lactam will result in increased failure rates and may be associated with increased mortality. Adverse events occur more frequently with combination treatment. Short-term combination therapy for sepsis does not prevent the development of resistant bacteria, as assessed by superinfection or colonization rates following antibiotic treatment. Thus, the use of beta lactam-aminoglycoside combination therapy for sepsis should be discouraged.</P>
<P>Clinicians usually face the dilemma of selecting an antibiotic treatment on two occasions during an uncomplicated infectious episode. On the initial encounter with a patient, the clinician must prescribe empirical antibiotic treatment because the causative pathogen and its susceptibilities are generally unknown. Most studies addressed this situation, and the results show no difference in overall mortality whether monotherapy or combination therapy is used. Adverse effects, most significantly nephrotoxicity, will occur more frequently with combination therapy. If the choice is between a narrower-spectrum beta lactam combined with an aminoglycoside versus a broad-spectrum beta lactam, our results show that treatment will ultimately have to be modified more frequently if the combination is chosen. We have not identified a specific site of infection or level of disease severity for which combination treatment provides an advantage.</P>
<P>The second decision point occurs when the causative pathogen is identified. Here, the choice of antibiotic treatment is dictated by known susceptibility results. However, the question remains whether for specific bacteria, beta lactam-aminoglycoside combination treatment offers an advantage over single beta lactam treatment. We addressed this question through subgroup analyses of participants with documented infection caused by specific pathogens (Gram-negative pathogens, <I>P aeruginosa</I>, <I>S aureus</I>). In addition, several semi-empirical studies addressed this question specifically. We have not identified a specific pathogen, or pathogen group, for which combination therapy is advantageous. However, data for these subgroups are very limited.</P>
<P>Overall, appropriate beta lactam monotherapy should be used. Beta lactam-aminoglycoside combination therapy does not offer an advantage and is associated with an increased rate of adverse events.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-12-20 14:19:09 +0000" MODIFIED_BY="[Empty name]">
<P>Innovative trial designs are needed to allow the assessment of participants with severe Gram-negative infection and <I>P aeruginosa</I> bacteraemia (<LINK REF="REF-Paul-2009" TYPE="REFERENCE">Paul 2009</LINK>). Similarly, the question is still open for endocarditis caused by Gram-positive bacteria, including mainly <I>S aureus</I> and <I>Enterococcus </I>sp. (<LINK REF="REF-Leibovici-2010" TYPE="REFERENCE">Leibovici 2010</LINK>). The pragmatic randomized trial design using electronic health records might serve as a solution for identification and recruitment of a necessary sample size in multi-centred trials (<LINK REF="REF-Staa-2012" TYPE="REFERENCE">Staa 2012</LINK>).</P>
<P>Future trials should differentiate between empirical and definitive antibiotic treatment. Appropriate antibiotic treatment has been shown to significantly reduce mortality and should therefore be reported, with results adjusted. Outcomes relevant to patients, such as survival and duration of hospitalization, should be assessed. Survival, if not assessed as a primary outcome, must at least be reported as a safety measure in all clinical trials.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-12-20 14:19:09 +0000" MODIFIED_BY="[Empty name]">
<P>We would like to thank all the authors who responded to our requests for additional data (see 'unpublished data' and 'unpublished data sought but not used', 'References to studies'). Dr Solomkin (<LINK REF="STD-Solomkin-1986" TYPE="STUDY">Solomkin 1986</LINK>) and Dr Sexton (<LINK REF="STD-Sexton-1984" TYPE="STUDY">Sexton 1984</LINK>) supplied supplementary data for their studies, which were not included in the review. Dr Finer and Dr Goustas of the GlaxoSmithKline Company supplied detailed data for their study (<LINK REF="STD-Finer-1992" TYPE="STUDY">Finer 1992</LINK>). Dr Kora Huber sent completed trial results for <LINK REF="STD-Kljucar-1990" TYPE="STUDY">Kljucar 1990</LINK> and supplied requested additional information. Ms Mary Forrest (Managing Editor, <I>Journal of Chemotherapy</I>) sent several publications that were not available to us. We would also like to warmly thank Ms Rika Fujiya, who translated the Japanese studies (<LINK REF="STD-Sukoh-1994" TYPE="STUDY">Sukoh 1994</LINK>; <LINK REF="STD-Takamoto-1994" TYPE="STUDY">Takamoto 1994</LINK>).</P>
<P>We thank Dr Vittoria Lutje, Dr Harriet G. MacLehose and Ms Rieve Robb (Managing Editor) of the Cochrane Infectious Diseases Group. We thank Dr Harald Herkner, Prof Nathan Pace, Kathie Godfrey, Janet Wale and Jane Cracknell (Managing Editor) of the Cochrane Anaesthesia Review Group. Both groups supported and provided helpful revisions for this review.</P>
<P>This review was initially developed within the Infectious Diseases Group and was supported by a grant from the Department for International Development, UK. The review was transferred to the Anaesthesia Group in May 2005.</P>
<P>Ishay Silbiger participated in the first version of this review: applied inclusion and exclusion criteria and performed risk of bias assessment, data extraction and analysis.</P>
<P>Karla Soares-Weiser participated in the first version of this review: assisted with inclusion and exclusion of studies; performed quality assessment, data extraction and analysis; and assisted with the writing and reviewed all versions of the protocol and the review. We thank Karla for her mentorship on systematic reviews and for guidance provided on the initial protocol and on initiation of this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-12-20 14:19:09 +0000" MODIFIED_BY="Jane Cracknell">
<P>Mical Paul: none known.</P>
<P>Adi Lador: none known.</P>
<P>Simona Grozinsky-Glasberg: none known.</P>
<P>Leonard Leibovici: none known.</P>
<P>We certify that we have no affiliations with or involvement in any organization or entity with a direct financial interest in the subject matter of this review (e.g. employment, consultancy, stock ownership, honoraria, expert testimony).</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-12-20 15:51:16 +0000" MODIFIED_BY="[Empty name]">
<P>Mical Paul (MP): performed the search and scanned abstracts; retrieved full-text articles and applied inclusion and exclusion criteria; performed risk of bias assessment, data extraction and analysis. MP communicated with authors and wrote the protocol and the review.</P>
<P>Adi Lador (AL): performed an update search (2011) and scanned the new abstracts; retrieved full-text articles and applied inclusion and exclusion criteria; performed risk of bias assessment, data extraction and analysis for the updated search; and wrote the updated review.</P>
<P>Simona Grozinsky-Glasberg (SG-G): extracted the data for the first version of this review; and reviewed and approved the final version of the updated review.</P>
<P>Leonard Leibovici (LL): assisted with inclusion and exclusion of studies; performed quality assessment, data extraction and analysis; assisted with communication with authors; and assisted with the writing and review of all versions of the protocol and the review.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-12-20 15:54:38 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abrams-1979" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Abrams 1979" YEAR="1979">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abrams B, Sklaver A, Hoffman T, Greenman R</AU>
<TI>Single or combination therapy of staphylococcal endocarditis in intravenous drug abusers</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1979</YR>
<VL>90</VL>
<NO>5</NO>
<PG>789-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aguilar-1992" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Aguilar 1992" YEAR="1992">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ramirez de Aguilar R</AU>
<TI>Clinical trial on efficacy and safety of ceftizoxime compared with penicillin-gentamicin of managing of adult severe infections</TI>
<TO>Estudio clinico para determinar la eficacia y seguridad de ceftizoxima en comparacion con penicilina-gentamicina en el manejo de las infecciones graves del adulto</TO>
<SO>Compend Invest Clin Latinoam</SO>
<YR>1992</YR>
<VL>12</VL>
<NO>3</NO>
<PG>75-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Alvarez_x002d_Lerma-2001a" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Alvarez-Lerma 2001a" YEAR="2001">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Alvarez Lerma F on behalf of the Serious Infection Study Group</AU>
<TI>Efficacy of meropenem as monotherapy in the treatment of ventilator- associated pneumonia</TI>
<SO>Journal of Chemotherapy</SO>
<YR>2001</YR>
<VL>13</VL>
<NO>1</NO>
<PG>70-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alvarez-Lerma F</AU>
<TI>[Efficacy of monotherapy by meropenem in ventilator-associated pneumonia]</TI>
<SO>Antibiotiki i khimioterapiia</SO>
<YR>2001</YR>
<VL>46</VL>
<NO>12</NO>
<PG>42-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Arich-1987" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Arich 1987" YEAR="1987">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arich C, Gouby A, Bengler C, Ardilouze JL, Dubois A, Joubert P, et al</AU>
<TI>[Comparison of the efficacy of cefotaxime alone and the combination cefazolin-tobramycin in the treatment of enterobacterial septicemia] In French</TI>
<SO>Pathologie Biologie (Paris)</SO>
<YR>1987</YR>
<VL>35</VL>
<NO>5</NO>
<PG>613-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Banasal-2006" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="[Empty name]" NAME="Banasal 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bansal A, Singhi SC, Jayashree M</AU>
<TI>Penicillin and gentamicin therapy vs amoxicillin/clavulanate in severe hypoxemic pneumonia</TI>
<SO>Indian Journal of Pediatrics</SO>
<YR>April 2006</YR>
<VL>73</VL>
<NO>4</NO>
<PG>305-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bergeron-1988" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="Jane Cracknell" NAME="Bergeron 1988" YEAR="1988">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bergeron MG, Mendelson J, Harding GK, Mandell L, Fong IW, Rachlis A, et al</AU>
<TI>Cefoperazone compared with ampicillin plus tobramycin for severe biliary tract infections</TI>
<SO>Antimicrobials Agents and Chemotherapy</SO>
<YR>1988</YR>
<VL>32</VL>
<NO>8</NO>
<PG>1231-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bergeron MG, Mendelson J, Harding GK, Mandell L, Fong IW, Rachlis A, et al</AU>
<TI>Cefoperazone compared with ampicillin plus tobramycin for severe biliary tract infections</TI>
<SO>13th International Congress of Chemotherapy</SO>
<YR>1983</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Biglino-1991" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Biglino 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Biglino A, Bonasso M, Gioannini P</AU>
<TI>Imipenem/cilastatin as empirical treatment of severe infections in compromised patients</TI>
<SO>Journal of Chemotherapy</SO>
<YR>1991</YR>
<VL>3 Suppl 1</VL>
<PG>208-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brown-1984" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="Jane Cracknell" NAME="Brown 1984" YEAR="1984">
<REFERENCE MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brown RB, Lemeshow S, Teres D</AU>
<TI>Moxalactam vs carbenicillin plus tobramycin: treatment of nosocomial gram-negative bacillary pneumonias in non-neutropenic patients</TI>
<SO>Current Therapeutic Research, Clinical and Experimental</SO>
<YR>1984</YR>
<VL>36</VL>
<NO>3</NO>
<PG>557-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carbon-1987" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Carbon 1987" YEAR="1987">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carbon C, Auboyer C, Becq Giraudon B, Bertrand P, Gallais H, Mouton Y, et al</AU>
<TI>Cefotaxime (C) vs cefotaxime + amikacin (C + A) in the treatment of septicemia due to enterobacteria: a multicenter study</TI>
<SO>Chemioterapia</SO>
<YR>1987</YR>
<VL>6</VL>
<NO>2 Suppl</NO>
<PG>367-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Cardozo-2001" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="Jane Cracknell" NAME="Cardozo 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cardozo M, Basualdo W, Martinez R, Matsumura K, Gonzalez-Cabello M, Navarro D, et al</AU>
<TI>Evolution of the association amoxicillin/sulbactam to a amoxicillin/sulbactam more gentamicins in children with peritonitis of appendicular origin</TI>
<TO>Evaluacion de la asociacion amoxicilina/sulbactam frente a amoxicilina/sulbactam mas gentamicina en ninos con peritonitis de origen apendicular</TO>
<SO>Pediatría (Asunción)</SO>
<YR>2001</YR>
<VL>28</VL>
<NO>2</NO>
<PG>15-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Cometta-1994" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Cometta 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cometta A, Baumgartner JD, Lew D, Zimmerli W, Pittet D, Chopart P, et al</AU>
<TI>Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1994</YR>
<VL>38</VL>
<NO>6</NO>
<PG>1309-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Iten A, Cometta A, Eggimann P, Siegrist H, Francioli P</AU>
<TI>The addition of netilmicin (NET) to imipenem (IMIP) does not prevent the emergence of bacteria resistant (R) to IMIP during treatment (ttt) of severe infections</TI>
<SO>32nd Interscience Conference on Antimicrobial Agents and Chemotherapy</SO>
<YR>1992</YR>
<VL>Abstract no. 522</VL>
<PG>198</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cone-1985" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Cone 1985" YEAR="1985">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cone LA, Woodard DR, Stoltzman DS, Byrd RG</AU>
<TI>Ceftazidime versus tobramycin-ticarcillin in the treatment of pneumonia and bacteremia</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1985</YR>
<VL>28</VL>
<NO>1</NO>
<PG>33-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Cone LA, Woodard DR, Stoltzman DS, Byrd RG</AU>
<TI>Ceftazidime versus tobramycin-ticarcillin in the treatment of pneumonia and bacteremia</TI>
<SO>23rd Interscience Conference Antimicrobial Agents and Chemotherapy</SO>
<YR>1983</YR>
<VL>Abstract no. 843</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coppens-1983" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Coppens 1983" YEAR="1983">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coppens L, Hanson B, Klastersky J</AU>
<TI>Therapy of staphylococcal infections with cefamandole or vancomycin alone or with a combination of cefamandole and tobramycin</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1983</YR>
<VL>23</VL>
<NO>1</NO>
<PG>36-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-D_x0027_Antonio-1992" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="D'Antonio 1992" YEAR="1992">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>D'Antonio D, Fioritoni G, Iacone A, Dell'Isola M, Natale D, D'Arcangelo L, et al</AU>
<TI>Randomized comparison of ceftriaxone versus ceftriaxone plus amikacin for the empirical treatment of infections in patients with altered host defense: microbiological and clinical evaluation</TI>
<SO>Chemotherapy</SO>
<YR>1992</YR>
<VL>38</VL>
<NO>6</NO>
<PG>420-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Damas-2006" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="[Empty name]" NAME="Damas 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Damas P, Garweg C, Monchi M, Nys M, Canivet JL, Ledoux D, et al</AU>
<TI>Combination therapy versus monotherapy: a randomised pilot study on the evolution of inflammatory parameters after ventilator associated pneumonia</TI>
<SO>Critical Care</SO>
<YR>2006</YR>
<VL>10</VL>
<NO>2</NO>
<PG>R52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Duff-1982" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Duff 1982" YEAR="1982">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duff P, Keiser JF</AU>
<TI>A comparative study of two antibiotic regimens for the treatment of operative site infections</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1982</YR>
<VL>142</VL>
<NO>8</NO>
<PG>996-1003</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dupont-2000" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Dupont 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Dupont H, Carbon C, Carlet J, and the Severe Generalized Peritonitis Study Group</AU>
<TI>Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial</TI>
<SO>38th Interscience Conference on Antimicrobial Agents and Chemotherapy</SO>
<YR>1998</YR>
<VL>Abstract MN-48</VL>
<PG>602</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dupont H, Carbon C, Carlet J, for The Severe Generalized Peritonitis Study Group</AU>
<TI>Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2000</YR>
<VL>44</VL>
<NO>8</NO>
<PG>2028-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Felisart-1985" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Felisart 1985" YEAR="1985">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Felisart J, Rimola A, Arroyo V, Perez-Ayuso RM, Quintero E, Gines P, et al</AU>
<TI>Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections</TI>
<SO>Hepatology</SO>
<YR>1985</YR>
<VL>5</VL>
<NO>3</NO>
<PG>457-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Figueroa_x002d_Damian-1996" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NAME="Figueroa-Damian 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Figueroa-Damian R, Villagrana-Zesati R, San Martin-Herrasti JM, Arredondo-Garcia JL</AU>
<TI>Comparison of the therapeutic efficacy of the piperacillin/tazobactam combination vs. ampicillin and gentamycin in the management of post-cesarean endometritis</TI>
<TO>Comparación de la eficacia terapéutica de piperacilina\tazobactam vs ampicilina más gentamicina en el tratamiento de endometritis poscesárea</TO>
<SO>Ginecologia y Obstetricia de Mexico</SO>
<YR>1996</YR>
<VL>64</VL>
<NO>5</NO>
<PG>214-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Finer-1992" NAME="Finer 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Finer N, Goustas P</AU>
<TI>Ceftazidime versus aminoglycoside and (ureido)penicillin combination in the empirical treatment of serious infection</TI>
<SO>Journal of the Royal Society of Medicine</SO>
<YR>1992</YR>
<VL>85</VL>
<NO>9</NO>
<PG>530-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garc_x00ed_a-Ram_x00ed_rez-1999" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="[Empty name]" NAME="García Ramírez 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luis Alberto GR, Enrique RJ, Manuel de Jesus UV, Ana Patricia MB, Jose Javier LN, Jaime MM</AU>
<TI>Ceftazidime vs crystalline sodium penicillin and amikacin in the treatment of nosocomial pneumonia</TI>
<TO>Ceftazidima vs penicilina sodica cristalina y amikacina en el manejo de la neumonia nosocomial</TO>
<SO>Medicina interna Mexico</SO>
<YR>1999</YR>
<VL>15</VL>
<NO>4</NO>
<PG>135-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerecht-1989" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Gerecht 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerecht WB, Henry NK, Hoffman WW, Muller SM, LaRusso NF, Rosenblatt JE, et al</AU>
<TI>Prospective randomized comparison of mezlocillin therapy alone with combined ampicillin and gentamicin therapy for patients with cholangitis</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1989</YR>
<VL>149</VL>
<NO>6</NO>
<PG>1279-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Gomez-1990a" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Gomez 1990a" YEAR="1990">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gomez J, Moldenauer F, Ruiz G, Canteras M, Redondo C, Molina B, et al</AU>
<TI>[Monotherapy (ceftazidime) versus combination therapy (cefradine + amikacin) in gram-negative bacteremia. A prospective, randomized study, 1987] In Spanish</TI>
<SO>Revista Espanola de Quimioterapia</SO>
<YR>1990</YR>
<VL>3</VL>
<NO>1</NO>
<PG>35-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hasali-2005" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="[Empty name]" NAME="Hasali 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hasali M, Ibrahim M, Sulaiman S, Ahmad Z, Hasali J</AU>
<TI>A clinical and economic study of community-acquired pneumonia between single versus combination therapy</TI>
<SO>Pharmacy World and Science</SO>
<YR>2005</YR>
<VL>27</VL>
<NO>3</NO>
<PG>249-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Havig-1973" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Havig 1973" YEAR="1973">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Havig O, Hertzberg J</AU>
<TI>Effect of ampicillin, chloramphenicol, and penicillin-streptomycin in acute cholecystitis</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>1973</YR>
<VL>8</VL>
<NO>1</NO>
<PG>55-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Havig O, Hertzberg J</AU>
<TI>[Effect of ampicillin, chloramphenicol and penicillin + streptomycin in the treatment of acute cholecystitis]</TI>
<SO>Tidsskrift for den Norske laegeforening</SO>
<YR>1975</YR>
<VL>95</VL>
<NO>5</NO>
<PG>298-300</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Hoepelman-1988" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Hoepelman 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoepelman IM, Rozenberg-Arska M, Verhoef J</AU>
<TI>Comparative study of ceftriaxone monotherapy versus a combination regimen of cefuroxime plus gentamicin for treatment of serious bacterial infections: the efficacy, safety and effect on fecal flora</TI>
<SO>Chemotherapy</SO>
<YR>1988</YR>
<VL>34</VL>
<NO>Suppl 1</NO>
<PG>21-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hoepelman IM, Rozenberg-Arska M, Verhoef J</AU>
<TI>Comparison of once daily ceftriaxone with gentamicin plus cefuroxime for treatment of serious bacterial infections</TI>
<SO>27th Interscience Conference on Antimicrobials Agents and Chemotherapy</SO>
<YR>1987</YR>
<VL>Abstract no. 89</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hoepelman IM, Rozenberg-Arska M, Verhoef J</AU>
<TI>Comparison of once daily ceftriaxone with gentamicin plus cefuroxime for treatment of serious bacterial infections</TI>
<SO>Lancet</SO>
<YR>1988</YR>
<VL>1</VL>
<NO>8598</NO>
<PG>1305-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Holloway--1985" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Holloway  1985" YEAR="1985">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holloway WJ</AU>
<TI>Treatment of infections in hospitalized patients with ticarcillin plus clavulanic acid. A comparative study</TI>
<SO>American Journal of Medicine</SO>
<YR>1985</YR>
<VL>79</VL>
<NO>5B</NO>
<PG>168-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iakovlev-1998" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Iakovlev 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iakovlev SV, Iakovlev VP, Derevianko, II, Kira EF, and the Meropenem Study Group</AU>
<TI>[Multicenter open randomized trial of meropenem in comparison to ceftazidime and amikacin used in combination in severe hospital infections]. In Russian</TI>
<SO>Antibiotiki i Khimioterapiia</SO>
<YR>1998</YR>
<VL>43</VL>
<NO>1</NO>
<PG>15-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Jaspers-1998" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Jaspers 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jaspers CA, Kieft H, Speelberg B, Buiting A, van Marwijk Kooij M, Ruys GJ, et al</AU>
<TI>Meropenem versus cefuroxime plus gentamicin for treatment of serious infections in elderly patients</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1998</YR>
<VL>42</VL>
<NO>5</NO>
<PG>1233-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klastersky-1973" NAME="Klastersky 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klastersky J, Cappel R, Daneau D</AU>
<TI>Therapy with carbenicillin and gentamicin for patients with cancer and severe infections caused by gram-negative rods</TI>
<SO>Cancer</SO>
<YR>1973</YR>
<VL>31</VL>
<NO>2</NO>
<PG>331-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Kljucar-1990" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Kljucar 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Kljucar S, Heimesaat M, von Pritzbuer E, Bauernfeind A</AU>
<TI>Comparative clinical trial with ceftazidime (CAZ) versus ceftazidime plus tobramycin (TOB) versus azlocillin (AZL) plus tobramycin in ventilated patients with nosocomial lower respiratory tract infections (LRTI)</TI>
<SO>30th Interscience Conference on Antimicrobial Agents and Chemotherapy</SO>
<YR>1990</YR>
<PG>Abtract no. 953</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kljucar S, Heimesaat M, von Pritzbuer E, Olms K</AU>
<TI>[Ceftazidime with and without tobramycin versus azlocillin plus tobramycin in the therapy of bronchopulmonary infections in intensive care patients]. In German</TI>
<SO>Infection</SO>
<YR>1987</YR>
<VL>15</VL>
<NO>Suppl 4</NO>
<PG>S185-S191</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koehler-1990" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Koehler 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koehler CO, Arnold H</AU>
<TI>Controlled clinical study of ceftazidime (3 x 1 g daily) versus piperacillin + tobramycin in patients with nosocomial pneumonia</TI>
<SO>International Journal of Experimental and Clinical Chemotherapy</SO>
<YR>1990</YR>
<VL>3</VL>
<NO>4</NO>
<PG>211-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Korzeniowski-1982" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="Jane Cracknell" NAME="Korzeniowski 1982" YEAR="1982">
<REFERENCE MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Korzeniowski O, Sande MA</AU>
<TI>Combination antimicrobial therapy for <I>Staphylococcus aureus</I> endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1982</YR>
<VL>97</VL>
<NO>4</NO>
<PG>496-503</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Landau-1990" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Landau 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Landau Z, Feld S, Krupsky M</AU>
<TI>[Ceftriaxone or combined cefazolin-gentamicin for complicated urinary tract infections]. In Hebrew</TI>
<SO>Harefuah</SO>
<YR>1990</YR>
<VL>118</VL>
<NO>3</NO>
<PG>152-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Limson-1988" NAME="Limson 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Limson BM, Navarro Almario E, Litam P, Que E, Kua LT</AU>
<TI>Ceftazidime monotherapy compared with amikacin/ticarcillin combination therapy in severe infections</TI>
<SO>Journal of the Philippines Medical Association</SO>
<YR>1988</YR>
<VL>64</VL>
<NO>1</NO>
<PG>33-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Limson BM, Navarro Almario E, Litam P, Que E, Kua LT</AU>
<TI>Ceftazidime versus a combination of amikacin and ticarcillin in the treatment of severe infections</TI>
<SO>Clinical Therapeutics</SO>
<YR>1988</YR>
<VL>10</VL>
<NO>5</NO>
<PG>589-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Mandell-1987" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="Jane Cracknell" NAME="Mandell 1987" YEAR="1987">
<REFERENCE MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mandell LA, Nicolle LE, Ronald AR, Duperval R, Robson HG, Feld R, et al</AU>
<TI>A multicentre prospective randomized trial comparing ceftazidime with cefazolin/tobramycin in the treatment of hospitalized patients with non-pneumococcal pneumonia</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1983</YR>
<VL>12</VL>
<NO>Suppl A</NO>
<PG>9-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mandell LA, Nicolle LE, Ronald AR, Landis SJ, Duperval R, Harding GK, et al</AU>
<TI>A prospective randomized trial of ceftazidime versus cefazolin/tobramycin in the treatment of hospitalized patients with pneumonia</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1987</YR>
<VL>20</VL>
<NO>1</NO>
<PG>95-107</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martin-1991" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Martin 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martin PY, Unger PF, Auckenthaler R, Waldvogel FA</AU>
<TI>Efficacy and costs of treatment with ceftriaxone compared to ampicillin-gentamycin in acute pyelonephritis. In French</TI>
<TO>Efficacite et cout d'un traitement de ceftriaxone compare a l'ampicilline-gentamicine dans les pyelonehrites aigues</TO>
<SO>Reveu Medicale Suisse Romande</SO>
<YR>1991</YR>
<VL>111</VL>
<NO>7</NO>
<PG>609-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-McCormick-1997" NAME="McCormick 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCormick PA, Greenslade L, Kibbler CC, Chin JK, Burroughs AK, McIntyre N</AU>
<TI>A prospective randomized trial of ceftazidime versus netilmicin plus mezlocillin in the empirical therapy of presumed sepsis in cirrhotic patients</TI>
<SO>Hepatology</SO>
<YR>1997</YR>
<VL>25</VL>
<NO>4</NO>
<PG>833-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Mergoni-1987" NAME="Mergoni 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mergoni M, Stocchetti N, De Cristofaro A, Antonioni M, Zuccoli P</AU>
<TI>Azlocillin versus azlocillin plus amikacin in the treatment of severe infections in intensive care unit patients</TI>
<SO>Chemioterapia</SO>
<YR>1987</YR>
<VL>6</VL>
<NO>4</NO>
<PG>286-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moreno-1997" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Moreno 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moreno A, Vilardell J, Ricart MJ, Claramonte X, Campistol JM, Oppenheimer F</AU>
<TI>Efficacy of several empirical antibacterial treatment regimens in renal transplant patients with fever</TI>
<TO>Eficacia de varias pautas de tratamiento empirico antibacteriano en pacientes receptores de trasplante renal con fiebre</TO>
<SO>Revista Espanola De Quimioterapia</SO>
<YR>1997</YR>
<VL>10</VL>
<NO>2</NO>
<PG>138-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mouton-1990" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Mouton 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mouton Y, Deboscker Y, Bazin C, Fourrier F, Moulront S, Philippon A, et al</AU>
<TI>[Prospective, randomized, controlled study of imipenem-cilastatin versus cefotaxime-amikacin in the treatment of lower respiratory tract infection and septicemia at intensive care units], in French</TI>
<SO>Presse Medicale</SO>
<YR>1990</YR>
<VL>19</VL>
<NO>13</NO>
<PG>607-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mouton-1995" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Mouton 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mouton YJ, Beuscart C, and the Meropenem Study Group</AU>
<TI>Empirical monotherapy with meropenem in serious bacterial infections</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1995</YR>
<VL>36</VL>
<NO>Suppl A</NO>
<PG>145-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muller-1987" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Muller 1987" YEAR="1987">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muller EL, Pitt HA, Thompson JE Jr, Doty JE, Mann LL, Manchester B</AU>
<TI>Antibiotics in infections of the biliary tract</TI>
<SO>Surgery, Gynecology &amp; Obstetrics</SO>
<YR>1987</YR>
<VL>165</VL>
<NO>4</NO>
<PG>285-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naime-Libien-1992" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="Jane Cracknell" NAME="Naime Libien 1992" YEAR="1992">
<REFERENCE MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naime LJ, Vigueras RA, Sanchez DG, Abraham JA</AU>
<TI>Clinical study to evaluate efficacy and safety of ceftizoxime compared vs penicillin-gentamicin fixed combination in the treatment of severe respiratory infections</TI>
<TO>Estudio clinico para determinar la eficacia y seguridad de ceftizoxima en comparacion con la asociacion penicilina gentamicina en el tratamiento de las infecciones respiratorias graves</TO>
<SO>Compend Invest Clin Latinoam</SO>
<YR>1992</YR>
<VL>12</VL>
<NO>2</NO>
<PG>42-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Piccart-1984" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Piccart 1984" YEAR="1984">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Piccart M, Klastersky J, Meunier F, Lagast H, Van Laethem Y, Weerts D</AU>
<TI>Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1984</YR>
<VL>26</VL>
<NO>6</NO>
<PG>870-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rapp-1984" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Rapp 1984" YEAR="1984">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Rapp RP, Young B, Foster TS, Tibbs PA, O'Neal W</AU>
<TI>Ceftazidime versus tobramycin/ticarcillin in treating hospital acquired pneumonia and bacteremia</TI>
<SO>International Conference on Antimicrobial Agents and Chemotherapy</SO>
<YR>1983</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rapp RP, Young B, Foster TS, Tibbs PA, O'Neal W</AU>
<TI>Ceftazidime versus tobramycin/ticarcillin in treating hospital acquired pneumonia and bacteremia</TI>
<SO>Pharmacotherapy</SO>
<YR>1984</YR>
<VL>4</VL>
<NO>4</NO>
<PG>211-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Rasmussen-1986" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Rasmussen 1986" YEAR="1986">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rasmussen D, Bremmelgaard A, Rasmussen F, Thorup J</AU>
<TI>Treatment of serious urological infections with cefotaxime compared to ampicillin plus netilmicin</TI>
<SO>Danish Medical Bulletin</SO>
<YR>1986</YR>
<VL>33</VL>
<NO>1</NO>
<PG>49-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Ribera-1996" MODIFIED="2013-12-16 05:26:52 +0000" MODIFIED_BY="Jane Cracknell" NAME="Ribera 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-12-16 05:26:52 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ribera E, Gomez-Jimenez J, Cortes E, del Valle O, Planes A, Gonzalez-Alujas T, et al</AU>
<TI>Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided <I>Staphylococcus aureus</I> endocarditis. A randomized, controlled trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1996</YR>
<VL>125</VL>
<NO>12</NO>
<PG>969-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Rubinstein-1995" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Rubinstein 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rubinstein E, Lode H, Grassi C, Castelo A, Ward K, Alanko K, et al (Antibiotic Study Group)</AU>
<TI>Ceftazidime monotherapy vs. Ceftriaxone/tobramycin for serious hospital- acquired gram-negative infections.</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1995</YR>
<VL>20</VL>
<NO>5</NO>
<PG>1217-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sage-1987" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Sage 1987" YEAR="1987">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sage R, Nazareth B, Noone P</AU>
<TI>A prospective randomised comparison of cefotaxime vs. netilmicin vs. cefotaxime plus netilmicin in the treatment of hospitalised patients with serious sepsis</TI>
<SO>Scandinavian Journal of Infectious Diseases</SO>
<YR>1987</YR>
<VL>19</VL>
<NO>3</NO>
<PG>331-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Sandberg-1997" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Sandberg 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sandberg T, Alestig K, Eilard T, Ek E, Hebelka M, Johansson E, et al</AU>
<TI>Aminoglycosides do not improve the efficacy of cephalosporins for treatment of acute pyelonephritis in women</TI>
<SO>Scandinavian Journal of Infectious Diseases</SO>
<YR>1997</YR>
<VL>29</VL>
<NO>2</NO>
<PG>175-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanfilippo-1989" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Sanfilippo 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanfilippo JS, Schikler KN</AU>
<TI>Mezlocillin versus penicillin and tobramycin in adolescent pelvic inflammatory disease: A prospective study</TI>
<SO>International Pediatrics</SO>
<YR>1989</YR>
<VL>4</VL>
<NO>1</NO>
<PG>53-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Sculier-1982" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Sculier 1982" YEAR="1982">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sculier JP, Coppens L, Klastersky J</AU>
<TI>Effectiveness of mezlocillin and endotracheally administered sisomicin with or without parenteral sisomicin in the treatment of Gram-negative bronchopneumonia</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1982</YR>
<VL>9</VL>
<NO>1</NO>
<PG>63-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sexton-1998" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Sexton 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sexton DJ, Tenenbaum MJ, Wilson WR, Steckelberg JM, Tice AD, Gilbert D, et al</AU>
<TI>Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Endocarditis Treatment Consortium Group</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1998</YR>
<VL>27</VL>
<NO>6</NO>
<PG>1470-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sieger-1997" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Sieger 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sieger B, Berman SJ, Geckler RW, Farkas SA, for the Meropenem Lower Respiratory Infection Group</AU>
<TI>Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study</TI>
<SO>Critical Care Medicine</SO>
<YR>1997</YR>
<VL>25</VL>
<NO>10</NO>
<PG>1663-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sieger B, Geckler RW</AU>
<TI>A comparison of meropenem and ceftazidime plus tobramycin in the treatment of hospital-acquired lower respiratory tract infections</TI>
<SO>33rd Interscience Conference on Antimicrobials Agents and Chemotherapy</SO>
<YR>1993</YR>
<VL>Abstract no. 640</VL>
<PG>236</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Smith-1984" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Smith 1984" YEAR="1984">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moore RD, Smith CR, Holloway JJ, Lietman PS</AU>
<TI>Cefotaxime vs nafcillin and tobramycin for the treatment of serious infection. Comparative cost-effectiveness</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1986</YR>
<VL>146</VL>
<NO>6</NO>
<PG>1153-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moore RD, Smith CR, Lietman PS</AU>
<TI>Increased risk of renal dysfunction due to interaction of liver disease and aminoglycosides</TI>
<SO>American Journal of Medicine</SO>
<YR>1986</YR>
<VL>80</VL>
<NO>6</NO>
<PG>1093-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Smith CR, Ambinder R, Lipsky JJ, Petty BG, Israel E, Levitt R, et al</AU>
<TI>Cefotaxime compared with nafcillin plus tobramycin for serious bacterial infections. A randomized, double-blind trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1984</YR>
<VL>101</VL>
<NO>4</NO>
<PG>469-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Speich-1998" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Speich 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Speich R, Imhof E, Vogt M, Grossenbacher M, Zimmerli W</AU>
<TI>Efficacy, safety, and tolerance of piperacillin/tazobactam compared to co-amoxiclav plus an aminoglycoside in the treatment of severe pneumonia</TI>
<SO>European Journal of Clinical Microbiology and Infectious Diseases</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>5</NO>
<PG>313-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stille-1992" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Stille 1992" YEAR="1992">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stille W, Shah PM, Ullmann U, Hoffstedt B, Kreisl C, Bommersbach B, et al. For the German and Austrian Imipenem/Cilastatin Study Group</AU>
<TI>Randomized multicenter clinical trial with imipenem/cilastatin versus cefotaxime/gentamicin in the treatment of patients with non-life-threatening infections</TI>
<SO>European Journal of Clinical Microbiology and Infectious Diseases</SO>
<YR>1992</YR>
<VL>11</VL>
<NO>8</NO>
<PG>683-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Sukoh-1994" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Sukoh 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sukoh M, Inoue T, Morita Y, Ito K, Togano Y, Yamanaka K, et al</AU>
<TI>[Clinical evaluation of combination therapy of sulbactam/cefoperazone and aminoglycoside in respiratory tract infections]. In Japanese</TI>
<SO>Japanese Journal of Antibiotics</SO>
<YR>1994</YR>
<VL>47</VL>
<NO>2</NO>
<PG>170-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Takamoto-1994" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Takamoto 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Takamoto M, Ishibashi T, Toyoshima H, Tanaka H, Tamaru N, Watanabe K, et al</AU>
<TI>[Imipenem/cilastatin sodium alone or combined with amikacin sulfate in respiratory infections]. In Japanese</TI>
<SO>Japanese Journal of Antibiotics</SO>
<YR>1994</YR>
<VL>47</VL>
<NO>9</NO>
<PG>1131-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thompson--1990" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Thompson  1990" YEAR="1990">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thompson JE Jr, Pitt HA, Doty JE, Coleman J, Irving C</AU>
<TI>Broad spectrum penicillin as an adequate therapy for acute cholangitis</TI>
<SO>Surgery, Gynecology &amp; Obstetrics</SO>
<YR>1990</YR>
<VL>171</VL>
<NO>4</NO>
<PG>275-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thompson-1993" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Thompson 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thompson JE Jr, Bennion RS, Roettger R, Lally KP, Hopkins JA, Wilson SE</AU>
<TI>Cefepime for infections of the biliary tract</TI>
<SO>Surgery, Gynecology &amp; Obstetrics</SO>
<YR>1993</YR>
<VL>177</VL>
<NO>Suppl</NO>
<PG>30-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trujillo-1992" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Trujillo 1992" YEAR="1992">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zavala Trujillo I</AU>
<TI>Research on efficacy and safety of ceftizoxime in treating lower respiratory tract and skin and soft tissues infections</TI>
<TO>Busqueda de la eficacia y seguridad de ceftizoxima en el tratamiento de infecciones del tracto respiratorio inferior y de la piel y de los tejidos blandos</TO>
<SO>Compend Invest Clin Latinoam</SO>
<YR>1992</YR>
<VL>12</VL>
<NO>2</NO>
<PG>31-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vergnon-1985" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="Jane Cracknell" NAME="Vergnon 1985" YEAR="1985">
<REFERENCE MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vergnon JM, Vincent M, Ros A, Brun Y, Brune J</AU>
<TI>[Comparative clinical trial of cefoperazone versus ampicillin + tobramycin in severe bronchopulmonary and pleural infectious pathology]. In French</TI>
<SO>Revue de Pneumologie Clinique</SO>
<YR>1985</YR>
<VL>41</VL>
<NO>3</NO>
<PG>205-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Verzasconi-1995" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Verzasconi 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Verzasconi R, Rodoni P, Monotti R, Marone C, Mombelli G</AU>
<TI>[Amoxicillin and clavulanic acid versus amoxicillin plus gentamicin in the empirical initial treatment of urinary tract infections in hospitalized patients] [In German]</TI>
<SO>Schweizerische Medizinische Wochenschrift</SO>
<YR>1995</YR>
<VL>125</VL>
<NO>33</NO>
<PG>1533-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Warren-1983" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Warren 1983" YEAR="1983">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Warren JW, Miller EH Jr, Fitzpatrick B, DiFranco DE, Caplan ES, Tenney JH, et al</AU>
<TI>A randomized, controlled trial of cefoperazone vs. cefamandole- tobramycin in the treatment of putative, severe infections with gram- negative bacilli</TI>
<SO>Reviews in Infectious Diseases</SO>
<YR>1983</YR>
<VL>5</VL>
<NO>Suppl 1</NO>
<PG>S173-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wiecek-1986" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="Jane Cracknell" NAME="Wiecek 1986" YEAR="1986">
<REFERENCE MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wiecek A, Kokot F, Andrzejowska H, Grzeszczak W</AU>
<TI>[Clinical evaluation of ceftazidime and the combined administration of cefotaxime and tobramycin in the treatment of urinary tract infections. Prospective and randomized studies] In Polish</TI>
<SO>Polski Tygodnik Lekarski</SO>
<YR>1986</YR>
<VL>41</VL>
<NO>39</NO>
<PG>1242-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Wing-1998" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Wing 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wing DA, Hendershott CM, Debuque L, Millar LK</AU>
<TI>A randomized trial of three antibiotic regimens for the treatment of pyelonephritis in pregnancy</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>1998</YR>
<VL>92</VL>
<NO>2</NO>
<PG>249-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Yellin-1993" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Yellin 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yellin AE, Berne TV, Appleman MD, Heseltine PN, Gill MA, Okamoto MP, et al</AU>
<TI>A randomized study of cefepime versus the combination of gentamicin and mezlocillin as an adjunct to surgical treatment in patients with acute cholecystitis</TI>
<SO>Surgery, Gynecology &amp; Obstetrics</SO>
<YR>1993</YR>
<VL>177</VL>
<NO>Suppl</NO>
<PG>23-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Alvarez_x002d_Lerma-2001b" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Alvarez-Lerma 2001b" YEAR="2001">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alvarez-Lerma F, Insausti-Ordenana J, Jorda-Marcos R, Maravi-Poma E, Torres-Marti A, Nava J, et al</AU>
<TI>Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial</TI>
<SO>Intensive Care Medicine</SO>
<YR>2001</YR>
<VL>27</VL>
<NO>3</NO>
<PG>493-502</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Badaro-2002" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Badaro 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Badaro R, Molinar F, Seas C, Stamboulian D, Mendonca J, Massud J, et al</AU>
<TI>A multicenter comparative study of cefepime versus broad-spectrum antibacterial therapy in moderate and severe bacterial infections</TI>
<SO>Brazilian Journal of Infectious Diseases</SO>
<YR>2002</YR>
<VL>6</VL>
<NO>5</NO>
<PG>206-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Benlloch-1995" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Benlloch 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benlloch C, Costa E, Segarra V, Velazquez JA, Ruiz CS</AU>
<TI>Systemic antibiotherapy in acute appendicitis. Comparison of three antibiotic regimes</TI>
<TO>Antibioterapia sistemica en apendicitis aguda. Comparacion entre tres pautas antibioticas</TO>
<SO>Acta Pediatrica Espanola</SO>
<YR>1995</YR>
<VL>53</VL>
<NO>6</NO>
<PG>367-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blumer-2003" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="Dolores Matthews" NAME="Blumer 2003" YEAR="">
<REFERENCE MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="Dolores Matthews" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Blumer JL, Minkwitz M, Saiman L, San Gabriel P, Iaconis J, Melnick D</AU>
<TI>Meropenem (MEM) compared with ceftazidime (CAZ) in combination with tobramycin (TOB) for treatment of actue pulmonary exacerbations (APE) in patients with cystic fibrosis (CF) infected with <I>Pseudomonas aeruginosa</I> (PA) or <I>Burkholderia cepacia </I>(BC)</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2003</YR>
<VL>Suppl 25</VL>
<PG>294</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bodey-1976" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="[Empty name]" NAME="Bodey 1976" YEAR="1976">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bodey GP, Feld R, Burgess MA</AU>
<TI>Beta-lactam antibiotics alone or in combination with gentamicin for therapy of gram-negative bacillary infections in neutropenic patients</TI>
<SO>The American Journal of the Medical Sciences</SO>
<YR>1976</YR>
<VL>271</VL>
<NO>2</NO>
<PG>179-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cetto-1983" NAME="Cetto 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cetto GL, Todeschini G, Caramaschi G, Vinante F, Benini F, Perona G</AU>
<TI>Empiric therapy of infections in hematologic malignancies: a prospective, randomized trial</TI>
<SO>Tumori</SO>
<YR>1983</YR>
<VL>69</VL>
<NO>2</NO>
<PG>155-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chaudhary-2008" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="[Empty name]" NAME="Chaudhary 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chaudhary M, Shrivastava SM, Varughese L, Sehgal R</AU>
<TI>Efficacy and safety evaluation of fixed dose combination of cefepime and amikacin in comparison with cefepime alone in treatment of nosocomial pneumonia patients</TI>
<SO>Current Clinical Pharmacology</SO>
<YR>2008</YR>
<VL>3</VL>
<NO>2</NO>
<PG>118-22</PG>
<IDENTIFIERS MODIFIED="2012-03-20 07:32:32 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-20 07:32:32 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ISRCTN65171867"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-03-19 16:22:09 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-19 16:22:09 +0000" MODIFIED_BY="[Empty name]" TYPE="ISRCTN" VALUE="ISRCTN65171867"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chaudhary-2009" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="[Empty name]" NAME="Chaudhary 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chaudhary M, Shrivastava SM, Sehgal R</AU>
<TI>Evaluation of efficacy and safety of fixed dose combination of ceftazidime-tobramycin in comparison with ceftazidime in lower respiratory tract infections</TI>
<SO>Current Clinical Pharmacology</SO>
<YR>2009</YR>
<VL>4</VL>
<NO>1</NO>
<PG>62-6</PG>
<IDENTIFIERS MODIFIED="2012-03-20 07:29:21 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-20 07:29:21 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ISTCRN69844323"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ciftci-1997" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Ciftci 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ciftci AO, Tanyel FC, Buyukpamukcu N, Hicsonmez A</AU>
<TI>Comparative trial of four antibiotic combinations for perforated appendicitis in children</TI>
<SO>European Journal of Surgery</SO>
<YR>1997</YR>
<VL>163</VL>
<NO>8</NO>
<PG>591-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crenshaw-1983" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Crenshaw 1983" YEAR="1983">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crenshaw C, Glanges E, Webber C, McReynolds DB</AU>
<TI>A prospective random study of a single agent versus combination antibiotics as therapy in penetrating injuries of the abdomen</TI>
<SO>Surgery Gynecology &amp; Obstetrics</SO>
<YR>1983</YR>
<VL>156</VL>
<NO>3</NO>
<PG>289-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Croce-1993" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Croce 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Croce M, Fabian TC, Stewart RM, Pritchard FE, Minard G, Trenthem L, et al</AU>
<TI>Empiric monotherapy versus combination therapy of nosocomial pneumonia in trauma patients</TI>
<SO>The Journal of Trauma</SO>
<YR>1993</YR>
<VL>35</VL>
<NO>2</NO>
<PG>303-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Louvois-1992" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="De Louvois 1992" YEAR="1992">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Louvois J, Dagan R, Tessin I</AU>
<TI>A comparison of ceftazidime and aminoglycoside based regimens as empirical treatment in 1316 cases of suspected sepsis in the newborn. European Society for Paediatric Infectious Diseases--Neonatal Sepsis Study Group</TI>
<SO>European Journal of Pediatrics</SO>
<YR>1992</YR>
<VL>151</VL>
<NO>12</NO>
<PG>876-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Extermann-1995" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="Jane Cracknell" NAME="Extermann 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Extermann M, Regamey C, Humair L, Murisier F, Rhyner K, Vonwiller HM</AU>
<TI>Initial treatment of sepsis in non-neutropenic patients - ceftazidime alone versus best guess combined antibiotic therapy</TI>
<SO>Chemotherapy</SO>
<YR>1995</YR>
<VL>41</VL>
<PG>306-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fainstein-1983" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Fainstein 1983" YEAR="1983">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fainstein V, Bodey GP, Elting L, Bolivar R, Keating MJ, McCredie KB, et al</AU>
<TI>A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1983</YR>
<VL>12 Suppl A</VL>
<PG>101-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fernandez-1991" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Fernandez 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fernandez GM, Gudiol F, Rodriguez TA, Arnau C, Valdes L, Vallve C</AU>
<TI>Nosocomial pneumonia: comparative multicentre trial between monotherapy with cefotaxime and treatment with antibiotic combinations</TI>
<SO>Infection</SO>
<YR>1991</YR>
<VL>19</VL>
<NO>Suppl 6</NO>
<PG>S320-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Foord-1985" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Foord 1985" YEAR="1985">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Foord RD</AU>
<TI>Aspects of clinical trials with ceftazidime worldwide</TI>
<SO>American Journal of Medicine</SO>
<YR>1985</YR>
<VL>79</VL>
<NO>2A</NO>
<PG>110-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gentry-1980" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Gentry 1980" YEAR="1980">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gentry LO, Wood BA, Martin MD, Smythe J</AU>
<TI>Cefamandole alone and combined with gentamicin or tobramycin in the treatment of acute pyelonephritis</TI>
<SO>Scandinavian Journal of Infectious Diseases</SO>
<YR>1980</YR>
<VL>suppl</VL>
<NO>25</NO>
<PG>96-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gentry-1984" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Gentry 1984" YEAR="1984">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gentry LO, Feliciano DV, Lea AS, Short HD, Mattox KL, Jordan GL Jr</AU>
<TI>Perioperative antibiotic therapy for penetrating injuries of the abdomen</TI>
<SO>Annals of Surgery</SO>
<YR>1984</YR>
<VL>200</VL>
<NO>5</NO>
<PG>561-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gentry-1985" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Gentry 1985" YEAR="1985">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gentry LO</AU>
<TI>Treatment of skin, skin structure, bone, and joint infections with ceftazidime</TI>
<SO>American Journal of Medicine</SO>
<YR>1985</YR>
<VL>79</VL>
<NO>2A</NO>
<PG>67-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerber-1989" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Gerber 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerber B, Retzke F, Wilken H</AU>
<TI>[Effectiveness of perioperative preventive use of antibiotics with ampicillin/gentamycin or cefotiam in abdominal cesarean section]</TI>
<SO>Zentralblatt für Gynäkologie</SO>
<YR>1989</YR>
<VL>111</VL>
<NO>10</NO>
<PG>658-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gilbert-1998" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Gilbert 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gilbert DN, Lee BL, Dworkin RJ, Leggett JL, Chambers HF, Modin G, et al</AU>
<TI>A randomized comparison of the safety and efficacy of once-daily gentamicin or thrice-daily gentamicin in combination with ticarcillin-clavulanate</TI>
<SO>American Journal of Medicine</SO>
<YR>1998</YR>
<VL>105</VL>
<NO>3</NO>
<PG>182-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giraud-1989" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Giraud 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giraud JR, Chartier M, Ciraru Vigneron N, Becue J, Landes P, Leng JJ, et al</AU>
<TI>[A comparison of the efficacy of and tolerance to Augmentin used alone and as one of three drugs used to treat acute upper genital tract infections. Results of a multicentre trial 152 cases]</TI>
<TO>Comparaison de l'efficacite et de la tolerance de l'Augmentine en monotherapie versus triple association dans le traitment des infections genitales hautes aigues. Resultats d'une etude multicentrique portant sur 152 cas</TO>
<SO>Contraception, Fertilité, Sexualité</SO>
<YR>1989</YR>
<VL>17</VL>
<NO>10</NO>
<PG>941-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gold-1985" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Gold 1985" YEAR="1985">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gold R, Overmeyer A, Knie B, Fleming PC, Levison H</AU>
<TI>Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis</TI>
<SO>Pediatric Infectious Disease</SO>
<YR>1985</YR>
<VL>4</VL>
<NO>2</NO>
<PG>172-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gomez-1990b" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Gomez 1990b" YEAR="1990">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gomez J, Moldenhauer F, Ruiz Gomez J, Ros CM, Martinez Hernandez J, Canteras M, et al</AU>
<TI>Monotherapy versus antibiotic combinations in bacteremias in an internal medicine department. A prospective study in 1987</TI>
<TO>Monoterapia frente a combinaciones antibioticas en las bacteriemias de un departamento de medicina interna. estudio prospectivo durante 1987</TO>
<SO>Revista Espanola de Microbiologia Clinica</SO>
<YR>1990</YR>
<VL>5</VL>
<NO>2</NO>
<PG>89-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greco-1989" NAME="Greco 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greco T</AU>
<TI>Treatment of nosocomial pneumonia: monotherapy versus combination therapy</TI>
<SO>Geriatrics</SO>
<YR>1989</YR>
<VL>44 Suppl A</VL>
<PG>28-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gribble-1983" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Gribble 1983" YEAR="1983">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gribble MJ, Chow AW, Naiman SC, Smith JA, Bowie WR, Sacks SL, et al</AU>
<TI>Prospective randomized trial of piperacillin monotherapy versus carboxypenicillin-aminoglycoside combination regimens in the empirical treatment of serious bacterial infections</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1983</YR>
<VL>24</VL>
<NO>3</NO>
<PG>388-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Gribble MJ, Chow AW, Naiman SC, Smith JA, Bowie WR, Sacks SL, et al</AU>
<TI>Prospective randomized trial of piperacillin monotherapy versus carboxypenicillin-aminoglycoside combination regimens in the empirical treatment of serious bacterial infections</TI>
<SO>21st Interscience Conference on Antimicrobial Agents and Chemotherapy</SO>
<YR>1981</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haffejee-1984" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Haffejee 1984" YEAR="1984">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haffejee IE</AU>
<TI>A therapeutic trial of cefotaxime versus penicillin-gentamicin for severe infections in children</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1984</YR>
<VL>14 Suppl B</VL>
<PG>147-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hall-1988" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Hall 1988" YEAR="1988">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hall MA, Ducker DA, Lowes JA, McMichael J, Clarke P, Rowe D, et al</AU>
<TI>A randomised prospective comparison of cefotaxime versus netilmicin/penicillin for treatment of suspected neonatal sepsis</TI>
<SO>Drugs</SO>
<YR>1988</YR>
<VL>35</VL>
<NO>Suppl 2</NO>
<PG>169-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hammerberg-1989" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Hammerberg 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hammerberg O, Kurnitzki C, Watts J, Rosenbloom D</AU>
<TI>Randomized trial using piperacillin versus ampicillin and amikacin for treatment of premature neonates with risk factors for sepsis</TI>
<SO>European Journal of Clinical Microbiology and Infectious Diseases</SO>
<YR>1989</YR>
<VL>8</VL>
<NO>3</NO>
<PG>241-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hanson-1982" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Hanson 1982" YEAR="1982">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hanson B, Coppens L, Klastersky J</AU>
<TI>Comparative studies of ticarcillin and mezlocillin plus sisomicin in Gram-negative bacillary bacteraemia and bronchopneumonia</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1982</YR>
<VL>10</VL>
<NO>4</NO>
<PG>335-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoogkamp-1983" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Hoogkamp 1983" YEAR="1983">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoogkamp-Korstanje JA, van der Laag J</AU>
<TI>Piperacillin and tobramycin in the treatment of Pseudomonas lung infections in cystic fibrosis</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1983</YR>
<VL>12</VL>
<NO>2</NO>
<PG>175-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iakovlev-1997" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Iakovlev 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iakovlev SV, Shakhova TV, Dvoretskii LI, Romanovskii I, Eremina LV, Koroleva TA, et al</AU>
<TI>[Use of piperacillin/tazobactam as empirical monotherapy in the treatment of bacterial infections in a resuscitation department]</TI>
<SO>Antibiotiki i Khimioterapia</SO>
<YR>1997</YR>
<VL>42</VL>
<NO>2</NO>
<PG>33-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iakovlev-2000" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Iakovlev 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iakovlev SV, Dvoretskii LI, Shakhova TV</AU>
<TI>[The clinical efficacy of ticarcillin/clavulanate in severe pneumonia]</TI>
<SO>Antibiotiki i Khimioterapia</SO>
<YR>2000</YR>
<VL>45</VL>
<NO>3</NO>
<PG>30-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iakovlev-2006" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="[Empty name]" NAME="Iakovlev 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iakovlev SV, Beloborodov VB, Sidorenko SV, Iakovlev VP, Grigor'ev KB, Eliseeva EV, et al</AU>
<TI>Multicentre study of comparative efficacy of meropenem and combined regimens for empirical antibacterial therapy of severe nosocomial infections: results of clinical and pharmacoeconomic analysis</TI>
<SO>Antibiotiki i khimioterapii&#65056;a&#65057;</SO>
<YR>2006</YR>
<VL>51</VL>
<NO>7</NO>
<PG>15-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ker-1989" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Ker 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ker CG, Hou MF, Chen JS, Lee KT, Sheen PC, Akbary MA</AU>
<TI>A comparative study of cefotaxime sodium versus a combination of cefapirin and gentamicin in the prophylactic treatment of patients undergoing cholecystectomy</TI>
<SO>Methods and Findings in Experimental and Clinical Pharmacology</SO>
<YR>1989</YR>
<VL>11</VL>
<NO>11</NO>
<PG>711-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krumpe-1999" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Krumpe 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krumpe PE, Cohn S, Garreltes J, Ramirez J, Coulter H, Haverstock D, et al</AU>
<TI>Intravenous and oral mono- or combination-therapy in the treatment of severe infections: ciprofloxacin versus standard antibiotic therapy. Ciprofloxacin Study Group</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1999</YR>
<VL>43</VL>
<NO>Suppl A</NO>
<PG>117-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ludwig-1980" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Ludwig 1980" YEAR="1980">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ludwig G, Knebel L</AU>
<TI>Cefotaxime in urinary tract infections--comparative clinical studies with gentamicin and with cefoxitin</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1980</YR>
<VL>6 Suppl A</VL>
<PG>207-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maller-1991" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Maller 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maller R, Ahrne H, Eilard T, Eriksson I, Lausen I</AU>
<TI>Efficacy and safety of amikacin in systemic infections when given as a single daily dose or in two divided doses. Scandinavian Amikacin Once Daily Study Group</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1991</YR>
<VL>27</VL>
<NO>Suppl C</NO>
<PG>121-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mangi-1988" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Mangi 1988" YEAR="1988">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mangi RJ, Greco T, Ryan J, Thornton G, Andriole VT</AU>
<TI>Cefoperazone versus combination antibiotic therapy of hospital-acquired pneumonia</TI>
<SO>American Journal of Medicine</SO>
<YR>1988</YR>
<VL>84</VL>
<NO>1</NO>
<PG>68-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McArdle-1987" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="McArdle 1987" YEAR="1987">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McArdle C, Morran C, Greig J, Mason B, Haddock G, Sleigh J, et al</AU>
<TI>Comparison of cefotetan and gentamicin/ampicillin in high-risk biliary tract surgery</TI>
<SO>Chemioterapia</SO>
<YR>1987</YR>
<VL>6</VL>
<NO>2 Suppl</NO>
<PG>593-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCarty-1988" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="McCarty 1988" YEAR="1988">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCarty JM, Tilden SJ, Black P, Craft JC, Blumer J, Waring W, et al</AU>
<TI>Comparison of piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections in children with cystic fibrosis</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1988</YR>
<VL>4</VL>
<NO>4</NO>
<PG>201-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McLaughlin-1983" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="McLaughlin 1983" YEAR="1983">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McLaughlin FJ, Matthews WJ Jr, Strieder DJ, Sullivan B, Taneja A, Murphy P, et al</AU>
<TI>Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1983</YR>
<VL>147</VL>
<NO>3</NO>
<PG>559-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McLaughlin FJ, Matthews WJ, Jr., Strieder DJ, Sullivan B, Goldmann DA</AU>
<TI>Randomized, double-blind evaluation of azlocillin for the treatment of pulmonary exacerbations of cystic fibrosis</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1983</YR>
<VL>11</VL>
<NO>Suppl B</NO>
<PG>195-203</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mondorf-1987" NAME="Mondorf 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mondorf A, Mondorf W, Banzer S</AU>
<TI>A multiple-center comparative study of the kidney tolerance of ceftazidime versus cefotaxime and tobramycin</TI>
<SO>Chemioterapia</SO>
<YR>1987</YR>
<VL>6</VL>
<NO>2 Suppl</NO>
<PG>331-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mondorf-1989" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Mondorf 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mondorf AW, Bonsiepe C, Mondorf W</AU>
<TI>Randomized multi center study comparing nephrotoxicity of ceftazidime versus the combination of piperacillin and netilmicin with and without furosemide</TI>
<SO>Advances in Experimental Medicine and Biology</SO>
<YR>1989</YR>
<VL>252</VL>
<PG>307-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moreno_x002d_Martinez-1998" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Moreno-Martinez 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moreno Martinez A, Mensa J, Martinez JA, Marco F, Vila J, Almela M, et al</AU>
<TI>Cefixime versus amoxicillin plus netilmicin in the treatment of community-acquired non-complicated acute pyelonephritis</TI>
<SO>Medicina Clinica</SO>
<YR>1998</YR>
<VL>111</VL>
<NO>14</NO>
<PG>521-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mouton-1985" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Mouton 1985" YEAR="1985">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Mouton Y, Deboscker Y, Beuscart C, Beaucaire G, Fourrier A</AU>
<TI>Third generation cephalosporins in combination with aminoglycosides or in monotherapy for life-threatening infections in an intensive care unit</TI>
<SO>25th Interscience Conference on Antimicrobial Agents and Chemotherapy</SO>
<YR>1985</YR>
<PG>Abstract no. 958</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oblinger-1982" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Oblinger 1982" YEAR="1982">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oblinger MJ, Bowers JT, Sande MA, Mandell GL</AU>
<TI>Moxalactam therapy vs. standard antimicrobial therapy for selected serious infections</TI>
<SO>Reviews of Infectious Diseases</SO>
<YR>1982</YR>
<VL>4</VL>
<NO>Suppl</NO>
<PG>S639-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Odio-1987" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Odio 1987" YEAR="1987">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Odio CM, Umana MA, Saenz A, Salas JL, McCracken GH</AU>
<TI>Comparative efficacy of ceftazidime vs. carbenicillin and amikacin for treatment of neonatal septicemia</TI>
<SO>Pediatric Infectious Diseases Journal</SO>
<YR>1987</YR>
<VL>6</VL>
<NO>4</NO>
<PG>371-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Padoan-1987" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Padoan 1987" YEAR="1987">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Padoan R, Cambisano W, Costantini D, Crossignani RM, Danza ML, Trezzi G, et al</AU>
<TI>Ceftazidime monotherapy vs. combined therapy in Pseudomonas pulmonary infections in cystic fibrosis</TI>
<SO>Pediatric Infectious Diseases Journal</SO>
<YR>1987</YR>
<VL>6</VL>
<NO>7</NO>
<PG>648-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paoletti-1989" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Paoletti 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paoletti V, Mammarella A, Mariani A, Filippello CP, Franchino L, Barlattani M</AU>
<TI>Netilmicin in the treatment of infections of the lower urinary tract</TI>
<TO>La netilimicina nel trattamento delle infeziono delle basse vie urinarie</TO>
<SO>Clinical Therapeutics</SO>
<YR>1989</YR>
<VL>128</VL>
<NO>6</NO>
<PG>405-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pereira-2009" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="[Empty name]" NAME="Pereira 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pereira CA, Petrilli AS, Carlesse FA, Luisi FA, da Silva KV, de Martino Lee ML</AU>
<TI>Cefepime monotherapy is as effective as ceftriaxone plus amikacin in pediatric patients with cancer and high-risk febrile neutropenia in a randomized comparison</TI>
<SO>Journal of Microbiology, Immunology, and Infection</SO>
<YR>2009</YR>
<VL>42</VL>
<NO>2</NO>
<PG>141-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodloff-1998" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Rodloff 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodloff AC, Kujath P, Lunstedt B, Gaus W</AU>
<TI>Comparative study of the cost-effectiveness of initial therapy with imipenem/cilastatin in secondary peritonitis</TI>
<SO>Chirurgia</SO>
<YR>1998</YR>
<VL>69</VL>
<NO>10</NO>
<PG>1093-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Romanelli-2002" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Romanelli 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Romanelli G, Cravarezza P, Pozzi A, Franchino L, Ravizzola G, Zulli R, et al</AU>
<TI>Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy</TI>
<SO>Journal of Chemotherapy</SO>
<YR>2002</YR>
<VL>14</VL>
<NO>6</NO>
<PG>609-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schoengut-1983" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Schoengut 1983" YEAR="1983">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schoengut H, Jelinek R</AU>
<TI>Comparative study of the effects of ceftazidime compared with tobramycin plus cefamandole in the treatment of gall bladder empyema</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1983</YR>
<VL>12 Suppl A</VL>
<PG>219-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schuler-1995" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Schuler 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schuler D, and the Meropenem Paediatric Study Group</AU>
<TI>Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1995</YR>
<VL>36</VL>
<NO>Suppl A</NO>
<PG>99-108</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scott-1987" NAME="Scott 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scott SD, Saddler B, Lowes JA, Karran SJ</AU>
<TI>Comparison of cefotetan versus combination therapy in peritonitis and serious intra-abdominal sepsis</TI>
<SO>Chemioterapia</SO>
<YR>1987</YR>
<VL>6</VL>
<NO>2 Suppl</NO>
<PG>475-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sexton-1984" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Sexton 1984" YEAR="1984">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sexton DJ, Wlodaver CG, Tobey LE, Finn LA, Chubb JM</AU>
<TI>Ceftazidime therapy for Gram-negative bone and joint infections</TI>
<SO>24th Interscience Conference on Antimicrobial Agents and Chemotherapy</SO>
<YR>1984</YR>
<VL>Abstract no. 1213</VL>
<PG>305</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sheftel-1986" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Sheftel 1986" YEAR="1986">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sheftel TG, Mader JT</AU>
<TI>Randomized evaluation of ceftazidime or ticarcillin and tobramycin for the treatment of osteomyelitis caused by gram-negative bacilli</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1986</YR>
<VL>29</VL>
<NO>1</NO>
<PG>112-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1999" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Smith 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith AL, Doershuk C, Goldmann D, Gore E, Hilman B, Marks M, et al</AU>
<TI>Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis</TI>
<SO>Journal of Pediatrica</SO>
<YR>1999</YR>
<VL>134</VL>
<NO>4</NO>
<PG>413-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Solberg-1995" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Solberg 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Solberg CO, Sjursen H</AU>
<TI>Safety and efficacy of meropenem in patients with septicaemia: a randomised comparison with ceftazidime, alone or combined with amikacin</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1995</YR>
<VL>36</VL>
<NO>Suppl A</NO>
<PG>157-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Solomkin-1986" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Solomkin 1986" YEAR="1986">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Solomkin JS, Cocchetto DM</AU>
<TI>Ceftazidime versus tobramycin plus ticarcillin in the treatment of soft-tissue infections</TI>
<SO>Clinical Therapeutics</SO>
<YR>1986</YR>
<VL>9</VL>
<NO>1</NO>
<PG>123-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stack-1985" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Stack 1985" YEAR="1985">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stack BHR, Geddes DM, Williams KJ, Dinwiddie R, Selkon JB, Godfrey RC, for the British Thoracic Society Research Committee</AU>
<TI>Ceftazidime compared with gentamicin and carbenicillin in patients with cystic fibrosis, pulmonary pseudomonas infection, and an exacerbation of respiratory symptoms</TI>
<SO>Thorax</SO>
<YR>1985</YR>
<VL>40</VL>
<NO>5</NO>
<PG>358-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tally-1986" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Tally 1986" YEAR="1986">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tally FP, Kellum JM, Ho JL, O'Donnell TF, Barza M, Gorbach SL</AU>
<TI>Randomized prospective study comparing moxalactam and cefoxitin with or without tobramycin for the treatment of serious surgical infections</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1986</YR>
<VL>29</VL>
<NO>2</NO>
<PG>244-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thompson-1980" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Thompson 1980" YEAR="1980">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thompson SE, Hager WD, Wong KH, Lopez B, Ramsey C, Allen SD, et al</AU>
<TI>The microbiology and therapy of acute pelvic inflammatory disease in hospitalized patients</TI>
<SO>American Journal of Obstetrics &amp; Gynecology</SO>
<YR>1980</YR>
<VL>136</VL>
<NO>2</NO>
<PG>179-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vazquez-1994" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Vazquez 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vazquez Vela Sanchez G, De Leon Zavala J, Ochoa Cozares M</AU>
<TI>Comparative study of two preventive antibiotic programs for treatment of open fractures</TI>
<TO>Estudio comparativo de dos esquemas de antibioticos para la prevencion de la infeccion en las fracturas expuestas</TO>
<SO>Revista Mexicana de Trastornos Alimentarios</SO>
<YR>1994</YR>
<VL>8</VL>
<NO>5</NO>
<PG>263-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vetter-1987" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Vetter 1987" YEAR="1987">
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vetter N, Feist H, Armbruster C, Drlicek M</AU>
<TI>Comparison of the effectiveness of ceftazidime and cefazolin/tobramycin in patients with inflammatory diseases of the lower respiratory tract. In German</TI>
<TO>Efficacy of ceftazidime and cefazolin/tobramycin in lower respiratory tract infections</TO>
<SO>Infection</SO>
<YR>1987</YR>
<VL>15</VL>
<NO>Suppl 4</NO>
<PG>S192-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vetter N, Feist H, Muhar F, Williams KJ</AU>
<TI>A comparative study of the efficacy of ceftazidime versus cefazolin and tobramycin in patients with acute exacerbations of chronic bronchitis</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1983</YR>
<VL>12</VL>
<NO>Suppl A</NO>
<PG>35-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vetter-1992" MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" NAME="Vetter 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Vetter N</AU>
<TI>Efficacy of meropenem in the treatment of respiratory tract infection: a comparative evaluation</TI>
<SO>Journal of Chemotherapy</SO>
<YR>1993</YR>
<VL>5 Suppl 1</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-16 14:22:12 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Vetter N</AU>
<TI>Efficacy of meropenem in the treatment of respiratory tract infection:a comparative evaluation</TI>
<SO>Proceedings of the Eighth Mediterranean Congress of Chemotherapy</SO>
<YR>1992</YR>
<PG>175</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Watanakunakorn-1997" MODIFIED="2013-12-16 05:33:27 +0000" MODIFIED_BY="Jane Cracknell" NAME="Watanakunakorn 1997" YEAR="1977">
<REFERENCE MODIFIED="2013-12-16 05:33:27 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Watanakunakorn C, Baird IM</AU>
<TI>Prognostic factors in <I>Staphylococcus aureus</I> endocarditis and results of therapy with a penicillin and gentamicin</TI>
<SO>The American Journal of Medical Sciences</SO>
<YR>1977</YR>
<VL>273</VL>
<NO>2</NO>
<PG>133-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yildirim-2008" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="[Empty name]" NAME="Yildirim 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yildirim I, Aytac S, Ceyhan M, Cetin M, Tuncer M, Cengiz AB, et al</AU>
<TI>Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies</TI>
<SO>International Journal of Pediatric Hematology/Oncology</SO>
<YR>2008</YR>
<VL>25</VL>
<NO>4</NO>
<PG>291-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2011-10-10 20:32:38 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Aziz-2012" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NAME="Aziz 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<TI>Comparison of Ampicillin/Sulbactam vs. Ampicillin/Gentamicin for Treatment of Intrapartum Chorioamnionitis: a randomized controlled trial</TI>
<SO>NCT00879190 on ClinicalTrials.gov</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-03-19 15:51:20 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-19 15:51:20 +0000" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00879190"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-12-20 15:54:38 +0000" MODIFIED_BY="Karen Hovhannisyan">
<ADDITIONAL_REFERENCES MODIFIED="2013-12-20 15:54:38 +0000" MODIFIED_BY="Karen Hovhannisyan">
<REFERENCE ID="REF-Allan-1985" MODIFIED="2012-02-11 13:05:10 +0000" MODIFIED_BY="Karen Hovhannisyan" NAME="Allan 1985" TYPE="JOURNAL_ARTICLE">
<AU>Allan JD, Moellering RC</AU>
<TI>Management of infections caused by gram-negative bacilli: the role of antimicrobial combinations</TI>
<SO>Reviews of Infectious Diseases</SO>
<YR>1985</YR>
<VL>7 Suppl 4</VL>
<PG>559-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bach-1980" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NAME="Bach 1980" TYPE="JOURNAL_ARTICLE">
<AU>Bach VT, Webb DW, Thadepalli H</AU>
<TI>Antimicrobial synergism of piperacillin and gentamicin against <I>P</I>
<I>seudomonas aeruginosa, Staphylococcus aureus</I> and <I>Streptococcus faecalis</I>
</TI>
<SO>Chemotherapy</SO>
<YR>1980</YR>
<VL>26</VL>
<NO>1</NO>
<PG>21-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="6766372"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Baddour-2005" MODIFIED="2012-02-08 17:50:30 +0000" MODIFIED_BY="[Empty name]" NAME="Baddour 2005" TYPE="JOURNAL_ARTICLE">
<AU>Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Bolger AF, Levison ME, et al</AU>
<TI>Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America</TI>
<SO>Circulation</SO>
<YR>2005</YR>
<VL>111</VL>
<NO>23</NO>
<PG>e394-434</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="15956145"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Barza-1996" MODIFIED="2008-09-02 10:07:57 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Barza 1996" TYPE="JOURNAL_ARTICLE">
<AU>Barza M, Ioannidis JP, Cappelleri JC, Lau J</AU>
<TI>Single or multiple daily doses of aminoglycosides: a meta-analysis</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>312</VL>
<NO>7027</NO>
<PG>338-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bliziotis-2005" MODIFIED="2012-02-08 17:50:35 +0000" MODIFIED_BY="[Empty name]" NAME="Bliziotis 2005" TYPE="JOURNAL_ARTICLE">
<AU>Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME</AU>
<TI>Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials</TI>
<SO>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</SO>
<YR>2005</YR>
<VL>41</VL>
<NO>2</NO>
<PG>149-58</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="15983909"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bliziotis-2011" MODIFIED="2013-12-16 05:35:00 +0000" MODIFIED_BY="[Empty name]" NAME="Bliziotis 2011" TYPE="JOURNAL_ARTICLE">
<AU>Bliziotis IA, Petrosillo N, Michalopoulos A, Samonis G, Falagas ME</AU>
<TI>Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for <I>Pseudomonas aeruginosa</I> bacteremia</TI>
<SO>PloS one</SO>
<YR>2011</YR>
<VL>6</VL>
<NO>10</NO>
<PG>e26470</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="22046290"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bone-1992" MODIFIED="2008-09-02 10:07:57 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Bone 1992" TYPE="JOURNAL_ARTICLE">
<AU>Bone RC, Sibbald WJ, Sprung CL</AU>
<TI>The ACCP-SCCM consensus conference on sepsis and organ failure</TI>
<SO>Chest</SO>
<YR>1992</YR>
<VL>101</VL>
<NO>6</NO>
<PG>1481-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dellinger-2008" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="[Empty name]" NAME="Dellinger 2008" TYPE="JOURNAL_ARTICLE">
<AU>Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al</AU>
<TI>Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008</TI>
<SO>Critical Care Medicine</SO>
<YR>2008</YR>
<VL>36</VL>
<NO>1</NO>
<PG>296-327</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="18158437"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Elphick-2005" MODIFIED="2012-02-11 13:16:29 +0000" MODIFIED_BY="Karen Hovhannisyan" NAME="Elphick 2005" TYPE="COCHRANE_REVIEW">
<AU>Elphick HE, Tan AA</AU>
<TI>Single versus combination intravenous antibiotic therapy for people with cystic fibrosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-02-11 13:16:16 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-02-11 13:16:16 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002007.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Falagas-2006" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="[Empty name]" NAME="Falagas 2006" TYPE="JOURNAL_ARTICLE">
<AU>Falagas ME, Matthaiou DK, Bliziotis IA</AU>
<TI>The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials</TI>
<SO>The Journal of Antimicrobial Chemotherapy</SO>
<YR>2006</YR>
<VL>57</VL>
<NO>4</NO>
<PG>639-47</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="16501057"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Giamarellou-1984" MODIFIED="2008-09-02 10:07:57 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Giamarellou 1984" TYPE="JOURNAL_ARTICLE">
<AU>Giamarellou H, Zissis NP, Tagari G, Bouzos J</AU>
<TI>In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1984</YR>
<VL>25</VL>
<NO>4</NO>
<PG>534-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Giamarellou-1986" MODIFIED="2008-09-02 10:07:57 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Giamarellou 1986" TYPE="JOURNAL_ARTICLE">
<AU>Giamarellou H</AU>
<TI>Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions</TI>
<SO>American Journal of Medicine</SO>
<YR>1986</YR>
<VL>80</VL>
<NO>6B</NO>
<PG>126-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="Karen Hovhannisyan" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</TI>
<SO>The Cochrane Collaboration, 2011. www.cochrane-handbook.org.</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hilf-1989" MODIFIED="2013-12-16 05:35:40 +0000" MODIFIED_BY="Karen Hovhannisyan" NAME="Hilf 1989" TYPE="JOURNAL_ARTICLE">
<AU>Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR</AU>
<TI>Antibiotic therapy for <I>Pseudomonas aeruginosa </I>bacteremia: outcome correlations in a prospective study of 200 patients</TI>
<SO>American Journal of Medicine</SO>
<YR>1989</YR>
<VL>87</VL>
<NO>5</NO>
<PG>540-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ibrahim-2000" MODIFIED="2008-09-02 10:07:57 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Ibrahim 2000" TYPE="JOURNAL_ARTICLE">
<AU>Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH</AU>
<TI>The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting</TI>
<SO>Chest</SO>
<YR>2000</YR>
<VL>118</VL>
<NO>1</NO>
<PG>146-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klastersky-1976" MODIFIED="2013-12-16 05:35:59 +0000" MODIFIED_BY="Karen Hovhannisyan" NAME="Klastersky 1976" TYPE="JOURNAL_ARTICLE">
<AU>Klastersky J, Meunier-Carpentier F, Prevost JM, Staquet M</AU>
<TI>Synergism between amikacin and cefazolin against <I>Klebsiella</I>: in vitro studies and effect on the bactericidal activity of serum</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1976</YR>
<VL>134</VL>
<NO>3</NO>
<PG>271-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klastersky-1982" MODIFIED="2008-09-02 10:07:57 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Klastersky 1982" TYPE="JOURNAL_ARTICLE">
<AU>Klastersky J, Zinner SH</AU>
<TI>Synergistic combinations of antibiotics in gram-negative bacillary infections</TI>
<SO>Reviews of Infectious Diseases</SO>
<YR>1982</YR>
<VL>4</VL>
<NO>2</NO>
<PG>294-301</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Korzeniowski-1978" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="[Empty name]" NAME="Korzeniowski 1978" TYPE="JOURNAL_ARTICLE">
<AU>Korzeniowski OM, Wennersten C, Moellering RC Jr, Sande MA</AU>
<TI>Penicillin-netilmicin synergism against Streptococcus faecalis</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1978</YR>
<VL>13</VL>
<NO>3</NO>
<PG>430-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="122522"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kumar-2010" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="[Empty name]" NAME="Kumar 2010" TYPE="JOURNAL_ARTICLE">
<AU>Kumar A, Safdar N, Kethireddy S, Chateau D</AU>
<TI>A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study</TI>
<SO>Critical Care Medicine</SO>
<YR>2010</YR>
<VL>38</VL>
<NO>8</NO>
<PG>1651-64</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="20562695"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kumar-2010b" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NAME="Kumar 2010b" TYPE="JOURNAL_ARTICLE">
<AU>Kumar A, Zarychanski R, Light B, Parrillo J, Maki D, Simon D, et al</AU>
<TI>Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis</TI>
<SO>Critical Care Medicine</SO>
<YR>2010</YR>
<VL>38</VL>
<NO>9</NO>
<PG>1773-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leibovici-1997" MODIFIED="2008-09-02 10:07:57 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Leibovici 1997" TYPE="JOURNAL_ARTICLE">
<AU>Leibovici L, Paul M, Poznanski O, Drucker M, Samra Z, Konigsberger H, et al</AU>
<TI>Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1997</YR>
<VL>41</VL>
<NO>5</NO>
<PG>1127-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leibovici-1998" MODIFIED="2008-09-02 10:07:57 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Leibovici 1998" TYPE="JOURNAL_ARTICLE">
<AU>Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD</AU>
<TI>The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection</TI>
<SO>Journal of Internal Medicine</SO>
<YR>1998</YR>
<VL>244</VL>
<NO>5</NO>
<PG>379-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leibovici-2010" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="[Empty name]" NAME="Leibovici 2010" TYPE="JOURNAL_ARTICLE">
<AU>Leibovici L</AU>
<TI>Aminoglycoside-containing antibiotic combinations for the treatment of bacterial endocarditis: an evidence-based approach</TI>
<SO>International Journal of Antimicrobial Agents</SO>
<YR>2010</YR>
<VL>36 Suppl 2</VL>
<PG>S46-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="21130606"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Levy-1979" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="[Empty name]" NAME="Levy 1979" TYPE="JOURNAL_ARTICLE">
<AU>Levy J, Klastersky J</AU>
<TI>Synergism between amikacin and cefazolin against Staphylococcus aureus: a comparative study of oxacillin-sensitive and oxacillin-resistant strains</TI>
<SO>The Journal of Antimicrobial Chemotherapy</SO>
<YR>1979</YR>
<VL>5</VL>
<NO>4</NO>
<PG>365-73</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="489490"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mandell-2004" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="Karen Hovhannisyan" NAME="Mandell 2004" TYPE="BOOK">
<AU>Mandell GL, Bennet JE, Dolin R, editors</AU>
<SO>Principles and Practice of Infectious Diseases</SO>
<YR>2004</YR>
<EN>6th</EN>
<PB>Churchill Livingstone</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Manian-1996" MODIFIED="2008-09-02 10:07:57 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Manian 1996" TYPE="JOURNAL_ARTICLE">
<AU>Manian FA, Meyer L, Jenne J, Owen A, Taff T</AU>
<TI>Loss of antimicrobial susceptibility in aerobic gram-negative bacilli repeatedly isolated from patients in intensive-care units</TI>
<SO>Infection Control and Hospital Epidemiology</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>4</NO>
<PG>222-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marcus-2011" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="[Empty name]" NAME="Marcus 2011" TYPE="JOURNAL_ARTICLE">
<AU>Marcus R, Paul M, Elphick H, Leibovici L</AU>
<TI>Clinical implications of beta-lactam-aminoglycoside synergism: systematic review of randomised trials</TI>
<SO>International Journal of Antimicrobial Agents</SO>
<YR>2011</YR>
<VL>37</VL>
<NO>6</NO>
<PG>491-503</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="21292449"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Milatovic-1987" MODIFIED="2008-09-02 10:07:57 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Milatovic 1987" TYPE="JOURNAL_ARTICLE">
<AU>Milatovic D, Braveny I</AU>
<TI>Development of resistance during antibiotic therapy</TI>
<SO>European Journal of Clinical Microbiology</SO>
<YR>1987</YR>
<VL>6</VL>
<NO>3</NO>
<PG>234-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moellering-1986" MODIFIED="2012-02-11 13:05:22 +0000" MODIFIED_BY="Karen Hovhannisyan" NAME="Moellering 1986" TYPE="JOURNAL_ARTICLE">
<AU>Moellering RC, Jr, Eliopoulos GM, Allan JD</AU>
<TI>Beta-lactam/aminoglycoside combinations: interactions and their mechanisms</TI>
<SO>American Journal of Medicine</SO>
<YR>1986</YR>
<VL>80</VL>
<NO>5C</NO>
<PG>30-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-2001" MODIFIED="2008-09-02 10:07:57 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Moore 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moore RB, Shapiro NI, Wolfe RE, Smith ES, Bermudez S, Bates D</AU>
<TI>The value of sirs criteria in ed patients with presumed infection in predicting mortality</TI>
<SO>Academic Emergency Medicine</SO>
<YR>2001</YR>
<VL>8</VL>
<NO>5</NO>
<PG>477</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Paul-2005" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NAME="Paul 2005" TYPE="OTHER">
<AU>Paul M, Leibovici L</AU>
<TI>Combination antibiotic therapy for <I>Pseudomonas aeruginosa</I> bacteraemia</TI>
<SO>The Lancet Infectious Diseases</SO>
<YR>2005</YR>
<VL>5</VL>
<NO>4</NO>
<PG>192-3; discussion 193-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="15792730"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Paul-2006a" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="[Empty name]" NAME="Paul 2006a" TYPE="JOURNAL_ARTICLE">
<AU>Paul M, Andreassen S, Tacconelli E, Nielsen AD, Almanasreh N, Frank U, et al, on behalf of the TREAT Study Group</AU>
<TI>Improving empirical antibiotic treatment using TREAT, a computerized decision support system: cluster randomised trial</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>2006</YR>
<VL>58</VL>
<NO>6</NO>
<PG>1238-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Paul-2009" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NAME="Paul 2009" TYPE="JOURNAL_ARTICLE">
<AU>Paul M, Leibovici L</AU>
<TI>Combination antimicrobial treatment versus monotherapy: the contribution of meta-analyses</TI>
<SO>Infectious Disease Clinics of North America</SO>
<YR>2009</YR>
<VL>23</VL>
<NO>2</NO>
<PG>277-93</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="19393909"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Paul-2010" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="[Empty name]" NAME="Paul 2010" TYPE="JOURNAL_ARTICLE">
<AU>Paul M, Shani V, Muchtar E, Kariv G, Robenshtok E, Leibovici L</AU>
<TI>Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2010</YR>
<VL>54</VL>
<NO>11</NO>
<PG>4851-63</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="20733044"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Paul-2010a" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NAME="Paul 2010a" TYPE="OTHER">
<AU>Paul M, Leibovici L</AU>
<TI>Odds ratios are contingent on event rates</TI>
<SO>Critical Care Medicine</SO>
<YR>2010</YR>
<VL>38</VL>
<NO>12</NO>
<PG>2425-6; author reply 2426-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="21088518"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Paul-2013" MODIFIED="2013-12-20 15:54:38 +0000" MODIFIED_BY="[Empty name]" NAME="Paul 2013" TYPE="COCHRANE_REVIEW">
<AU>Paul M, Dickstein Y, Schlesinger A, Grozinsky-Glasberg S, Soares-Weiser K, Leibovici L</AU>
<TI>Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>6</NO>
<IDENTIFIERS MODIFIED="2013-12-20 15:54:29 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-20 13:53:49 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003038.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rangel_x002d_Frausto-1995" MODIFIED="2008-09-02 10:07:57 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Rangel-Frausto 1995" TYPE="JOURNAL_ARTICLE">
<AU>Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP</AU>
<TI>The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>2</NO>
<PG>117-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Russell-2000" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Karen Hovhannisyan" NAME="Russell 2000" TYPE="JOURNAL_ARTICLE">
<AU>Russell JA, Singer J, Bernard GR, Wheeler A, Fulkerson W, Hudson L, et al</AU>
<TI>Changing pattern of organ dysfunction in early human sepsis is related to mortality</TI>
<SO>Critical Care Medicine</SO>
<YR>2000</YR>
<VL>28</VL>
<NO>10</NO>
<PG>3405-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Safdar-2004" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="Karen Hovhannisyan" NAME="Safdar 2004" TYPE="JOURNAL_ARTICLE">
<AU>Safdar N, Handelsman J, Maki DG</AU>
<TI>Does combination antibiotic therapy reduce mortality in Gram-negative bacteremia? A meta-analysis.</TI>
<SO>Lancet Infectious Diseases</SO>
<YR>2004</YR>
<VL>4</VL>
<PG>519-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saleh_x002d_Mghir-1992" MODIFIED="2013-12-16 05:39:02 +0000" MODIFIED_BY="[Empty name]" NAME="Saleh-Mghir 1992" TYPE="JOURNAL_ARTICLE">
<AU>Saleh-Mghir A, Cremieux AC, Vallois JM, Muffat-Joly M, Devine C, Carbon C</AU>
<TI>Optimal aminoglycoside dosing regimen for penicillin-tobramycin synergism in experimental <I>Streptococcus adjacens</I> endocarditis</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1992</YR>
<VL>36</VL>
<NO>11</NO>
<PG>2403-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="1489184"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sande-1974" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NAME="Sande 1974" TYPE="JOURNAL_ARTICLE">
<AU>Sande MA, Irvin RG</AU>
<TI>Penicillin-aminoglycoside synergy in experimental <I>Streptococcus viridans</I> endocarditis</TI>
<SO>The Journal of Infectious Diseases</SO>
<YR>1974</YR>
<VL>129</VL>
<NO>5</NO>
<PG>572-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="4823583"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sande-1975" MODIFIED="2013-12-16 05:39:37 +0000" MODIFIED_BY="Karen Hovhannisyan" NAME="Sande 1975" TYPE="JOURNAL_ARTICLE">
<AU>Sande MA, Johnson ML</AU>
<TI>Antimicrobial therapy of experimental endocarditis caused by <I>Staphylococcus aureus</I>
</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1975</YR>
<VL>131</VL>
<NO>4</NO>
<PG>367-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sande-1976" MODIFIED="2012-02-11 13:05:42 +0000" MODIFIED_BY="Karen Hovhannisyan" NAME="Sande 1976" TYPE="JOURNAL_ARTICLE">
<AU>Sande MA, Courtney KB</AU>
<TI>Nafcillin-gentamicin synergism in experimental staphylococcal endocarditis</TI>
<SO>Journal of Laboratory and Clinical Medicine</SO>
<YR>1976</YR>
<VL>88</VL>
<NO>1</NO>
<PG>118-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Karen Hovhannisyan" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Staa-2012" MODIFIED="2012-02-11 12:43:32 +0000" MODIFIED_BY="[Empty name]" NAME="Staa 2012" TYPE="JOURNAL_ARTICLE">
<AU>Staa TP, Goldacre B, Gulliford M, Cassell J, Pirmohamed M, Taweel A, et al</AU>
<TI>Pragmatic randomised trials using routine electronic health records: putting them to the test</TI>
<SO>BMJ (Clinical research ed.)</SO>
<YR>2012</YR>
<VL>344</VL>
<PG>e55</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="22315246"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sun-2011" MODIFIED="2013-12-16 05:40:04 +0000" MODIFIED_BY="[Empty name]" NAME="Sun 2011" TYPE="JOURNAL_ARTICLE">
<AU>Sun HY, Fujitani S, Quintiliani R, Yu VL</AU>
<TI>Pneumonia due to <I>Pseudomonas aeruginosa</I>: part II: antimicrobial resistance, pharmacodynamic concepts, and antibiotic therapy</TI>
<SO>Chest</SO>
<YR>2011</YR>
<VL>139</VL>
<NO>5</NO>
<PG>1172-85</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="21540216"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Torres-1993" MODIFIED="2013-12-16 05:40:17 +0000" MODIFIED_BY="[Empty name]" NAME="Torres 1993" TYPE="JOURNAL_ARTICLE">
<AU>Torres C, Tenorio C, Lantero M, Gastanares MJ, Baquero F</AU>
<TI>High-level penicillin resistance and penicillin-gentamicin synergy in <I>Enterococcus faecium</I>
</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1993</YR>
<VL>37</VL>
<NO>11</NO>
<PG>2427-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="8285628"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Weinstein-1985" MODIFIED="2012-02-11 13:05:48 +0000" MODIFIED_BY="Karen Hovhannisyan" NAME="Weinstein 1985" TYPE="JOURNAL_ARTICLE">
<AU>Weinstein L</AU>
<TI>Gram-negative bacterial infections: a look at the past, a view of the present, and a glance at the future</TI>
<SO>Reviews of Infectious Diseases</SO>
<YR>1985</YR>
<VL>7 Suppl 4</VL>
<PG>538-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wood-2008" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="[Empty name]" NAME="Wood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al</AU>
<TI>Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes:meta-epidemiological study</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7644</NO>
<PG>601-5</PG>
<IDENTIFIERS MODIFIED="2012-03-21 08:18:28 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-21 08:18:28 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1136/bmj.39465.451748.AD"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-11-27 19:41:34 +0000" MODIFIED_BY="Jane Cracknell">
<REFERENCE ID="REF-Paul-2003" MODIFIED="2013-11-27 19:41:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Paul 2003" TYPE="COCHRANE_REVIEW">
<AU>Paul M, Schlesinger A, Grozinsky-Glasberg S, Soares-Weiser K, Leibovici L</AU>
<TI>Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>3</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD003038"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Paul-2004" NAME="Paul 2004" TYPE="JOURNAL_ARTICLE">
<AU>Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L</AU>
<TI>Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials</TI>
<SO>BMJ</SO>
<YR>2004</YR>
<VL>328</VL>
<NO>7441</NO>
<PG>668-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Paul-2006" MODIFIED="2013-11-27 18:33:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="Paul 2006" TYPE="COCHRANE_REVIEW">
<AU>Paul M, Silbiger I, Grozinsky S, Soares-Weiser K, Leibovici L</AU>
<TI>Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>1</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD003344.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2012-02-11 12:53:43 +0000" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-12-20 14:19:09 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-02-20 16:22:49 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Abrams-1979">
<CHAR_METHODS>
<P>RCT<BR/>Empirical and semi-empirical<BR/>Gram positive infections</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>36 IV drug users with suspected Staphylococcal endocarditis were included. Only those with Staphylococcus aureus bacteraemia and endocarditis according to inclusion criteria were evaluated Patients excluded because they did not fulfil inclusion criteria for bacteraemia were not considered as dropouts for the review</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oxacillin 12gr/d vs. oxacillin 12gr/d + gentamicin 80mgX3 (gentamicin administered for the first 2 weeks of a 4-week treatment protocol)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure (clinical and bacteriological)<BR/>Adverse events<BR/>Duration of fever</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>USA<BR/>Outcomes in subgroups: Bacteraemia.<BR/>Cephalothin was permitted instead of oxacillin for patients with penicillin allergy, and oxacillin was replaced by penicillin for penicillin-susceptible Staphylococcus aureus.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Aguilar-1992">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>36 patients &gt; 16 yrs. with severe infections</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ceftizoxime 60-150 mg/kg/d vs. penicillin 20-30mU/d + gentamicin 3-5mg/kg/d</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Treatment failure (clinical and bacteriological)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mexico<BR/>No outcomes in subgroups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Alvarez_x002d_Lerma-2001a">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>140 adult patients hospitalized in the ICU, mechanically ventilated and diagnosed with pneumonia. All infections were hospital acquired. 66% of patients were on inotropic drugs upon entry to study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Meropenem 1grX3 for 9.3 days vs.<BR/>ceftazidime 2grX3 + amikacin 7.5mg/kgX2 for 8.3 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure (clinical and bacteriological)<BR/>Bacterial superinfections<BR/>Adverse events<BR/>Duration of treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre<BR/>Spain<BR/>Outcomes in subgroups: Gram negative and Pseudomonas sp. infections</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Arich-1987">
<CHAR_METHODS>
<P>RCT<BR/>Partially semi-empirical<BR/>Sepsis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adult patients with enterobacteriacae bacteraemia (at least 2 positive blood cultures with same pathogen). Patients could enter the trial before or at diagnosis of bacteraemia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cefotaxime 1grX3-4 for 17.5 days vs. cefazolin 1grX3 + tobramycin 1.5mg/kgX3 for 10 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure (clinical and bacteriological)<BR/>Superinfection<BR/>Adverse events<BR/>Duration of hospitalizations, treatment and fever</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>France (French)<BR/>Outcomes in subgroups:<BR/>Bacteraemia<BR/>Gram-negative infections</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-02-20 16:18:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Banasal-2006">
<CHAR_METHODS MODIFIED="2011-12-26 06:50:42 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
<P>Community acquired pneumonia</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-02-20 16:18:08 +0000" MODIFIED_BY="[Empty name]">
<P>Children aged 2-59 months with severe or very severe pneumonia with<BR/>hypoxaemia (SpO2 &lt;90%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-02-20 16:18:10 +0000" MODIFIED_BY="[Empty name]">
<P>sequential IV and oral amoxicillin-clavulanate Vs. IV c penicillin 50,000 IU/kg q6h +IV gentamicin 2.5 mg/kg q8h for at least 3 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-26 06:51:00 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment failure (clinical)<BR/>Duration of treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-12-26 06:51:05 +0000" MODIFIED_BY="[Empty name]">
<P>Chandigarh, India</P>
<P>No outcomes in subgroups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bergeron-1988">
<CHAR_METHODS>
<P>RCT<BR/>Abdominal<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>77 adult patients with severe biliary tract infections (cholecystitis, cholangitis and necrotizing cholecystitis)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cefoperazone 2grX2 for 7.2 days vs. ampicillin 1grX4 + tobramycin 1.5mg/kgX3 following loading dose 2mg/kg for 6.8 days (Surgery in addition to medical treatment was performed in 28/36 monotherapy patients and in 19/29 combination patients, not counted as failure)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure (clinical and bacteriological)<BR/>Superinfections<BR/>Colonization<BR/>Treatment duration<BR/>Dropouts<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre<BR/>Canada<BR/>Outcomes in subgroups: <BR/>Bacteraemia</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Biglino-1991">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>22 patients with severe infections. Patients were compromised by background diseases, including some immune-<BR/>compromise in 73%. Randomized to 4 arms monotherapy vs. combination, and high vs. low dose of imipenem</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Imipenem 0.5-1grX4 vs. imipenem 0.5-1grX4 + netilmicin 5mg/kg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Treatment failure (clinical)<BR/>Adverse events<BR/>Duration of fever and hospital stay</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Italy<BR/>No outcomes in subgroups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Brown-1984">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>48 adult patients (34 evaluated) with hospital acquired pneumonia of a documented Gram-negative origin (By sputum's Gram stain or cultures). 85% (29/34) acquired infection in the ICU</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Moxalactam 2grX3 for 10.1 days vs.<BR/>carbenicillin 66mg/kgX6 + tobramycin 1.7mg/kgX3 (following a 2-2.5mg/kg loading dose) for 10.6 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure (x-ray non-clearing)<BR/>Superinfections<BR/>Adverse events<BR/>Duration of treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>USA<BR/>Outcomes in subgroups:<BR/>Gram-negative and Pseudomonas sp. infections <BR/>4 deaths among 11 excluded patients not included in outcome assessment</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-02-11 10:21:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carbon-1987">
<CHAR_METHODS>
<P>RCT<BR/>Probably semi-empirical<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-02-11 10:21:39 +0000" MODIFIED_BY="[Empty name]">
<P>47 patients with bacteraemia due to enterobacteriaceae, with at least 3 positive blood cultures entered the study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cefotaxime 1grX4 for 12.9 days vs. cefotaxime 1grX4 + amikacin 7.5mg/kg loading dose followed by a renal-function adjusted maintenance dose for 13.2 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure (clinical)<BR/>Superinfections<BR/>Adverse events<BR/>Duration of treatment and fever</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre<BR/>France<BR/>Outcomes in subgroups: <BR/>Gram negative infections<BR/>Bacteraemia</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-02-20 16:18:21 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Cardozo-2001">
<CHAR_METHODS>
<P>RCT<BR/>Abdominal<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>110 children &lt;15 years, with acute appendicitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-02-20 16:18:21 +0000" MODIFIED_BY="Jane Cracknell">
<P>Amoxycillin-sulbactam 33mg/kgX3 vs. amoxacillin<BR/>-sulbactam 33mg/kgX3 + gentamicin 5mg/kgX1</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Paraguay (Spanish)<BR/>No outcomes in subgroups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Cometta-1994">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>313 adult patients with nosocomial pneumonia, nosocomial sepsis or severe diffuse peritonitis. 73% were in ICU and 48% on mechanical ventilation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Imipenem 500mgX4 for 10.2 days vs. imipenem 500mgX4 + netilmicin 150mgX2 for 10.5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure (clinical)<BR/>Superinfections<BR/>Colonization<BR/>Adverse events<BR/>Duration of treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre<BR/>Switzerland<BR/>Outcomes in subgroups: Gram-negative and Pseudomonas sp. infections<BR/>A secondary reference, Iten 1992, described 71 patients from this study, for whom surveillance cultures were performed, and detailed data concerning resistance development are given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Cone-1985">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>57 hospitalized patients with pneumonia or bacteraemia. Pneumonia was community acquired or nosocomial. Only patients with positive bacteriological cultures were evaluated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ceftazidime 2grX3 vs. ticarcillin 3grX4 + tobramycin 1mg/kgX3</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure (clinical)<BR/>Superinfections<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>USA<BR/>Outcomes in subgroups: Bacteraemia</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-02-20 16:22:16 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Coppens-1983">
<CHAR_METHODS>
<P>RCT<BR/>Semi-empirical<BR/>Gram positive infections<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-02-20 16:22:16 +0000" MODIFIED_BY="Jane Cracknell">
<P>80 patients in whom staphylococcal infections were clinically and microbiologically suspected. Inclusion criteria mandated a positive Gram stain showing Staphylococci Patients were randomized to the designated interventions. 24-48 hours following randomization, patients with documented methicillin-<BR/>resistant Staphylococci were switched to vancomycin, only in the monotherapy group (N=14). These were excluded from analysis in the review</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cefamandole 2grX3 vs.<BR/>cefamandole 2grX3 + tobramycin 80mgX3</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Treatment failure<BR/>(clinical and bacteriological)<BR/>Bacterial superinfection and colonization</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Belgium<BR/>Outcomes in subgroups: Bacteraemia</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-D_x0027_Antonio-1992">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Non-neutropenic adult patients with altered immune defence, with fever &gt; 38 lasting &gt; 8 hours. 88% of patients with underlying haematological malignancy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ceftriaxone 2grX1 for a median of 12 days vs. ceftriaxone 2grX1 + amikacin 5mg/kgX3 for a median of 11 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure<BR/>(clinical and bacteriological)<BR/>Superinfection and colonization (bacterial and fungal)<BR/>Adverse events<BR/>Treatment duration</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Italy<BR/>Outcomes in subgroups: <BR/>Gram-negative and Pseudomonas sp. infections Bacteraemia<BR/>Urinary tract infection</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-02-20 16:18:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Damas-2006">
<CHAR_METHODS MODIFIED="2011-12-26 07:52:08 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
<P>Sepsis, ventilator associated pneumonia</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-02-20 16:18:27 +0000" MODIFIED_BY="[Empty name]">
<P>50 adult patients who were mechanically ventilated for more than 48 hours<BR/>and developed clinical evidence of VAP</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-10-09 21:12:23 +0100" MODIFIED_BY="[Empty name]">
<P>IV Cefepime 2 g every 8 hours, for 8-10d Vs. IV Cefepime 2 g every 8 hours+ IV AMIKACIN 20 mg/kg, once daily for 5d</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-13 09:41:48 +0100" MODIFIED_BY="[Empty name]">
<P>Overall mortality<BR/>Treatment failure (bacteriological)<BR/>Superinfection<BR/>Hospitalisation duration</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-10-09 21:17:02 +0100" MODIFIED_BY="[Empty name]">
<P>Belgium</P>
<P>No outcomes in subgroups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Duff-1982">
<CHAR_METHODS>
<P>Quasi-randomized<BR/>Abdominal<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>74 patients included who developed endomyo-<BR/>parametritis after caesarian section or vaginal delivery, or who developed pelvic cellulitis after hysterectomy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cefoxitin 2grX3<BR/>vs. penicillin 5millUX4 + gentamicin 60-80mgX3</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure<BR/>Adverse events<BR/>Dropouts</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>USA<BR/>Outcomes in subgroups: Gram-negative infections<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-02-11 10:21:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dupont-2000">
<CHAR_METHODS>
<P>RCT<BR/>Abdominal<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-02-11 10:21:40 +0000" MODIFIED_BY="[Empty name]">
<P>241 patients evaluated with severe generalized peritonitis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Piperacillin- tazobactam 4grX4 for 8.2 days vs. <BR/>piperacillin- tazobactam 4grX4 + amikacin 7.5mg/kgX2 for 8.6 days. In addition all patients were operated on</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure (clinical)<BR/>Adverse events<BR/>Dropouts<BR/>Treatment duration</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre<BR/>France<BR/>No outcomes in subgroups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Felisart-1985">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>73 adult patients with underlying advanced cirrhosis, presenting with severe bacterial infections. Most patients had spontaneous bacterial peritonitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cefotaxime 2grX6 vs.<BR/>ampicillin 2grX6 + tobramycin renal adjusted maintenance dose X3/d following 1.75mg/kg loading dose</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure (clinical)<BR/>Superinfections<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Spain<BR/>Outcomes in subgroups: Bacteraemia<BR/>Urinary tract infections</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-26 07:56:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Figueroa_x002d_Damian-1996">
<CHAR_METHODS MODIFIED="2011-12-26 07:56:50 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
<P>Abdominal, post cesarean endometritis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-10-10 17:30:11 +0100" MODIFIED_BY="[Empty name]">
<P>56 adult patients with post cesarean endometritis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-10-10 17:31:35 +0100" MODIFIED_BY="[Empty name]">
<P>IV pipracellin/tazobactam 500MG x 4/D for 5 days Vs. IV ampicillin 1gr X 4/d + IV Gentamicin 80mg X 3/d,  for 4 days;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-10 17:34:49 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment failure (clinical)<BR/>Adverse events</P>
<P>Duration of fever and hospitalization</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-10-10 17:35:09 +0100" MODIFIED_BY="[Empty name]">
<P>Mexico</P>
<P>No outcomes in subgroups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-02-20 16:22:20 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Finer-1992">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>471 adult patients hospitalized with signs and symptoms of serious bacterial infections, thought by the physician to require parenteral antibiotic treatment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ceftazidime 2grX2 vs. ureidopenillin + aminoglycoside used routinely in specific Center: piperacillin-<BR/>gentamicin (73p); ampicillin-<BR/>gentamicin (69p); mezlocillin-<BR/>netilmicin (44p); piperacillin-<BR/>netilmicin (20p)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-02-20 16:22:20 +0000" MODIFIED_BY="Jane Cracknell">
<P>Overall mortality<BR/>Treatment failure (clinical and bacteriological)<BR/>Superinfections<BR/>Colonization<BR/>Drop-outs after randomization<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre<BR/>UK<BR/>Outcomes in subgroups: Bacteraemia<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-02-20 16:18:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garc_x00ed_a-Ram_x00ed_rez-1999">
<CHAR_METHODS MODIFIED="2011-12-26 07:57:50 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
<P>Sepsis, Nosocomial pneumonia</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-02-20 16:18:43 +0000" MODIFIED_BY="[Empty name]">
<P>60 adult patients with Nosocomial pneumonia, de vided to 2 groups.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-10-10 17:43:28 +0100" MODIFIED_BY="[Empty name]">
<P>IV Ceftazidime Vs. IV penicillin + amikacin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-11 15:46:41 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment failure (clinical)<BR/>Duration of hospitalization<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-10-10 17:44:53 +0100" MODIFIED_BY="[Empty name]">
<P>Tacuba</P>
<P>Outcomes in subgroups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gerecht-1989">
<CHAR_METHODS>
<P>RCT<BR/>Abdominal<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>82 patients with suspected cholangitis were randomized empirically. Only those with bacteraemia or positive bile cultures, and fulfilling clinical criteria for cholangitis were evaluated. Patients who were not evaluated because they did not meet inclusion criteria are not considered as dropouts for the review</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Mezlocillin 4grX4 for 11.9 days vs. ampicillin 1grX4 + gentamicin 1.5mg/kgX3 for 10.3 days. In addition to antibiotic therapy all patients underwent surgical intervention</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Treatment failure (clinical and bacteriological)<BR/>Superinfections<BR/>Adverse events<BR/>Duration of treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>USA<BR/>No outcomes in subgroups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gomez-1990a">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>197 patients with suspected Gram-negative bacteraemia randomized. Patients with proven Gram-negative bacteraemia (78) were analysed. Patients who were not evaluated because they did not meet inclusion criteria for bacteraemia were not considered as dropouts</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ceftazidime 1grX4 for 10 days vs. cefradine 1grX6 + amikacin 7.5mg/kgX2 for 10 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure (clinical and bacteriological)<BR/>Superinfection (bacterial and fungal)<BR/>Adverse events<BR/>Duration of treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Spain (Spanish)<BR/>Outcomes in subgroups:<BR/>Bacteremia<BR/>Gram-negative infections</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-26 08:00:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hasali-2005">
<CHAR_METHODS MODIFIED="2011-12-26 07:59:14 +0000" MODIFIED_BY="[Empty name]">
<P>RCT single blind</P>
<P>Sepsis, Community-acquired pneumonia</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-26 07:59:23 +0000" MODIFIED_BY="[Empty name]">
<P>Pediatric patients (aged 2m to 5 years) diagnosed with Community-acquired pneumonia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-10-09 21:21:53 +0100" MODIFIED_BY="[Empty name]">
<P>IV ampicillin 100 mg/kg/day divided every 6 h Vs. IV ampicillin 100 mg/kg/day divided every 6 h + IV Gentamicin 5mg/kg x 1/d</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-26 08:00:29 +0000" MODIFIED_BY="[Empty name]">
<P>Duration of treatment, fever and hospitalization</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-10-09 21:28:07 +0100" MODIFIED_BY="[Empty name]">
<P>Malaysia</P>
<P>No outcome in subgroups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Havig-1973">
<CHAR_METHODS>
<P>RCT<BR/>Abdominal<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>68 adult patients evaluated with acute cholecystitis verified histologically or by roengten. Trial included 3 arms, of which 2 are included in the review</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IM ampicillin 0.5grX4<BR/>vs. IM chloramphenicol 1grX2 (arm not included in review) vs. IM benzyl-penicillin 400,000IEX2 + IM streptomycin 0.5grX2. In addition 10/24 patients in the ampicillin arm and 15/26 patients in the combination arm were operated on</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure (clinical)<BR/>Duration of fever</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Norway<BR/>No outcomes in subgroups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hoepelman-1988">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>105 patients with serious bacterial infections were included. Of these 18% were neutropenic and are not included for the analysis in this review</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ceftriaxone 2grX1 vs. cefuroxime 1.5grX3 + gentamicin 80mgX3 (following by an initial 1.5mg/kg dose)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality Treatment failure (clinical)<BR/>Superinfections<BR/>Fungal colonization<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Netherlands Outcomes for subgroups were not extracted, as they are given in the publication for the whole group including neutropenic patients<BR/>Outcomes for non-neutropenic patients were obtained from the author</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Holloway--1985">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>Semi-empirical<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>43 adult patients with suspected Gram-negative septicaemia, or pneumonia, randomized when blood cultures were positive for a Gram-negative pathogen</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ticarcillin-clavulanic acid 3.1grX4-6 vs. piperacillin 50mg/kgX4-6 + tobramycin 1-1.5mg/kgX3-4</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Treatment failure (clinical and bacteriological)<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>USA<BR/>Outcomes in subgroups:<BR/>Bacteremia<BR/>Gram-negative infections</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Iakovlev-1998">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>95 adult patients with severe nosocomial infections</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Meropenem 1grX3 for 9 days vs. ceftazidime 1grX3 + amikacin 500mgX2 for 9 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Treatment failure (clinical and bacteriological)<BR/>Duration of treatment<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre<BR/>Russia (Russian)<BR/>Outcomes in subgroups: Urinary tract and Pseudomonas sp. infections</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Jaspers-1998">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>79 elderly patients ( &gt; 65yrs.) with sepsis syndrome and suspected bacteraemia, pneumonia, intra-abdominal sepsis, or complicated urinary tract infection</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Meropenem 1grX3 for 7.5 days vs. cefuroxime 1.5grX3 + gentamicin 4mg/kgX1 for 7.4 days (metronidazole 500mgX4 added to patients receiving combination in case of abdominal sepsis (15 patients overall)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure (clinical and microbiological)<BR/>Bacterial superinfections<BR/>Adverse events<BR/>Duration of treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre<BR/>Netherlands<BR/>Outcomes in subgroups:<BR/>Urinary tract infections</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Klastersky-1973">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>75 adult patients with disseminated cancer and life threatening infections, presumed Gram-negative. Randomized to 3 arms, of which 2 are relevant for the review. 18% of patients leukopenic (leukopenia not defined) - no information for neutropenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Carbenicillin 10grX3 for 8.3 days vs. carbenicillin 10grX3 + gentamicin 160mgX3 (IM or IV) for 9 days vs. gentamicin 160mgX3 (3rd arm, not included in review)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure (clinical and bacteriological)<BR/>Colonization and Superinfection<BR/>Duration of treatment<BR/>Dropouts</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Belgium<BR/>Outcomes in subgroups:<BR/>Gram-negative and Pseudomonas sp. infections<BR/>Bacteremia<BR/>Urinary tract infections</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kljucar-1990">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>150 patients &gt; 14yrs. hospitalized in the intensive care unit and ventilated, with nosocomially acquired pneumonia. Randomized to 3 arms (2 combination and 1 monotherapy)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ceftazidime 2grX3 vs.<BR/>ceftazidime 2grX3 + tobramycin 80mgX3 vs. azlocillin 5mgX3 + tobramycin 80mgX3, overall for 6.6 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure (clinical and bacteriological)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Germany<BR/>No outcomes in subgroups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Koehler-1990">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>144 patients &gt; 18 yrs. with nosocomially acquired pneumonia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ceftazidime 1grX3 vs. piperacillin 4grX3 + tobramycin 80mgX3</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure (clinical and bacteriological)<BR/>Bacterial and fungal colonization<BR/>Dropouts</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre<BR/>Germany<BR/>Outcomes in subgroups:<BR/>Gram negative and Pseudomonas sp. infections</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-02-20 16:19:05 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Korzeniowski-1982">
<CHAR_METHODS>
<P>RCT<BR/>Partially semi-empirical<BR/>Gram positive infections<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-02-20 16:19:04 +0000" MODIFIED_BY="Jane Cracknell">
<P>156 patients with clinically suspected infective endocarditis were randomized (prior antibiotic treatment of &lt; 48 hours permitted) 78 patients with Staphylococcus aureus bacteraemia and endocarditis were analysed: 48 drug addicts and 30 non-addicts (14 patients randomized semi-empirically)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Nafcillin 1.5-6grX6 vs. nafcillin 1.5-6grX6 + gentamicin 1mg/kgX3 administered for the first 2 weeks of a 4-week treatment protocol</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-02-20 16:19:05 +0000" MODIFIED_BY="Jane Cracknell">
<P>Overall mortality<BR/>Treatment failure (clinical and bacteriological)<BR/>Dropouts<BR/>Need for surgery<BR/>Adverse events<BR/>Duration of bacteraemia and fever are other outcomes shown in the study, but these are shown by groups of empirical treatment regimen which was not always randomly allocated<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre<BR/>USA<BR/>Outcomes in subgroups:<BR/>Bacteremia</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Landau-1990">
<CHAR_METHODS>
<P>Quasi-randomized<BR/>Urinary tract infections<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>40 adult patients hospitalized with complicated urinary tract infection</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ceftriaxone 2grX1<BR/>vs. cefazolin 1grX3 + gentamicin 80mgX3</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure (bacteriological only)<BR/>Adverse events<BR/>Drop-outs after randomization<BR/>Duration of fever</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Israel (Hebrew) Outcomes in subgroups:<BR/>Urinary tract and<BR/>Gram-negative infections</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Limson-1988">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>54 adult patients randomized, of which 40 patients with severe Gram-negative infections were evaluated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ceftazidime 2grX2 vs.<BR/>ticarcillin 3grX3-4 + amikacin 500mgX2 (or 15mg/kgX1)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Treatment failure (clinical and microbiological)<BR/>Fungal superinfections<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The Philippines Outcomes in subgroups:<BR/>Bacteremia<BR/>Gram negative, and Pseudomonas sp. infections</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mandell-1987">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>110 patients &gt; 16yrs. evaluated with community acquired or nosocomial pneumonia (2/3 nosocomial)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ceftazidime 2grX3 vs.<BR/>cefazolin 1.5grX3 or ticarcillin 3grX4 + tobramycin 1.7mg/kgX3</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Treatment failure (clinical and bacteriological)<BR/>Superinfections<BR/>Colonization (including resistant development)<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre<BR/>Canada<BR/>Outcomes in subgroups:<BR/>Bacteraemia<BR/>Gram-negative infections.<BR/>Cefazolin replaced by ticarcillin for combination group patients with documented Pseudomonas infections</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Martin-1991">
<CHAR_METHODS>
<P>RCT<BR/>Urinary tract infections<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>116 patients hospitalized with suspected pyelonephritis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ceftriaxone 2grX1 vs. ampicillin 1grX4 + gentamicin 1mg/kgX3<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Treatment failure (clinical)<BR/>Superinfection (relapse and re-infections)<BR/>Dropouts<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Brussels (French)<BR/>Outcomes in subgroups:<BR/>Urinary tract infections<BR/>Bacteremia</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-McCormick-1997">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>128 adult patients with chronic liver disease (cirrhosis) and suspected or proven sepsis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ceftazidime 2grX2 for 5 days vs. mezlocillin 5grX3 + netilmicin 3mg/kgX2 for 4 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure<BR/>(clinical)<BR/>Adverse events<BR/>Duration of treatment and hospital stay</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Ireland<BR/>Outcomes in subgroups:<BR/>Bacteremia</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-26 08:06:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mergoni-1987">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-26 08:06:34 +0000" MODIFIED_BY="[Empty name]">
<P>42 adult patients in ICU with severe infections</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Azlocillin 13+-2.2gr for 6.5 days vs. azloclillin 14.1+-1gr + amikacin 1.16+-0.027gr for 7.2 days (all in for daily doses)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Treatment failure (clinical and bacteriological)<BR/>Adverse events<BR/>Duration of treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Italy<BR/>Outcomes in subgroups:<BR/>Gram negative and Pseudomonas sp. infections</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Moreno-1997">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Renal or (kidney-<BR/>pancreas) transplant patients with fever and suspected bacterial infection</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Imipenem-cilastatin 500mgX4 vs. piperacillin 4grX3 + tobramycin 80mgX2</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Treatment failure (clinical and bacteriological)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Spain<BR/>Outcomes in subgroups:<BR/>Gram negative and Pseudomonas sp. infections</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mouton-1990">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>211 adult patients hospitalized in intensive care unit with respiratory tract infections</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Imipenem 500mgX4 for 11.1 days vs. cefotaxime 1grX4 + amikacin 5mg/kgX3 for 10.4 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure (clinical and bacteriological)<BR/>Superinfections<BR/>Colonization<BR/>Hospitalization duration<BR/>Duration of treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre<BR/>France (French) Outcomes in subgroups:<BR/>Bacteremia</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mouton-1995">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>237 adult patients with community or hospital acquired serious infections, excluding intra-abdominal sepsis (urinary tract infection included)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Meropenem 1grX3 for 8.8 days vs. ceftazidime 2grX3 + amikacin 5-7.5mg/kgX2-3 for 8.3 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure (clinical and bacteriological)<BR/>Superinfections<BR/>Adverse events<BR/>Dropouts<BR/>Duration of treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre<BR/>Europe<BR/>Outcomes in subgroups:<BR/>Bacteremia<BR/>Gram negative and Pseudomonas sp. and urinary tract infections</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Muller-1987">
<CHAR_METHODS>
<P>RCT<BR/>Abdominal<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Trial includes 3 arms (2 monotherapies, 1 combination treatment)<BR/>106 patients evaluated with acute cholecystitis or cholangitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Piperacillin 3grX6 for 7.4 days vs. cefoperazone 2grX3 for 8.1 days vs.<BR/>ampicillin 2grX4 + tobramycin 1-1.5mg/kgX3 following 1.5mg/kg loading dose for 11.1 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Treatment failure (clinical)<BR/>Adverse events<BR/>Duration of treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Bi-centre<BR/>USA<BR/>No outcomes in subgroups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Naime-Libien-1992">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>30 children aged 1m - 11yr with severe lower respiratory tract infections</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ceftizoxime 20-50mg/kgX2-3 vs. penicillin 0.7-1.7 megaunit/kgX3 + gentamicin 1-1.5mg/kgX2</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure (clinical and bacteriological)<BR/>Adverse events<BR/>Duration of fever</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mexico (Spanish)<BR/>No outcomes in subgroups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-02-20 16:19:54 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Piccart-1984">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-02-20 16:19:54 +0000" MODIFIED_BY="Jane Cracknell">
<P>105 adult, non-neutropenic, cancer patients with suspected Gram-negative infections. Study included both neutropenic and non-neutropenic patients, but analysis was completely separated Patients with Gram-positive bacteraemia were excluded</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cefoperazone 6grX2 vs.<BR/>cefoperazone 2grX2 + amikacin 500mgX2</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Treatment failure (clinical and bacteriological)<BR/>Superinfections (bacterial and fungal)<BR/>Drop-outs after randomization</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Belgium<BR/>Outcomes in subgroups:<BR/>Gram-negative and Pseudomonas sp. infections<BR/>Bacteremia</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-02-20 16:19:56 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Rapp-1984">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>35 adult patients hospitalized in a neurosurgical intensive care unit. All with nosocomial pneumonia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ceftazidime 2grX3 vs.<BR/>ticarcillin 3grX4 + tobramycin pharmacokinetically adjusted doses after 1.75mg/kd loading dose</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Treatment failure (clinical and bacteriological)<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-02-20 16:19:56 +0000" MODIFIED_BY="Jane Cracknell">
<P>USA<BR/>Outcomes in subgroups:<BR/>Gram negative bacteraemia<BR/>Pseudomonas sp. infections</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rasmussen-1986">
<CHAR_METHODS>
<P>RCT<BR/>Urinary tract infections<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>62 adult patients hospitalized in a urosurgical department with urinary tract infections, mostly post-operative</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cefotaxime 3grX3 for 5.4 days vs. ampicillin 1grX4 + netilmicin 150mgX3 for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Treatment failure (clinical)<BR/>Relapse<BR/>Duration of fever and treatment<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Denmark<BR/>Outcomes in subgroups:<BR/>Urinary tract infections</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ribera-1996">
<CHAR_METHODS>
<P>RCT<BR/>Semi-empirical<BR/>Gram-positive infections<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Spain<BR/>90 intravenous drug users randomized, of which 74 had Staphylococcus aureus right-sided endocarditis. 90.5% of patients were HIV positive. Diagnostic criteria for possible (13% of study patients), probable (34%) and definitive endocarditis (53%) are defined in study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cloxacillin 2grX6 vs. cloxacillin 2grX6 + gentamicin 1mg/kgX3</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure (clinical and bacteriological)<BR/>Relapse, re-infection and need for surgery<BR/>Duration of treatment<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Spain<BR/>Journal publication.<BR/>Outcomes in subgroups:<BR/>Bacteremia</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rubinstein-1995">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>580 adult patients with serious hospital acquired infections and a diagnosis of sepsis, pneumonia or upper urinary tract infection</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ceftazidime 2grX2 for 9 days vs. ceftriaxone 2grX1 + tobramycin 3-5mg/kgX1 following 2mg/kg loading dose for 9 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure (clinical and bacteriological)<BR/>Superinfections<BR/>Duration of treatment<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre<BR/>Europe, Middle East, Asia, South America<BR/>Outcomes in subgroups:<BR/>Gram-negative and Pseudomonas sp. infections<BR/>Bacteremia<BR/>Urinary tract infections</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sage-1987">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>93 patients &gt; 14yrs. randomized to 3 arms, of which 2 are usable in the review. The 3rd arm is aminoglycoside monotherapy. Patients were suspected of a life threatening sepsis, thought to be caused by Enterobacteriaceae or Staphylococci</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cefotaxime 1-2grX4 for 7.4 days vs. cefotaxime 1-2grX4 + netilmicin 2-3mg/kgX3 (3rd arm, not used - netilmicin 2-3mg/kgX3) for 8.7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Treatment failure (clinical and bacteriological)<BR/>Bacterial and fungal superinfections<BR/>Dropouts<BR/>Adverse events<BR/>Duration of treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>UK<BR/>Outcomes in subgroups:<BR/>Bacteremia<BR/>Gram negative and urinary tract infections</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sandberg-1997">
<CHAR_METHODS>
<P>RCT<BR/>Urinary tract infections<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>73 adult female patients with suspected pyelonephritis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cefotaxime 1grX2 for 2 days followed by oral cefadroxil 1grX2 vs.<BR/>cefotaxime 1grX2 + tobramycin 160mgX1 for 2 days, followed by oral cefadroxil 1 grX2</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Treatment failure (clinical and bacteriological)<BR/>Superinfection and colonization (relapse, re-infections and asymptomatic bacteriuria recurrence)<BR/>Adverse events<BR/>Drop-outs after randomization<BR/>Duration of fever</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre<BR/>Sweden<BR/>Outcomes in subgroups: Urinary tract infections</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sanfilippo-1989">
<CHAR_METHODS>
<P>RCT<BR/>Abdominal<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>26 female patients aged 16-19 years with acute pelvic inflammatory disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Mezlocillin 62.5mg/kgX4 vs. penicillin 480,000U/kgX4 + tobramycin 1mg/kgX3</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Treatment failure (clinical)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>USA<BR/>No outcomes in subgroups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sculier-1982">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>20 adult, intubated, patients with Gram-negative pneumonia in the neurosurgical intensive-care unit Patients were randomized when presenting with radiographic broncho-<BR/>pneumonia, purulent sputum and Gram-negative rods on sputum direct smear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Mezlocillin 10grX3 vs. mezlocillin 10grX3 + sisomicin 75mgX3.<BR/>In addition to allocated systemic treatment, all patients received intra-tracheal sisomycin 25mgX3/d</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure (clinical and bacteriological)<BR/>Bacterial colonization<BR/>Resistance development<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Belgium<BR/>Outcomes in subgroups:<BR/>Gram negative and Pseudomonas sp. infections</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sexton-1998">
<CHAR_METHODS>
<P>RCT<BR/>Semi-empirical<BR/>Gram-positive infections<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>67 adult patients randomized, of which 51 with native valve endocarditis (defined by Duke criteria) caused by penicillin-<BR/>susceptible Streptococci.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ceftriaxone 2grX1 for 4 weeks vs. ceftriaxone 2grX1 + gentamicin 3mg/kgX1 for 2 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Treatment failure (clinical and bacteriological)<BR/>Relapse and re-infection Adverse events<BR/>Dropouts<BR/>Duration of hospital stay<BR/>Need for surgery</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre <BR/>USA<BR/>Outcomes in subgroups:<BR/>Bacteremia</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sieger-1997">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>211 adults &gt;18yrs. with hospital-<BR/>acquired lower respiratory tract infections. 70% intubated and 27% with severe pneumonia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Meropenem 1grX3 for 7.8 days vs. ceftazidime 2grX3 + tobramycin 1mg/kgX3 (following 1.5-2mg/kg loading dose) for 7.4 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure (clinical and bacteriological) Superinfections<BR/>Adverse events<BR/>Duration of treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre <BR/>USA<BR/>Outcomes in subgroups:<BR/>Gram-negative and Pseudomonas sp. infections.<BR/>Study performs both efficacy and ITT analysis, with a drop-out rate of 43% for the efficacy analysis. Outcomes were extracted by ITT. Superinfections and subgroup analyses are given only by efficacy analysis in study<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Smith-1984">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>200 adult patients randomized with suspected or proven serious infections. 195 who actually received study drugs were evaluated for efficacy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cefotaxime 2grX6<BR/>+ placebo X3 for 5 days vs.<BR/>nafcillin 1.5grX6 + tobramycin 2mg/kgX3 for 5.3 days<BR/>(Addition of clindamycin 600mgX3 to both groups permitted for suspected anaerobic infections)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure<BR/>(clinical and microbiological)<BR/>Bacterial superinfections<BR/>Colonization<BR/>Adverse events<BR/>Duration of treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>USA<BR/>Outcomes in subgroups:<BR/>Urinary tract and Gram negative infections.<BR/>Two additional references refer to the same trial: Moore 1986a (cost-effectiveness analysis), and Moore 1986b (nephrotoxicity analysis). Overall mortality, and treatment duration are taken from Moore 1986a that analysed all patients given study drugs. Cost outcome not included in the review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Speich-1998">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>89 adults &gt;16yrs. with severe pneumonia. Community acquired in 89%<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Piperacillin-tazobactam 4.5grX3 for 10.2 days vs.<BR/>amoxicllin-clavulonic acid 2.2grX3 + gentamicin or netilmicin 3-6mg/kgX1 for 10.1 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure (clinical and bacteriological)<BR/>Dropouts<BR/>Adverse events<BR/>Duration of treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre <BR/>Switzerland<BR/>No outcomes in subgroups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Stille-1992">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>337 adult patients randomized with non-life-<BR/>threatening infections, of abdominal, gynaecological or respiratory tract origin (UTI, skin, bone, and CNS infections excluded)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Imipenem 500mgX3 for 8.4 days vs. cefotaxime 2grX3 + gentamicin 0.66-1mg/kgX3 for 8.2 days (metronidazile allowed in combination treatment group for suspected anaerobic infection)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure (clinical and bacteriological)<BR/>Colonization and resistance development<BR/>Adverse events<BR/>Duration of treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre<BR/>Germany and Austria<BR/>Outcomes in subgroups:<BR/>Gram negative and Pseudomonas sp. infections</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sukoh-1994">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>63 patients with respiratory tract infections and underlying respiratory disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cefoperazone/ sulbactam 1-4gr/d for 11.7 days vs. Cefoperazone/ sulbactam 2-6gr/d + one of several aminoglycosides in low doses (amikacin 100-400 mg/d 16 patients, tobramycin 40-180 mg/d 15 patients, isepamicin 400 mg/d 1 patient, netilmicin 200 mg/d 1 patient) for 11.1 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Treatment failure (clinical and bacteriological)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Japan (Japanese)<BR/>Outcomes in subgroups:<BR/>Gram-negative and Pseudomonas sp. infections</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Takamoto-1994">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>171 adult patients with respiratory tract infections</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Imipenem/cilastatin sodium vs.<BR/>imipenem/cilastatin sodium + amikacin sulfate<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Treatment failure (clinical and bacteriological)<BR/>Drop-outs after randomization<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre Japan (Japanese) Outcomes in subgroups:<BR/>Gram-negative and Pseudomonas sp. infections</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Thompson--1990">
<CHAR_METHODS>
<P>RCT<BR/>Abdominal<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>96 patients evaluated with acute cholangitis (cholecystitis not included)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Piperacillin 3grX6 for 8.4 days vs. ampicillin 2grX4 + tobramycin 1-1.5mg/kgX3 for 9.1 days (following 1.5mg/kg loading dose). In addition 35/96 patients were operated on</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure (clinical)<BR/>Adverse events<BR/>Treatment duration</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre<BR/>USA<BR/>No outcomes in subgroups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Thompson-1993">
<CHAR_METHODS>
<P>RCT<BR/>Abdominal<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>120 patients evaluated with acute biliary tract infections (cholecystitis and cholangitis)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cefepime 2grX2 for 7.5 days vs. mezlocillin 3grX6 + gentamicin 1.5mg/kgX3 for 7 days. In addition, 118/120 patients were operated on</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure (clinical)<BR/>Adverse events<BR/>Treatment and hospitalization duration</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicenter<BR/>USA<BR/>No outcomes in subgroups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Trujillo-1992">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>30 adult patients with severe skin and soft tissue or respiratory tract infections</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ceftizoxime 1-2grX3 vs. ampicillin 1-3grX4 + gentamicin 3-5mg/kg/d, overall for 10 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure (clinical and bacteriological)<BR/>Adverse events<BR/>Fever duration</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mexico (Spanish)<BR/>No outcomes in subgroups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-02-20 16:20:54 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Vergnon-1985">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-02-20 16:20:54 +0000" MODIFIED_BY="Jane Cracknell">
<P>30 adult patients with severe broncho-<BR/>pulmonary infections</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cefoperazone 2grX2 for 16.8 days vs. ampicillin 1.5grX4 + tobramycin 1mg/kgX3 for 11.8 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Treatment failure (clinical)<BR/>Resistant colonization<BR/>Adverse events<BR/>Duration of treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>France (French)<BR/>No outcomes in subgroups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-02-20 16:21:00 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Verzasconi-1995">
<CHAR_METHODS>
<P>RCT<BR/>Urinary tract infections<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-02-20 16:21:00 +0000" MODIFIED_BY="Jane Cracknell">
<P>93 adult patients with acute pyelonephritis or complicated urinary tract infections</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Amoxicillin-clavulonate 2.2grX3 for 4.1 days vs. amoxicillin 2grX3 + gentamicin 1.5mg/kg loading followed by maintenance for 4.2 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Treatment failure (bacteriological)<BR/>Superinfection<BR/>Dropouts<BR/>Treatment and fever duration<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Bi-centre<BR/>Switzerland (German)<BR/>Outcomes in subgroups:<BR/>Urinary tract infection</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Warren-1983">
<CHAR_METHODS>
<P>RCT<BR/>Sepsis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>120 adult patients with suspected or known life-threatening infections caused by Gram-negative bacilli</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cefoperazone 1.5grX4 for a median of 9 days vs.<BR/>cefamandole 2grX6 + tobramycin 1.7mg/kg loading dose, followed by drug- level-adjusted maintenance dose for a median of 8 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure (clinical and bacteriological)<BR/>Superinfection<BR/>Duration of treatment<BR/>Adverse events<BR/>Drop-outs after randomization</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>USA<BR/>Outcomes in subgroups:<BR/>Bacteremia<BR/>Gram-negative infections</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-02-20 16:21:05 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Wiecek-1986">
<CHAR_METHODS>
<P>RCT<BR/>Urinary tract infections<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-02-20 16:21:05 +0000" MODIFIED_BY="Jane Cracknell">
<P>20 adult patient with acute pyelonephritis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ceftazidime 1grX3 vs.<BR/>cefotaxime 1grX2 + tobramycin 1mg/kgX3</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Treatment failure (bacteriological)<BR/>Re-infection<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Poland<BR/>Outcomes in subgroups:<BR/>Gram negative and Pseudomonas sp. infections<BR/>Urinary tract infections<BR/>Bacteremia</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wing-1998">
<CHAR_METHODS>
<P>RCT<BR/>Urinary tract infections<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>179 pregnant women &lt;24 weeks gestation with pyelonephritis randomized to 2 monotherapy arms and 1 combination therapy arm</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cefazolin 1grX3 vs. ceftriaxone 1grX1 vs. ampicillin 2grX4 + gentamicin 1.75mg/kgX3 (after 2mg/kg loading)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure (clinical and bacteriological)<BR/>Re-infection<BR/>Fever and hospitalization duration<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Bi-centre<BR/>USA<BR/>Outcomes in subgroups:<BR/>Urinary tract infections</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Yellin-1993">
<CHAR_METHODS>
<P>RCT<BR/>Abdominal<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>179 patients with clinically suspected cholecystitisOnly those operated on while on allocated treatment were evaluated (infection proven at surgery) Patients who were not evaluated because surgery was not performed or incorrect diagnosis are not considered as drop-outs for the review</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cefepime 2grX2 for 7.3 days vs. mezlocillin 4grX4 + gentamicin 1.5mg/kgX3 for 7.2 days. In addition to antibiotic treatment all patients operated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall mortality<BR/>Treatment failure (clinical)<BR/>Fever, treatment and hospitalization duration</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>USA<BR/>No outcomes in subgroups<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>RCT - randomized controlled trial<BR/>vs - versus<BR/>Semi-empirical - comparison of second-line antibiotic treatment, given following establishment of microbiological or clinical diagnosis.<BR/>Treatment duration represents means unless otherwise specified.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-03-19 07:35:58 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Alvarez_x002d_Lerma-2001b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Beta-lactam-aminoglycoside combination treatment versus beta-lactam-aminoglycoside combination treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Badaro-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation to additional aminoglycoside treatment not randomized. Patients were randomized to treatment with beta-lactam monotherapy versus 'standard' antibiotic treatment, which was a beta-lactam with or without an aminoglycoside.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Benlloch-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Antibiotic regimens incompatible with protocol. Randomization to 3 arms: 1) beta-lactam-aminoglycoside-nitroimmidazole combination 2) beta-lactam-aminoglycoside combination 3) double beta-lactam combination.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Blumer-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>No sepsis in inclusion criteria. Study included patients with acute exacerbation of cystic fibrosis, but the definition of exacerbation does answer the criteria for sepsis as defined in review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-26 04:44:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bodey-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-26 04:44:17 +0000" MODIFIED_BY="[Empty name]">
<P>Study includes 100% patients with neutropenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cetto-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study includes 71% patients with neutropenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-10 19:45:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chaudhary-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-10 19:45:31 +0100" MODIFIED_BY="[Empty name]">
<P>Sepsis was not mandated for inclusion to the study. Patients with bronchitis were included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-10 19:43:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chaudhary-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-10 19:43:28 +0100" MODIFIED_BY="[Empty name]">
<P>Sepsis was not mandated for inclusion to the study. Patients with bronchitis were included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ciftci-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Antibiotic regimens incompatible with protocol. Randomization to 4 arms: 1) beta-lactam-aminlglycoside-lincosamide combination 2) beta-lactam-aminoglycoside-imidazole combination 3) beta-lactam monotherapy 4) beta-lactam-imidazole combination.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Crenshaw-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Prophylaxis study. Randomization to beta-lactam monotherapy versus beta-lactam aminoglycoside combination therapy as preventive therapy for patients with penetrating abdominal wounds requiring surgical intervention.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Croce-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomized trial. Monotherapy and combination therapy groups were studied consecutively.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-De-Louvois-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Included patients were newborns with suspected sepsis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Extermann-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomization to beta-lactam monotherapy versus best-guess antibiotic treatment as chosen by physician. The best guess treatment group includes monotherapy and various combinations.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fainstein-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study includes 62.5% neutropenic patients. The study randomized 321 episodes, of which 275 were evaluable - 172 in neutropenic patients and 103 episodes in non-neutropenic patients. Although analysis was intended to be separated, the number of evaluated patients in each group, is not separated to neutropenic and non-neutropenic patients. Although outcomes (death and failures) are given for non-neutropenic patients, the number of patients in the group is unknown. Information was unavailable from authors.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fernandez-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomization to beta-lactam monotherapy versus<BR/>combination therapy commonly used in specific centre (multicentre trial). Combinations consisted of different beta-lactams with aminoglycoside antibiotics in 211/273 patients evaluated in the combination group, and other antibiotic combinations in 62/273 patients. Outcomes are given per specific combination (failure), but the study is excluded since the decision as to which combination the patient received was left to the care-taker.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Foord-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomized trial. Article describes all patients on Glaxo data files who have been administered Ceftazidime monotherapy in comparative and non-comparative trials. No references in the article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gentry-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomized trial. Study describes centre's experience with monotherapy versus combination therapy. One study group was previously reported. All prospective, comparative, but no mention of randomization.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gentry-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Prophylaxis study. Randomization to 3 arms (2 beta-lactam monotherapy arms and 1 beta-lactam-aminoglycoside combination therapy arm), as perioperative prophylaxis for patients with penetrating injuries of the abdomen.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gentry-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pooled analysis of patients with skin, soft-tissue and bone infections, comparing ceftazidime monotherapy to control regimens, including ticalcillin and tobramycin combination therapy. However, randomized patients cannot be separate from those who entered open comparative trials.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gerber-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Prophylaxis study. Antibiotic treatment was administered as prophylaxis and patients did not fulfil the criteria for sepsis when randomized.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gilbert-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study includes 18% neutropenic patients (32/175 evaluable patients). In addition neutropenic patients were not randomized - all were allocated only to the combination regimen. Outcome data was unavailable separating randomized from non randomized (neutropenic) patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Giraud-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Antibiotic regimens incompatible with protocol. Randomization to 2 arms: 1) beta-lactam monotherapy versus 2) beta-lactam-aminoglycoside-nitroimidazole triple combination therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gold-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>No sepsis in inclusion criteria. Study included patients with acute exacerbation of cystic fibrosis, but the definition of exacerbation does answer the criteria for sepsis as defined in review.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gomez-1990b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Observational study according to author correspondence.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Greco-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized prospective comparative trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gribble-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study includes 60% neutropenic patients (30/50 evaluable episodes).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Haffejee-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Included patients were neonates and children.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hall-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Included patients were neonates.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hammerberg-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Included patients were premature neonates with risk factors for sepsis (31/72 patients between ages 0-1 months).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hanson-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Antibiotic regimens incompatible with protocol. Combination therapy versus combination therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-20 16:21:22 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Hoogkamp-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-20 16:21:22 +0000" MODIFIED_BY="Jane Cracknell">
<P>Not a randomized trial. Study groups were studied sequentially. In addition study population consists of cystic fibrosis patients with an exacerbation - sepsis not part of inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Iakovlev-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Aminoglycoside was added only to patients that did not respond to the initial beta-lactam monotherapy that was administered empirically.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Iakovlev-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomized trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-10 20:46:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Iakovlev-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-10 20:46:08 +0100" MODIFIED_BY="[Empty name]">
<P>Study compares meropenem to "standard regimen" for sepsis at the study hospital (betalactams and fluoroquinolones in combination with aminoglycosides and/ or metronidazole). </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ker-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Prophylaxis study. Randomization to prophylactic antibiotic treatment, patients did not fulfil criteria for sepsis when randomized.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Krumpe-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients first stratified by disease severity to monotherapy (severe disease) or combination therapy. Following stratification, the patients were randomized to 4 arms: 1) quinolone monotherapy 2) 'standard monotherapy'' from a defined choice of various beta-lactams, at investigator's discretion 3) quinolone-beta-lactam combination therapy 4) 'standard combination therapy' which consisted of various possible combinations of beta-lactams and aminoglycosides at investigators discretion.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ludwig-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Description of two separate randomized trials: 1) beta-lactam versus aminoglycoside 2) beta-lactam versus beta-lactam. All administered as monotherapies.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Maller-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomization to once daily aminoglycoside treatment versus twice daily aminoglycoside treatment. In addition to the aminoglycoside, a beta-lactam was administered if considered necessary. Administration of the beta-lactam not randomized (interim analysis of a multicentre study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mangi-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomization to beta-lactam monotherapy versus combination. The combination group consisted of clindamycin-aminoglycoside or beta-lactam-aminoglycoside combinations. The decision as to which combination treatment was administered was made on a case-by-case basis, according to the sputum's Gram stain. Patients with Gram-negative bacilli in the sputum were administered the beta-lactam based combination while all others received the clindamycin-based regimen. Outcomes for the two different combination treatments are given together.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McArdle-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Prophylaxis study. Randomization to beta-lactam monotherapy versus beta-lactam aminoglycoside combination therapy for prophylaxis prior to high-risk biliary tract surgery.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McCarty-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>No sepsis in inclusion criteria. Study included patients with acute exacerbation of cystic fibrosis, but the definition of exacerbation does answer the criteria for sepsis as defined in review.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McLaughlin-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>No sepsis in inclusion criteria. Study included patients with acute exacerbation of cystic fibrosis, but the definition of exacerbation does answer the criteria for sepsis as defined in review.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mondorf-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Infection or sepsis not mentioned as part of inclusion criteria. Patients were randomized to receive beta-lactam monotherapy versus beta-lactam-aminoglycoside combination therapy, and the only outcome given is urinary enzyme excretion.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mondorf-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>No outcomes relevant for this review. The study randomized patients with severe infections to beta-lactam monotherapy versus beta-lactam aminoglycoside combination therapy. The only outcomes given are renal functions, mainly urinary enzyme levels, and mean serum creatinine per group. Author contacted to ask number of patients per group developing nephrotoxicity and other outcomes - but did not respond.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Moreno_x002d_Martinez-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of oral cefixime versus oral amoxicillin and intramuscular netilmicin. By protocol only intravenously administered beta-lactams are included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mouton-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study published as conference proceeding, comparative without mention on randomization. No further details regarding the study were available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Oblinger-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomization to beta-lactam monotherapy versus combination of antibiotics as deemed appropriate by the attending physicians.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Odio-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Included patients were neonates with proven invasive bacterial infections.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Padoan-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Inclusion criteria did not mandate sepsis for all included patients. Study included patients with acute exacerbation of cystic fibrosis, but the definition of exacerbation does answer the criteria for sepsis as defined in review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-20 16:21:32 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Paoletti-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-20 16:21:32 +0000" MODIFIED_BY="Jane Cracknell">
<P>Comparison between aminoglycoside monotherapy (netimicin) to beta-lactam-aminoglycoside combination therapy (ampicillin + netilmicin).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-10 20:34:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pereira-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-10 20:34:04 +0100" MODIFIED_BY="[Empty name]">
<P>Study include patients with neutropenia and fever. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rodloff-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study randomized patients to imipenem monotherapy versus various combination regimens: beta-lactam-aminoglycoside, two beta-lactams, beta-lactam-beta-lactamsa inhibitor, beta-lactam-anaerobic agent and quinolone-anaerobic agent. Patients allocated to the combination group were analysed as one group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Romanelli-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study randomized patients to beta-lactam monotherapy versus macrolide-aminogycoside or macrolide-beta-lactam combination therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schoengut-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized, prospective comparative trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schuler-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomization to meropenem versus cefotaxime monotherapy. Aminoglycoside added to the cefotaxime arm for urinary tract infections and metronidazole added to the cefotaxime arm when anaerobic infection was suspected. These additions were performed non-randomly, by protocol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Scott-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomization to 3 arms comparing beta-lactam monotherapy versus beta-lactam-metronidazole-aminoglycoside triple combination therapy versus beta-lactam-metronidazole combination therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sexton-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>ICAAC abstract. Twenty-two patients were enrolled in a prospective randomized trial, and 8 patients received monotherapy in an open study. Results are shown for all 30 patients combined. Author contacted and replied that original data are no longer available, and therefore randomized patients cannot be separated from the non-randomized. However, results of these trials were pooled with other trials and are described in Gentry 1985.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-20 16:22:53 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Sheftel-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-20 16:22:53 +0000" MODIFIED_BY="Jane Cracknell">
<P>No relevant outcomes for this review. The study randomized patients with osteomyelitis and provides outcomes only for evaluated patients at a follow up range of 2-38 months (appropriate for the type of infection). The number of randomized patients is unknown and outcomes at 30-days were unavailable.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Smith-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>No sepsis in inclusion criteria. Study included patients with acute exacerbation of cystic fibrosis, but the definition of exacerbation does answer the criteria for sepsis as defined in review.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Solberg-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Article describes results from 4 separate trials. Randomization to meropenem versus ceftazidime monotherapy. An aminoglycoside was added to patients allocated to ceftazidime when resistance to ceftazidime and severe infections were suspected.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Solomkin-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Inadequate methodology. A publication stating that 'case report forms from an open multicentre study were reviewed': 69 patients assigned to ceftazidime and 66 patients assigned to ticarcillin and tobramycin with soft tissue infections are reported. Information obtained through author contact: these were the only arms of the trial, all patients included in the trial are reported in the publication, and this is the only report of the trial. However, according to the author, the study was not well designed and considered more as a collection of case reports, as stated in the publication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stack-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>No sepsis in inclusion criteria. Study included patients with acute exacerbation of cystic fibrosis, but the definition of exacerbation does answer the criteria for sepsis as defined in review.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tally-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomization to beta-lactam monotherapy (moxalactam) versus another beta-lactam (cefoxitime). An aminoglycoside could be added to the cefoxitime arm by the attending physician's decision, in consultation with an infectious diseases consultant.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Thompson-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Oral versus intravenous antibiotic administration. Study randomized women with PID to monotherapy of oral amoxicillin versus combination therapy consisting of IV penicillin + IV gentamicin. Inclusion criteria for the review specify IV administration of the beta-lactam in both arms.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vazquez-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Prophylaxis study. Antibiotic treatment administered for prophylaxis, without sepsis. In addition trial is probably not randomized.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vetter-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>No sepsis in inclusion criteria. Study randomized patients with acute exacerbations of chronic bronchitis. Only 19/102 included patients were febrile.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vetter-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of monotherapy (meropenem) versus monotherapy (ceftazidime)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Watanakunakorn-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized comparison of penicillin versus penicillin + gentamicin for Staphylococcus aureus endocarditis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-19 07:35:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yildirim-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-19 07:35:58 +0000" MODIFIED_BY="[Empty name]">
<P>Study included children with neutropenic fever.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2011-10-10 20:32:38 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2013-12-20 14:19:09 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2013-12-20 14:19:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aziz-2012">
<CHAR_STUDY_NAME MODIFIED="2013-12-20 14:19:09 +0000" MODIFIED_BY="[Empty name]">
<P>Comparison of Ampicillin/Sulbactam versus Ampicillin/Gentamicin for Treatment of Intrapartum Chorioamnionitis: A Randomized Controlled Trial</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-12-20 14:19:09 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial, double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-19 15:53:41 +0000" MODIFIED_BY="[Empty name]">
<P>Pregnant women in labor or undergoing induction of labor diagnosed with chorioamnionitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-20 14:19:09 +0000" MODIFIED_BY="[Empty name]">
<P>Unasyn 3 grams intravenously every six hours, plus intravenous normal saline placebo dose every eight hours until 24 hours post delivery</P>
<P>versus</P>
<P>Gentamicin 1.5 mg/kg intravenously every eight hours plus ampicillin 2 grams intravenously every six hours until 24 hours post delivery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-20 14:19:09 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Proportion of participants in each arm experiencing treatment failure as indicated by resolution of maternal infection</LI>
<LI>Maternal adverse events</LI>
<LI>Neonatal adverse outcomes</LI>
<LI>Cost</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-03-19 15:56:03 +0000" MODIFIED_BY="[Empty name]">
<P>May 2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-12-20 14:19:09 +0000" MODIFIED_BY="[Empty name]">
<P>Principal Investigator: Natali Aziz, MD, Stanford University</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-12-20 14:19:09 +0000" MODIFIED_BY="[Empty name]">
<P>Estimated completion date: May 2014</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-02-20 16:22:49 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-02-20 16:22:49 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 08:20:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abrams-1979">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 08:26:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aguilar-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-11 10:21:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alvarez_x002d_Lerma-2001a">
<DESCRIPTION>
<P>Computer generated in blocks of 6 </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-11 10:21:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Arich-1987">
<DESCRIPTION>
<P>Table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-26 06:49:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Banasal-2006">
<DESCRIPTION>
<P>Adequate randomization generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 08:54:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bergeron-1988">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 08:57:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Biglino-1991">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-11 10:21:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brown-1984">
<DESCRIPTION>
<P>Table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 09:15:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carbon-1987">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 09:17:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cardozo-2001">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-11 10:21:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cometta-1994">
<DESCRIPTION>
<P>Table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 09:22:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cone-1985">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-11 10:21:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coppens-1983">
<DESCRIPTION>
<P>Adequate randomization generation, Consecutively numbered envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-11 10:21:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-D_x0027_Antonio-1992">
<DESCRIPTION>
<P>Table of random numbers, stratified according to underlying malignancy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 09:38:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Damas-2006">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-11 10:21:40 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Duff-1982">
<DESCRIPTION>
<P>Inadequate randomization generation - Based ob the last digit of hospitalization number, odds/evens</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-11 10:21:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dupont-2000">
<DESCRIPTION>
<P>Computer generated in blocks of 4 patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-11 10:21:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Felisart-1985">
<DESCRIPTION>
<P>Table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-26 07:37:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Figueroa_x002d_Damian-1996">
<DESCRIPTION>
<P>Not reported, Randomization ratio 1:3</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-11 10:21:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Finer-1992">
<DESCRIPTION>
<P>Computer generated randomization</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-26 07:35:29 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Garc_x00ed_a-Ram_x00ed_rez-1999">
<DESCRIPTION>
<P>According to patient descriptives, groups very different at baseline. Randomization methods not given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:22:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gerecht-1989">
<DESCRIPTION>
<P>Randomization by computer generated table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:22:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gomez-1990a">
<DESCRIPTION>
<P>Randomization by computer generated table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 19:22:03 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hasali-2005">
<DESCRIPTION>
<P>consecutive, fixed sample of 20 per group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-11 10:21:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Havig-1973">
<DESCRIPTION>
<P>Randomization list prepared in advanced</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-11 10:21:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hoepelman-1988">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 19:32:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Holloway--1985">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 19:35:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Iakovlev-1998">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-11 10:21:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jaspers-1998">
<DESCRIPTION>
<P>Table of random numbers in consecutive envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 19:40:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klastersky-1973">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-11 10:21:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kljucar-1990">
<DESCRIPTION>
<P>Computer generated randomization </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-15 13:53:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koehler-1990">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:22:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Korzeniowski-1982">
<DESCRIPTION>
<P>Central randomization by table of random number</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:19:09 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Landau-1990">
<DESCRIPTION>
<P>Randomization according to last digit of identification number - odds vs. evens</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-15 14:03:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Limson-1988">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-11 10:21:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mandell-1987">
<DESCRIPTION>
<P>Generated by coin tosses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-15 14:16:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Martin-1991">
<DESCRIPTION>
<P>Allocation by randomization table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-15 14:21:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCormick-1997">
<DESCRIPTION>
<P>Allocation by randomization table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-15 14:29:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mergoni-1987">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-15 14:32:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moreno-1997">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-15 19:22:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mouton-1990">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-15 19:24:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mouton-1995">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:19:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Muller-1987">
<DESCRIPTION>
<P>The randomization was computer generated for each c enter</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-15 19:29:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Naime-Libien-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-15 19:42:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Piccart-1984">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-15 19:58:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rapp-1984">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-16 07:39:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rasmussen-1986">
<DESCRIPTION>
<P>Using a table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-16 07:45:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ribera-1996">
<DESCRIPTION>
<P>Adequate randomization generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-16 07:54:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rubinstein-1995">
<DESCRIPTION>
<P>Computer generated randomization</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-16 07:59:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sage-1987">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:20:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sandberg-1997">
<DESCRIPTION>
<P>Computer generated lists in blocks of four were used at each c enter</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-16 08:07:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sanfilippo-1989">
<DESCRIPTION>
<P>Computer generated code</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-16 08:11:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sculier-1982">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-16 08:14:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sexton-1998">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-16 08:17:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sieger-1997">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:22:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Smith-1984">
<DESCRIPTION>
<P>Randomization by table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:22:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Speich-1998">
<DESCRIPTION>
<P>Randomization by computer derived program</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-11 10:21:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stille-1992">
<DESCRIPTION>
<P>By a computer generated list of blocks of 16 patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-16 08:42:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sukoh-1994">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-26 18:45:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Takamoto-1994">
<DESCRIPTION>
<P>By a computer generated code</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:20:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thompson--1990">
<DESCRIPTION>
<P>By computer generated for each c enter</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:20:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thompson-1993">
<DESCRIPTION>
<P>By computer generated for each c enter</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-16 08:56:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Trujillo-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-16 09:00:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vergnon-1985">
<DESCRIPTION>
<P>Adequate randomization generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-16 09:05:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Verzasconi-1995">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-26 18:48:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Warren-1983">
<DESCRIPTION>
<P>Adequate randomization generation by random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-16 09:11:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wiecek-1986">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-11 10:21:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wing-1998">
<DESCRIPTION>
<P>Computer generated random number table n</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-16 09:17:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yellin-1993">
<DESCRIPTION>
<P>By table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-02-20 16:22:45 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 08:20:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abrams-1979">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 08:26:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aguilar-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-11 10:21:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alvarez_x002d_Lerma-2001a">
<DESCRIPTION>
<P>Central randomization and by sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-11 10:21:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Arich-1987">
<DESCRIPTION>
<P>Sealed opaque numbered envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-11 10:21:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Banasal-2006">
<DESCRIPTION>
<P>Labeled sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 08:54:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bergeron-1988">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 08:57:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Biglino-1991">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 09:01:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brown-1984">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 09:15:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carbon-1987">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 09:17:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cardozo-2001">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-11 10:21:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cometta-1994">
<DESCRIPTION>
<P>Sealed, opaque numbered envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 09:22:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cone-1985">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 09:32:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Coppens-1983">
<DESCRIPTION>
<P>Sealed envelopes, opaque not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-11 10:21:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-D_x0027_Antonio-1992">
<DESCRIPTION>
<P>Sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 09:38:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Damas-2006">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-11 10:21:40 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Duff-1982">
<DESCRIPTION>
<P>Inadequate randomization concealment </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-11 10:21:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dupont-2000">
<DESCRIPTION>
<P>Central randomization</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 10:10:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Felisart-1985">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 10:16:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Figueroa_x002d_Damian-1996">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-11 10:21:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Finer-1992">
<DESCRIPTION>
<P>Sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-26 07:36:01 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Garc_x00ed_a-Ram_x00ed_rez-1999">
<DESCRIPTION>
<P>According to patient descriptives, groups very different at baseline. Randomization methods not given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 10:29:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gerecht-1989">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-11 10:21:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gomez-1990a">
<DESCRIPTION>
<P>Sealed opaque closed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 19:21:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hasali-2005">
<DESCRIPTION>
<P>consecutive, fixed sample of 20 per group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 19:25:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Havig-1973">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 19:31:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hoepelman-1988">
<DESCRIPTION>
<P>Adequate randomization concealment by sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 19:32:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Holloway--1985">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 19:35:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Iakovlev-1998">
<DESCRIPTION>
<P>By sealed envelopes, opaque not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-11 10:21:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jaspers-1998">
<DESCRIPTION>
<P>Randomization by consecutive sealed, opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 19:40:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klastersky-1973">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-11 10:21:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kljucar-1990">
<DESCRIPTION>
<P>Adequate randomization concealment by sealed consecutive envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-15 13:53:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koehler-1990">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:22:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Korzeniowski-1982">
<DESCRIPTION>
<P>Adequate randomization concealment, central randomization</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-15 14:01:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Landau-1990">
<DESCRIPTION>
<P>Inadequate randomization concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-15 14:03:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Limson-1988">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-11 10:21:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mandell-1987">
<DESCRIPTION>
<P>Sealed envelopes opened in numerical order, opaque not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-15 14:17:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martin-1991">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-15 14:20:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCormick-1997">
<DESCRIPTION>
<P>Sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:19:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mergoni-1987">
<DESCRIPTION>
<P>Sealed opaque envelopes that were provided by the study c enter</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-15 14:32:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moreno-1997">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-15 19:22:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mouton-1990">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-15 19:24:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mouton-1995">
<DESCRIPTION>
<P>No reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-15 19:27:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Muller-1987">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-15 19:29:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Naime-Libien-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-15 19:43:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Piccart-1984">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-15 19:58:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rapp-1984">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-11 10:21:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rasmussen-1986">
<DESCRIPTION>
<P>Sealed envelopes, opaque not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:20:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ribera-1996">
<DESCRIPTION>
<P>Opaque sealed envelops</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-16 07:54:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rubinstein-1995">
<DESCRIPTION>
<P>Opaque sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-16 07:59:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sage-1987">
<DESCRIPTION>
<P>No reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-16 08:03:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sandberg-1997">
<DESCRIPTION>
<P>Sealed opaque envelope allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-16 08:08:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sanfilippo-1989">
<DESCRIPTION>
<P>Adequate central randomization</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-16 08:11:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sculier-1982">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-16 08:14:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sexton-1998">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-16 08:17:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sieger-1997">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:22:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Smith-1984">
<DESCRIPTION>
<P>Central randomization. Identically labelled mini bottles containing antibiotic or placebo, with colour added to mask the yellow colour of cefotaxime.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-16 08:33:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Speich-1998">
<DESCRIPTION>
<P>Sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-16 08:40:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stille-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-16 08:43:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sukoh-1994">
<DESCRIPTION>
<P>Randomized by envelope method</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-16 08:46:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Takamoto-1994">
<DESCRIPTION>
<P>Sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-16 08:48:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Thompson--1990">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-16 08:55:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Thompson-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-16 08:56:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Trujillo-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-16 08:59:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vergnon-1985">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-16 09:05:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Verzasconi-1995">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-16 09:10:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Warren-1983">
<DESCRIPTION>
<P>By sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-16 09:11:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wiecek-1986">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-11 10:21:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wing-1998">
<DESCRIPTION>
<P>Sealed opaque envelopes </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-16 09:17:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yellin-1993">
<DESCRIPTION>
<P>Central randomization at the research pharmacy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2012-02-20 16:20:55 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>Mortality</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2">
<NAME>Failure</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-13 08:30:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Abrams-1979">
<DESCRIPTION>
<P>Number of randomized patients is unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 08:30:07 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Abrams-1979">
<DESCRIPTION>
<P>Number of randomized patients is unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-13 08:28:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aguilar-1992">
<DESCRIPTION>
<P>No mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 08:56:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aguilar-1992">
<DESCRIPTION>
<P>All 36 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-13 08:56:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alvarez_x002d_Lerma-2001a">
<DESCRIPTION>
<P>All 140 randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 09:06:18 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Alvarez_x002d_Lerma-2001a">
<DESCRIPTION>
<P>116 out of 140 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-13 09:06:27 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Arich-1987">
<DESCRIPTION>
<P>47 out of 65 randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 09:06:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Arich-1987">
<DESCRIPTION>
<P>47 out of 65 patients randomized were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-12-26 06:52:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Banasal-2006">
<DESCRIPTION>
<P>No mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-12-26 06:52:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Banasal-2006">
<DESCRIPTION>
<P>All randomized (71) patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-13 09:06:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bergeron-1988">
<DESCRIPTION>
<P>67 out of 77 randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 09:06:55 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bergeron-1988">
<DESCRIPTION>
<P>67 out of 77 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-13 08:58:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Biglino-1991">
<DESCRIPTION>
<P>No mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 08:59:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Biglino-1991">
<DESCRIPTION>
<P>All randomized (22) patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-13 09:07:10 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Brown-1984">
<DESCRIPTION>
<P>34 out of 48 randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 09:07:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Brown-1984">
<DESCRIPTION>
<P>34 out of 48 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-13 09:16:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carbon-1987">
<DESCRIPTION>
<P>All (47) randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 09:16:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carbon-1987">
<DESCRIPTION>
<P>All (47) randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-13 09:18:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cardozo-2001">
<DESCRIPTION>
<P>All (110) randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 09:18:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cardozo-2001">
<DESCRIPTION>
<P>All (110) randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-13 09:21:30 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cometta-1994">
<DESCRIPTION>
<P>292 out of 313 randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 09:21:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cometta-1994">
<DESCRIPTION>
<P>292 out of 313 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-13 09:23:49 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cone-1985">
<DESCRIPTION>
<P>40 out of 57 randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 09:23:51 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cone-1985">
<DESCRIPTION>
<P>40 out of 57 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-13 09:33:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Coppens-1983">
<DESCRIPTION>
<P>No mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 09:36:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Coppens-1983">
<DESCRIPTION>
<P>66 out of 80 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-13 09:38:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-D_x0027_Antonio-1992">
<DESCRIPTION>
<P>All (300) randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 09:38:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-D_x0027_Antonio-1992">
<DESCRIPTION>
<P>286 out of 300 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-13 09:40:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Damas-2006">
<DESCRIPTION>
<P>All (50) randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-12-26 07:54:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Damas-2006">
<DESCRIPTION>
<P>All (50) randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-13 09:45:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Duff-1982">
<DESCRIPTION>
<P>All (74) randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 09:45:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Duff-1982">
<DESCRIPTION>
<P>All (74) randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-13 09:48:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dupont-2000">
<DESCRIPTION>
<P>227 out of 241 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 09:48:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dupont-2000">
<DESCRIPTION>
<P>204 out of 241 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-13 10:11:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Felisart-1985">
<DESCRIPTION>
<P>All (73) randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 10:11:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Felisart-1985">
<DESCRIPTION>
<P>All (73) randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-13 10:17:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Figueroa_x002d_Damian-1996">
<DESCRIPTION>
<P>No mortality outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 10:18:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Figueroa_x002d_Damian-1996">
<DESCRIPTION>
<P>All (56) randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-13 19:20:36 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Finer-1992">
<DESCRIPTION>
<P>All (471) randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 19:20:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Finer-1992">
<DESCRIPTION>
<P>415 out of 471 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-15 14:09:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Garc_x00ed_a-Ram_x00ed_rez-1999">
<DESCRIPTION>
<P>All (60) randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-15 14:09:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Garc_x00ed_a-Ram_x00ed_rez-1999">
<DESCRIPTION>
<P>All (60) randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-02-20 16:18:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gerecht-1989">
<DESCRIPTION>
<P>Only infection related mortally was reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-02-20 16:18:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gerecht-1989">
<DESCRIPTION>
<P>415 out of 82 randomized patients were evaluated for failure outcome (36 were not evaluated - 32 did not fulfil the study inclusion criteria for evaluation, 3 did not adhere to the protocol and 1 excluded because of resistant infection)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-13 19:21:10 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gomez-1990a">
<DESCRIPTION>
<P>78 out of 197 randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 19:21:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gomez-1990a">
<DESCRIPTION>
<P>78 out of 197 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-13 19:23:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hasali-2005">
<DESCRIPTION>
<P>No mortality outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 19:23:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hasali-2005">
<DESCRIPTION>
<P>No failure outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-13 19:27:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Havig-1973">
<DESCRIPTION>
<P>50 out of 90 randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 19:27:32 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Havig-1973">
<DESCRIPTION>
<P>68 out of 90 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-13 19:30:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hoepelman-1988">
<DESCRIPTION>
<P>All (86) randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 19:30:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hoepelman-1988">
<DESCRIPTION>
<P>All (86) randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-13 19:34:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Holloway--1985">
<DESCRIPTION>
<P>No mortality outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-16 08:36:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Holloway--1985">
<DESCRIPTION>
<P>33 out of 43 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-13 19:37:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Iakovlev-1998">
<DESCRIPTION>
<P>No mortality outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 19:37:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Iakovlev-1998">
<DESCRIPTION>
<P>All (95) randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-13 19:39:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jaspers-1998">
<DESCRIPTION>
<P>All (79) randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 19:39:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jaspers-1998">
<DESCRIPTION>
<P>All (79) randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-16 08:36:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Klastersky-1973">
<DESCRIPTION>
<P>45 out of 50 randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-16 08:36:32 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Klastersky-1973">
<DESCRIPTION>
<P>46 out of 50 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-16 08:36:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kljucar-1990">
<DESCRIPTION>
<P>99 out of 100 randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-16 08:36:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kljucar-1990">
<DESCRIPTION>
<P>99 out of 100 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-15 13:58:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Koehler-1990">
<DESCRIPTION>
<P>All (144) randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-16 08:36:25 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Koehler-1990">
<DESCRIPTION>
<P>127 out of 144 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-16 08:36:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Korzeniowski-1982">
<DESCRIPTION>
<P>74 out of 156 randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-16 08:36:21 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Korzeniowski-1982">
<DESCRIPTION>
<P>74 out of 156 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-15 14:03:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Landau-1990">
<DESCRIPTION>
<P>All (40) randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-15 14:03:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Landau-1990">
<DESCRIPTION>
<P>All (40) randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-15 14:04:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Limson-1988">
<DESCRIPTION>
<P>No mortality outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-16 08:36:16 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Limson-1988">
<DESCRIPTION>
<P>40 out of 54 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-15 14:14:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mandell-1987">
<DESCRIPTION>
<P>No mortality outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-16 08:36:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mandell-1987">
<DESCRIPTION>
<P>110 out of 129 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-15 14:17:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martin-1991">
<DESCRIPTION>
<P>No mortality outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-16 08:36:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martin-1991">
<DESCRIPTION>
<P>94 out of 116 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-02-20 16:19:15 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McCormick-1997">
<DESCRIPTION>
<P>128 out of 147 randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-16 08:36:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McCormick-1997">
<DESCRIPTION>
<P>128 out of 147 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-15 14:31:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mergoni-1987">
<DESCRIPTION>
<P>No mortality outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-15 14:31:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mergoni-1987">
<DESCRIPTION>
<P>All (42) randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-15 18:45:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moreno-1997">
<DESCRIPTION>
<P>No mortality outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-16 08:35:56 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moreno-1997">
<DESCRIPTION>
<P>58 out of 70 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-15 19:23:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mouton-1990">
<DESCRIPTION>
<P>All (211) randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-15 19:24:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mouton-1990">
<DESCRIPTION>
<P>All (211) randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-15 19:26:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mouton-1995">
<DESCRIPTION>
<P>All (237) randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-16 08:35:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mouton-1995">
<DESCRIPTION>
<P>229 out of 237 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-15 19:28:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Muller-1987">
<DESCRIPTION>
<P>No mortality outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-16 08:35:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Muller-1987">
<DESCRIPTION>
<P>106 out of 131 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-15 19:32:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Naime-Libien-1992">
<DESCRIPTION>
<P>All (30) randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-15 19:32:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Naime-Libien-1992">
<DESCRIPTION>
<P>All (30) randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-15 19:43:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Piccart-1984">
<DESCRIPTION>
<P>No mortality outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-16 08:35:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Piccart-1984">
<DESCRIPTION>
<P>87 out of 105 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-15 19:59:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rapp-1984">
<DESCRIPTION>
<P>No mortality outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-15 20:00:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rapp-1984">
<DESCRIPTION>
<P>All (35) randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-16 08:35:32 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rasmussen-1986">
<DESCRIPTION>
<P>59 out of 62 randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-16 08:35:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rasmussen-1986">
<DESCRIPTION>
<P>59 out of 62 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-16 07:48:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ribera-1996">
<DESCRIPTION>
<P>All (90) randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-16 07:48:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ribera-1996">
<DESCRIPTION>
<P>All (90) randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-16 07:58:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rubinstein-1995">
<DESCRIPTION>
<P>All (580) randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-16 08:35:27 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rubinstein-1995">
<DESCRIPTION>
<P>491 out of 580 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-16 08:00:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sage-1987">
<DESCRIPTION>
<P>No mortality outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-16 08:35:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sage-1987">
<DESCRIPTION>
<P>48 out of 61 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-16 08:05:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sandberg-1997">
<DESCRIPTION>
<P>All (73) randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-16 08:35:21 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sandberg-1997">
<DESCRIPTION>
<P>61 out of 73 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-16 08:09:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sanfilippo-1989">
<DESCRIPTION>
<P>No mortality outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-16 08:09:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sanfilippo-1989">
<DESCRIPTION>
<P>All (26) randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-16 08:14:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sculier-1982">
<DESCRIPTION>
<P>All (20) randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-16 08:14:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sculier-1982">
<DESCRIPTION>
<P>All (20) randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-16 08:16:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sexton-1998">
<DESCRIPTION>
<P>No mortality outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-16 08:34:30 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sexton-1998">
<DESCRIPTION>
<P>51 out of 67 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-16 08:18:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sieger-1997">
<DESCRIPTION>
<P>All (211) randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-02-20 16:20:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sieger-1997">
<DESCRIPTION>
<P>All (211) randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-16 08:33:56 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Smith-1984">
<DESCRIPTION>
<P>187 out of 200 randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-16 08:33:58 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Smith-1984">
<DESCRIPTION>
<P>195 out of 200 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-16 08:37:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Speich-1998">
<DESCRIPTION>
<P>All (89) randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-16 08:37:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Speich-1998">
<DESCRIPTION>
<P>84 out of 89 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-16 08:41:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stille-1992">
<DESCRIPTION>
<P>All (337) randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-16 08:41:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stille-1992">
<DESCRIPTION>
<P>All (337) randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-16 08:44:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sukoh-1994">
<DESCRIPTION>
<P>No mortality outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-16 08:44:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sukoh-1994">
<DESCRIPTION>
<P>All (63) randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-16 08:47:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Takamoto-1994">
<DESCRIPTION>
<P>No mortality outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-16 08:47:32 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Takamoto-1994">
<DESCRIPTION>
<P>154 out of 171 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-16 08:49:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Thompson--1990">
<DESCRIPTION>
<P>96 out of 106 randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-16 08:49:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Thompson--1990">
<DESCRIPTION>
<P>96 out of 106 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-16 08:56:20 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Thompson-1993">
<DESCRIPTION>
<P>120 out of 147 randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-16 08:56:21 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Thompson-1993">
<DESCRIPTION>
<P>120 out of 147 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-16 08:57:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Trujillo-1992">
<DESCRIPTION>
<P>All (30) randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-02-20 16:20:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Trujillo-1992">
<DESCRIPTION>
<P>All (30) randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-16 08:59:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vergnon-1985">
<DESCRIPTION>
<P>No mortality outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-02-20 16:20:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vergnon-1985">
<DESCRIPTION>
<P>All (30) randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-16 09:06:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Verzasconi-1995">
<DESCRIPTION>
<P>No mortality outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-16 09:07:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Verzasconi-1995">
<DESCRIPTION>
<P>87 out of 93 randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-16 09:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Warren-1983">
<DESCRIPTION>
<P>120 out of 123 randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-16 09:09:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Warren-1983">
<DESCRIPTION>
<P>120 out of 123 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-16 09:12:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wiecek-1986">
<DESCRIPTION>
<P>All (20) randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-16 09:13:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wiecek-1986">
<DESCRIPTION>
<P>All (20) randomized patients were evaluated for bacteriologic failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-16 09:15:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wing-1998">
<DESCRIPTION>
<P>All (179) randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-16 09:15:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wing-1998">
<DESCRIPTION>
<P>All (179) randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-16 09:20:04 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yellin-1993">
<DESCRIPTION>
<P>90 out of 149 randomized patients were evaluated for mortality outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-16 09:20:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yellin-1993">
<DESCRIPTION>
<P>90 out of 149 randomized patients were evaluated for failure outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2012-02-20 16:21:07 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:17:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abrams-1979">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:17:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aguilar-1992">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:17:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alvarez_x002d_Lerma-2001a">
<DESCRIPTION>
<P>Fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:18:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Arich-1987">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:18:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Banasal-2006">
<DESCRIPTION>
<P>Fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:18:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bergeron-1988">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:18:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Biglino-1991">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:18:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brown-1984">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:18:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carbon-1987">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:18:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cardozo-2001">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:18:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cometta-1994">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:18:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cone-1985">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:18:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Coppens-1983">
<DESCRIPTION>
<P>Fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:18:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Antonio-1992">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:18:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Damas-2006">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:18:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Duff-1982">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:18:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dupont-2000">
<DESCRIPTION>
<P>Fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:18:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Felisart-1985">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:18:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Figueroa_x002d_Damian-1996">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:18:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Finer-1992">
<DESCRIPTION>
<P>Fixed time for outcome assessment (within 72 hours of stopping the treatment)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-15 14:15:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garc_x00ed_a-Ram_x00ed_rez-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:18:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gerecht-1989">
<DESCRIPTION>
<P>Fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:18:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gomez-1990a">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:18:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hasali-2005">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:18:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Havig-1973">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:18:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hoepelman-1988">
<DESCRIPTION>
<P>Fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:18:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Holloway--1985">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:18:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Iakovlev-1998">
<DESCRIPTION>
<P>Fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:18:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jaspers-1998">
<DESCRIPTION>
<P>Fixed time for outcome assessment (end of treatment)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:18:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klastersky-1973">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:19:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kljucar-1990">
<DESCRIPTION>
<P>Fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:19:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koehler-1990">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:19:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Korzeniowski-1982">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:19:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Landau-1990">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:19:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Limson-1988">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:19:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mandell-1987">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:19:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martin-1991">
<DESCRIPTION>
<P>Fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:19:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McCormick-1997">
<DESCRIPTION>
<P>Fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:19:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mergoni-1987">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:19:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moreno-1997">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:19:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mouton-1990">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:19:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mouton-1995">
<DESCRIPTION>
<P>Fixed time for outcome assessment (end of treatment)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:19:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Muller-1987">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:19:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Naime-Libien-1992">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:19:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Piccart-1984">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:19:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rapp-1984">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:20:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rasmussen-1986">
<DESCRIPTION>
<P>Fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:20:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ribera-1996">
<DESCRIPTION>
<P>Fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:20:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rubinstein-1995">
<DESCRIPTION>
<P>Fixed time for outcome assessment - 14 days after treatment cessation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:20:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sage-1987">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:20:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sandberg-1997">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:20:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sanfilippo-1989">
<DESCRIPTION>
<P>Fixed time for outcome assessment - 4 weeks after discharge</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:20:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sculier-1982">
<DESCRIPTION>
<P>Fixed time for outcome assessment -1 week after treatment cessation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:20:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sexton-1998">
<DESCRIPTION>
<P>Fixed time for outcome assessment (3 month)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:20:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sieger-1997">
<DESCRIPTION>
<P>Fixed time for outcome assessment (30 days)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:20:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-1984">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:20:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Speich-1998">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:20:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stille-1992">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:20:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sukoh-1994">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:20:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Takamoto-1994">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:20:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Thompson--1990">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:20:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Thompson-1993">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:20:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Trujillo-1992">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:20:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vergnon-1985">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:21:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Verzasconi-1995">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:21:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Warren-1983">
<DESCRIPTION>
<P>Fixed time for outcome assessment (14 days after treatment cessation)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:21:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wiecek-1986">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:21:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wing-1998">
<DESCRIPTION>
<P>Fixed time for outcome assessment (2 weeks following treatment cessation)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 16:21:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yellin-1993">
<DESCRIPTION>
<P>No fixed time for outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2012-02-08 15:20:25 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-10 20:52:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Abrams-1979">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-13 08:23:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Aguilar-1992">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-13 08:34:45 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Alvarez_x002d_Lerma-2001a">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-13 08:43:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Arich-1987">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-12-26 06:52:57 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Banasal-2006">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-13 08:54:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bergeron-1988">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-13 08:57:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Biglino-1991">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-13 09:04:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Brown-1984">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-13 09:15:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Carbon-1987">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-13 09:17:55 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cardozo-2001">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-13 09:20:35 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cometta-1994">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-13 09:22:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cone-1985">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-13 09:32:35 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Coppens-1983">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-13 09:37:04 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-D_x0027_Antonio-1992">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-13 09:39:03 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Damas-2006">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-13 09:44:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Duff-1982">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-13 09:47:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dupont-2000">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-13 10:11:00 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Felisart-1985">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-12-26 07:36:59 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Figueroa_x002d_Damian-1996">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-13 10:21:47 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Finer-1992">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-15 14:06:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Garc_x00ed_a-Ram_x00ed_rez-1999">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-13 10:32:06 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gerecht-1989">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-13 19:19:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gomez-1990a">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-13 19:22:21 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hasali-2005">
<DESCRIPTION>
<P>open (stated as single blind but no blinding described)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-13 19:25:25 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Havig-1973">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-13 19:29:00 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hoepelman-1988">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-13 19:32:57 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Holloway--1985">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-13 19:35:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Iakovlev-1998">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-13 19:38:47 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jaspers-1998">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-13 19:41:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Klastersky-1973">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-13 19:44:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kljucar-1990">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-15 13:54:01 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Koehler-1990">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-15 13:58:03 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Korzeniowski-1982">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-15 14:01:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Landau-1990">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-15 14:04:01 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Limson-1988">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-15 14:14:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mandell-1987">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-15 14:17:20 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Martin-1991">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-15 14:21:16 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McCormick-1997">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-15 14:29:55 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mergoni-1987">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-15 14:32:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moreno-1997">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-15 19:24:52 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mouton-1990">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-15 19:24:49 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mouton-1995">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-15 19:27:57 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Muller-1987">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-15 19:31:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Naime-Libien-1992">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-15 19:43:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Piccart-1984">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-15 19:58:53 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rapp-1984">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-16 07:41:00 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rasmussen-1986">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-16 07:46:03 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ribera-1996">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-16 07:56:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rubinstein-1995">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-16 07:59:58 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sage-1987">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-16 08:03:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sandberg-1997">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-16 08:07:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sanfilippo-1989">
<DESCRIPTION>
<P>Double blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-16 08:11:42 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sculier-1982">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-16 08:15:04 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sexton-1998">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-16 08:17:29 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sieger-1997">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-16 08:25:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Smith-1984">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-16 08:33:29 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Speich-1998">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-16 08:40:47 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stille-1992">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-16 08:43:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sukoh-1994">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-16 08:47:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Takamoto-1994">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-16 08:48:47 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Thompson--1990">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-16 08:56:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Thompson-1993">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-16 08:57:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Trujillo-1992">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-16 08:59:07 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vergnon-1985">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-16 09:05:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Verzasconi-1995">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-16 09:09:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Warren-1983">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-16 09:11:47 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wiecek-1986">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-16 09:14:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wing-1998">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-16 09:48:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yellin-1993">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2012-02-11 10:21:42 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-10 20:53:25 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Abrams-1979">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-13 08:23:01 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Aguilar-1992">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-13 08:34:47 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Alvarez_x002d_Lerma-2001a">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-13 08:43:16 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Arich-1987">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-12-26 06:55:52 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Banasal-2006">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-13 08:54:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bergeron-1988">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-13 08:58:00 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Biglino-1991">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-13 09:04:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brown-1984">
<DESCRIPTION>
<P>For failure the assessors were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-13 09:15:35 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Carbon-1987">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-13 09:17:56 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cardozo-2001">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-13 09:20:36 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cometta-1994">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-13 09:22:43 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cone-1985">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-13 09:32:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Coppens-1983">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-13 09:37:06 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-D_x0027_Antonio-1992">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-13 09:39:04 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Damas-2006">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-13 09:45:03 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Duff-1982">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-13 09:47:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dupont-2000">
<DESCRIPTION>
<P>Only outcome assessor blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-13 10:11:03 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Felisart-1985">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-12-26 07:37:05 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Figueroa_x002d_Damian-1996">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-13 10:21:49 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Finer-1992">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-15 14:07:00 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Garc_x00ed_a-Ram_x00ed_rez-1999">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-13 10:32:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gerecht-1989">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-13 19:19:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gomez-1990a">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-13 19:22:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hasali-2005">
<DESCRIPTION>
<P>open (stated as single blind but no blinding described)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-13 19:25:26 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Havig-1973">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-13 19:29:06 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hoepelman-1988">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-13 19:33:01 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Holloway--1985">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-13 19:36:00 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Iakovlev-1998">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-13 19:38:48 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jaspers-1998">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-13 19:41:06 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Klastersky-1973">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-13 19:44:35 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kljucar-1990">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-15 13:54:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Koehler-1990">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-15 13:58:04 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Korzeniowski-1982">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-15 14:01:56 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Landau-1990">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-15 14:04:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Limson-1988">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-15 14:14:10 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mandell-1987">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-15 14:17:21 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Martin-1991">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-15 14:21:18 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McCormick-1997">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-15 14:29:56 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mergoni-1987">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-15 14:32:47 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moreno-1997">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-15 19:24:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mouton-1990">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-15 19:24:48 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mouton-1995">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-15 19:27:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Muller-1987">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-15 19:31:27 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Naime-Libien-1992">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-15 19:43:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Piccart-1984">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-15 19:58:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rapp-1984">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-16 07:41:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rasmussen-1986">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-16 07:46:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ribera-1996">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-16 07:56:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rubinstein-1995">
<DESCRIPTION>
<P>Outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-16 07:59:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sage-1987">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-16 08:04:01 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sandberg-1997">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-16 08:08:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sanfilippo-1989">
<DESCRIPTION>
<P>Assessment were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-16 08:11:43 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sculier-1982">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-16 08:15:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sexton-1998">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-16 08:17:30 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sieger-1997">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-16 08:25:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Smith-1984">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-16 08:33:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Speich-1998">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-16 08:40:48 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stille-1992">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-16 08:43:25 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sukoh-1994">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-16 08:47:36 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Takamoto-1994">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-16 08:48:49 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Thompson--1990">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-16 08:56:16 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Thompson-1993">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-16 08:57:12 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Trujillo-1992">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-16 08:59:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vergnon-1985">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-02-11 10:21:42 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Verzasconi-1995">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-16 09:09:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Warren-1983">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-16 09:11:48 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wiecek-1986">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-16 09:14:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wing-1998">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-16 09:48:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yellin-1993">
<DESCRIPTION>
<P>The clinician was kept blinded throughout the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="Grade Profiler">Monotherapy versus combination therapy compared for sepsis</TITLE>
<TABLE COLS="7" ROWS="6">
<TR>
<TD COLSPAN="7">
<P>
<B>Monotherapy versus combination therapy compared for sepsis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> participants with sepsis<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> monotherapy versus combination therapy<BR/>
<B>Comparison: </B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Monotherapy versus combination therapy</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>All-cause mortality</B>&#8212;<B>same beta lactam</B>
<BR/>Survival<BR/>Follow-up: mean 30 days<SUP>1</SUP>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.97 </B>
<BR/>(0.73 to 1.3)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1431<BR/>(13 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>112 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>109 per 1000</B>
<BR/>(82 to 145)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>300 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>291 per 1000</B>
<BR/>(219 to 390)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>All-cause mortality</B>&#8212;<B>different beta lactam</B>
<BR/>Follow-up: mean 30 days<SUP>1</SUP>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.85 </B>
<BR/>(0.71 to 1.01)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>4146<BR/>(31 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>113 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>96 per 1000</B>
<BR/>(80 to 114)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>300 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>255 per 1000</B>
<BR/>(213 to 303)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Clinical failure</B>&#8212;<B>same beta lactam</B>
<BR/>Antibiotic modifications<BR/>Follow-up: two to 30 days<SUP>5</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>232 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>258 per 1000</B>
<BR/>(221 to 300)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.11 </B>
<BR/>(0.95 to 1.29)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1870<BR/>(20 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>6,7</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Clinical failure</B>&#8212;<B>different beta lactam</B>
<BR/>Antibiotic modifications<BR/>Follow-up: two to 30 days<SUP>5</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>227 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>170 per 1000</B>
<BR/>(152 to 190)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.75 </B>
<BR/>(0.67 to 0.84)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>4933<BR/>(46 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>6,7</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio.</P>
<P>Same and different beta lactams refer to comparisons involving the same beta lactam with versus without aminoglycoside and comparisons between one beta lactam versus a different beta lactam combined with an aminoglycoside, respectively.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence.<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Extracted preferentially at 30 days and if unavailable in-hospital or at end of follow-up.<BR/>
<SUP>2</SUP>95% confidence intervals range from 27% improved survival to 30% higher risk of death with monotherapy.<BR/>
<SUP>3</SUP>Funnel plot asymmetrical pointing out missing studies (unpublished or published but not reporting on mortality) favouring combination therapy.<BR/>
<SUP>4</SUP>Advantage of monotherapy accentuated in studies with unclear allocation concealment and per-protocol analysis.<BR/>
<SUP>5</SUP>Days after treatment cessation.<BR/>
<SUP>6</SUP>Assessment of treatment failure in open trials prone to bias.<BR/>
<SUP>7</SUP>Although this was the primary outcome in all studies, its clinical significance is unclear, and correlation with mortality is unclear (see discussion).</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="Karen Hovhannisyan">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]">Beta lactam monotherapies</TITLE>
<TABLE COLS="4" ROWS="27">
<TR>
<TD ALIGN="LEFT">
<P>
<B>Monotherapy</B>
</P>
</TD>
<TD ALIGN="LEFT">
<P>
<B>No. studies</B>
</P>
</TD>
<TD ALIGN="LEFT">
<P>
<B>No. of participants treated</B>
</P>
</TD>
<TD ALIGN="LEFT">
<P>
<B>Doses (no. studies: dose)</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>ceftazidime</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>939</P>
</TD>
<TD>
<P>Four: 2 g × 2/d; five: 2 g × 3/d; one:1 g × 4/d; one: 1 g × 3/d; one: NS</P>
</TD>
</TR>
<TR>
<TD>
<P>cefotaxime</P>
</TD>
<TD>
<P>Seven</P>
</TD>
<TD>
<P>281</P>
</TD>
<TD>
<P>One:1 g × 4/d; one: 2 g × 6/d; one: 3 g × 3/d; 1 to 2 g × 4/d; one: 1 g × 2/d; one: 2 g × 6/d; one: 1 g × 3 to 4/d</P>
</TD>
</TR>
<TR>
<TD>
<P>imipenem</P>
</TD>
<TD>
<P>Six</P>
</TD>
<TD>
<P>580</P>
</TD>
<TD>
<P>Three: 500 mg × 4/d; one: 500 to 1000 mg × 4/d; one: 500 mg × 3/d; one: NS</P>
</TD>
</TR>
<TR>
<TD>
<P>cefoperazone</P>
</TD>
<TD>
<P>Six</P>
</TD>
<TD>
<P>238</P>
</TD>
<TD>
<P>Two: 2 g × 2/d; one: 2 g × 3/d; one: 6 g × 2/d; one: 1 to 4 g/d; one: 1.5 gr × 4/d</P>
</TD>
</TR>
<TR>
<TD>
<P>meropenem</P>
</TD>
<TD>
<P>Five</P>
</TD>
<TD>
<P>376</P>
</TD>
<TD>
<P>Five: 1 g × 3/d</P>
</TD>
</TR>
<TR>
<TD>
<P>ceftriaxone</P>
</TD>
<TD>
<P>Three</P>
</TD>
<TD>
<P>237</P>
</TD>
<TD>
<P>Three: 2 g × 1/d; one: 2 g × 2/d</P>
</TD>
</TR>
<TR>
<TD>
<P>piperacillin-tazobactam</P>
</TD>
<TD>
<P>Three</P>
</TD>
<TD>
<P>269</P>
</TD>
<TD>
<P>One: 4 g × 4/d; one: 0.5 g × 4/d; two: 4.5 g × 3/d</P>
</TD>
</TR>
<TR>
<TD>
<P>cefepime</P>
</TD>
<TD>
<P>Three</P>
</TD>
<TD>
<P>160</P>
</TD>
<TD>
<P>One: 2 g × 3/d; two: 2 g × 2/d</P>
</TD>
</TR>
<TR>
<TD>
<P>ceftizoxime</P>
</TD>
<TD>
<P>Three</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>One: 60 to 150 mg/kg/d; one: 1 to 2 g × 3/d; one: 20 to 50 mg/kg × 2 to 3/d</P>
</TD>
</TR>
<TR>
<TD>
<P>mezlocillin</P>
</TD>
<TD>
<P>Three</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P>One: 4 g × 4/d; one: 62.5 mg/kg × 4/d; one: 10 g × 3/d</P>
</TD>
</TR>
<TR>
<TD>
<P>piperacillin</P>
</TD>
<TD>
<P>Two</P>
</TD>
<TD>
<P>83</P>
</TD>
<TD>
<P>Two: 3 g × 6/d</P>
</TD>
</TR>
<TR>
<TD>
<P>amoxicillin-clavulanate</P>
</TD>
<TD>
<P>Two</P>
</TD>
<TD>
<P>81</P>
</TD>
<TD>
<P>One: 2.2 gr × 3/d; one: NS</P>
</TD>
</TR>
<TR>
<TD>
<P>ampicillin</P>
</TD>
<TD>
<P>Two</P>
</TD>
<TD>
<P>44</P>
</TD>
<TD>
<P>One: 25 mg/kg × 4/d, one: 500 mg × 4/d</P>
</TD>
</TR>
<TR>
<TD>
<P>cefazoline </P>
</TD>
<TD>
<P>One</P>
</TD>
<TD>
<P>58</P>
</TD>
<TD>
<P>One: 1 g × 3/d</P>
</TD>
</TR>
<TR>
<TD>
<P>amoxicillin-sulbactam</P>
</TD>
<TD>
<P>One</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>One: 33 mg/kg × 3/d</P>
</TD>
</TR>
<TR>
<TD>
<P>cefoxitin</P>
</TD>
<TD>
<P>One</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>One: 2 g × 3/d</P>
</TD>
</TR>
<TR>
<TD>
<P>carbenicillin</P>
</TD>
<TD>
<P>One</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>One: 10 g × 3/d</P>
</TD>
</TR>
<TR>
<TD>
<P>ticarcillin-clavulanic acid</P>
</TD>
<TD>
<P>One</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>One: 3.1 g × 4 to 6/d</P>
</TD>
</TR>
<TR>
<TD>
<P>azlocillin</P>
</TD>
<TD>
<P>One</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>One: 13 + -2.2 gr/d</P>
</TD>
</TR>
<TR>
<TD>
<P>moxalactam</P>
</TD>
<TD>
<P>One</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>One: 2 g × 3/d</P>
</TD>
</TR>
<TR>
<TD>
<P>Gram-positive infection</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>oxacillin</P>
</TD>
<TD>
<P>One</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>One: 12 g/d </P>
</TD>
</TR>
<TR>
<TD>
<P>cloxacillin</P>
</TD>
<TD>
<P>One</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>One: 2 g × 6/d</P>
</TD>
</TR>
<TR>
<TD>
<P>cefamandole</P>
</TD>
<TD>
<P>One</P>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>One: 2 g × 3/d</P>
</TD>
</TR>
<TR>
<TD>
<P>nafcillin</P>
</TD>
<TD>
<P>One</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>One: 1.5 to 6 g × 6/d</P>
</TD>
</TR>
<TR>
<TD>
<P>ceftriaxone</P>
</TD>
<TD>
<P>One</P>
</TD>
<TD>
<P>67</P>
</TD>
<TD>
<P>One: 2 g × 1/d</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Monotherapy versus combination therapy</NAME>
<DICH_OUTCOME CHI2="33.39089293583769" CI_END="1.0241503968046566" CI_START="0.7578960648225567" CI_STUDY="95" CI_TOTAL="95" DF="31" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8810218814108474" ESTIMABLE="YES" EVENTS_1="273" EVENTS_2="302" I2="7.160314461886101" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.010363737602945844" LOG_CI_START="-0.12039034788900568" LOG_EFFECT_SIZE="-0.055013305143029906" METHOD="MH" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.35181051226161564" P_Q="0.4374720155494177" P_Z="0.09909326789455412" Q="0.6029048231678489" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="44" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2891" TOTAL_2="2686" WEIGHT="200.0" Z="1.6492654335835308">
<NAME>All-cause mortality</NAME>
<GROUP_LABEL_1>Monotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours monotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.830729960020044" CI_END="1.2969749351994428" CI_START="0.727447027040165" DF="9" EFFECT_SIZE="0.9713292751464074" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="80" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.11293158316985057" LOG_CI_START="-0.13819862667439028" LOG_EFFECT_SIZE="-0.012633521752269864" MODIFIED="2011-12-26 06:37:48 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6547377401360674" P_Z="0.8436722213994424" STUDIES="13" TAU2="0.0" TOTAL_1="716" TOTAL_2="715" WEIGHT="100.00000000000001" Z="0.1971984784125337">
<NAME>Same BL</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.0" STUDY_ID="STD-Abrams-1979" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="13.251516091767591" CI_START="0.0584385963566154" EFFECT_SIZE="0.88" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1222655682820444" LOG_CI_START="-1.2333002239817072" LOG_EFFECT_SIZE="-0.05551732784983137" ORDER="2" O_E="0.0" SE="1.3836710066144533" STUDY_ID="STD-Carbon-1987" TOTAL_1="25" TOTAL_2="22" VAR="1.9145454545454546" WEIGHT="1.340525259239118"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3" O_E="0.0" SE="0.0" STUDY_ID="STD-Cardozo-2001" TOTAL_1="56" TOTAL_2="48" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.143933394780039" CI_START="0.7045398228271409" EFFECT_SIZE="1.229018492176387" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="19" LOG_CI_END="0.33121128907632275" LOG_CI_START="-0.15209445415818415" LOG_EFFECT_SIZE="0.08955841745906934" ORDER="4" O_E="0.0" SE="0.2838961859779625" STUDY_ID="STD-Cometta-1994" TOTAL_1="148" TOTAL_2="144" VAR="0.08059704441283387" WEIGHT="24.26975073453134"/>
<DICH_DATA CI_END="1.7629588148188347" CI_START="0.2702748393715548" EFFECT_SIZE="0.6902777777777778" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.24624216669192472" LOG_CI_START="-0.5681943820877975" LOG_EFFECT_SIZE="-0.16097610769793635" ORDER="5" O_E="0.0" SE="0.47840406027914484" STUDY_ID="STD-D_x0027_Antonio-1992" TOTAL_1="144" TOTAL_2="142" VAR="0.22887044489157166" WEIGHT="12.689055880462028"/>
<DICH_DATA CI_END="2.0276339895692987" CI_START="0.09260930658282401" EFFECT_SIZE="0.43333333333333335" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3069895627637647" LOG_CI_START="-1.033345367589416" LOG_EFFECT_SIZE="-0.36317790241282566" MODIFIED="2011-12-26 06:37:48 +0000" MODIFIED_BY="[Empty name]" ORDER="1034" O_E="0.0" SE="0.7873193728543677" STUDY_ID="STD-Damas-2006" TOTAL_1="24" TOTAL_2="26" VAR="0.6198717948717949" WEIGHT="6.048449969686899"/>
<DICH_DATA CI_END="1.5452478612798557" CI_START="0.5411130099195283" EFFECT_SIZE="0.9144144144144144" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.18899815117342472" LOG_CI_START="-0.26671202424827617" LOG_EFFECT_SIZE="-0.03885693653742572" ORDER="6" O_E="0.0" SE="0.26768641284445654" STUDY_ID="STD-Dupont-2000" TOTAL_1="111" TOTAL_2="116" VAR="0.07165601562153284" WEIGHT="29.576120997147395"/>
<DICH_DATA CI_END="8.260092687698416" CI_START="0.7204087189498556" EFFECT_SIZE="2.4393939393939394" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9169849206291129" LOG_CI_START="-0.14242103964915054" LOG_EFFECT_SIZE="0.38728194048998105" ORDER="7" O_E="0.0" SE="0.6223003052115317" STUDY_ID="STD-Klastersky-1973" TOTAL_1="22" TOTAL_2="23" VAR="0.38725766986636545" WEIGHT="3.6962749814753275"/>
<DICH_DATA CI_END="2.74230421376631" CI_START="0.5671952289593608" EFFECT_SIZE="1.2471655328798186" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.43811563099017203" LOG_CI_START="-0.2462674309373614" LOG_EFFECT_SIZE="0.0959241000264053" ORDER="8" O_E="0.0" SE="0.40200999832702655" STUDY_ID="STD-Kljucar-1990" TOTAL_1="49" TOTAL_2="50" VAR="0.1616120387548959" WEIGHT="11.22628971646432"/>
<DICH_DATA CI_END="1.9188136720990658" CI_START="0.08938497437295481" EFFECT_SIZE="0.41414141414141414" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.28303280427792576" LOG_CI_START="-1.0487354800335547" LOG_EFFECT_SIZE="-0.38285133787781445" ORDER="9" O_E="0.0" SE="0.7822872825638911" STUDY_ID="STD-Korzeniowski-1982" TOTAL_1="33" TOTAL_2="41" VAR="0.6119733924611973" WEIGHT="6.743204358096882"/>
<DICH_DATA CI_END="5.320030029638535" CI_START="0.04699221594750772" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7259140837366838" LOG_CI_START="-1.3279740750646463" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="10" O_E="0.0" SE="1.2064640713902572" STUDY_ID="STD-Ribera-1996" TOTAL_1="45" TOTAL_2="45" VAR="1.4555555555555557" WEIGHT="2.5201874873695416"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11" O_E="0.0" SE="0.0" STUDY_ID="STD-Sandberg-1997" TOTAL_1="37" TOTAL_2="36" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.3225436971144395" CI_START="0.015173840636129785" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8646619720038995" LOG_CI_START="-1.8189044814432243" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="12" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Sculier-1982" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="1.890140615527156"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="26.063493646095306" CI_END="1.01324267136507" CI_START="0.7119839913393643" DF="21" EFFECT_SIZE="0.8493600893342366" ESTIMABLE="YES" EVENTS_1="197" EVENTS_2="222" I2="19.427532298049737" ID="CMP-001.01.02" LOG_CI_END="0.005713471237100702" LOG_CI_START="-0.14752977118215752" LOG_EFFECT_SIZE="-0.0709081499725284" NO="2" P_CHI2="0.20403844523990555" P_Z="0.06970626407215276" STUDIES="31" TAU2="0.0" TOTAL_1="2175" TOTAL_2="1971" WEIGHT="100.0" Z="1.8138146643529267">
<NAME>Different BL</NAME>
<DICH_DATA CI_END="1.4524039103370738" CI_START="0.4665638439939939" EFFECT_SIZE="0.8231884057971014" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" LOG_CI_END="0.16208740950244066" LOG_CI_START="-0.33108891955491365" LOG_EFFECT_SIZE="-0.08450075502623647" ORDER="13" O_E="0.0" SE="0.2896942169504909" STUDY_ID="STD-Alvarez_x002d_Lerma-2001a" TOTAL_1="69" TOTAL_2="71" VAR="0.08392273933455809" WEIGHT="8.709557395939125"/>
<DICH_DATA CI_END="3.6745949117762566" CI_START="0.5395054550493839" EFFECT_SIZE="1.408" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.5652094693312208" LOG_CI_START="-0.2680041597190341" LOG_EFFECT_SIZE="0.1486026548060934" ORDER="14" O_E="0.0" SE="0.48943381017810217" STUDY_ID="STD-Arich-1987" TOTAL_1="25" TOTAL_2="22" VAR="0.23954545454545456" WEIGHT="2.349942251448268"/>
<DICH_DATA CI_END="6.2314434482611825" CI_START="0.011113328418578669" EFFECT_SIZE="0.2631578947368421" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7945886580562603" LOG_CI_START="-1.9541558512898807" LOG_EFFECT_SIZE="-0.5797835966168102" ORDER="15" O_E="0.0" SE="1.6146261312946875" STUDY_ID="STD-Bergeron-1988" TOTAL_1="37" TOTAL_2="29" VAR="2.6070175438596492" WEIGHT="0.7406465048976365"/>
<DICH_DATA CI_END="1.9171115225660975" CI_START="0.61566991069799" EFFECT_SIZE="1.0864197530864197" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.2826473774718505" LOG_CI_START="-0.2106520709288128" LOG_EFFECT_SIZE="0.035997653271518854" ORDER="16" O_E="0.0" SE="0.2897665378622012" STUDY_ID="STD-Brown-1984" TOTAL_1="18" TOTAL_2="16" VAR="0.08396464646464646" WEIGHT="4.209990659418144"/>
<DICH_DATA CI_END="4.598004635829613" CI_START="0.04450811651697542" EFFECT_SIZE="0.4523809523809524" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6625694048006385" LOG_CI_START="-1.3515607836907813" LOG_EFFECT_SIZE="-0.3444956894450715" ORDER="17" O_E="0.0" SE="1.183110042825089" STUDY_ID="STD-Cone-1985" TOTAL_1="21" TOTAL_2="19" VAR="1.399749373433584" WEIGHT="0.9277572008717764"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="18" O_E="0.0" SE="0.0" STUDY_ID="STD-Duff-1982" TOTAL_1="31" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.418721045629022" CI_START="0.2702186076723028" EFFECT_SIZE="0.6191646191646192" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.15189701120549098" LOG_CI_START="-0.5682847480928428" LOG_EFFECT_SIZE="-0.20819386844367593" ORDER="19" O_E="0.0" SE="0.42303833036904465" STUDY_ID="STD-Felisart-1985" TOTAL_1="37" TOTAL_2="36" VAR="0.17896142896142897" WEIGHT="4.926251542789471"/>
<DICH_DATA CI_END="2.7893228503916" CI_START="1.0339269681475727" EFFECT_SIZE="1.6982214572576018" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="21" LOG_CI_END="0.44549878462417336" LOG_CI_START="0.01448986327371745" LOG_EFFECT_SIZE="0.2299943239489454" ORDER="20" O_E="0.0" SE="0.25317677392982757" STUDY_ID="STD-Finer-1992" TOTAL_1="249" TOTAL_2="222" VAR="0.064098478857515" WEIGHT="9.809407346797125"/>
<DICH_DATA CI_END="3.6075179132023756" CI_START="0.39916641708972667" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.557208496268825" LOG_CI_START="-0.39884600417357535" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="21" O_E="0.0" SE="0.5615911461059686" STUDY_ID="STD-Gomez-1990a" TOTAL_1="39" TOTAL_2="39" VAR="0.3153846153846154" WEIGHT="2.208945716361372"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="22" O_E="0.0" SE="0.0" STUDY_ID="STD-Havig-1973" TOTAL_1="24" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.357375570364182" CI_START="0.08803470554565483" EFFECT_SIZE="0.45555555555555555" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.37242877859690693" LOG_CI_START="-1.0553460840360858" LOG_EFFECT_SIZE="-0.34145865271958936" ORDER="23" O_E="0.0" SE="0.8386820219101747" STUDY_ID="STD-Hoepelman-1988" TOTAL_1="45" TOTAL_2="41" VAR="0.7033875338753387" WEIGHT="1.8493499020699862"/>
<DICH_DATA CI_END="3.215975079542482" CI_START="0.1839927119135329" EFFECT_SIZE="0.7692307692307693" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5073126747595234" LOG_CI_START="-0.7351993793731969" LOG_EFFECT_SIZE="-0.11394335230683675" ORDER="24" O_E="0.0" SE="0.7298577311314224" STUDY_ID="STD-Jaspers-1998" TOTAL_1="39" TOTAL_2="40" VAR="0.5326923076923076" WEIGHT="1.744787502543666"/>
<DICH_DATA CI_END="12.12734418453573" CI_START="0.4875119785752522" EFFECT_SIZE="2.4315068493150687" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0837657033986128" LOG_CI_START="-0.3120147088572987" LOG_EFFECT_SIZE="0.385875497270657" ORDER="25" O_E="0.0" SE="0.8198883233835935" STUDY_ID="STD-Koehler-1990" TOTAL_1="73" TOTAL_2="71" VAR="0.6722168628207601" WEIGHT="0.8958502071910008"/>
<DICH_DATA CI_END="5.208499115067838" CI_START="0.34132246900739327" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7167125947102104" LOG_CI_START="-0.46683512149361067" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="26" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-Landau-1990" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="1.3253674298168232"/>
<DICH_DATA CI_END="3.0420157098392417" CI_START="0.6443096245888809" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.4831614525436979" LOG_CI_START="-0.19090538118722192" LOG_EFFECT_SIZE="0.146128035678238" ORDER="27" O_E="0.0" SE="0.3959501948181826" STUDY_ID="STD-McCormick-1997" TOTAL_1="65" TOTAL_2="63" VAR="0.15677655677655677" WEIGHT="4.038228887723133"/>
<DICH_DATA CI_END="1.4042559079538888" CI_START="0.3940358551877818" EFFECT_SIZE="0.743859649122807" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="19" LOG_CI_END="0.14744625970600495" LOG_CI_START="-0.4044642578655225" LOG_EFFECT_SIZE="-0.12850899907975877" ORDER="28" O_E="0.0" SE="0.32419497002263836" STUDY_ID="STD-Mouton-1990" TOTAL_1="105" TOTAL_2="106" VAR="0.10510237858797938" WEIGHT="8.35421176140462"/>
<DICH_DATA CI_END="2.4364795063951146" CI_START="0.3419070889891188" EFFECT_SIZE="0.9127155172413793" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3867627628148112" LOG_CI_START="-0.46609189459112144" LOG_EFFECT_SIZE="-0.03966456588815514" ORDER="29" O_E="0.0" SE="0.5009710474588857" STUDY_ID="STD-Mouton-1995" TOTAL_1="116" TOTAL_2="121" VAR="0.2509719903920531" WEIGHT="3.4597495776934233"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="30" O_E="0.0" SE="0.0" STUDY_ID="STD-Naime-Libien-1992" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="31" O_E="0.0" SE="0.0" STUDY_ID="STD-Rasmussen-1986" TOTAL_1="29" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.335567150499819" CI_START="0.5297708425076304" EFFECT_SIZE="0.8411566646860764" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="33" LOG_CI_END="0.1256657286422107" LOG_CI_START="-0.27591194805182445" LOG_EFFECT_SIZE="-0.07512310970480685" ORDER="32" O_E="0.0" SE="0.2358887151316354" STUDY_ID="STD-Rubinstein-1995" TOTAL_1="306" TOTAL_2="274" VAR="0.05564348592645383" WEIGHT="15.383402650908371"/>
<DICH_DATA CI_END="1.0856025424423192" CI_START="0.3115021565079405" EFFECT_SIZE="0.5815217391304348" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="23" LOG_CI_END="0.035670851755012306" LOG_CI_START="-0.5065389424036659" LOG_EFFECT_SIZE="-0.2354340453243268" ORDER="33" O_E="0.0" SE="0.3184967170705754" STUDY_ID="STD-Sieger-1997" TOTAL_1="104" TOTAL_2="107" VAR="0.10144015878473417" WEIGHT="10.016678964050051"/>
<DICH_DATA CI_END="0.8257784681916034" CI_START="0.160892393837605" EFFECT_SIZE="0.364501679731243" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="19" LOG_CI_END="-0.08313644535025404" LOG_CI_START="-0.7934644866184174" LOG_EFFECT_SIZE="-0.4383004659843357" ORDER="34" O_E="0.0" SE="0.41725020762143167" STUDY_ID="STD-Smith-1984" TOTAL_1="94" TOTAL_2="93" VAR="0.17409773576012785" WEIGHT="8.438881389136707"/>
<DICH_DATA CI_END="1.3587073697477343" CI_START="0.02138411310119719" EFFECT_SIZE="0.17045454545454544" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.13312593106030254" LOG_CI_START="-1.6699087572492775" LOG_EFFECT_SIZE="-0.7683914130944874" ORDER="35" O_E="0.0" SE="1.0591115010786976" STUDY_ID="STD-Speich-1998" TOTAL_1="44" TOTAL_2="45" VAR="1.121717171717172" WEIGHT="2.620951321884954"/>
<DICH_DATA CI_END="1.596094261813414" CI_START="0.10323084411702192" EFFECT_SIZE="0.40591397849462363" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2030585362481443" LOG_CI_START="-0.9861905214256007" LOG_EFFECT_SIZE="-0.3915659925887281" ORDER="36" O_E="0.0" SE="0.6985707833553355" STUDY_ID="STD-Stille-1992" TOTAL_1="186" TOTAL_2="151" VAR="0.48800113935768713" WEIGHT="2.926033732295895"/>
<DICH_DATA CI_END="3.6573286525107553" CI_START="0.1118039247724491" EFFECT_SIZE="0.6394557823129252" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5631639883825202" LOG_CI_START="-0.9515429506794751" LOG_EFFECT_SIZE="-0.19418948114847742" ORDER="37" O_E="0.0" SE="0.8897463539252893" STUDY_ID="STD-Thompson--1990" TOTAL_1="49" TOTAL_2="47" VAR="0.7916485743233462" WEIGHT="1.3529792512713403"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38" O_E="0.0" SE="0.0" STUDY_ID="STD-Thompson-1993" TOTAL_1="80" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="39" O_E="0.0" SE="0.0" STUDY_ID="STD-Trujillo-1992" TOTAL_1="16" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.338273443885321" CI_START="0.1084417517334551" EFFECT_SIZE="0.38095238095238093" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.1265448600964545" LOG_CI_START="-0.964803475580406" LOG_EFFECT_SIZE="-0.4191293077419757" ORDER="40" O_E="0.0" SE="0.641063414637976" STUDY_ID="STD-Warren-1983" TOTAL_1="56" TOTAL_2="64" VAR="0.41096230158730157" WEIGHT="3.7110288034871055"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="41" O_E="0.0" SE="0.0" STUDY_ID="STD-Wiecek-1986" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="42" O_E="0.0" SE="0.0" STUDY_ID="STD-Wing-1998" TOTAL_1="117" TOTAL_2="62" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="43" O_E="0.0" SE="0.0" STUDY_ID="STD-Yellin-1993" TOTAL_1="56" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="32.11741167230163" CI_END="1.0380448751942548" CI_START="0.7664164071031813" CI_STUDY="95" CI_TOTAL="95" DF="29" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8919498997467576" ESTIMABLE="YES" EVENTS_1="270" EVENTS_2="294" I2="9.706297954857037" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.01621612868389618" LOG_CI_START="-0.11553520664597186" LOG_EFFECT_SIZE="-0.04965953898103783" METHOD="MH" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.31474338760954934" P_Q="0.6576922405171731" P_Z="0.1395432484893146" Q="2.4273401977099818" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="41" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2801" TOTAL_2="2588" WEIGHT="500.0" Z="1.4774940633126492">
<NAME>All-cause mortality by study groups</NAME>
<GROUP_LABEL_1>Monotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours monotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.848954475474043" CI_END="1.5509395450623376" CI_START="0.7516512555367099" DF="6" EFFECT_SIZE="1.0797062824248267" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="48" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.19059486953666563" LOG_CI_START="-0.12398361276818341" LOG_EFFECT_SIZE="0.0333056283842411" MODIFIED="2011-12-26 06:38:26 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5633269284995562" P_Z="0.6781288863479769" STUDIES="7" TAU2="0.0" TOTAL_1="422" TOTAL_2="417" WEIGHT="100.00000000000001" Z="0.4150177827632129">
<NAME>Same sepsis</NAME>
<DICH_DATA CI_END="13.251516091767591" CI_START="0.0584385963566154" EFFECT_SIZE="0.88" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1222655682820444" LOG_CI_START="-1.2333002239817072" LOG_EFFECT_SIZE="-0.05551732784983137" ORDER="44" O_E="0.0" SE="1.3836710066144533" STUDY_ID="STD-Carbon-1987" TOTAL_1="25" TOTAL_2="22" VAR="1.9145454545454546" WEIGHT="2.1918158627309534"/>
<DICH_DATA CI_END="2.143933394780039" CI_START="0.7045398228271409" EFFECT_SIZE="1.229018492176387" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="19" LOG_CI_END="0.33121128907632275" LOG_CI_START="-0.15209445415818415" LOG_EFFECT_SIZE="0.08955841745906934" ORDER="45" O_E="0.0" SE="0.2838961859779625" STUDY_ID="STD-Cometta-1994" TOTAL_1="148" TOTAL_2="144" VAR="0.08059704441283387" WEIGHT="39.68207557287311"/>
<DICH_DATA CI_END="1.7629588148188347" CI_START="0.2702748393715548" EFFECT_SIZE="0.6902777777777778" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.24624216669192472" LOG_CI_START="-0.5681943820877975" LOG_EFFECT_SIZE="-0.16097610769793635" ORDER="46" O_E="0.0" SE="0.47840406027914484" STUDY_ID="STD-D_x0027_Antonio-1992" TOTAL_1="144" TOTAL_2="142" VAR="0.22887044489157166" WEIGHT="20.7471465160323"/>
<DICH_DATA CI_END="2.0276339895692987" CI_START="0.09260930658282401" EFFECT_SIZE="0.43333333333333335" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3069895627637647" LOG_CI_START="-1.033345367589416" LOG_EFFECT_SIZE="-0.36317790241282566" MODIFIED="2011-12-26 06:38:26 +0000" MODIFIED_BY="[Empty name]" ORDER="1035" O_E="0.0" SE="0.7873193728543677" STUDY_ID="STD-Damas-2006" TOTAL_1="24" TOTAL_2="26" VAR="0.6198717948717949" WEIGHT="9.889473172642061"/>
<DICH_DATA CI_END="8.260092687698416" CI_START="0.7204087189498556" EFFECT_SIZE="2.4393939393939394" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9169849206291129" LOG_CI_START="-0.14242103964915054" LOG_EFFECT_SIZE="0.38728194048998105" ORDER="47" O_E="0.0" SE="0.6223003052115317" STUDY_ID="STD-Klastersky-1973" TOTAL_1="22" TOTAL_2="23" VAR="0.38725766986636545" WEIGHT="6.043566938836815"/>
<DICH_DATA CI_END="2.74230421376631" CI_START="0.5671952289593608" EFFECT_SIZE="1.2471655328798186" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.43811563099017203" LOG_CI_START="-0.2462674309373614" LOG_EFFECT_SIZE="0.0959241000264053" ORDER="48" O_E="0.0" SE="0.40200999832702655" STUDY_ID="STD-Kljucar-1990" TOTAL_1="49" TOTAL_2="50" VAR="0.1616120387548959" WEIGHT="18.355461570434127"/>
<DICH_DATA CI_END="7.3225436971144395" CI_START="0.015173840636129785" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8646619720038995" LOG_CI_START="-1.8189044814432243" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="49" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Sculier-1982" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="3.0904603664506443"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5452478612798557" CI_START="0.5411130099195283" DF="0" EFFECT_SIZE="0.9144144144144144" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.18899815117342472" LOG_CI_START="-0.26671202424827617" LOG_EFFECT_SIZE="-0.03885693653742572" NO="2" P_CHI2="1.0" P_Z="0.7381987554204532" STUDIES="2" TAU2="0.0" TOTAL_1="167" TOTAL_2="164" WEIGHT="100.0" Z="0.3342396122379245">
<NAME>Same abdominal</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="50" O_E="0.0" SE="0.0" STUDY_ID="STD-Cardozo-2001" TOTAL_1="56" TOTAL_2="48" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.5452478612798557" CI_START="0.5411130099195283" EFFECT_SIZE="0.9144144144144144" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.18899815117342472" LOG_CI_START="-0.26671202424827617" LOG_EFFECT_SIZE="-0.03885693653742572" ORDER="51" O_E="0.0" SE="0.26768641284445654" STUDY_ID="STD-Dupont-2000" TOTAL_1="111" TOTAL_2="116" VAR="0.07165601562153284" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Same UTI</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="52" O_E="0.0" SE="0.0" STUDY_ID="STD-Sandberg-1997" TOTAL_1="37" TOTAL_2="36" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="23.517624715222816" CI_END="0.9937179432228315" CI_START="0.686857241606647" DF="17" EFFECT_SIZE="0.8261612224118635" ESTIMABLE="YES" EVENTS_1="178" EVENTS_2="206" I2="27.71378825091973" ID="CMP-001.02.04" LOG_CI_END="-0.0027368682031348886" LOG_CI_START="-0.16313351858102723" LOG_EFFECT_SIZE="-0.08293519339208108" NO="4" P_CHI2="0.1331453587761291" P_Z="0.042677733959516094" STUDIES="21" TAU2="0.0" TOTAL_1="1688" TOTAL_2="1610" WEIGHT="100.0" Z="2.026850208110675">
<NAME>Different sepsis</NAME>
<DICH_DATA CI_END="1.4524039103370738" CI_START="0.4665638439939939" EFFECT_SIZE="0.8231884057971014" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" LOG_CI_END="0.16208740950244066" LOG_CI_START="-0.33108891955491365" LOG_EFFECT_SIZE="-0.08450075502623647" ORDER="53" O_E="0.0" SE="0.2896942169504909" STUDY_ID="STD-Alvarez_x002d_Lerma-2001a" TOTAL_1="69" TOTAL_2="71" VAR="0.08392273933455809" WEIGHT="9.411385297809145"/>
<DICH_DATA CI_END="3.6745949117762566" CI_START="0.5395054550493839" EFFECT_SIZE="1.408" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.5652094693312208" LOG_CI_START="-0.2680041597190341" LOG_EFFECT_SIZE="0.1486026548060934" ORDER="54" O_E="0.0" SE="0.48943381017810217" STUDY_ID="STD-Arich-1987" TOTAL_1="25" TOTAL_2="22" VAR="0.23954545454545456" WEIGHT="2.5393037729210617"/>
<DICH_DATA CI_END="1.9171115225660975" CI_START="0.61566991069799" EFFECT_SIZE="1.0864197530864197" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.2826473774718505" LOG_CI_START="-0.2106520709288128" LOG_EFFECT_SIZE="0.035997653271518854" ORDER="55" O_E="0.0" SE="0.2897665378622012" STUDY_ID="STD-Brown-1984" TOTAL_1="18" TOTAL_2="16" VAR="0.08396464646464646" WEIGHT="4.549237394593168"/>
<DICH_DATA CI_END="4.598004635829613" CI_START="0.04450811651697542" EFFECT_SIZE="0.4523809523809524" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6625694048006385" LOG_CI_START="-1.3515607836907813" LOG_EFFECT_SIZE="-0.3444956894450715" ORDER="56" O_E="0.0" SE="1.183110042825089" STUDY_ID="STD-Cone-1985" TOTAL_1="21" TOTAL_2="19" VAR="1.399749373433584" WEIGHT="1.0025171295492352"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="57" O_E="0.0" SE="0.0" STUDY_ID="STD-Duff-1982" TOTAL_1="31" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.418721045629022" CI_START="0.2702186076723028" EFFECT_SIZE="0.6191646191646192" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.15189701120549098" LOG_CI_START="-0.5682847480928428" LOG_EFFECT_SIZE="-0.20819386844367593" ORDER="58" O_E="0.0" SE="0.42303833036904465" STUDY_ID="STD-Felisart-1985" TOTAL_1="37" TOTAL_2="36" VAR="0.17896142896142897" WEIGHT="5.323215547639121"/>
<DICH_DATA CI_END="2.7893228503916" CI_START="1.0339269681475727" EFFECT_SIZE="1.6982214572576018" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="21" LOG_CI_END="0.44549878462417336" LOG_CI_START="0.01448986327371745" LOG_EFFECT_SIZE="0.2299943239489454" ORDER="59" O_E="0.0" SE="0.25317677392982757" STUDY_ID="STD-Finer-1992" TOTAL_1="249" TOTAL_2="222" VAR="0.064098478857515" WEIGHT="10.599862643641593"/>
<DICH_DATA CI_END="3.6075179132023756" CI_START="0.39916641708972667" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.557208496268825" LOG_CI_START="-0.39884600417357535" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="60" O_E="0.0" SE="0.5615911461059686" STUDY_ID="STD-Gomez-1990a" TOTAL_1="39" TOTAL_2="39" VAR="0.3153846153846154" WEIGHT="2.386945546545798"/>
<DICH_DATA CI_END="2.357375570364182" CI_START="0.08803470554565483" EFFECT_SIZE="0.45555555555555555" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.37242877859690693" LOG_CI_START="-1.0553460840360858" LOG_EFFECT_SIZE="-0.34145865271958936" ORDER="61" O_E="0.0" SE="0.8386820219101747" STUDY_ID="STD-Hoepelman-1988" TOTAL_1="45" TOTAL_2="41" VAR="0.7033875338753387" WEIGHT="1.998373015712761"/>
<DICH_DATA CI_END="3.215975079542482" CI_START="0.1839927119135329" EFFECT_SIZE="0.7692307692307693" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5073126747595234" LOG_CI_START="-0.7351993793731969" LOG_EFFECT_SIZE="-0.11394335230683675" ORDER="62" O_E="0.0" SE="0.7298577311314224" STUDY_ID="STD-Jaspers-1998" TOTAL_1="39" TOTAL_2="40" VAR="0.5326923076923076" WEIGHT="1.8853848367652886"/>
<DICH_DATA CI_END="12.12734418453573" CI_START="0.4875119785752522" EFFECT_SIZE="2.4315068493150687" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0837657033986128" LOG_CI_START="-0.3120147088572987" LOG_EFFECT_SIZE="0.385875497270657" ORDER="63" O_E="0.0" SE="0.8198883233835935" STUDY_ID="STD-Koehler-1990" TOTAL_1="73" TOTAL_2="71" VAR="0.6722168628207601" WEIGHT="0.9680390272102402"/>
<DICH_DATA CI_END="1.4042559079538888" CI_START="0.3940358551877818" EFFECT_SIZE="0.743859649122807" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="19" LOG_CI_END="0.14744625970600495" LOG_CI_START="-0.4044642578655225" LOG_EFFECT_SIZE="-0.12850899907975877" ORDER="64" O_E="0.0" SE="0.32419497002263836" STUDY_ID="STD-Mouton-1990" TOTAL_1="105" TOTAL_2="106" VAR="0.10510237858797938" WEIGHT="9.027405431959936"/>
<DICH_DATA CI_END="2.4364795063951146" CI_START="0.3419070889891188" EFFECT_SIZE="0.9127155172413793" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3867627628148112" LOG_CI_START="-0.46609189459112144" LOG_EFFECT_SIZE="-0.03966456588815514" ORDER="65" O_E="0.0" SE="0.5009710474588857" STUDY_ID="STD-Mouton-1995" TOTAL_1="116" TOTAL_2="121" VAR="0.2509719903920531" WEIGHT="3.7385408729021106"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="66" O_E="0.0" SE="0.0" STUDY_ID="STD-Naime-Libien-1992" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.335567150499819" CI_START="0.5297708425076304" EFFECT_SIZE="0.8411566646860764" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="33" LOG_CI_END="0.1256657286422107" LOG_CI_START="-0.27591194805182445" LOG_EFFECT_SIZE="-0.07512310970480685" ORDER="67" O_E="0.0" SE="0.2358887151316354" STUDY_ID="STD-Rubinstein-1995" TOTAL_1="306" TOTAL_2="274" VAR="0.05564348592645383" WEIGHT="16.623018020013426"/>
<DICH_DATA CI_END="1.0856025424423192" CI_START="0.3115021565079405" EFFECT_SIZE="0.5815217391304348" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="23" LOG_CI_END="0.035670851755012306" LOG_CI_START="-0.5065389424036659" LOG_EFFECT_SIZE="-0.2354340453243268" ORDER="68" O_E="0.0" SE="0.3184967170705754" STUDY_ID="STD-Sieger-1997" TOTAL_1="104" TOTAL_2="107" VAR="0.10144015878473417" WEIGHT="10.823836487843694"/>
<DICH_DATA CI_END="0.8257784681916034" CI_START="0.160892393837605" EFFECT_SIZE="0.364501679731243" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="19" LOG_CI_END="-0.08313644535025404" LOG_CI_START="-0.7934644866184174" LOG_EFFECT_SIZE="-0.4383004659843357" ORDER="69" O_E="0.0" SE="0.41725020762143167" STUDY_ID="STD-Smith-1984" TOTAL_1="94" TOTAL_2="93" VAR="0.17409773576012785" WEIGHT="9.118897852686192"/>
<DICH_DATA CI_END="1.3587073697477343" CI_START="0.02138411310119719" EFFECT_SIZE="0.17045454545454544" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.13312593106030254" LOG_CI_START="-1.6699087572492775" LOG_EFFECT_SIZE="-0.7683914130944874" ORDER="70" O_E="0.0" SE="1.0591115010786976" STUDY_ID="STD-Speich-1998" TOTAL_1="44" TOTAL_2="45" VAR="1.121717171717172" WEIGHT="2.832151120395913"/>
<DICH_DATA CI_END="1.596094261813414" CI_START="0.10323084411702192" EFFECT_SIZE="0.40591397849462363" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2030585362481443" LOG_CI_START="-0.9861905214256007" LOG_EFFECT_SIZE="-0.3915659925887281" ORDER="71" O_E="0.0" SE="0.6985707833553355" STUDY_ID="STD-Stille-1992" TOTAL_1="186" TOTAL_2="151" VAR="0.48800113935768713" WEIGHT="3.1618174836143744"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="72" O_E="0.0" SE="0.0" STUDY_ID="STD-Trujillo-1992" TOTAL_1="16" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.338273443885321" CI_START="0.1084417517334551" EFFECT_SIZE="0.38095238095238093" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.1265448600964545" LOG_CI_START="-0.964803475580406" LOG_EFFECT_SIZE="-0.4191293077419757" ORDER="73" O_E="0.0" SE="0.641063414637976" STUDY_ID="STD-Warren-1983" TOTAL_1="56" TOTAL_2="64" VAR="0.41096230158730157" WEIGHT="4.010068518196941"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5304049964414592" CI_END="2.15030147051588" CI_START="0.5574778137287373" DF="2" EFFECT_SIZE="1.094872304262411" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" I2="0.0" ID="CMP-001.02.05" LOG_CI_END="0.33249935191706864" LOG_CI_START="-0.25377241180789717" LOG_EFFECT_SIZE="0.03936347005458569" NO="5" P_CHI2="0.4652398360199842" P_Z="0.7924026899450759" STUDIES="6" TAU2="0.0" TOTAL_1="311" TOTAL_2="239" WEIGHT="100.00000000000001" Z="0.2631918792176465">
<NAME>Different abdominal</NAME>
<DICH_DATA CI_END="6.2314434482611825" CI_START="0.011113328418578669" EFFECT_SIZE="0.2631578947368421" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7945886580562603" LOG_CI_START="-1.9541558512898807" LOG_EFFECT_SIZE="-0.5797835966168102" ORDER="74" O_E="0.0" SE="1.6146261312946875" STUDY_ID="STD-Bergeron-1988" TOTAL_1="37" TOTAL_2="29" VAR="2.6070175438596492" WEIGHT="12.07867028673598"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="75" O_E="0.0" SE="0.0" STUDY_ID="STD-Havig-1973" TOTAL_1="24" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.0420157098392417" CI_START="0.6443096245888809" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.4831614525436979" LOG_CI_START="-0.19090538118722192" LOG_EFFECT_SIZE="0.146128035678238" ORDER="76" O_E="0.0" SE="0.3959501948181826" STUDY_ID="STD-McCormick-1997" TOTAL_1="65" TOTAL_2="63" VAR="0.15677655677655677" WEIGHT="65.85656579034502"/>
<DICH_DATA CI_END="3.6573286525107553" CI_START="0.1118039247724491" EFFECT_SIZE="0.6394557823129252" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5631639883825202" LOG_CI_START="-0.9515429506794751" LOG_EFFECT_SIZE="-0.19418948114847742" ORDER="77" O_E="0.0" SE="0.8897463539252893" STUDY_ID="STD-Thompson--1990" TOTAL_1="49" TOTAL_2="47" VAR="0.7916485743233462" WEIGHT="22.064763922919013"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="78" O_E="0.0" SE="0.0" STUDY_ID="STD-Thompson-1993" TOTAL_1="80" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="79" O_E="0.0" SE="0.0" STUDY_ID="STD-Yellin-1993" TOTAL_1="56" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.208499115067839" CI_START="0.3413224690073932" DF="0" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-001.02.06" LOG_CI_END="0.7167125947102105" LOG_CI_START="-0.4668351214936107" LOG_EFFECT_SIZE="0.12493873660829993" NO="6" P_CHI2="1.0" P_Z="0.6790213257374376" STUDIES="4" TAU2="0.0" TOTAL_1="176" TOTAL_2="122" WEIGHT="100.0" Z="0.41379898870766496">
<NAME>Different UTI</NAME>
<DICH_DATA CI_END="5.208499115067838" CI_START="0.34132246900739327" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7167125947102104" LOG_CI_START="-0.46683512149361067" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="80" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-Landau-1990" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="81" O_E="0.0" SE="0.0" STUDY_ID="STD-Rasmussen-1986" TOTAL_1="29" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="82" O_E="0.0" SE="0.0" STUDY_ID="STD-Wiecek-1986" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="83" O_E="0.0" SE="0.0" STUDY_ID="STD-Wing-1998" TOTAL_1="117" TOTAL_2="62" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="80.30085927608631" CI_END="0.9330798302358894" CI_START="0.7797855402900828" CI_STUDY="95" CI_TOTAL="95" DF="63" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8529959903506416" ESTIMABLE="YES" EVENTS_1="655" EVENTS_2="756" I2="21.545048747988343" I2_Q="93.63996717395005" ID="CMP-001.03" LOG_CI_END="-0.030081198324460597" LOG_CI_START="-0.10802482227761769" LOG_EFFECT_SIZE="-0.06905301030103914" METHOD="MH" MODIFIED="2013-08-13 07:02:57 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.06978359872616469" P_Q="7.33204853252678E-5" P_Z="5.150538685185065E-4" Q="15.723189287704905" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="66" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="3491" TOTAL_2="3312" WEIGHT="200.0" Z="3.472802683525419">
<NAME>Clinical failure</NAME>
<GROUP_LABEL_1>Monotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours monotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="14.728005801575021" CI_END="1.2911246908586913" CI_START="0.9475934119267334" DF="18" EFFECT_SIZE="1.106101826702061" ESTIMABLE="YES" EVENTS_1="236" EVENTS_2="221" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.11096818644681347" LOG_CI_START="-0.02337796733911217" LOG_EFFECT_SIZE="0.04379510955385066" MODIFIED="2011-12-11 14:38:23 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6805508724984853" P_Z="0.20130381054071866" STUDIES="20" TAU2="0.0" TOTAL_1="919" TOTAL_2="951" WEIGHT="99.99999999999999" Z="1.2778458482899384">
<NAME>Same BL</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1068" O_E="0.0" SE="0.0" STUDY_ID="STD-Abrams-1979" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="11.697696457498267" CI_START="0.0593659142180342" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0681003477040096" LOG_CI_START="-1.226462839799259" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="1063" O_E="0.0" SE="1.347837774610382" STUDY_ID="STD-Biglino-1991" TOTAL_1="12" TOTAL_2="10" VAR="1.8166666666666667" WEIGHT="0.5062576949214331"/>
<DICH_DATA CI_END="2.6312143240480275" CI_START="0.1655509382184593" EFFECT_SIZE="0.66" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4201562247335235" LOG_CI_START="-0.781068353649786" LOG_EFFECT_SIZE="-0.1804560644581313" ORDER="1057" O_E="0.0" SE="0.7056052634999174" STUDY_ID="STD-Carbon-1987" TOTAL_1="25" TOTAL_2="22" VAR="0.49787878787878775" WEIGHT="1.974764058204172"/>
<DICH_DATA CI_END="1.9847833295834896" CI_START="0.37016326497723917" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.2977131035916891" LOG_CI_START="-0.4316066828529156" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="1075" O_E="0.0" SE="0.4284060527487281" STUDY_ID="STD-Cardozo-2001" TOTAL_1="56" TOTAL_2="48" VAR="0.18353174603174602" WEIGHT="4.497904904878887"/>
<DICH_DATA CI_END="2.155845445955638" CI_START="0.8606766127447515" EFFECT_SIZE="1.3621621621621622" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="25" LOG_CI_END="0.3336176227602601" LOG_CI_START="-0.06515999800319945" LOG_EFFECT_SIZE="0.13422881237853032" ORDER="1073" O_E="0.0" SE="0.23424394841751486" STUDY_ID="STD-Cometta-1994" TOTAL_1="148" TOTAL_2="144" VAR="0.05487022737022737" WEIGHT="11.760666771291286"/>
<DICH_DATA CI_END="2.5248479213118067" CI_START="0.1293268436046026" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.40223522446491633" LOG_CI_START="-0.8883113218375052" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="1069" O_E="0.0" SE="0.758073429606476" STUDY_ID="STD-Coppens-1983" TOTAL_1="22" TOTAL_2="44" VAR="0.5746753246753247" WEIGHT="2.1656579171639088"/>
<DICH_DATA CI_END="1.7738115910050403" CI_START="0.8274562460098094" EFFECT_SIZE="1.2115079365079364" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="35" LOG_CI_END="0.24890748847637187" LOG_CI_START="-0.08225496144213654" LOG_EFFECT_SIZE="0.08332626351711768" ORDER="1064" O_E="0.0" SE="0.1945264623626969" STUDY_ID="STD-D_x0027_Antonio-1992" TOTAL_1="144" TOTAL_2="142" VAR="0.03784054455934573" WEIGHT="16.356017835923225"/>
<DICH_DATA CI_END="1.3667256675620698" CI_START="0.8230512110018743" EFFECT_SIZE="1.0606060606060606" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="55" LOG_CI_END="0.13568135069047074" LOG_CI_START="-0.08457314174569446" LOG_EFFECT_SIZE="0.025554104472388137" ORDER="1066" O_E="0.0" SE="0.12937857913432477" STUDY_ID="STD-Dupont-2000" TOTAL_1="99" TOTAL_2="105" VAR="0.016738816738816734" WEIGHT="24.77312470369219"/>
<DICH_DATA CI_END="7.689843930627566" CI_START="1.0748755208254848" EFFECT_SIZE="2.875" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.8859175256590314" LOG_CI_START="0.0313581723922671" LOG_EFFECT_SIZE="0.4586378490256493" ORDER="1071" O_E="0.0" SE="0.5019723942459189" STUDY_ID="STD-Klastersky-1973" TOTAL_1="22" TOTAL_2="23" VAR="0.2519762845849802" WEIGHT="1.8150275877183233"/>
<DICH_DATA CI_END="2.9094577025383535" CI_START="0.6391239613516574" EFFECT_SIZE="1.3636363636363635" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.46381204783713936" LOG_CI_START="-0.19441490004222706" LOG_EFFECT_SIZE="0.13469857389745618" ORDER="1076" O_E="0.0" SE="0.3866457674602807" STUDY_ID="STD-Kljucar-1990" TOTAL_1="44" TOTAL_2="45" VAR="0.14949494949494946" WEIGHT="4.1296976012692195"/>
<DICH_DATA CI_END="1.9007156127572655" CI_START="0.14916575169326518" EFFECT_SIZE="0.5324675324675324" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.27891714208928725" LOG_CI_START="-0.8263308789947802" LOG_EFFECT_SIZE="-0.2737068684527464" ORDER="1058" O_E="0.0" SE="0.6492281586507218" STUDY_ID="STD-Korzeniowski-1982" TOTAL_1="33" TOTAL_2="41" VAR="0.42149720198500684" WEIGHT="2.897299105394959"/>
<DICH_DATA CI_END="3.826396404729478" CI_START="0.31622442424010855" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.582789959802314" LOG_CI_START="-0.5000045894858638" LOG_EFFECT_SIZE="0.04139268515822508" ORDER="1065" O_E="0.0" SE="0.6360388781713383" STUDY_ID="STD-Mergoni-1987" TOTAL_1="20" TOTAL_2="22" VAR="0.40454545454545454" WEIGHT="1.7678840140113539"/>
<DICH_DATA CI_END="1.5195651886332249" CI_START="0.279337797304769" EFFECT_SIZE="0.6515151515151515" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.18171933584499625" LOG_CI_START="-0.5538702957695606" LOG_EFFECT_SIZE="-0.18607547996228216" ORDER="1070" O_E="0.0" SE="0.4320889908377921" STUDY_ID="STD-Piccart-1984" TOTAL_1="42" TOTAL_2="43" VAR="0.1867008960032216" WEIGHT="5.044709030570046"/>
<DICH_DATA CI_END="1.5400316693721572" CI_START="0.4008663919406224" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.18752965180539463" LOG_CI_START="-0.3970003528454206" LOG_EFFECT_SIZE="-0.104735350520013" ORDER="1074" O_E="0.0" SE="0.34335581820207717" STUDY_ID="STD-Ribera-1996" TOTAL_1="45" TOTAL_2="45" VAR="0.11789321789321788" WEIGHT="6.496973751491726"/>
<DICH_DATA CI_END="17.294732547204912" CI_START="1.0349630001602124" EFFECT_SIZE="4.230769230769231" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.2379138502953821" LOG_CI_START="0.014924824079431976" LOG_EFFECT_SIZE="0.626419337187407" ORDER="1059" O_E="0.0" SE="0.7183898078925648" STUDY_ID="STD-Sage-1987" TOTAL_1="26" TOTAL_2="22" VAR="0.5160839160839161" WEIGHT="1.0054840329689576"/>
<DICH_DATA CI_END="2.0855643415267795" CI_START="0.45957924110915704" EFFECT_SIZE="0.9790209790209791" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.3192235927620454" LOG_CI_START="-0.33763959633569307" LOG_EFFECT_SIZE="-0.009208001786823765" ORDER="1072" O_E="0.0" SE="0.38584468880123757" STUDY_ID="STD-Sandberg-1997" TOTAL_1="26" TOTAL_2="35" VAR="0.14887612387612387" WEIGHT="4.351603027931226"/>
<DICH_DATA CI_END="2.523907854293063" CI_START="0.22286867527402432" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.40207349514318896" LOG_CI_START="-0.6519509683597887" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="1062" O_E="0.0" SE="0.6191391873668903" STUDY_ID="STD-Sculier-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.3833333333333333" WEIGHT="1.8562782147119217"/>
<DICH_DATA CI_END="14.55119169880151" CI_START="0.06353817832623988" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1628985621892929" LOG_CI_START="-1.1969652407868534" LOG_EFFECT_SIZE="-0.017033339298780342" ORDER="1067" O_E="0.0" SE="1.3861956793824102" STUDY_ID="STD-Sexton-1998" TOTAL_1="26" TOTAL_2="25" VAR="1.9215384615384614" WEIGHT="0.4731689566912741"/>
<DICH_DATA CI_END="3.8827994475086087" CI_START="0.44874838980365256" EFFECT_SIZE="1.32" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5891449591554481" LOG_CI_START="-0.3479970967437483" LOG_EFFECT_SIZE="0.12057393120584989" ORDER="1061" O_E="0.0" SE="0.5504818825631803" STUDY_ID="STD-Sukoh-1994" TOTAL_1="30" TOTAL_2="33" VAR="0.3030303030303031" WEIGHT="2.2098550175141924"/>
<DICH_DATA CI_END="1.9693429049207163" CI_START="0.46703880711684953" EFFECT_SIZE="0.9590409590409591" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.2943213427246578" LOG_CI_START="-0.33064703160415826" LOG_EFFECT_SIZE="-0.018162844439750202" ORDER="1060" O_E="0.0" SE="0.36710951672409314" STUDY_ID="STD-Takamoto-1994" TOTAL_1="77" TOTAL_2="80" VAR="0.13476939726939724" WEIGHT="5.917625773651699"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="50.67726120717071" CI_END="0.8409037339020538" CI_START="0.6738015366933258" DF="44" EFFECT_SIZE="0.7527298506863929" ESTIMABLE="YES" EVENTS_1="419" EVENTS_2="535" I2="13.176049865587236" ID="CMP-001.03.02" LOG_CI_END="-0.07525371909876752" LOG_CI_START="-0.17146800288788946" LOG_EFFECT_SIZE="-0.1233608609933285" MODIFIED="2011-12-26 07:17:15 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.22693903912464386" P_Z="5.010139842785323E-7" STUDIES="46" TAU2="0.0" TOTAL_1="2572" TOTAL_2="2361" WEIGHT="100.00000000000001" Z="5.02592411701997">
<NAME>Different BL</NAME>
<DICH_DATA CI_END="2.3225990308636475" CI_START="0.007117290597831311" EFFECT_SIZE="0.12857142857142856" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3659742404872978" LOG_CI_START="-2.147685301637162" LOG_EFFECT_SIZE="-0.890855530574932" ORDER="1113" O_E="0.0" SE="1.4765360578593163" STUDY_ID="STD-Aguilar-1992" TOTAL_1="19" TOTAL_2="17" VAR="2.1801587301587304" WEIGHT="0.6772977774129413"/>
<DICH_DATA CI_END="1.0074864919644275" CI_START="0.2658612783365917" EFFECT_SIZE="0.5175438596491229" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="20" LOG_CI_END="0.0032392319797593778" LOG_CI_START="-0.575344911368416" LOG_EFFECT_SIZE="-0.2860528396943284" ORDER="1083" O_E="0.0" SE="0.33986318984041847" STUDY_ID="STD-Alvarez_x002d_Lerma-2001a" TOTAL_1="57" TOTAL_2="59" VAR="0.11550698780850434" WEIGHT="3.6133669602867755"/>
<DICH_DATA CI_END="1.9601526210417917" CI_START="0.14222565988347913" EFFECT_SIZE="0.528" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.2922898876298273" LOG_CI_START="-0.8470220425622028" LOG_EFFECT_SIZE="-0.27736607746618774" ORDER="1081" O_E="0.0" SE="0.6692374674798086" STUDY_ID="STD-Arich-1987" TOTAL_1="25" TOTAL_2="22" VAR="0.4478787878787879" WEIGHT="0.977861532739049"/>
<DICH_DATA CI_END="17.69656322236463" CI_START="0.0749290767652106" EFFECT_SIZE="1.1515151515151516" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2478889319840376" LOG_CI_START="-1.1253496185061924" LOG_EFFECT_SIZE="0.06126965673892271" MODIFIED="2011-12-26 06:56:11 +0000" MODIFIED_BY="[Empty name]" ORDER="2068" O_E="0.0" SE="1.3940520722782508" STUDY_ID="STD-Banasal-2006" TOTAL_1="33" TOTAL_2="38" VAR="1.9433811802232854" WEIGHT="0.17089163236938198"/>
<DICH_DATA CI_END="1.5550666855189255" CI_START="0.06764100107599494" EFFECT_SIZE="0.32432432432432434" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.19174901749913703" LOG_CI_START="-1.1697899735378774" LOG_EFFECT_SIZE="-0.48902047801937015" ORDER="1091" O_E="0.0" SE="0.7997747430618447" STUDY_ID="STD-Bergeron-1988" TOTAL_1="37" TOTAL_2="30" VAR="0.6396396396396397" WEIGHT="1.0152246002586307"/>
<DICH_DATA CI_END="1.423999570845346" CI_START="0.3356573471587424" EFFECT_SIZE="0.691358024691358" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.1535098584163388" LOG_CI_START="-0.4741038421612374" LOG_EFFECT_SIZE="-0.16029699187244936" ORDER="1118" O_E="0.0" SE="0.368663394457191" STUDY_ID="STD-Brown-1984" TOTAL_1="18" TOTAL_2="16" VAR="0.1359126984126984" WEIGHT="1.7518676965353221"/>
<DICH_DATA CI_END="2.6498175935704897" CI_START="0.17377014357166556" EFFECT_SIZE="0.6785714285714286" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4232159792831023" LOG_CI_START="-0.7600248400618829" LOG_EFFECT_SIZE="-0.16840443038939024" ORDER="1098" O_E="0.0" SE="0.6950415144197627" STUDY_ID="STD-Cone-1985" TOTAL_1="21" TOTAL_2="19" VAR="0.48308270676691717" WEIGHT="0.7721194662507531"/>
<DICH_DATA CI_END="1.87491372144196" CI_START="0.5772378000241282" EFFECT_SIZE="1.0403225806451613" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.27298128744304856" LOG_CI_START="-0.23864523716902078" LOG_EFFECT_SIZE="0.01716802513701388" ORDER="1104" O_E="0.0" SE="0.3005319531492715" STUDY_ID="STD-Duff-1982" TOTAL_1="31" TOTAL_2="43" VAR="0.09031945486371591" WEIGHT="2.4644224920229956"/>
<DICH_DATA CI_END="0.9370474331203014" CI_START="0.2525689662751385" EFFECT_SIZE="0.4864864864864865" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="18" LOG_CI_END="-0.028238424671436866" LOG_CI_START="-0.5976200132559408" LOG_EFFECT_SIZE="-0.3129292189636889" ORDER="1110" O_E="0.0" SE="0.3344575636188571" STUDY_ID="STD-Felisart-1985" TOTAL_1="37" TOTAL_2="36" VAR="0.11186186186186185" WEIGHT="3.3544133367449547"/>
<DICH_DATA CI_END="6.586766671602955" CI_START="0.4918953655924044" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.8186722793470714" LOG_CI_START="-0.30812726914045924" LOG_EFFECT_SIZE="0.25527250510330607" MODIFIED="2011-12-26 07:17:15 +0000" MODIFIED_BY="[Empty name]" ORDER="2086" O_E="0.0" SE="0.6618876325292973" STUDY_ID="STD-Figueroa_x002d_Damian-1996" TOTAL_1="14" TOTAL_2="42" VAR="0.4380952380952381" WEIGHT="0.45959492038735306"/>
<DICH_DATA CI_END="1.668340822997299" CI_START="0.5604233296704261" EFFECT_SIZE="0.9669421487603306" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" LOG_CI_END="0.22228477677345543" LOG_CI_START="-0.25148379391403236" LOG_EFFECT_SIZE="-0.014599508570288439" ORDER="1093" O_E="0.0" SE="0.278294003614078" STUDY_ID="STD-Finer-1992" TOTAL_1="220" TOTAL_2="195" VAR="0.07744755244755246" WEIGHT="4.288075980095978"/>
<DICH_DATA CI_END="0.5205513287712564" CI_START="0.09922728020675375" EFFECT_SIZE="0.22727272727272727" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="22" LOG_CI_END="-0.2835364405952395" LOG_CI_START="-1.0033689123771354" LOG_EFFECT_SIZE="-0.6434526764861874" MODIFIED="2011-12-26 07:08:32 +0000" MODIFIED_BY="[Empty name]" ORDER="2078" O_E="0.0" SE="0.42283315715288794" STUDY_ID="STD-Garc_x00ed_a-Ram_x00ed_rez-1999" TOTAL_1="30" TOTAL_2="30" VAR="0.17878787878787883" WEIGHT="4.044435299408707"/>
<DICH_DATA CI_END="0.7364746482815971" CI_START="0.10801855283463083" EFFECT_SIZE="0.28205128205128205" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.132842198313418" LOG_CI_START="-0.9665016454231303" LOG_EFFECT_SIZE="-0.5496719218682742" ORDER="1120" O_E="0.0" SE="0.4896956859130625" STUDY_ID="STD-Gerecht-1989" TOTAL_1="24" TOTAL_2="22" VAR="0.23980186480186477" WEIGHT="2.4938020027974632"/>
<DICH_DATA CI_END="3.6075179132023756" CI_START="0.39916641708972667" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.557208496268825" LOG_CI_START="-0.39884600417357535" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="1090" O_E="0.0" SE="0.5615911461059686" STUDY_ID="STD-Gomez-1990a" TOTAL_1="39" TOTAL_2="39" VAR="0.3153846153846154" WEIGHT="0.9191898407747061"/>
<DICH_DATA CI_END="5.597705211534098" CI_START="0.052414831915982264" EFFECT_SIZE="0.5416666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7480100237523192" LOG_CI_START="-1.2805458025618577" LOG_EFFECT_SIZE="-0.2662678894047693" ORDER="1102" O_E="0.0" SE="1.191583733890235" STUDY_ID="STD-Havig-1973" TOTAL_1="24" TOTAL_2="26" VAR="1.4198717948717947" WEIGHT="0.3529688988574871"/>
<DICH_DATA CI_END="1.2138694205384808" CI_START="0.2589786629232571" EFFECT_SIZE="0.5606837606837607" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.08417197093223315" LOG_CI_START="-0.5867360156732359" LOG_EFFECT_SIZE="-0.25128202237050135" ORDER="1097" O_E="0.0" SE="0.39409467238014734" STUDY_ID="STD-Hoepelman-1988" TOTAL_1="45" TOTAL_2="41" VAR="0.15531061079841568" WEIGHT="2.5010514272242"/>
<DICH_DATA CI_END="4.177208504264446" CI_START="0.15321236642763564" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6208861535010605" LOG_CI_START="-0.8147061795171733" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="1096" O_E="0.0" SE="0.8432740427115678" STUDY_ID="STD-Holloway--1985" TOTAL_1="15" TOTAL_2="18" VAR="0.711111111111111" WEIGHT="0.5013762767862033"/>
<DICH_DATA CI_END="1.1620638386085749" CI_START="0.1320089074981098" EFFECT_SIZE="0.39166666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.0652299869130772" LOG_CI_START="-0.879396763136892" LOG_EFFECT_SIZE="-0.40708338811190736" ORDER="1114" O_E="0.0" SE="0.5548784289571779" STUDY_ID="STD-Iakovlev-1998" TOTAL_1="48" TOTAL_2="47" VAR="0.30789007092198584" WEIGHT="1.8577310466183532"/>
<DICH_DATA CI_END="1.5219304663112376" CI_START="0.4423600838070252" EFFECT_SIZE="0.8205128205128205" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="15" LOG_CI_END="0.1823948109186749" LOG_CI_START="-0.3542240683318614" LOG_EFFECT_SIZE="-0.08591462870659325" ORDER="1084" O_E="0.0" SE="0.3152125859780576" STUDY_ID="STD-Jaspers-1998" TOTAL_1="39" TOTAL_2="40" VAR="0.09935897435897437" WEIGHT="2.72266357900356"/>
<DICH_DATA CI_END="5.427988616422285" CI_START="0.8925326758770527" EFFECT_SIZE="2.201058201058201" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" LOG_CI_END="0.734638928186268" LOG_CI_START="-0.04937587527927091" LOG_EFFECT_SIZE="0.3426315264534986" ORDER="1080" O_E="0.0" SE="0.46053417649152567" STUDY_ID="STD-Koehler-1990" TOTAL_1="63" TOTAL_2="64" VAR="0.2120917277167277" WEIGHT="1.0943425505916187"/>
<DICH_DATA CI_END="5.208499115067838" CI_START="0.34132246900739327" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7167125947102104" LOG_CI_START="-0.46683512149361067" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="1107" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-Landau-1990" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="0.5515139044648236"/>
<DICH_DATA CI_END="3.5713646359076354" CI_START="0.12444667228203433" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5528341938718855" LOG_CI_START="-0.905016711983248" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="1092" O_E="0.0" SE="0.8563488385776752" STUDY_ID="STD-Limson-1988" TOTAL_1="20" TOTAL_2="20" VAR="0.7333333333333332" WEIGHT="0.5515139044648236"/>
<DICH_DATA CI_END="2.163966825485128" CI_START="0.34778413155082627" EFFECT_SIZE="0.8675213675213675" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.3352505985698439" LOG_CI_START="-0.4586902375637037" LOG_EFFECT_SIZE="-0.06171981949692991" ORDER="1119" O_E="0.0" SE="0.46636477721536806" STUDY_ID="STD-Mandell-1987" TOTAL_1="52" TOTAL_2="58" VAR="0.2174961054271399" WEIGHT="1.5642939835729546"/>
<DICH_DATA CI_END="2.3294358192549933" CI_START="0.4375837344074471" EFFECT_SIZE="1.0096153846153846" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.3672507492434021" LOG_CI_START="-0.35893882970108676" LOG_EFFECT_SIZE="0.0041559597711577035" ORDER="1099" O_E="0.0" SE="0.42656735336838303" STUDY_ID="STD-Martin-1991" TOTAL_1="52" TOTAL_2="42" VAR="0.18195970695970695" WEIGHT="1.6271615904777776"/>
<DICH_DATA CI_END="3.5393716644310933" CI_START="0.7008659262685055" EFFECT_SIZE="1.575" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.5489261696836956" LOG_CI_START="-0.15436505343245688" LOG_EFFECT_SIZE="0.19728055812561932" ORDER="1106" O_E="0.0" SE="0.41311674580612884" STUDY_ID="STD-McCormick-1997" TOTAL_1="65" TOTAL_2="63" VAR="0.17066544566544567" WEIGHT="1.4936834912588974"/>
<DICH_DATA CI_END="66.16971022291247" CI_START="0.11902984959483541" EFFECT_SIZE="2.806451612903226" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8206592327414395" LOG_CI_START="-0.9243441151727481" LOG_EFFECT_SIZE="0.4481575587843459" ORDER="1111" O_E="0.0" SE="1.6124285545505104" STUDY_ID="STD-Moreno-1997" TOTAL_1="30" TOTAL_2="28" VAR="2.599925843529848" WEIGHT="0.0949829502133863"/>
<DICH_DATA CI_END="1.2852729000490246" CI_START="0.6522740256592976" EFFECT_SIZE="0.9156146179401994" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="43" LOG_CI_END="0.10899535054827328" LOG_CI_START="-0.18556991526478353" LOG_EFFECT_SIZE="-0.03828728235825513" ORDER="1094" O_E="0.0" SE="0.17302909526017163" STUDY_ID="STD-Mouton-1990" TOTAL_1="105" TOTAL_2="106" VAR="0.029939067806553546" WEIGHT="7.867568021038479"/>
<DICH_DATA CI_END="1.399873218217452" CI_START="0.39557189898178535" EFFECT_SIZE="0.7441441441441441" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="20" LOG_CI_END="0.146088704876939" LOG_CI_START="-0.4027745678094895" LOG_EFFECT_SIZE="-0.12834293146627523" ORDER="1078" O_E="0.0" SE="0.3224050032930258" STUDY_ID="STD-Mouton-1995" TOTAL_1="111" TOTAL_2="118" VAR="0.10394498614837597" WEIGHT="3.5643693388992967"/>
<DICH_DATA CI_END="3.6159719739665412" CI_START="0.5787047677624713" EFFECT_SIZE="1.4465753424657535" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="5" LOG_CI_END="0.558225055763821" LOG_CI_START="-0.2375429396091458" LOG_EFFECT_SIZE="0.16034105807733756" ORDER="1088" O_E="0.0" SE="0.46743805959718704" STUDY_ID="STD-Muller-1987" TOTAL_1="73" TOTAL_2="33" VAR="0.2184983395599834" WEIGHT="1.2660539316330857"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1105" O_E="0.0" SE="0.0" STUDY_ID="STD-Naime-Libien-1992" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.7194272700246453" CI_START="0.133964145557945" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5704760708987405" LOG_CI_START="-0.8730114215600387" LOG_EFFECT_SIZE="-0.15126767533064908" ORDER="1087" O_E="0.0" SE="0.8479116984486138" STUDY_ID="STD-Rapp-1984" TOTAL_1="17" TOTAL_2="18" VAR="0.718954248366013" WEIGHT="0.5357563643372573"/>
<DICH_DATA CI_END="15.773173963622442" CI_START="0.06784649559762428" EFFECT_SIZE="1.0344827586206897" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1979190932141035" LOG_CI_START="-1.1684725795726907" LOG_EFFECT_SIZE="0.014723256820706378" ORDER="1103" O_E="0.0" SE="1.3900301824226613" STUDY_ID="STD-Rasmussen-1986" TOTAL_1="29" TOTAL_2="30" VAR="1.9321839080459768" WEIGHT="0.18072207038960325"/>
<DICH_DATA CI_END="0.867426039722828" CI_START="0.4210317967449039" EFFECT_SIZE="0.604329334095093" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="59" LOG_CI_END="-0.061767544674934186" LOG_CI_START="-0.37568510456955584" LOG_EFFECT_SIZE="-0.21872632462224503" ORDER="1079" O_E="0.0" SE="0.1843967285990835" STUDY_ID="STD-Rubinstein-1995" TOTAL_1="267" TOTAL_2="238" VAR="0.03400215351804405" WEIGHT="11.469304999385303"/>
<DICH_DATA CI_END="7.501364429912652" CI_START="0.014812120134843915" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.875140264790061" LOG_CI_START="-1.8293827742293858" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="1117" O_E="0.0" SE="1.5886502207249786" STUDY_ID="STD-Sanfilippo-1989" TOTAL_1="13" TOTAL_2="13" VAR="2.5238095238095233" WEIGHT="0.2757569522324118"/>
<DICH_DATA CI_END="1.0107859270454354" CI_START="0.47251247521932604" EFFECT_SIZE="0.6910925844668714" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="43" LOG_CI_END="0.004659186701519816" LOG_CI_START="-0.3255867208110324" LOG_EFFECT_SIZE="-0.1604637670547563" ORDER="1112" O_E="0.0" SE="0.19398808081648017" STUDY_ID="STD-Sieger-1997" TOTAL_1="106" TOTAL_2="105" VAR="0.03763137549886124" WEIGHT="7.942497240286466"/>
<DICH_DATA CI_END="0.8499294497951944" CI_START="0.45564346622766727" EFFECT_SIZE="0.6223060344827587" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="58" LOG_CI_END="-0.07061712232836635" LOG_CI_START="-0.34137485298099385" LOG_EFFECT_SIZE="-0.2059959876546801" ORDER="1085" O_E="0.0" SE="0.15904443125773576" STUDY_ID="STD-Smith-1984" TOTAL_1="96" TOTAL_2="99" VAR="0.025295131114096633" WEIGHT="10.49856211986372"/>
<DICH_DATA CI_END="1.8956893891166395" CI_START="0.18946365936729576" EFFECT_SIZE="0.5993031358885017" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2777671791816151" LOG_CI_START="-0.7224740788345019" LOG_EFFECT_SIZE="-0.22235344982644345" ORDER="1100" O_E="0.0" SE="0.5875466662327474" STUDY_ID="STD-Speich-1998" TOTAL_1="41" TOTAL_2="43" VAR="0.34521108500121545" WEIGHT="1.2562261157254315"/>
<DICH_DATA CI_END="1.1619390455620113" CI_START="0.406109665538784" EFFECT_SIZE="0.6869313482216708" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="26" LOG_CI_END="0.06518334589389115" LOG_CI_START="-0.39135667404060837" LOG_EFFECT_SIZE="-0.16308666407335862" ORDER="1082" O_E="0.0" SE="0.268173867619071" STUDY_ID="STD-Stille-1992" TOTAL_1="186" TOTAL_2="151" VAR="0.07191722327377102" WEIGHT="5.276204237372675"/>
<DICH_DATA CI_END="1.8887018010491008" CI_START="0.5591992858596423" EFFECT_SIZE="1.0276967930029155" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.27616339445866245" LOG_CI_START="-0.25243339188936836" LOG_EFFECT_SIZE="0.011865001284647039" ORDER="1089" O_E="0.0" SE="0.3105003688971257" STUDY_ID="STD-Thompson--1990" TOTAL_1="49" TOTAL_2="47" VAR="0.09641047908525113" WEIGHT="2.6273509615477013"/>
<DICH_DATA CI_END="51.50073659814336" CI_START="0.12437246551099736" EFFECT_SIZE="2.5308641975308643" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7118134406571388" LOG_CI_START="-0.9052757563029298" LOG_EFFECT_SIZE="0.40326884217710457" ORDER="1095" O_E="0.0" SE="1.5372911490948016" STUDY_ID="STD-Thompson-1993" TOTAL_1="80" TOTAL_2="40" VAR="2.363264077085215" WEIGHT="0.1220563559061495"/>
<DICH_DATA CI_END="3.3916425334872047" CI_START="0.009181943027495709" EFFECT_SIZE="0.17647058823529413" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.530410072972988" LOG_CI_START="-2.037065406290211" LOG_EFFECT_SIZE="-0.7533276666586115" ORDER="1077" O_E="0.0" SE="1.5081478057277968" STUDY_ID="STD-Trujillo-1992" TOTAL_1="16" TOTAL_2="14" VAR="2.2745098039215685" WEIGHT="0.4883196029115626"/>
<DICH_DATA CI_END="4.151262680181564" CI_START="0.5648224993551716" EFFECT_SIZE="1.53125" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.6181802151766247" LOG_CI_START="-0.24808801175940942" LOG_EFFECT_SIZE="0.1850461017086077" ORDER="1101" O_E="0.0" SE="0.5088502445991073" STUDY_ID="STD-Vergnon-1985" TOTAL_1="16" TOTAL_2="14" VAR="0.2589285714285714" WEIGHT="0.7843753307944159"/>
<DICH_DATA CI_END="1.8491276278552056" CI_START="0.26498982148049377" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.26696688744925967" LOG_CI_START="-0.5767708074207462" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="1109" O_E="0.0" SE="0.4956156985355898" STUDY_ID="STD-Verzasconi-1995" TOTAL_1="45" TOTAL_2="42" VAR="0.24563492063492062" WEIGHT="1.5214176674891688"/>
<DICH_DATA CI_END="2.4878692263738946" CI_START="0.6161416373272557" EFFECT_SIZE="1.2380952380952381" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.3958275481422332" LOG_CI_START="-0.21031944166843577" LOG_EFFECT_SIZE="0.09275405323689871" ORDER="1115" O_E="0.0" SE="0.3560537422907775" STUDY_ID="STD-Warren-1983" TOTAL_1="56" TOTAL_2="64" VAR="0.1267742673992674" WEIGHT="2.0589852433353415"/>
<DICH_DATA CI_END="121.21138446425599" CI_START="0.3974297533358782" EFFECT_SIZE="6.940677966101695" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.08354341172641" LOG_CI_START="-0.40073962281782394" LOG_EFFECT_SIZE="0.841401894454293" ORDER="1116" O_E="0.0" SE="1.459280151890634" STUDY_ID="STD-Wing-1998" TOTAL_1="117" TOTAL_2="62" VAR="2.1294985617019515" WEIGHT="0.11985016708443681"/>
<DICH_DATA CI_END="9.392068384176333" CI_START="0.039248271403202646" EFFECT_SIZE="0.6071428571428571" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.9727612460375162" LOG_CI_START="-1.406179465965407" LOG_EFFECT_SIZE="-0.21670910996394532" ORDER="1108" O_E="0.0" SE="1.3974015501769614" STUDY_ID="STD-Yellin-1993" TOTAL_1="56" TOTAL_2="34" VAR="1.952731092436975" WEIGHT="0.2287761381483713"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="79.38290407409134" CI_END="0.9404252378887183" CI_START="0.7839833452955236" CI_STUDY="95" CI_TOTAL="95" DF="59" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8586487780229679" ESTIMABLE="YES" EVENTS_1="638" EVENTS_2="727" I2="25.676692370774365" I2_Q="77.92849480147257" ID="CMP-001.04" LOG_CI_END="-0.02667572436980147" LOG_CI_START="-0.10569316323785698" LOG_EFFECT_SIZE="-0.06618444380382922" METHOD="MH" MODIFIED="2013-08-13 04:49:47 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.039597069616498226" P_Q="3.9310632895384057E-4" P_Z="0.0010259805678652701" Q="22.653643034429706" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="61" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="3353" TOTAL_2="3145" WEIGHT="600.0" Z="3.2833037377717917">
<NAME>Clinical failure by study groups</NAME>
<GROUP_LABEL_1>Monotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours monotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.278311201845751" CI_END="1.5483400307566304" CI_START="1.007651114946045" DF="11" EFFECT_SIZE="1.2490742805403978" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="117" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.18986634217685935" LOG_CI_START="0.0033101897668849746" LOG_EFFECT_SIZE="0.09658826597187219" MODIFIED="2011-12-11 14:38:23 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.505540416272265" P_Z="0.042405570624802866" STUDIES="12" TAU2="0.0" TOTAL_1="600" TOTAL_2="596" WEIGHT="100.00000000000001" Z="2.0295178710377777">
<NAME>Same sepsis</NAME>
<DICH_DATA CI_END="11.697696457498267" CI_START="0.0593659142180342" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0681003477040096" LOG_CI_START="-1.226462839799259" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="1132" O_E="0.0" SE="1.347837774610382" STUDY_ID="STD-Biglino-1991" TOTAL_1="12" TOTAL_2="10" VAR="1.8166666666666667" WEIGHT="0.9315751540578091"/>
<DICH_DATA CI_END="2.6312143240480275" CI_START="0.1655509382184593" EFFECT_SIZE="0.66" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4201562247335235" LOG_CI_START="-0.781068353649786" LOG_EFFECT_SIZE="-0.1804560644581313" ORDER="1124" O_E="0.0" SE="0.7056052634999174" STUDY_ID="STD-Carbon-1987" TOTAL_1="25" TOTAL_2="22" VAR="0.49787878787878775" WEIGHT="3.6338037924240782"/>
<DICH_DATA CI_END="2.155845445955638" CI_START="0.8606766127447515" EFFECT_SIZE="1.3621621621621622" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="25" LOG_CI_END="0.3336176227602601" LOG_CI_START="-0.06515999800319945" LOG_EFFECT_SIZE="0.13422881237853032" ORDER="1131" O_E="0.0" SE="0.23424394841751486" STUDY_ID="STD-Cometta-1994" TOTAL_1="148" TOTAL_2="144" VAR="0.05487022737022737" WEIGHT="21.641043818580386"/>
<DICH_DATA CI_END="1.7738115910050403" CI_START="0.8274562460098094" EFFECT_SIZE="1.2115079365079364" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="35" LOG_CI_END="0.24890748847637187" LOG_CI_START="-0.08225496144213654" LOG_EFFECT_SIZE="0.08332626351711768" ORDER="1127" O_E="0.0" SE="0.1945264623626969" STUDY_ID="STD-D_x0027_Antonio-1992" TOTAL_1="144" TOTAL_2="142" VAR="0.03784054455934573" WEIGHT="30.09704343879076"/>
<DICH_DATA CI_END="7.689843930627566" CI_START="1.0748755208254848" EFFECT_SIZE="2.875" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.8859175256590314" LOG_CI_START="0.0313581723922671" LOG_EFFECT_SIZE="0.4586378490256493" ORDER="1122" O_E="0.0" SE="0.5019723942459189" STUDY_ID="STD-Klastersky-1973" TOTAL_1="22" TOTAL_2="23" VAR="0.2519762845849802" WEIGHT="3.339869441214664"/>
<DICH_DATA CI_END="2.9094577025383535" CI_START="0.6391239613516574" EFFECT_SIZE="1.3636363636363635" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.46381204783713936" LOG_CI_START="-0.19441490004222706" LOG_EFFECT_SIZE="0.13469857389745618" ORDER="1126" O_E="0.0" SE="0.3866457674602807" STUDY_ID="STD-Kljucar-1990" TOTAL_1="44" TOTAL_2="45" VAR="0.14949494949494946" WEIGHT="7.599141144336736"/>
<DICH_DATA CI_END="3.826396404729478" CI_START="0.31622442424010855" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.582789959802314" LOG_CI_START="-0.5000045894858638" LOG_EFFECT_SIZE="0.04139268515822508" ORDER="1130" O_E="0.0" SE="0.6360388781713383" STUDY_ID="STD-Mergoni-1987" TOTAL_1="20" TOTAL_2="22" VAR="0.40454545454545454" WEIGHT="3.2531195855986987"/>
<DICH_DATA CI_END="1.5195651886332249" CI_START="0.279337797304769" EFFECT_SIZE="0.6515151515151515" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.18171933584499625" LOG_CI_START="-0.5538702957695606" LOG_EFFECT_SIZE="-0.18607547996228216" ORDER="1125" O_E="0.0" SE="0.4320889908377921" STUDY_ID="STD-Piccart-1984" TOTAL_1="42" TOTAL_2="43" VAR="0.1867008960032216" WEIGHT="9.2828724174937"/>
<DICH_DATA CI_END="17.294732547204912" CI_START="1.0349630001602124" EFFECT_SIZE="4.230769230769231" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.2379138502953821" LOG_CI_START="0.014924824079431976" LOG_EFFECT_SIZE="0.626419337187407" ORDER="1128" O_E="0.0" SE="0.7183898078925648" STUDY_ID="STD-Sage-1987" TOTAL_1="26" TOTAL_2="22" VAR="0.5160839160839161" WEIGHT="1.8502117643092597"/>
<DICH_DATA CI_END="2.523907854293063" CI_START="0.22286867527402432" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.40207349514318896" LOG_CI_START="-0.6519509683597887" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="1121" O_E="0.0" SE="0.6191391873668903" STUDY_ID="STD-Sculier-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.3833333333333333" WEIGHT="3.4157755648786337"/>
<DICH_DATA CI_END="3.8827994475086087" CI_START="0.44874838980365256" EFFECT_SIZE="1.32" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5891449591554481" LOG_CI_START="-0.3479970967437483" LOG_EFFECT_SIZE="0.12057393120584989" ORDER="1129" O_E="0.0" SE="0.5504818825631803" STUDY_ID="STD-Sukoh-1994" TOTAL_1="30" TOTAL_2="33" VAR="0.3030303030303031" WEIGHT="4.066399481998373"/>
<DICH_DATA CI_END="1.9693429049207163" CI_START="0.46703880711684953" EFFECT_SIZE="0.9590409590409591" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.2943213427246578" LOG_CI_START="-0.33064703160415826" LOG_EFFECT_SIZE="-0.018162844439750202" ORDER="1123" O_E="0.0" SE="0.36710951672409314" STUDY_ID="STD-Takamoto-1994" TOTAL_1="77" TOTAL_2="80" VAR="0.13476939726939724" WEIGHT="10.889144396316917"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.23609520936432385" CI_END="1.3185690799329377" CI_START="0.8035552155484884" DF="1" EFFECT_SIZE="1.0293410811004697" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="64" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.12010288744594397" LOG_CI_START="-0.094984275734327" LOG_EFFECT_SIZE="0.01255930585580849" MODIFIED="2011-12-11 14:38:23 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6270407202604357" P_Z="0.8189534248907946" STUDIES="2" TAU2="0.0" TOTAL_1="155" TOTAL_2="153" WEIGHT="100.0" Z="0.2288912716522875">
<NAME>Same abdominal</NAME>
<DICH_DATA CI_END="1.9847833295834896" CI_START="0.37016326497723917" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.2977131035916891" LOG_CI_START="-0.4316066828529156" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="1134" O_E="0.0" SE="0.4284060527487281" STUDY_ID="STD-Cardozo-2001" TOTAL_1="56" TOTAL_2="48" VAR="0.18353174603174602" WEIGHT="15.366404820832884"/>
<DICH_DATA CI_END="1.3667256675620698" CI_START="0.8230512110018743" EFFECT_SIZE="1.0606060606060606" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="55" LOG_CI_END="0.13568135069047074" LOG_CI_START="-0.08457314174569446" LOG_EFFECT_SIZE="0.025554104472388137" ORDER="1133" O_E="0.0" SE="0.12937857913432477" STUDY_ID="STD-Dupont-2000" TOTAL_1="99" TOTAL_2="105" VAR="0.016738816738816734" WEIGHT="84.63359517916712"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0855643415267795" CI_START="0.45957924110915704" DF="0" EFFECT_SIZE="0.9790209790209791" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" I2="0.0" ID="CMP-001.04.03" LOG_CI_END="0.3192235927620454" LOG_CI_START="-0.33763959633569307" LOG_EFFECT_SIZE="-0.009208001786823765" MODIFIED="2011-12-11 14:38:23 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.9561782110585088" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="35" WEIGHT="100.0" Z="0.054950108854614696">
<NAME>Same UTI</NAME>
<DICH_DATA CI_END="2.0855643415267795" CI_START="0.45957924110915704" EFFECT_SIZE="0.9790209790209791" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.3192235927620454" LOG_CI_START="-0.33763959633569307" LOG_EFFECT_SIZE="-0.009208001786823765" ORDER="1135" O_E="0.0" SE="0.38584468880123757" STUDY_ID="STD-Sandberg-1997" TOTAL_1="26" TOTAL_2="35" VAR="0.14887612387612387" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="34.80095644994805" CI_END="0.8147540261062971" CI_START="0.6393088354878009" DF="29" EFFECT_SIZE="0.7217197847080362" ESTIMABLE="YES" EVENTS_1="336" EVENTS_2="453" I2="16.66895695321245" ID="CMP-001.04.04" LOG_CI_END="-0.08897348479171881" LOG_CI_START="-0.1942892934120906" LOG_EFFECT_SIZE="-0.1416313891019047" MODIFIED="2011-12-26 07:08:58 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.21115031129567174" P_Z="1.3522538608180238E-7" STUDIES="31" TAU2="0.0" TOTAL_1="1908" TOTAL_2="1835" WEIGHT="100.00000000000003" Z="5.271619244186593">
<NAME>Different sepsis</NAME>
<DICH_DATA CI_END="2.3225990308636475" CI_START="0.007117290597831311" EFFECT_SIZE="0.12857142857142856" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3659742404872978" LOG_CI_START="-2.147685301637162" LOG_EFFECT_SIZE="-0.890855530574932" ORDER="1160" O_E="0.0" SE="1.4765360578593163" STUDY_ID="STD-Aguilar-1992" TOTAL_1="19" TOTAL_2="17" VAR="2.1801587301587304" WEIGHT="0.7997061854041213"/>
<DICH_DATA CI_END="1.0074864919644275" CI_START="0.2658612783365917" EFFECT_SIZE="0.5175438596491229" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="20" LOG_CI_END="0.0032392319797593778" LOG_CI_START="-0.575344911368416" LOG_EFFECT_SIZE="-0.2860528396943284" ORDER="1136" O_E="0.0" SE="0.33986318984041847" STUDY_ID="STD-Alvarez_x002d_Lerma-2001a" TOTAL_1="57" TOTAL_2="59" VAR="0.11550698780850434" WEIGHT="4.266412801934303"/>
<DICH_DATA CI_END="1.9601526210417917" CI_START="0.14222565988347913" EFFECT_SIZE="0.528" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.2922898876298273" LOG_CI_START="-0.8470220425622028" LOG_EFFECT_SIZE="-0.27736607746618774" ORDER="1138" O_E="0.0" SE="0.6692374674798086" STUDY_ID="STD-Arich-1987" TOTAL_1="25" TOTAL_2="22" VAR="0.4478787878787879" WEIGHT="1.154590997164005"/>
<DICH_DATA CI_END="17.69656322236463" CI_START="0.0749290767652106" EFFECT_SIZE="1.1515151515151516" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2478889319840376" LOG_CI_START="-1.1253496185061924" LOG_EFFECT_SIZE="0.06126965673892271" MODIFIED="2011-12-26 06:56:41 +0000" MODIFIED_BY="[Empty name]" ORDER="2069" O_E="0.0" SE="1.3940520722782508" STUDY_ID="STD-Banasal-2006" TOTAL_1="33" TOTAL_2="38" VAR="1.9433811802232854" WEIGHT="0.20177697313818274"/>
<DICH_DATA CI_END="1.423999570845346" CI_START="0.3356573471587424" EFFECT_SIZE="0.691358024691358" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.1535098584163388" LOG_CI_START="-0.4741038421612374" LOG_EFFECT_SIZE="-0.16029699187244936" ORDER="1162" O_E="0.0" SE="0.368663394457191" STUDY_ID="STD-Brown-1984" TOTAL_1="18" TOTAL_2="16" VAR="0.1359126984126984" WEIGHT="2.068483729978055"/>
<DICH_DATA CI_END="2.6498175935704897" CI_START="0.17377014357166556" EFFECT_SIZE="0.6785714285714286" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4232159792831023" LOG_CI_START="-0.7600248400618829" LOG_EFFECT_SIZE="-0.16840443038939024" ORDER="1143" O_E="0.0" SE="0.6950415144197627" STUDY_ID="STD-Cone-1985" TOTAL_1="21" TOTAL_2="19" VAR="0.48308270676691717" WEIGHT="0.9116650513606984"/>
<DICH_DATA CI_END="0.9370474331203014" CI_START="0.2525689662751385" EFFECT_SIZE="0.4864864864864865" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="18" LOG_CI_END="-0.028238424671436866" LOG_CI_START="-0.5976200132559408" LOG_EFFECT_SIZE="-0.3129292189636889" ORDER="1158" O_E="0.0" SE="0.3344575636188571" STUDY_ID="STD-Felisart-1985" TOTAL_1="37" TOTAL_2="36" VAR="0.11186186186186185" WEIGHT="3.9606583444633077"/>
<DICH_DATA CI_END="1.668340822997299" CI_START="0.5604233296704261" EFFECT_SIZE="0.9669421487603306" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" LOG_CI_END="0.22228477677345543" LOG_CI_START="-0.25148379391403236" LOG_EFFECT_SIZE="-0.014599508570288439" ORDER="1155" O_E="0.0" SE="0.278294003614078" STUDY_ID="STD-Finer-1992" TOTAL_1="220" TOTAL_2="195" VAR="0.07744755244755246" WEIGHT="5.063062362117934"/>
<DICH_DATA CI_END="0.5205513287712564" CI_START="0.09922728020675375" EFFECT_SIZE="0.22727272727272727" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="22" LOG_CI_END="-0.2835364405952395" LOG_CI_START="-1.0033689123771354" LOG_EFFECT_SIZE="-0.6434526764861874" MODIFIED="2011-12-26 07:08:58 +0000" MODIFIED_BY="[Empty name]" ORDER="2079" O_E="0.0" SE="0.42283315715288794" STUDY_ID="STD-Garc_x00ed_a-Ram_x00ed_rez-1999" TOTAL_1="30" TOTAL_2="30" VAR="0.17878787878787883" WEIGHT="4.7753883642703245"/>
<DICH_DATA CI_END="3.6075179132023756" CI_START="0.39916641708972667" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.557208496268825" LOG_CI_START="-0.39884600417357535" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="1151" O_E="0.0" SE="0.5615911461059686" STUDY_ID="STD-Gomez-1990a" TOTAL_1="39" TOTAL_2="39" VAR="0.3153846153846154" WEIGHT="1.0853155373341647"/>
<DICH_DATA CI_END="1.2138694205384808" CI_START="0.2589786629232571" EFFECT_SIZE="0.5606837606837607" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.08417197093223315" LOG_CI_START="-0.5867360156732359" LOG_EFFECT_SIZE="-0.25128202237050135" ORDER="1164" O_E="0.0" SE="0.39409467238014734" STUDY_ID="STD-Hoepelman-1988" TOTAL_1="45" TOTAL_2="41" VAR="0.15531061079841568" WEIGHT="2.9530678573976106"/>
<DICH_DATA CI_END="4.177208504264446" CI_START="0.15321236642763564" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6208861535010605" LOG_CI_START="-0.8147061795171733" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="1142" O_E="0.0" SE="0.8432740427115678" STUDY_ID="STD-Holloway--1985" TOTAL_1="15" TOTAL_2="18" VAR="0.711111111111111" WEIGHT="0.5919902930913625"/>
<DICH_DATA CI_END="1.1620638386085749" CI_START="0.1320089074981098" EFFECT_SIZE="0.39166666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.0652299869130772" LOG_CI_START="-0.879396763136892" LOG_EFFECT_SIZE="-0.40708338811190736" ORDER="1157" O_E="0.0" SE="0.5548784289571779" STUDY_ID="STD-Iakovlev-1998" TOTAL_1="48" TOTAL_2="47" VAR="0.30789007092198584" WEIGHT="2.1934798228227326"/>
<DICH_DATA CI_END="1.5219304663112376" CI_START="0.4423600838070252" EFFECT_SIZE="0.8205128205128205" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="15" LOG_CI_END="0.1823948109186749" LOG_CI_START="-0.3542240683318614" LOG_EFFECT_SIZE="-0.08591462870659325" ORDER="1147" O_E="0.0" SE="0.3152125859780576" STUDY_ID="STD-Jaspers-1998" TOTAL_1="39" TOTAL_2="40" VAR="0.09935897435897437" WEIGHT="3.2147320979265133"/>
<DICH_DATA CI_END="5.427988616422285" CI_START="0.8925326758770527" EFFECT_SIZE="2.201058201058201" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" LOG_CI_END="0.734638928186268" LOG_CI_START="-0.04937587527927091" LOG_EFFECT_SIZE="0.3426315264534986" ORDER="1149" O_E="0.0" SE="0.46053417649152567" STUDY_ID="STD-Koehler-1990" TOTAL_1="63" TOTAL_2="64" VAR="0.2120917277167277" WEIGHT="1.2921236948419346"/>
<DICH_DATA CI_END="3.5713646359076354" CI_START="0.12444667228203433" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5528341938718855" LOG_CI_START="-0.905016711983248" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="1154" O_E="0.0" SE="0.8563488385776752" STUDY_ID="STD-Limson-1988" TOTAL_1="20" TOTAL_2="20" VAR="0.7333333333333332" WEIGHT="0.6511893224004988"/>
<DICH_DATA CI_END="2.163966825485128" CI_START="0.34778413155082627" EFFECT_SIZE="0.8675213675213675" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.3352505985698439" LOG_CI_START="-0.4586902375637037" LOG_EFFECT_SIZE="-0.06171981949692991" ORDER="1141" O_E="0.0" SE="0.46636477721536806" STUDY_ID="STD-Mandell-1987" TOTAL_1="52" TOTAL_2="58" VAR="0.2174961054271399" WEIGHT="1.8470097144450512"/>
<DICH_DATA CI_END="3.5393716644310933" CI_START="0.7008659262685055" EFFECT_SIZE="1.575" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.5489261696836956" LOG_CI_START="-0.15436505343245688" LOG_EFFECT_SIZE="0.19728055812561932" ORDER="1159" O_E="0.0" SE="0.41311674580612884" STUDY_ID="STD-McCormick-1997" TOTAL_1="65" TOTAL_2="63" VAR="0.17066544566544567" WEIGHT="1.7636377481680177"/>
<DICH_DATA CI_END="66.16971022291247" CI_START="0.11902984959483541" EFFECT_SIZE="2.806451612903226" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8206592327414395" LOG_CI_START="-0.9243441151727481" LOG_EFFECT_SIZE="0.4481575587843459" ORDER="1137" O_E="0.0" SE="1.6124285545505104" STUDY_ID="STD-Moreno-1997" TOTAL_1="30" TOTAL_2="28" VAR="2.599925843529848" WEIGHT="0.11214927219119702"/>
<DICH_DATA CI_END="1.2852729000490246" CI_START="0.6522740256592976" EFFECT_SIZE="0.9156146179401994" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="43" LOG_CI_END="0.10899535054827328" LOG_CI_START="-0.18556991526478353" LOG_EFFECT_SIZE="-0.03828728235825513" ORDER="1139" O_E="0.0" SE="0.17302909526017163" STUDY_ID="STD-Mouton-1990" TOTAL_1="105" TOTAL_2="106" VAR="0.029939067806553546" WEIGHT="9.289478011495268"/>
<DICH_DATA CI_END="1.399873218217452" CI_START="0.39557189898178535" EFFECT_SIZE="0.7441441441441441" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="20" LOG_CI_END="0.146088704876939" LOG_CI_START="-0.4027745678094895" LOG_EFFECT_SIZE="-0.12834293146627523" ORDER="1163" O_E="0.0" SE="0.3224050032930258" STUDY_ID="STD-Mouton-1995" TOTAL_1="111" TOTAL_2="118" VAR="0.10394498614837597" WEIGHT="4.208559812894054"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1144" O_E="0.0" SE="0.0" STUDY_ID="STD-Naime-Libien-1992" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.7194272700246453" CI_START="0.133964145557945" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5704760708987405" LOG_CI_START="-0.8730114215600387" LOG_EFFECT_SIZE="-0.15126767533064908" ORDER="1156" O_E="0.0" SE="0.8479116984486138" STUDY_ID="STD-Rapp-1984" TOTAL_1="17" TOTAL_2="18" VAR="0.718954248366013" WEIGHT="0.6325839131890559"/>
<DICH_DATA CI_END="0.867426039722828" CI_START="0.4210317967449039" EFFECT_SIZE="0.604329334095093" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="59" LOG_CI_END="-0.061767544674934186" LOG_CI_START="-0.37568510456955584" LOG_EFFECT_SIZE="-0.21872632462224503" ORDER="1152" O_E="0.0" SE="0.1843967285990835" STUDY_ID="STD-Rubinstein-1995" TOTAL_1="267" TOTAL_2="238" VAR="0.03400215351804405" WEIGHT="13.542158938316907"/>
<DICH_DATA CI_END="1.0107859270454354" CI_START="0.47251247521932604" EFFECT_SIZE="0.6910925844668714" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="43" LOG_CI_END="0.004659186701519816" LOG_CI_START="-0.3255867208110324" LOG_EFFECT_SIZE="-0.1604637670547563" ORDER="1153" O_E="0.0" SE="0.19398808081648017" STUDY_ID="STD-Sieger-1997" TOTAL_1="106" TOTAL_2="105" VAR="0.03763137549886124" WEIGHT="9.377949230652366"/>
<DICH_DATA CI_END="0.8499294497951944" CI_START="0.45564346622766727" EFFECT_SIZE="0.6223060344827587" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="58" LOG_CI_END="-0.07061712232836635" LOG_CI_START="-0.34137485298099385" LOG_EFFECT_SIZE="-0.2059959876546801" ORDER="1161" O_E="0.0" SE="0.15904443125773576" STUDY_ID="STD-Smith-1984" TOTAL_1="96" TOTAL_2="99" VAR="0.025295131114096633" WEIGHT="12.395973152567445"/>
<DICH_DATA CI_END="1.8956893891166395" CI_START="0.18946365936729576" EFFECT_SIZE="0.5993031358885017" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2777671791816151" LOG_CI_START="-0.7224740788345019" LOG_EFFECT_SIZE="-0.22235344982644345" ORDER="1145" O_E="0.0" SE="0.5875466662327474" STUDY_ID="STD-Speich-1998" TOTAL_1="41" TOTAL_2="43" VAR="0.34521108500121545" WEIGHT="1.4832645676900251"/>
<DICH_DATA CI_END="1.1619390455620113" CI_START="0.406109665538784" EFFECT_SIZE="0.6869313482216708" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="26" LOG_CI_END="0.06518334589389115" LOG_CI_START="-0.39135667404060837" LOG_EFFECT_SIZE="-0.16308666407335862" ORDER="1140" O_E="0.0" SE="0.268173867619071" STUDY_ID="STD-Stille-1992" TOTAL_1="186" TOTAL_2="151" VAR="0.07191722327377102" WEIGHT="6.229775594715751"/>
<DICH_DATA CI_END="3.3916425334872047" CI_START="0.009181943027495709" EFFECT_SIZE="0.17647058823529413" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.530410072972988" LOG_CI_START="-2.037065406290211" LOG_EFFECT_SIZE="-0.7533276666586115" ORDER="1146" O_E="0.0" SE="1.5081478057277968" STUDY_ID="STD-Trujillo-1992" TOTAL_1="16" TOTAL_2="14" VAR="2.2745098039215685" WEIGHT="0.576573879208775"/>
<DICH_DATA CI_END="4.151262680181564" CI_START="0.5648224993551716" EFFECT_SIZE="1.53125" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.6181802151766247" LOG_CI_START="-0.24808801175940942" LOG_EFFECT_SIZE="0.1850461017086077" ORDER="1150" O_E="0.0" SE="0.5088502445991073" STUDY_ID="STD-Vergnon-1985" TOTAL_1="16" TOTAL_2="14" VAR="0.2589285714285714" WEIGHT="0.9261359251918205"/>
<DICH_DATA CI_END="2.4878692263738946" CI_START="0.6161416373272557" EFFECT_SIZE="1.2380952380952381" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.3958275481422332" LOG_CI_START="-0.21031944166843577" LOG_EFFECT_SIZE="0.09275405323689871" ORDER="1148" O_E="0.0" SE="0.3560537422907775" STUDY_ID="STD-Warren-1983" TOTAL_1="56" TOTAL_2="64" VAR="0.1267742673992674" WEIGHT="2.431106803628529"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.955837820355235" CI_END="1.1768430933010485" CI_START="0.6236899172962646" DF="9" EFFECT_SIZE="0.8567293455529646" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="62" I2="17.85201508479265" ID="CMP-001.04.05" LOG_CI_END="0.07071856288075395" LOG_CI_START="-0.2050312767889992" LOG_EFFECT_SIZE="-0.06715635695412261" MODIFIED="2011-12-26 07:21:44 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.2787483636095879" P_Z="0.33974831850359677" STUDIES="10" TAU2="0.0" TOTAL_1="401" TOTAL_2="330" WEIGHT="100.00000000000001" Z="0.954662683544139">
<NAME>Different abdominal</NAME>
<DICH_DATA CI_END="1.5550666855189255" CI_START="0.06764100107599494" EFFECT_SIZE="0.32432432432432434" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.19174901749913703" LOG_CI_START="-1.1697899735378774" LOG_EFFECT_SIZE="-0.48902047801937015" ORDER="1169" O_E="0.0" SE="0.7997747430618447" STUDY_ID="STD-Bergeron-1988" TOTAL_1="37" TOTAL_2="30" VAR="0.6396396396396397" WEIGHT="8.979514849666835"/>
<DICH_DATA CI_END="1.87491372144196" CI_START="0.5772378000241282" EFFECT_SIZE="1.0403225806451613" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.27298128744304856" LOG_CI_START="-0.23864523716902078" LOG_EFFECT_SIZE="0.01716802513701388" ORDER="1166" O_E="0.0" SE="0.3005319531492715" STUDY_ID="STD-Duff-1982" TOTAL_1="31" TOTAL_2="43" VAR="0.09031945486371591" WEIGHT="21.797460736605423"/>
<DICH_DATA CI_END="6.586766671602955" CI_START="0.4918953655924044" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.8186722793470714" LOG_CI_START="-0.30812726914045924" LOG_EFFECT_SIZE="0.25527250510330607" MODIFIED="2011-12-26 07:21:44 +0000" MODIFIED_BY="[Empty name]" ORDER="2087" O_E="0.0" SE="0.6618876325292973" STUDY_ID="STD-Figueroa_x002d_Damian-1996" TOTAL_1="14" TOTAL_2="42" VAR="0.4380952380952381" WEIGHT="4.065050641403229"/>
<DICH_DATA CI_END="0.7364746482815971" CI_START="0.10801855283463083" EFFECT_SIZE="0.28205128205128205" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.132842198313418" LOG_CI_START="-0.9665016454231303" LOG_EFFECT_SIZE="-0.5496719218682742" ORDER="1170" O_E="0.0" SE="0.4896956859130625" STUDY_ID="STD-Gerecht-1989" TOTAL_1="24" TOTAL_2="22" VAR="0.23980186480186477" WEIGHT="22.05731826291839"/>
<DICH_DATA CI_END="5.597705211534098" CI_START="0.052414831915982264" EFFECT_SIZE="0.5416666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7480100237523192" LOG_CI_START="-1.2805458025618577" LOG_EFFECT_SIZE="-0.2662678894047693" ORDER="1165" O_E="0.0" SE="1.191583733890235" STUDY_ID="STD-Havig-1973" TOTAL_1="24" TOTAL_2="26" VAR="1.4198717948717947" WEIGHT="3.1219588925976796"/>
<DICH_DATA CI_END="3.6159719739665412" CI_START="0.5787047677624713" EFFECT_SIZE="1.4465753424657535" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="5" LOG_CI_END="0.558225055763821" LOG_CI_START="-0.2375429396091458" LOG_EFFECT_SIZE="0.16034105807733756" ORDER="1168" O_E="0.0" SE="0.46743805959718704" STUDY_ID="STD-Muller-1987" TOTAL_1="73" TOTAL_2="33" VAR="0.2184983395599834" WEIGHT="11.19806403103531"/>
<DICH_DATA CI_END="7.501364429912652" CI_START="0.014812120134843915" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.875140264790061" LOG_CI_START="-1.8293827742293858" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="1173" O_E="0.0" SE="1.5886502207249786" STUDY_ID="STD-Sanfilippo-1989" TOTAL_1="13" TOTAL_2="13" VAR="2.5238095238095233" WEIGHT="2.4390303848419372"/>
<DICH_DATA CI_END="1.8887018010491008" CI_START="0.5591992858596423" EFFECT_SIZE="1.0276967930029155" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.27616339445866245" LOG_CI_START="-0.25243339188936836" LOG_EFFECT_SIZE="0.011865001284647039" ORDER="1171" O_E="0.0" SE="0.3105003688971257" STUDY_ID="STD-Thompson--1990" TOTAL_1="49" TOTAL_2="47" VAR="0.09641047908525113" WEIGHT="23.23853950002179"/>
<DICH_DATA CI_END="51.50073659814336" CI_START="0.12437246551099736" EFFECT_SIZE="2.5308641975308643" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7118134406571388" LOG_CI_START="-0.9052757563029298" LOG_EFFECT_SIZE="0.40326884217710457" ORDER="1167" O_E="0.0" SE="1.5372911490948016" STUDY_ID="STD-Thompson-1993" TOTAL_1="80" TOTAL_2="40" VAR="2.363264077085215" WEIGHT="1.0795708260775787"/>
<DICH_DATA CI_END="9.392068384176333" CI_START="0.039248271403202646" EFFECT_SIZE="0.6071428571428571" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.9727612460375162" LOG_CI_START="-1.406179465965407" LOG_EFFECT_SIZE="-0.21670910996394532" ORDER="1172" O_E="0.0" SE="1.3974015501769614" STUDY_ID="STD-Yellin-1993" TOTAL_1="56" TOTAL_2="34" VAR="1.952731092436975" WEIGHT="2.0234918748318296"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.576321672467911" CI_END="1.914999900984926" CI_START="0.6495544732109368" DF="4" EFFECT_SIZE="1.1153011933479045" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="20" I2="0.0" ID="CMP-001.04.06" LOG_CI_END="0.282168755849445" LOG_CI_START="-0.18738442207685072" LOG_EFFECT_SIZE="0.04739216688629713" MODIFIED="2011-12-11 14:38:23 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.6310234391607392" P_Z="0.692370843184845" STUDIES="5" TAU2="0.0" TOTAL_1="263" TOTAL_2="196" WEIGHT="100.0" Z="0.39563970435329193">
<NAME>Different UTI</NAME>
<DICH_DATA CI_END="5.208499115067838" CI_START="0.34132246900739327" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7167125947102104" LOG_CI_START="-0.46683512149361067" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="1178" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-Landau-1990" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="13.785554384973267"/>
<DICH_DATA CI_END="2.3294358192549933" CI_START="0.4375837344074471" EFFECT_SIZE="1.0096153846153846" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.3672507492434021" LOG_CI_START="-0.35893882970108676" LOG_EFFECT_SIZE="0.0041559597711577035" ORDER="1176" O_E="0.0" SE="0.42656735336838303" STUDY_ID="STD-Martin-1991" TOTAL_1="52" TOTAL_2="42" VAR="0.18195970695970695" WEIGHT="40.67227393013389"/>
<DICH_DATA CI_END="15.773173963622442" CI_START="0.06784649559762428" EFFECT_SIZE="1.0344827586206897" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1979190932141035" LOG_CI_START="-1.1684725795726907" LOG_EFFECT_SIZE="0.014723256820706378" ORDER="1175" O_E="0.0" SE="1.3900301824226613" STUDY_ID="STD-Rasmussen-1986" TOTAL_1="29" TOTAL_2="30" VAR="1.9321839080459768" WEIGHT="4.517300306940393"/>
<DICH_DATA CI_END="1.8491276278552056" CI_START="0.26498982148049377" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.26696688744925967" LOG_CI_START="-0.5767708074207462" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="1177" O_E="0.0" SE="0.4956156985355898" STUDY_ID="STD-Verzasconi-1995" TOTAL_1="45" TOTAL_2="42" VAR="0.24563492063492062" WEIGHT="38.02911554475384"/>
<DICH_DATA CI_END="121.21138446425599" CI_START="0.3974297533358782" EFFECT_SIZE="6.940677966101695" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.08354341172641" LOG_CI_START="-0.40073962281782394" LOG_EFFECT_SIZE="0.841401894454293" ORDER="1174" O_E="0.0" SE="1.459280151890634" STUDY_ID="STD-Wing-1998" TOTAL_1="117" TOTAL_2="62" VAR="2.1294985617019515" WEIGHT="2.9957558331986105"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.12255050729811" CI_END="1.6671265470015535" CI_START="0.6138859797730128" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0116450037990838" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.22196856718166016" LOG_CI_START="-0.21191228513533344" LOG_EFFECT_SIZE="0.005028141023163348" METHOD="MH" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.8319412391311805" P_Q="1.0" P_Z="0.9637668773624013" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="256" TOTAL_2="202" WEIGHT="100.0" Z="0.045427104063068866">
<NAME>UTI relapse or reinfection</NAME>
<GROUP_LABEL_1>Monotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours monotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.309170813995455" CI_START="0.3625987614427503" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6343937097080784" LOG_CI_START="-0.4405736836919656" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="1224" O_E="0.0" SE="0.631441168057602" STUDY_ID="STD-Gomez-1990a" TOTAL_1="39" TOTAL_2="39" VAR="0.3987179487179487" WEIGHT="15.861646072345728"/>
<DICH_DATA CI_END="2.558466541413332" CI_START="0.14342824305376056" EFFECT_SIZE="0.6057692307692307" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4079797418183662" LOG_CI_START="-0.8433653215087635" LOG_EFFECT_SIZE="-0.2176927898451987" ORDER="1227" O_E="0.0" SE="0.7350462844563193" STUDY_ID="STD-Martin-1991" TOTAL_1="52" TOTAL_2="42" VAR="0.5402930402930401" WEIGHT="17.549055228978254"/>
<DICH_DATA CI_END="7.071548373927387" CI_START="0.1924770982447765" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8495145165731292" LOG_CI_START="-0.7156209373119028" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="1223" O_E="0.0" SE="0.9193683131575153" STUDY_ID="STD-Rasmussen-1986" TOTAL_1="12" TOTAL_2="14" VAR="0.8452380952380952" WEIGHT="7.320759725698029"/>
<DICH_DATA CI_END="2.5493714145088546" CI_START="0.5757597482396514" EFFECT_SIZE="1.2115384615384615" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.4064331118604385" LOG_CI_START="-0.2397587002228735" LOG_EFFECT_SIZE="0.08333720581878251" ORDER="1226" O_E="0.0" SE="0.3795762691187952" STUDY_ID="STD-Sandberg-1997" TOTAL_1="26" TOTAL_2="35" VAR="0.14407814407814407" WEIGHT="33.80350802303188"/>
<DICH_DATA CI_END="3.704864004538551" CI_START="0.010796617622400985" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5687722708409982" LOG_CI_START="-1.9667122795130358" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="1222" O_E="0.0" SE="1.4893561757289013" STUDY_ID="STD-Wiecek-1986" TOTAL_1="10" TOTAL_2="10" VAR="2.2181818181818183" WEIGHT="9.91352879521608"/>
<DICH_DATA CI_END="4.614726753253492" CI_START="0.33129832135327375" EFFECT_SIZE="1.2364672364672364" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.6641459907210939" LOG_CI_START="-0.47978076462772073" LOG_EFFECT_SIZE="0.09218261304668661" ORDER="1225" O_E="0.0" SE="0.6719482386206568" STUDY_ID="STD-Wing-1998" TOTAL_1="117" TOTAL_2="62" VAR="0.4515144353854031" WEIGHT="15.55150215473003"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="49.803047895062974" CI_END="1.0076562911763847" CI_START="0.773792387637464" CI_STUDY="95" CI_TOTAL="95" DF="39" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8830157232276707" ESTIMABLE="YES" EVENTS_1="302" EVENTS_2="337" I2="21.6915396781045" I2_Q="79.1406667648629" ID="CMP-001.06" LOG_CI_END="0.0033124207002569873" LOG_CI_START="-0.11137554706670635" LOG_EFFECT_SIZE="-0.05403156318322467" METHOD="MH" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.1151516758452592" P_Q="0.0285588499065883" P_Z="0.06478359480080548" Q="4.794017089268806" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="44" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1838" TOTAL_2="1723" WEIGHT="200.0" Z="1.8467485287157723">
<NAME>Bacteriological failure&#8212;all</NAME>
<GROUP_LABEL_1>Monotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours monotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="19.3129447484328" CI_END="1.479483954633211" CI_START="0.8724600887871253" DF="12" EFFECT_SIZE="1.1361297031670365" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="84" I2="37.86550856790613" ID="CMP-001.06.01" LOG_CI_END="0.1701102594918911" LOG_CI_START="-0.05925443097734499" LOG_EFFECT_SIZE="0.055427914257273045" MODIFIED="2011-12-26 06:39:04 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.08125092104670317" P_Z="0.34349424885286084" STUDIES="15" TAU2="0.0" TOTAL_1="393" TOTAL_2="408" WEIGHT="100.00000000000001" Z="0.9472836944534011">
<NAME>Same BL</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1189" O_E="0.0" SE="0.0" STUDY_ID="STD-Abrams-1979" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.83287055353535" CI_START="0.48329280378274286" EFFECT_SIZE="0.9411764705882353" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="17" LOG_CI_END="0.26313179400179854" LOG_CI_START="-0.3157896714464969" LOG_EFFECT_SIZE="-0.026328938722349152" ORDER="1179" O_E="0.0" SE="0.34006133451180026" STUDY_ID="STD-Coppens-1983" TOTAL_1="22" TOTAL_2="44" VAR="0.11564171122994651" WEIGHT="14.610916755430997"/>
<DICH_DATA CI_END="2.793374564467108" CI_START="0.6005788642512582" EFFECT_SIZE="1.2952380952380953" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="7" LOG_CI_END="0.44612917428832094" LOG_CI_START="-0.2214299556877621" LOG_EFFECT_SIZE="0.11234960930027946" ORDER="1182" O_E="0.0" SE="0.39212753741893835" STUDY_ID="STD-D_x0027_Antonio-1992" TOTAL_1="60" TOTAL_2="32" VAR="0.1537640056022409" WEIGHT="11.77094316614006"/>
<DICH_DATA CI_END="2.854486988798545" CI_START="0.26313348565209405" EFFECT_SIZE="0.8666666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.45552806776453625" LOG_CI_START="-0.5798238812622253" LOG_EFFECT_SIZE="-0.06214790674884446" MODIFIED="2011-12-26 06:39:04 +0000" MODIFIED_BY="[Empty name]" ORDER="1036" O_E="0.0" SE="0.6081708599331235" STUDY_ID="STD-Damas-2006" TOTAL_1="24" TOTAL_2="26" VAR="0.3698717948717949" WEIGHT="6.188152978770774"/>
<DICH_DATA CI_END="11.008218497188842" CI_START="1.103191126289147" EFFECT_SIZE="3.484848484848485" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="1.0417170410932606" LOG_CI_START="0.042650759858187816" LOG_EFFECT_SIZE="0.5421839004757242" ORDER="1192" O_E="0.0" SE="0.5868564790553331" STUDY_ID="STD-Klastersky-1973" TOTAL_1="22" TOTAL_2="23" VAR="0.34440052700922263" WEIGHT="3.78164904258214"/>
<DICH_DATA CI_END="19.11951674209537" CI_START="0.08073519948152638" EFFECT_SIZE="1.2424242424242424" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.281476911010496" LOG_CI_START="-1.0929370773267997" LOG_EFFECT_SIZE="0.09426991684184802" ORDER="1187" O_E="0.0" SE="1.3947425302881284" STUDY_ID="STD-Korzeniowski-1982" TOTAL_1="33" TOTAL_2="41" VAR="1.9453067257945307" WEIGHT="1.1498257224067319"/>
<DICH_DATA CI_END="1.2468599971081706" CI_START="0.3230007276876277" EFFECT_SIZE="0.6346153846153846" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="0.09581769173289019" LOG_CI_START="-0.4907964992467136" LOG_EFFECT_SIZE="-0.1974894037569117" ORDER="1184" O_E="0.0" SE="0.3445800795684963" STUDY_ID="STD-Mergoni-1987" TOTAL_1="26" TOTAL_2="33" VAR="0.11873543123543123" WEIGHT="18.179884457405667"/>
<DICH_DATA CI_END="1.2684302357642463" CI_START="0.19300926964680182" EFFECT_SIZE="0.4947916666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.10326658582198703" LOG_CI_START="-0.7144218326513907" LOG_EFFECT_SIZE="-0.30557762341470185" ORDER="1183" O_E="0.0" SE="0.4803142246342127" STUDY_ID="STD-Piccart-1984" TOTAL_1="24" TOTAL_2="19" VAR="0.2307017543859649" WEIGHT="11.512842751201442"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1181" O_E="0.0" SE="0.0" STUDY_ID="STD-Ribera-1996" TOTAL_1="45" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="264.97509168030007" CI_START="1.059916106222517" EFFECT_SIZE="16.75862068965517" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="0" LOG_CI_END="2.4232050510906893" LOG_CI_START="0.02527149163598472" LOG_EFFECT_SIZE="1.2242382713633373" ORDER="1191" O_E="0.0" SE="1.4085580427862492" STUDY_ID="STD-Sage-1987" TOTAL_1="28" TOTAL_2="17" VAR="1.9840357598978289" WEIGHT="0.795462927235605"/>
<DICH_DATA CI_END="2.321746504557611" CI_START="0.5651203148693801" EFFECT_SIZE="1.1454545454545455" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.36581480038030156" LOG_CI_START="-0.24785908046162572" LOG_EFFECT_SIZE="0.05897785995933788" ORDER="1186" O_E="0.0" SE="0.3604750753412502" STUDY_ID="STD-Sandberg-1997" TOTAL_1="22" TOTAL_2="28" VAR="0.12994227994227997" WEIGHT="11.344947127746421"/>
<DICH_DATA CI_END="147.9523539715359" CI_START="0.5474735468932344" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.1701218793223758" LOG_CI_START="-0.26163686044372564" LOG_EFFECT_SIZE="0.9542425094393249" ORDER="1185" O_E="0.0" SE="1.4284271211385062" STUDY_ID="STD-Sculier-1982" TOTAL_1="10" TOTAL_2="10" VAR="2.0404040404040407" WEIGHT="0.6445992686219557"/>
<DICH_DATA CI_END="7.780254682310321" CI_START="0.014281166317568032" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8909938136107249" LOG_CI_START="-1.8452363230500497" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="1188" O_E="0.0" SE="1.6072751268321592" STUDY_ID="STD-Sexton-1998" TOTAL_1="23" TOTAL_2="23" VAR="2.5833333333333335" WEIGHT="1.9337978058658671"/>
<DICH_DATA CI_END="10.98242459219154" CI_START="0.43344987607717983" EFFECT_SIZE="2.1818181818181817" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="1.0406982299835645" LOG_CI_START="-0.3630611168768026" LOG_EFFECT_SIZE="0.33881855655338095" ORDER="1180" O_E="0.0" SE="0.8245751890666141" STUDY_ID="STD-Sukoh-1994" TOTAL_1="11" TOTAL_2="16" VAR="0.6799242424242423" WEIGHT="2.1009161347678553"/>
<DICH_DATA CI_END="1.3654850223876691" CI_START="0.28977365199792554" EFFECT_SIZE="0.6290322580645161" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" LOG_CI_END="0.13528694085066145" LOG_CI_START="-0.5379411057941708" LOG_EFFECT_SIZE="-0.20132708247175468" ORDER="1190" O_E="0.0" SE="0.3954574871317518" STUDY_ID="STD-Takamoto-1994" TOTAL_1="31" TOTAL_2="39" VAR="0.1563866241285596" WEIGHT="15.986061861824503"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="28.99201252668672" CI_END="0.9414745611831609" CI_START="0.6932963246447885" DF="26" EFFECT_SIZE="0.8079114140887295" ESTIMABLE="YES" EVENTS_1="213" EVENTS_2="253" I2="10.320127048553866" ID="CMP-001.06.02" LOG_CI_END="-0.02619141020603832" LOG_CI_START="-0.15908110211006754" LOG_EFFECT_SIZE="-0.09263625615805293" MODIFIED="2011-12-11 14:38:31 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.31144563410593273" P_Z="0.006284652814359732" STUDIES="29" TAU2="0.0" TOTAL_1="1445" TOTAL_2="1315" WEIGHT="100.0" Z="2.7325479219792754">
<NAME>Different BL</NAME>
<DICH_DATA CI_END="1.2525280128936942" CI_START="0.11739500606080999" EFFECT_SIZE="0.38345864661654133" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.09778744768028727" LOG_CI_START="-0.9303503774185862" LOG_EFFECT_SIZE="-0.41628146486914946" ORDER="1212" O_E="0.0" SE="0.6039332478273928" STUDY_ID="STD-Aguilar-1992" TOTAL_1="19" TOTAL_2="17" VAR="0.364735367831343" WEIGHT="2.8264913635341777"/>
<DICH_DATA CI_END="0.9597750194373887" CI_START="0.31085893040530327" EFFECT_SIZE="0.5462184873949579" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="21" LOG_CI_END="-0.01783055786440271" LOG_CI_START="-0.5074366516349478" LOG_EFFECT_SIZE="-0.26263360474967523" ORDER="1200" O_E="0.0" SE="0.2875970430700695" STUDY_ID="STD-Alvarez_x002d_Lerma-2001a" TOTAL_1="51" TOTAL_2="45" VAR="0.08271205918264742" WEIGHT="8.535260104356498"/>
<DICH_DATA CI_END="6.888382500738583" CI_START="0.012622611389769816" EFFECT_SIZE="0.2948717948717949" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8381172547853014" LOG_CI_START="-1.898850788131076" LOG_EFFECT_SIZE="-0.5303667666728875" ORDER="1217" O_E="0.0" SE="1.6077085766193955" STUDY_ID="STD-Arich-1987" TOTAL_1="25" TOTAL_2="22" VAR="2.584726867335563" WEIGHT="0.6089295495476424"/>
<DICH_DATA CI_END="1.0396632307982492" CI_START="0.018011372546546264" EFFECT_SIZE="0.1368421052631579" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.016892684787888582" LOG_CI_START="-1.7444531907519107" LOG_EFFECT_SIZE="-0.863780252982011" ORDER="1194" O_E="0.0" SE="1.034623286094777" STUDY_ID="STD-Bergeron-1988" TOTAL_1="19" TOTAL_2="13" VAR="1.0704453441295547" WEIGHT="2.271287702839964"/>
<DICH_DATA CI_END="1.548221422946568" CI_START="0.22743041903590763" EFFECT_SIZE="0.5933908045977011" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.1898330725529775" LOG_CI_START="-0.6431514484612997" LOG_EFFECT_SIZE="-0.22665918795416112" ORDER="1195" O_E="0.0" SE="0.4892992309836658" STUDY_ID="STD-Finer-1992" TOTAL_1="87" TOTAL_2="59" VAR="0.23941373744120675" WEIGHT="3.6471607583022125"/>
<DICH_DATA CI_END="1.5482161904568916" CI_START="0.177220997251417" EFFECT_SIZE="0.5238095238095238" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.1898316047750489" LOG_CI_START="-0.7514848239264373" LOG_EFFECT_SIZE="-0.2808266095756942" ORDER="1220" O_E="0.0" SE="0.5529339298107241" STUDY_ID="STD-Gerecht-1989" TOTAL_1="24" TOTAL_2="22" VAR="0.3057359307359307" WEIGHT="2.7941516454159374"/>
<DICH_DATA CI_END="3.8123381331979793" CI_START="0.5901889920012389" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.581191413180737" LOG_CI_START="-0.2290088950693744" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="1202" O_E="0.0" SE="0.4759156716223227" STUDY_ID="STD-Gomez-1990a" TOTAL_1="39" TOTAL_2="39" VAR="0.2264957264957265" WEIGHT="2.295195994448806"/>
<DICH_DATA CI_END="4.177208504264446" CI_START="0.15321236642763564" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6208861535010605" LOG_CI_START="-0.8147061795171733" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="1213" O_E="0.0" SE="0.8432740427115678" STUDY_ID="STD-Holloway--1985" TOTAL_1="15" TOTAL_2="18" VAR="0.711111111111111" WEIGHT="1.043270906567639"/>
<DICH_DATA CI_END="2.291097994432375" CI_START="0.3062628458682644" EFFECT_SIZE="0.8376623376623377" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.36004366515232794" LOG_CI_START="-0.5139056862267563" LOG_EFFECT_SIZE="-0.0769310105372141" ORDER="1207" O_E="0.0" SE="0.5133621751191341" STUDY_ID="STD-Iakovlev-1998" TOTAL_1="44" TOTAL_2="43" VAR="0.26354072284304847" WEIGHT="2.7085071505372884"/>
<DICH_DATA CI_END="2.018542725097781" CI_START="0.36950804128206427" EFFECT_SIZE="0.8636363636363636" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.3050379462545474" LOG_CI_START="-0.4323761059933019" LOG_EFFECT_SIZE="-0.06366907986937727" ORDER="1209" O_E="0.0" SE="0.4331606645488159" STUDY_ID="STD-Jaspers-1998" TOTAL_1="22" TOTAL_2="19" VAR="0.1876281613123718" WEIGHT="2.8736600255700497"/>
<DICH_DATA CI_END="12.19100908107563" CI_START="0.5126729016798136" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0860396547738687" LOG_CI_START="-0.29015963742979334" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="1218" O_E="0.0" SE="0.8083862765367947" STUDY_ID="STD-Koehler-1990" TOTAL_1="43" TOTAL_2="43" VAR="0.6534883720930231" WEIGHT="0.7650653314829353"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1199" O_E="0.0" SE="0.0" STUDY_ID="STD-Landau-1990" TOTAL_1="19" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.177502039819886" CI_START="0.21712245016573506" EFFECT_SIZE="0.9523809523809523" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6209166706258249" LOG_CI_START="-0.6632952687657011" LOG_EFFECT_SIZE="-0.021189299069938095" ORDER="1216" O_E="0.0" SE="0.754352450150206" STUDY_ID="STD-Limson-1988" TOTAL_1="21" TOTAL_2="20" VAR="0.569047619047619" WEIGHT="1.1755881922786566"/>
<DICH_DATA CI_END="1.9062241211435622" CI_START="0.4858952982007645" EFFECT_SIZE="0.9624060150375939" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.2801739607586176" LOG_CI_START="-0.3134573033970526" LOG_EFFECT_SIZE="-0.01664167131921745" ORDER="1206" O_E="0.0" SE="0.3487019430871901" STUDY_ID="STD-Mandell-1987" TOTAL_1="57" TOTAL_2="64" VAR="0.12159304511278196" WEIGHT="5.045637475399854"/>
<DICH_DATA CI_END="72.92191868001707" CI_START="0.13545380043757582" EFFECT_SIZE="3.142857142857143" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8628580870424774" LOG_CI_START="-0.8682088054265785" LOG_EFFECT_SIZE="0.4973246408079494" ORDER="1208" O_E="0.0" SE="1.6042422116354729" STUDY_ID="STD-Moreno-1997" TOTAL_1="20" TOTAL_2="21" VAR="2.5735930735930737" WEIGHT="0.18681827861792605"/>
<DICH_DATA CI_END="1.8490824726930144" CI_START="0.7741930686059704" EFFECT_SIZE="1.1964726631393299" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="27" LOG_CI_END="0.26695628197405036" LOG_CI_START="-0.11115072126254869" LOG_EFFECT_SIZE="0.07790278035575085" ORDER="1211" O_E="0.0" SE="0.22210192536103007" STUDY_ID="STD-Mouton-1990" TOTAL_1="105" TOTAL_2="106" VAR="0.04932926524907657" WEIGHT="10.2794322974129"/>
<DICH_DATA CI_END="2.283740430281298" CI_START="0.4851835288744915" EFFECT_SIZE="1.0526315789473684" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.3586467405095889" LOG_CI_START="-0.3140939510872845" LOG_EFFECT_SIZE="0.022276394711152208" ORDER="1201" O_E="0.0" SE="0.39517121236413427" STUDY_ID="STD-Mouton-1995" TOTAL_1="76" TOTAL_2="80" VAR="0.15616028708133972" WEIGHT="4.099965494357268"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1219" O_E="0.0" SE="0.0" STUDY_ID="STD-Naime-Libien-1992" TOTAL_1="6" TOTAL_2="1" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.1895068307491266" CI_START="0.32071096980006697" EFFECT_SIZE="0.6176470588235294" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.07536694031875388" LOG_CI_START="-0.49388618493542547" LOG_EFFECT_SIZE="-0.20925962230833584" ORDER="1193" O_E="0.0" SE="0.33438210362272064" STUDY_ID="STD-Rapp-1984" TOTAL_1="17" TOTAL_2="18" VAR="0.11181139122315589" WEIGHT="4.459237932071965"/>
<DICH_DATA CI_END="2.0133314477058715" CI_START="0.5058869598509236" EFFECT_SIZE="1.0092165898617511" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="0.3039152771541258" LOG_CI_START="-0.29594651517094817" LOG_EFFECT_SIZE="0.003984380991588811" ORDER="1196" O_E="0.0" SE="0.35236178617550973" STUDY_ID="STD-Rubinstein-1995" TOTAL_1="217" TOTAL_2="219" VAR="0.12415882835679565" WEIGHT="5.711668931139804"/>
<DICH_DATA CI_END="0.9149160940171458" CI_START="0.5504507524819372" EFFECT_SIZE="0.7096592509152352" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="67" LOG_CI_END="-0.0386187327928235" LOG_CI_START="-0.25928153024731926" LOG_EFFECT_SIZE="-0.14895013152007136" ORDER="1221" O_E="0.0" SE="0.12961841952323452" STUDY_ID="STD-Sieger-1997" TOTAL_1="106" TOTAL_2="105" VAR="0.016800934679701222" WEIGHT="25.75115632318392"/>
<DICH_DATA CI_END="1.4545909875870726" CI_START="0.12153383755432226" EFFECT_SIZE="0.42045454545454547" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.16274089242465758" LOG_CI_START="-0.9153027885910048" LOG_EFFECT_SIZE="-0.37628094808317364" ORDER="1203" O_E="0.0" SE="0.6332481946308856" STUDY_ID="STD-Smith-1984" TOTAL_1="33" TOTAL_2="37" VAR="0.40100327600327595" WEIGHT="2.8853892501642133"/>
<DICH_DATA CI_END="7.545522164113119" CI_START="0.014725436980300866" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8776892991343043" LOG_CI_START="-1.8319318085736291" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="1214" O_E="0.0" SE="1.5916448515084427" STUDY_ID="STD-Speich-1998" TOTAL_1="14" TOTAL_2="14" VAR="2.5333333333333328" WEIGHT="0.5737989986122015"/>
<DICH_DATA CI_END="1.6299567966764128" CI_START="0.17299659152065286" EFFECT_SIZE="0.5310150375939849" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.21217609322991154" LOG_CI_START="-0.7619624535090933" LOG_EFFECT_SIZE="-0.27489318013959085" ORDER="1210" O_E="0.0" SE="0.572213804418067" STUDY_ID="STD-Stille-1992" TOTAL_1="152" TOTAL_2="113" VAR="0.3274286379665979" WEIGHT="3.0718094818786534"/>
<DICH_DATA CI_END="1.333104980731854" CI_START="0.0048265293782111425" EFFECT_SIZE="0.08021390374331551" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.12486435103225266" LOG_CI_START="-2.3163650459938876" LOG_EFFECT_SIZE="-1.0957503474808177" ORDER="1205" O_E="0.0" SE="1.433990232093563" STUDY_ID="STD-Trujillo-1992" TOTAL_1="16" TOTAL_2="14" VAR="2.0563279857397503" WEIGHT="2.2354252654267017"/>
<DICH_DATA CI_END="194.77818399446633" CI_START="0.6642973168066708" EFFECT_SIZE="11.375" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.289540312391687" LOG_CI_START="-0.17763750173338674" LOG_EFFECT_SIZE="1.05595140532915" ORDER="1215" O_E="0.0" SE="1.4492324607442124" STUDY_ID="STD-Verzasconi-1995" TOTAL_1="39" TOTAL_2="34" VAR="2.1002747252747254" WEIGHT="0.20401742172878276"/>
<DICH_DATA CI_END="6.341211041538326" CI_START="0.6568037637213733" EFFECT_SIZE="2.0408163265306123" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.8021722071611551" LOG_CI_START="-0.18256436721818248" LOG_EFFECT_SIZE="0.3098039199714864" ORDER="1198" O_E="0.0" SE="0.5784391383150814" STUDY_ID="STD-Warren-1983" TOTAL_1="49" TOTAL_2="50" VAR="0.33459183673469384" WEIGHT="1.5146747976833872"/>
<DICH_DATA CI_END="13.867772482168174" CI_START="0.07210963413813187" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1420067079086855" LOG_CI_START="-1.1420067079086855" LOG_EFFECT_SIZE="0.0" ORDER="1197" O_E="0.0" SE="1.3416407864998738" STUDY_ID="STD-Wiecek-1986" TOTAL_1="10" TOTAL_2="10" VAR="1.7999999999999998" WEIGHT="0.38253266574146766"/>
<DICH_DATA CI_END="1.877141510993971" CI_START="0.12790724545474672" EFFECT_SIZE="0.49" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.27349701376531194" LOG_CI_START="-0.8931048537082846" LOG_EFFECT_SIZE="-0.3098039199714863" ORDER="1204" O_E="0.0" SE="0.6852677117263689" STUDY_ID="STD-Wing-1998" TOTAL_1="100" TOTAL_2="49" VAR="0.46959183673469385" WEIGHT="2.053866661699155"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="20.246621304949638" CI_END="0.9885188482365199" CI_START="0.5680236139340653" CI_STUDY="95" CI_TOTAL="95" DF="23" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7493344037325711" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="104" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-0.00501504551361201" LOG_CI_START="-0.24563360938037487" LOG_EFFECT_SIZE="-0.12532432744699346" METHOD="MH" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.6269923466963896" P_Q="1.0" P_Z="0.04118484042095563" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="28" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1595" TOTAL_2="1540" WEIGHT="100.0" Z="2.041664319123977">
<NAME>Bacterial superinfection</NAME>
<GROUP_LABEL_1>Monotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours monotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1239" O_E="0.0" SE="0.0" STUDY_ID="STD-Abrams-1979" TOTAL_1="1" TOTAL_2="1" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.886806555547592" CI_START="0.43214941255197903" EFFECT_SIZE="1.7251461988304093" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8380178841994722" LOG_CI_START="-0.3643660730274539" LOG_EFFECT_SIZE="0.23682590558600916" ORDER="1252" O_E="0.0" SE="0.7062862883716756" STUDY_ID="STD-Alvarez_x002d_Lerma-2001a" TOTAL_1="57" TOTAL_2="59" VAR="0.4988403211418377" WEIGHT="2.7225518484927984"/>
<DICH_DATA CI_END="61.99544250664726" CI_START="0.1136035025079283" EFFECT_SIZE="2.6538461538461537" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7923597642246263" LOG_CI_START="-0.9446082786917515" LOG_EFFECT_SIZE="0.42387574276643736" ORDER="1242" O_E="0.0" SE="1.6077085766193955" STUDY_ID="STD-Arich-1987" TOTAL_1="25" TOTAL_2="22" VAR="2.584726867335563" WEIGHT="0.48998784909024234"/>
<DICH_DATA CI_END="86.76762068482145" CI_START="0.23066035760288578" EFFECT_SIZE="4.473684210526316" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.938357688524523" LOG_CI_START="-0.6370270390015956" LOG_EFFECT_SIZE="0.6506653247614638" ORDER="1244" O_E="0.0" SE="1.5127937373088463" STUDY_ID="STD-Brown-1984" TOTAL_1="18" TOTAL_2="16" VAR="2.288544891640867" WEIGHT="0.4873703926314269"/>
<DICH_DATA CI_END="5.444868391782754" CI_START="0.3950712774541087" EFFECT_SIZE="1.4666666666666666" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7359873868625401" LOG_CI_START="-0.40332454332949" LOG_EFFECT_SIZE="0.16633142176652496" ORDER="1248" O_E="0.0" SE="0.6692374674798086" STUDY_ID="STD-Carbon-1987" TOTAL_1="25" TOTAL_2="22" VAR="0.4478787878787879" WEIGHT="2.94714459150023"/>
<DICH_DATA CI_END="3.2827297108718856" CI_START="0.287704303542747" EFFECT_SIZE="0.971830985915493" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5162351258273371" LOG_CI_START="-0.541053641790977" LOG_EFFECT_SIZE="-0.012409257981819953" ORDER="1240" O_E="0.0" SE="0.6210566557628049" STUDY_ID="STD-Cometta-1994" TOTAL_1="142" TOTAL_2="138" VAR="0.3857113696672791" WEIGHT="4.683153096112508"/>
<DICH_DATA CI_END="115.72929405345836" CI_START="0.3499189042826871" EFFECT_SIZE="6.363636363636363" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0634433039428495" LOG_CI_START="-0.4560325942307859" LOG_EFFECT_SIZE="0.8037053548560318" ORDER="1228" O_E="0.0" SE="1.479952614194029" STUDY_ID="STD-Cone-1985" TOTAL_1="21" TOTAL_2="19" VAR="2.1902597402597404" WEIGHT="0.48370595358908536"/>
<DICH_DATA CI_END="8.016601515706123" CI_START="0.4302296409618833" EFFECT_SIZE="1.8571428571428572" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.9039902964911074" LOG_CI_START="-0.36629967190594753" LOG_EFFECT_SIZE="0.26884531229257996" ORDER="1231" O_E="0.0" SE="0.7461746154731859" STUDY_ID="STD-Coppens-1983" TOTAL_1="14" TOTAL_2="26" VAR="0.5567765567765568" WEIGHT="1.9392211412071514"/>
<DICH_DATA CI_END="1.1234826195386802" CI_START="0.23911389526474608" EFFECT_SIZE="0.5183052241875771" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="17" LOG_CI_END="0.05056635819989177" LOG_CI_START="-0.6213951856514375" LOG_EFFECT_SIZE="-0.28541441372577286" ORDER="1234" O_E="0.0" SE="0.39471353712155816" STUDY_ID="STD-D_x0027_Antonio-1992" TOTAL_1="143" TOTAL_2="140" VAR="0.15579877638701167" WEIGHT="15.864871594395373"/>
<DICH_DATA CI_END="3.239906071132739" CI_START="0.04024846143836208" EFFECT_SIZE="0.3611111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5105324196572129" LOG_CI_START="-1.3952507165781138" LOG_EFFECT_SIZE="-0.4423591484604505" MODIFIED="2011-12-26 06:39:36 +0000" MODIFIED_BY="[Empty name]" ORDER="1037" O_E="0.0" SE="1.1194664480033012" STUDY_ID="STD-Damas-2006" TOTAL_1="24" TOTAL_2="26" VAR="1.253205128205128" WEIGHT="2.6595032793698072"/>
<DICH_DATA CI_END="1.544786648766681" CI_START="0.005072036582870696" EFFECT_SIZE="0.08851674641148326" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.18886850728090981" LOG_CI_START="-2.2948176226969905" LOG_EFFECT_SIZE="-1.0529745577080403" ORDER="1230" O_E="0.0" SE="1.4589295271936442" STUDY_ID="STD-Felisart-1985" TOTAL_1="37" TOTAL_2="36" VAR="2.1284753653174704" WEIGHT="5.146631346187868"/>
<DICH_DATA CI_END="5.903167182237365" CI_START="0.17529234592827836" EFFECT_SIZE="1.0172413793103448" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.7710850829493019" LOG_CI_START="-0.7562370467908883" LOG_EFFECT_SIZE="0.007424018079206875" ORDER="1253" O_E="0.0" SE="0.8971565793758619" STUDY_ID="STD-Finer-1992" TOTAL_1="87" TOTAL_2="59" VAR="0.8048899279173972" WEIGHT="2.2010729195697607"/>
<DICH_DATA CI_END="3.6337674038680188" CI_START="0.009317052039148534" EFFECT_SIZE="0.184" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5603571248296005" LOG_CI_START="-2.0307214788105274" LOG_EFFECT_SIZE="-0.7351821769904635" ORDER="1235" O_E="0.0" SE="1.522012397824155" STUDY_ID="STD-Gerecht-1989" TOTAL_1="24" TOTAL_2="22" VAR="2.3165217391304345" WEIGHT="2.4047881215366456"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1246" O_E="0.0" SE="0.0" STUDY_ID="STD-Hoepelman-1988" TOTAL_1="13" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="21.716067266289453" CI_START="0.19376243416061517" EFFECT_SIZE="2.051282051282051" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3367811782283043" LOG_CI_START="-0.7127304182974156" LOG_EFFECT_SIZE="0.3120253799654443" ORDER="1247" O_E="0.0" SE="1.203893257045231" STUDY_ID="STD-Jaspers-1998" TOTAL_1="39" TOTAL_2="40" VAR="1.4493589743589745" WEIGHT="0.9117495419780458"/>
<DICH_DATA CI_END="21.4517839091991" CI_START="0.2038012710249002" EFFECT_SIZE="2.090909090909091" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3314634135234054" LOG_CI_START="-0.6907931118046698" LOG_EFFECT_SIZE="0.3203351508593678" ORDER="1243" O_E="0.0" SE="1.1878834933089564" STUDY_ID="STD-Klastersky-1973" TOTAL_1="22" TOTAL_2="23" VAR="1.4110671936758894" WEIGHT="0.9029177800329593"/>
<DICH_DATA CI_END="2.2021644415454094" CI_START="0.09038982315879215" EFFECT_SIZE="0.4461538461538462" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3428497457843642" LOG_CI_START="-1.0438804632721632" LOG_EFFECT_SIZE="-0.35051535874389944" ORDER="1254" O_E="0.0" SE="0.814572189225047" STUDY_ID="STD-Mandell-1987" TOTAL_1="52" TOTAL_2="58" VAR="0.6635278514588858" WEIGHT="4.365346291894886"/>
<DICH_DATA CI_END="1.8659091750056456" CI_START="0.21335492228782996" EFFECT_SIZE="0.6309523809523809" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.27089050020691263" LOG_CI_START="-0.6708973331290979" LOG_EFFECT_SIZE="-0.20000341646109263" ORDER="1236" O_E="0.0" SE="0.5532108352265341" STUDY_ID="STD-Mouton-1990" TOTAL_1="105" TOTAL_2="106" VAR="0.3060422282120395" WEIGHT="7.352497217847018"/>
<DICH_DATA CI_END="2.861809941829007" CI_START="0.007891357513862952" EFFECT_SIZE="0.150278293135436" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4566407880695644" LOG_CI_START="-2.1028482806857425" LOG_EFFECT_SIZE="-0.8231037463080889" ORDER="1229" O_E="0.0" SE="1.5034565486620912" STUDY_ID="STD-Mouton-1995" TOTAL_1="76" TOTAL_2="80" VAR="2.2603815937149268" WEIGHT="3.1502115585010686"/>
<DICH_DATA CI_END="3.8806390045543955" CI_START="0.12004734727827752" EFFECT_SIZE="0.6825396825396826" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5889032444864916" LOG_CI_START="-0.9206474322344819" LOG_EFFECT_SIZE="-0.16587209387399518" ORDER="1232" O_E="0.0" SE="0.8867175399022628" STUDY_ID="STD-Piccart-1984" TOTAL_1="42" TOTAL_2="43" VAR="0.786267995570321" WEIGHT="2.737723964057155"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1233" O_E="0.0" SE="0.0" STUDY_ID="STD-Rasmussen-1986" TOTAL_1="29" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.2166600673148897" CI_START="0.32291267970047727" EFFECT_SIZE="0.626797385620915" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="20" LOG_CI_END="0.08516925406297625" LOG_CI_START="-0.4909149013568466" LOG_EFFECT_SIZE="-0.2028728236469352" ORDER="1251" O_E="0.0" SE="0.3383946845561643" STUDY_ID="STD-Rubinstein-1995" TOTAL_1="306" TOTAL_2="274" VAR="0.11451096253586593" WEIGHT="19.487739547106347"/>
<DICH_DATA CI_END="2.403299854706511" CI_START="0.02958894661931195" EFFECT_SIZE="0.26666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.38080796020053204" LOG_CI_START="-1.5288704956559698" LOG_EFFECT_SIZE="-0.5740312677277188" ORDER="1241" O_E="0.0" SE="1.1217545780309226" STUDY_ID="STD-Sage-1987" TOTAL_1="30" TOTAL_2="24" VAR="1.258333333333333" WEIGHT="3.078128795566907"/>
<DICH_DATA CI_END="7.97298009754506" CI_START="0.23918653441079554" EFFECT_SIZE="1.380952380952381" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9016206799923733" LOG_CI_START="-0.6212632736622997" LOG_EFFECT_SIZE="0.1401787031650368" ORDER="1245" O_E="0.0" SE="0.8945495727739031" STUDY_ID="STD-Sieger-1997" TOTAL_1="63" TOTAL_2="58" VAR="0.8002189381499726" WEIGHT="1.9231945202054395"/>
<DICH_DATA CI_END="2.1020192589061732" CI_START="0.0062713229886485235" EFFECT_SIZE="0.11481481481481481" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.32263669075899903" LOG_CI_START="-2.2026408314084285" LOG_EFFECT_SIZE="-0.9400020703247146" ORDER="1249" O_E="0.0" SE="1.483360516846484" STUDY_ID="STD-Smith-1984" TOTAL_1="89" TOTAL_2="92" VAR="2.2003584229390682" WEIGHT="4.087351351490483"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1237" O_E="0.0" SE="0.0" STUDY_ID="STD-Trujillo-1992" TOTAL_1="16" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="88.07515104946967" CI_START="0.21732151204883177" EFFECT_SIZE="4.375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9448533966718429" LOG_CI_START="-0.6628972819551788" LOG_EFFECT_SIZE="0.640978057358332" ORDER="1238" O_E="0.0" SE="1.5318056571995586" STUDY_ID="STD-Verzasconi-1995" TOTAL_1="39" TOTAL_2="34" VAR="2.3464285714285715" WEIGHT="0.49250060729070505"/>
<DICH_DATA CI_END="1.9197731872087949" CI_START="0.35985585719685587" EFFECT_SIZE="0.8311688311688312" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.28324992174401975" LOG_CI_START="-0.44387142412120917" LOG_EFFECT_SIZE="-0.08031075118859467" ORDER="1250" O_E="0.0" SE="0.4271146778699464" STUDY_ID="STD-Warren-1983" TOTAL_1="56" TOTAL_2="64" VAR="0.18242694805194806" WEIGHT="9.480636690346074"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.7899283979249745" CI_END="1.4794634237215125" CI_START="0.42341694413612696" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7914732350707349" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="19" I2="0.0" I2_Q="100.0" ID="CMP-001.08" LOG_CI_END="0.17010423271241912" LOG_CI_START="-0.3732317665396137" LOG_EFFECT_SIZE="-0.10156376691359731" METHOD="MH" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.4542552875441923" P_Q="0.0" P_Z="0.46371856563247715" Q="7.562899194675773E-33" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="561" TOTAL_2="558" WEIGHT="100.00000000000001" Z="0.732737479419377">
<NAME>Fungal superinfection</NAME>
<GROUP_LABEL_1>Monotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours monotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.842616666677241" CI_START="0.012999478214868448" EFFECT_SIZE="0.2982456140350877" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.835222210870207" LOG_CI_START="-1.8860740794586417" LOG_EFFECT_SIZE="-0.5254259342942175" ORDER="1257" O_E="0.0" SE="1.5985029115730547" STUDY_ID="STD-Brown-1984" TOTAL_1="18" TOTAL_2="16" VAR="2.5552115583075334" WEIGHT="7.525102746973235"/>
<DICH_DATA CI_END="1.9045334473892759" CI_START="0.12397464933999106" EFFECT_SIZE="0.4859154929577465" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.27978860413744444" LOG_CI_START="-0.9066671114290468" LOG_EFFECT_SIZE="-0.31343925364580116" ORDER="1265" O_E="0.0" SE="0.6969299603742682" STUDY_ID="STD-Cometta-1994" TOTAL_1="142" TOTAL_2="138" VAR="0.48571136966727907" WEIGHT="28.923552813930208"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1259" O_E="0.0" SE="0.0" STUDY_ID="STD-Cone-1985" TOTAL_1="21" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.655691274762065" CI_START="0.2491522173804048" EFFECT_SIZE="1.4685314685314685" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9373017579221146" LOG_CI_START="-0.6035352433843998" LOG_EFFECT_SIZE="0.16688325726885747" ORDER="1264" O_E="0.0" SE="0.905095281833614" STUDY_ID="STD-D_x0027_Antonio-1992" TOTAL_1="143" TOTAL_2="140" VAR="0.8191974691974692" WEIGHT="9.606156826338905"/>
<DICH_DATA CI_END="7.157201826957097" CI_START="0.01313983407457264" EFFECT_SIZE="0.30666666666666664" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8547432641187759" LOG_CI_START="-1.8814101188669905" LOG_EFFECT_SIZE="-0.5133334273741073" ORDER="1263" O_E="0.0" SE="1.6072300413435225" STUDY_ID="STD-Gerecht-1989" TOTAL_1="24" TOTAL_2="22" VAR="2.583188405797101" WEIGHT="7.42608823714464"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1256" O_E="0.0" SE="0.0" STUDY_ID="STD-Hoepelman-1988" TOTAL_1="13" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1260" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Limson-1988" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="2.376348235886285"/>
<DICH_DATA CI_END="23.88951032410458" CI_START="0.20830612655654204" EFFECT_SIZE="2.230769230769231" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.378207247878014" LOG_CI_START="-0.6812979566937755" LOG_EFFECT_SIZE="0.3484546455921193" ORDER="1258" O_E="0.0" SE="1.20976355188065" STUDY_ID="STD-Mandell-1987" TOTAL_1="52" TOTAL_2="58" VAR="1.463527851458886" WEIGHT="4.493458482403157"/>
<DICH_DATA CI_END="3.1512114673363416" CI_START="0.03695883496475987" EFFECT_SIZE="0.3412698412698413" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4984775482123045" LOG_CI_START="-1.4322817272882573" LOG_EFFECT_SIZE="-0.46690208953797635" ORDER="1261" O_E="0.0" SE="1.1341375558415836" STUDY_ID="STD-Piccart-1984" TOTAL_1="42" TOTAL_2="43" VAR="1.2862679955703211" WEIGHT="14.090347186902207"/>
<DICH_DATA CI_END="1.6738266625265714" CI_START="0.023897337099184256" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.2237104814911927" LOG_CI_START="-1.6216504901632303" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="1255" O_E="0.0" SE="1.08397416943394" STUDY_ID="STD-Sage-1987" TOTAL_1="30" TOTAL_2="24" VAR="1.1749999999999998" WEIGHT="21.12309543010031"/>
<DICH_DATA CI_END="39.709285400061354" CI_START="0.5262738670094822" EFFECT_SIZE="4.571428571428571" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5988920716621562" LOG_CI_START="-0.27878819505085795" LOG_EFFECT_SIZE="0.6600519383056491" ORDER="1262" O_E="0.0" SE="1.1029586833344471" STUDY_ID="STD-Warren-1983" TOTAL_1="56" TOTAL_2="64" VAR="1.2165178571428572" WEIGHT="4.435850040321065"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.127146250061987" CI_END="1.101665850032764" CI_START="0.65138536999738" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8471180657600628" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="100" I2="19.39057413862026" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.04204988717183405" LOG_CI_START="-0.18616199984047238" LOG_EFFECT_SIZE="-0.0720560563343192" METHOD="MH" MODIFIED="2012-02-11 10:15:58 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.2423322248007328" P_Q="1.0" P_Z="0.21583270983421632" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="824" TOTAL_2="811" WEIGHT="99.99999999999999" Z="1.237685531040187">
<NAME>Bacterial colonization</NAME>
<GROUP_LABEL_1>Monotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours monotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.1831251513628755" CI_START="0.11671303584978515" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7145916954091044" LOG_CI_START="-0.9328806342592404" LOG_EFFECT_SIZE="-0.10914446942506803" ORDER="1279" O_E="0.0" SE="0.9677334015667417" STUDY_ID="STD-Bergeron-1988" TOTAL_1="36" TOTAL_2="28" VAR="0.9365079365079365" WEIGHT="2.3488731403349328"/>
<DICH_DATA CI_END="1.3978178380437576" CI_START="0.2558728314829114" EFFECT_SIZE="0.5980498374864572" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.14545057835739417" LOG_CI_START="-0.5919758249508204" LOG_EFFECT_SIZE="-0.22326262329671312" ORDER="1275" O_E="0.0" SE="0.4331679196228132" STUDY_ID="STD-Cometta-1994" TOTAL_1="142" TOTAL_2="138" VAR="0.18763444659035597" WEIGHT="13.76514227637551"/>
<DICH_DATA CI_END="4.191884156504632" CI_START="1.041325244912823" EFFECT_SIZE="2.0892857142857144" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.6224092723330267" LOG_CI_START="0.01758639714689592" LOG_EFFECT_SIZE="0.31999783473996124" ORDER="1274" O_E="0.0" SE="0.35527595080585067" STUDY_ID="STD-Coppens-1983" TOTAL_1="14" TOTAL_2="26" VAR="0.12622100122100122" WEIGHT="5.846084260389166"/>
<DICH_DATA CI_END="7.621413608600866" CI_START="0.7860107443532003" EFFECT_SIZE="2.4475524475524475" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.8820355311134447" LOG_CI_START="-0.10457151734301702" LOG_EFFECT_SIZE="0.3887320068852138" ORDER="1271" O_E="0.0" SE="0.57953786404698" STUDY_ID="STD-D_x0027_Antonio-1992" TOTAL_1="143" TOTAL_2="140" VAR="0.3358641358641359" WEIGHT="4.220040632184002"/>
<DICH_DATA CI_END="4.6810301660106886" CI_START="0.09824808140119126" EFFECT_SIZE="0.6781609195402298" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.6703414398648422" LOG_CI_START="-1.007675921817791" LOG_EFFECT_SIZE="-0.16866724097647437" ORDER="1268" O_E="0.0" SE="0.9856757045722817" STUDY_ID="STD-Finer-1992" TOTAL_1="87" TOTAL_2="59" VAR="0.971556594584064" WEIGHT="2.4883039660169155"/>
<DICH_DATA CI_END="100.88747695862293" CI_START="0.24780082477682808" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0038372611298576" LOG_CI_START="-0.60589725245782" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="1277" O_E="0.0" SE="1.5329709716755893" STUDY_ID="STD-Gomez-1990a" TOTAL_1="39" TOTAL_2="39" VAR="2.35" WEIGHT="0.5219718089633184"/>
<DICH_DATA CI_END="3.1192427950895256" CI_START="0.3503976055766447" EFFECT_SIZE="1.0454545454545454" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.49404918061277686" LOG_CI_START="-0.4554388702220035" LOG_EFFECT_SIZE="0.019305155195386624" ORDER="1276" O_E="0.0" SE="0.5577339811020029" STUDY_ID="STD-Klastersky-1973" TOTAL_1="22" TOTAL_2="23" VAR="0.3110671936758893" WEIGHT="5.103724354308002"/>
<DICH_DATA CI_END="2.146539550629656" CI_START="0.029116630989476325" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.33173889489417746" LOG_CI_START="-1.535858877550102" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="1267" O_E="0.0" SE="1.097036176291841" STUDY_ID="STD-Koehler-1990" TOTAL_1="43" TOTAL_2="43" VAR="1.2034883720930232" WEIGHT="4.175774471706547"/>
<DICH_DATA CI_END="1.3071860016754777" CI_START="0.40210421418702713" EFFECT_SIZE="0.725" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" LOG_CI_END="0.11633738846339599" LOG_CI_START="-0.39566137532140866" LOG_EFFECT_SIZE="-0.13966199342900631" ORDER="1270" O_E="0.0" SE="0.3007506082819499" STUDY_ID="STD-Mandell-1987" TOTAL_1="52" TOTAL_2="58" VAR="0.09045092838196286" WEIGHT="19.740024775340043"/>
<DICH_DATA CI_END="2.48887433486511" CI_START="0.3008406953532546" EFFECT_SIZE="0.8653061224489796" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.39600296930750417" LOG_CI_START="-0.5216634161790661" LOG_EFFECT_SIZE="-0.062830223435781" ORDER="1272" O_E="0.0" SE="0.5390417773566805" STUDY_ID="STD-Mouton-1990" TOTAL_1="105" TOTAL_2="106" VAR="0.29056603773584905" WEIGHT="7.2729721248917345"/>
<DICH_DATA CI_END="1.5565502534393978" CI_START="0.2910490961519968" EFFECT_SIZE="0.6730769230769231" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="0.1921631465020645" LOG_CI_START="-0.5360337450711115" LOG_EFFECT_SIZE="-0.1719352992845235" ORDER="1278" O_E="0.0" SE="0.4277464587428316" STUDY_ID="STD-Sandberg-1997" TOTAL_1="26" TOTAL_2="35" VAR="0.18296703296703296" WEIGHT="10.679029796495433"/>
<DICH_DATA CI_END="1.1351497483419437" CI_START="0.22023526003081312" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.05505315720201257" LOG_CI_START="-0.6571131485299749" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="1266" O_E="0.0" SE="0.4183300132670378" STUDY_ID="STD-Sculier-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.17500000000000002" WEIGHT="8.351548943413095"/>
<DICH_DATA CI_END="1.3389166525015845" CI_START="0.26059495336325383" EFFECT_SIZE="0.5906902086677368" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.12675354304243405" LOG_CI_START="-0.584033999013738" LOG_EFFECT_SIZE="-0.22864022798565192" ORDER="1269" O_E="0.0" SE="0.41752012065887356" STUDY_ID="STD-Smith-1984" TOTAL_1="89" TOTAL_2="92" VAR="0.17432305115500035" WEIGHT="14.372969590459553"/>
<DICH_DATA CI_END="12.728737323171048" CI_START="0.06014932829246754" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.104785324252448" LOG_CI_START="-1.2207692182078216" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="1273" O_E="0.0" SE="1.3660422499218055" STUDY_ID="STD-Vergnon-1985" TOTAL_1="16" TOTAL_2="14" VAR="1.8660714285714286" WEIGHT="1.113539859121746"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.729581803292836" CI_END="1.0078472045079594" CI_START="0.6020529714218275" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7789591800686343" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="83" I2="25.701178079840542" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.003394695533171123" LOG_CI_START="-0.22036529581174946" LOG_EFFECT_SIZE="-0.10848530013928921" METHOD="MH" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.24154111818133428" P_Q="1.0" P_Z="0.057368297451092044" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="368" TOTAL_2="383" WEIGHT="100.0" Z="1.900494184389426">
<NAME>Bacterial colonization&#8212;surveillance cultures</NAME>
<GROUP_LABEL_1>Monotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours monotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0883378389508862" CI_START="0.6195032311398085" EFFECT_SIZE="0.8211143695014663" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="33" LOG_CI_END="0.036763728833963547" LOG_CI_START="-0.20795642413452048" LOG_EFFECT_SIZE="-0.08559634765027847" ORDER="1290" O_E="0.0" SE="0.14374982923798166" STUDY_ID="STD-Cometta-1994" TOTAL_1="31" TOTAL_2="40" VAR="0.020664013405948888" WEIGHT="37.1656662417675"/>
<DICH_DATA CI_END="7.621413608600866" CI_START="0.7860107443532003" EFFECT_SIZE="2.4475524475524475" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.8820355311134447" LOG_CI_START="-0.10457151734301702" LOG_EFFECT_SIZE="0.3887320068852138" ORDER="1288" O_E="0.0" SE="0.57953786404698" STUDY_ID="STD-D_x0027_Antonio-1992" TOTAL_1="143" TOTAL_2="140" VAR="0.3358641358641359" WEIGHT="5.213558256947666"/>
<DICH_DATA CI_END="2.146539550629656" CI_START="0.029116630989476325" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.33173889489417746" LOG_CI_START="-1.535858877550102" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="1291" O_E="0.0" SE="1.097036176291841" STUDY_ID="STD-Koehler-1990" TOTAL_1="43" TOTAL_2="43" VAR="1.2034883720930232" WEIGHT="5.158870582923739"/>
<DICH_DATA CI_END="1.3071860016754777" CI_START="0.40210421418702713" EFFECT_SIZE="0.725" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" LOG_CI_END="0.11633738846339599" LOG_CI_START="-0.39566137532140866" LOG_EFFECT_SIZE="-0.13966199342900631" ORDER="1289" O_E="0.0" SE="0.3007506082819499" STUDY_ID="STD-Mandell-1987" TOTAL_1="52" TOTAL_2="58" VAR="0.09045092838196286" WEIGHT="24.387388210184948"/>
<DICH_DATA CI_END="1.1351497483419437" CI_START="0.22023526003081312" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.05505315720201257" LOG_CI_START="-0.6571131485299749" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="1292" O_E="0.0" SE="0.4183300132670378" STUDY_ID="STD-Sculier-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.17500000000000002" WEIGHT="10.317741165847478"/>
<DICH_DATA CI_END="1.3389166525015845" CI_START="0.26059495336325383" EFFECT_SIZE="0.5906902086677368" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.12675354304243405" LOG_CI_START="-0.584033999013738" LOG_EFFECT_SIZE="-0.22864022798565192" ORDER="1287" O_E="0.0" SE="0.41752012065887356" STUDY_ID="STD-Smith-1984" TOTAL_1="89" TOTAL_2="92" VAR="0.17432305115500035" WEIGHT="17.756775542328672"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.4960725869365152" CI_END="1.4455239977925445" CI_START="0.536682436707727" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8807879094622029" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.16002530598410203" LOG_CI_START="-0.2702826170582724" LOG_EFFECT_SIZE="-0.055128655537085174" METHOD="MH" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.8356413108849149" P_Q="1.0" P_Z="0.6155273028583033" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="716" TOTAL_2="654" WEIGHT="100.00000000000001" Z="0.5021993488052108">
<NAME>Development of bacterial resistance</NAME>
<GROUP_LABEL_1>Monotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours monotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1297" O_E="0.0" SE="0.0" STUDY_ID="STD-Carbon-1987" TOTAL_1="25" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.7718681360753137" CI_START="0.23690136753440535" EFFECT_SIZE="0.647887323943662" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.24843139819112303" LOG_CI_START="-0.6254324322661254" LOG_EFFECT_SIZE="-0.1885005170375012" ORDER="1301" O_E="0.0" SE="0.5133119397063124" STUDY_ID="STD-Cometta-1994" TOTAL_1="142" TOTAL_2="138" VAR="0.26348914744505686" WEIGHT="29.11875276976552"/>
<DICH_DATA CI_END="10.580050252264304" CI_START="0.13610521364884978" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.0244877304807605" LOG_CI_START="-0.8661252383855109" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="1293" O_E="0.0" SE="1.1105554165971787" STUDY_ID="STD-Hoepelman-1988" TOTAL_1="10" TOTAL_2="6" VAR="1.2333333333333332" WEIGHT="3.9873096515719615"/>
<DICH_DATA CI_END="6.6285201628463435" CI_START="0.1440837411680985" EFFECT_SIZE="0.9772727272727273" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8214165816709411" LOG_CI_START="-0.8413850234841428" LOG_EFFECT_SIZE="-0.009984220906600895" ORDER="1298" O_E="0.0" SE="0.9767378938687896" STUDY_ID="STD-Iakovlev-1998" TOTAL_1="44" TOTAL_2="43" VAR="0.9540169133192389" WEIGHT="6.453025275187727"/>
<DICH_DATA CI_END="102.92635130735574" CI_START="0.2644723307192462" EFFECT_SIZE="5.217391304347826" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0125265775055743" LOG_CI_START="-0.5776197574455103" LOG_EFFECT_SIZE="0.7174534100300319" ORDER="1300" O_E="0.0" SE="1.5214647785814064" STUDY_ID="STD-Klastersky-1973" TOTAL_1="22" TOTAL_2="23" VAR="2.314855072463768" WEIGHT="1.5609893104026402"/>
<DICH_DATA CI_END="101.92951665256997" CI_START="0.24526752231361296" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0082999648024122" LOG_CI_START="-0.610359956130375" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="1296" O_E="0.0" SE="1.5382138001315857" STUDY_ID="STD-Mandell-1987" TOTAL_1="58" TOTAL_2="58" VAR="2.3661016949152542" WEIGHT="1.5949238606287846"/>
<DICH_DATA CI_END="1.5996778881669909" CI_START="0.3566551802797375" EFFECT_SIZE="0.7553366174055829" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.20403254173406105" LOG_CI_START="-0.4477514636366636" LOG_EFFECT_SIZE="-0.1218594609513013" ORDER="1295" O_E="0.0" SE="0.38286115113762476" STUDY_ID="STD-Rubinstein-1995" TOTAL_1="261" TOTAL_2="230" VAR="0.14658266105042717" WEIGHT="47.477407631263375"/>
<DICH_DATA CI_END="4.671852101612958" CI_START="0.05351196796527171" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6694890857160593" LOG_CI_START="-1.2715490770440216" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="1299" O_E="0.0" SE="1.1401754250991378" STUDY_ID="STD-Sculier-1982" TOTAL_1="10" TOTAL_2="10" VAR="1.2999999999999998" WEIGHT="6.379695442515138"/>
<DICH_DATA CI_END="13.624311956572688" CI_START="0.05442567287379892" EFFECT_SIZE="0.8611111111111112" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1343145791315148" LOG_CI_START="-1.2641961929975438" LOG_EFFECT_SIZE="-0.06494080693301456" ORDER="1294" O_E="0.0" SE="1.4088971003684134" STUDY_ID="STD-Stille-1992" TOTAL_1="144" TOTAL_2="124" VAR="1.9849910394265233" WEIGHT="3.4278960586648504"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="49.86591703550275" CI_END="1.009177223002496" CI_START="0.8330501376507226" CI_STUDY="95" CI_TOTAL="95" DF="36" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9168943366256568" ESTIMABLE="YES" EVENTS_1="569" EVENTS_2="590" I2="27.80640136554736" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.003967439986679311" LOG_CI_START="-0.0793288595178522" LOG_EFFECT_SIZE="-0.03768070976558645" METHOD="MH" MODIFIED="2013-08-13 04:51:37 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.062015172442650535" P_Q="1.0" P_Z="0.07618628602719431" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="40" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2550" TOTAL_2="2451" WEIGHT="99.99999999999994" Z="1.7732560627963645">
<NAME>Any adverse event</NAME>
<GROUP_LABEL_1>Monotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours monotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.768735649211788" CI_START="0.0401306318798411" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4422814925570199" LOG_CI_START="-1.3965240019963447" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="1331" O_E="0.0" SE="1.0801234497346435" STUDY_ID="STD-Abrams-1979" TOTAL_1="12" TOTAL_2="12" VAR="1.1666666666666667" WEIGHT="0.49654736954063006"/>
<DICH_DATA CI_END="1.2958937553853636" CI_START="0.6409681028649598" EFFECT_SIZE="0.9113871635610766" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="35" LOG_CI_END="0.11256939710457155" LOG_CI_START="-0.19316358217293747" LOG_EFFECT_SIZE="-0.040297092534182975" ORDER="1315" O_E="0.0" SE="0.17958906543026407" STUDY_ID="STD-Alvarez_x002d_Lerma-2001a" TOTAL_1="69" TOTAL_2="71" VAR="0.03225223242211567" WEIGHT="5.710294749717245"/>
<DICH_DATA CI_END="2.6195449292633275" CI_START="0.032847096258296286" EFFECT_SIZE="0.29333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.41822585167260906" LOG_CI_START="-1.4835030168115966" LOG_EFFECT_SIZE="-0.5326385825694938" ORDER="1320" O_E="0.0" SE="1.1170849510573437" STUDY_ID="STD-Arich-1987" TOTAL_1="25" TOTAL_2="22" VAR="1.2478787878787878" WEIGHT="0.5282418824900319"/>
<DICH_DATA CI_END="3.068217363134286" CI_START="0.38643905304494736" EFFECT_SIZE="1.0888888888888888" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.4868861232906047" LOG_CI_START="-0.41291899078426486" LOG_EFFECT_SIZE="0.036983566253169946" ORDER="1336" O_E="0.0" SE="0.5285499781147279" STUDY_ID="STD-Bergeron-1988" TOTAL_1="36" TOTAL_2="28" VAR="0.27936507936507937" WEIGHT="0.9310263178886813"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1309" O_E="0.0" SE="0.0" STUDY_ID="STD-Biglino-1991" TOTAL_1="12" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="9.911262867984199" CI_START="0.4982484745601991" EFFECT_SIZE="2.2222222222222223" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.9961289947127174" LOG_CI_START="-0.30255402226340483" LOG_EFFECT_SIZE="0.3467874862246563" ORDER="1313" O_E="0.0" SE="0.7628528327563872" STUDY_ID="STD-Brown-1984" TOTAL_1="18" TOTAL_2="16" VAR="0.5819444444444444" WEIGHT="0.3505040255580918"/>
<DICH_DATA CI_END="0.8684629485549188" CI_START="0.45478454034308446" EFFECT_SIZE="0.6284612341772152" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="64" LOG_CI_END="-0.06124870523230297" LOG_CI_START="-0.3421943068642626" LOG_EFFECT_SIZE="-0.2017215060482828" ORDER="1326" O_E="0.0" SE="0.16502883710177016" STUDY_ID="STD-Cometta-1994" TOTAL_1="158" TOTAL_2="155" VAR="0.027234517075162588" WEIGHT="10.694541002757935"/>
<DICH_DATA CI_END="0.5805480323123163" CI_START="0.10318720674428665" EFFECT_SIZE="0.24475524475524477" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="24" LOG_CI_END="-0.2361618425830763" LOG_CI_START="-0.9863741436464959" LOG_EFFECT_SIZE="-0.6112679931147862" ORDER="1308" O_E="0.0" SE="0.44067841925543527" STUDY_ID="STD-D_x0027_Antonio-1992" TOTAL_1="143" TOTAL_2="140" VAR="0.19419746919746916" WEIGHT="4.0144889805970365"/>
<DICH_DATA CI_END="98.0145258662667" CI_START="0.1736030945374006" EFFECT_SIZE="4.125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9912904434075727" LOG_CI_START="-0.760442537635685" LOG_EFFECT_SIZE="0.6154239528859439" ORDER="1323" O_E="0.0" SE="1.6163815743627472" STUDY_ID="STD-Duff-1982" TOTAL_1="31" TOTAL_2="43" VAR="2.6126893939393936" WEIGHT="0.06969085888289545"/>
<DICH_DATA CI_END="1.165315086342238" CI_START="0.7237603177764858" EFFECT_SIZE="0.9183729183729183" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="66" LOG_CI_END="0.06644336893127262" LOG_CI_START="-0.1404052320086133" LOG_EFFECT_SIZE="-0.03698093153867036" ORDER="1339" O_E="0.0" SE="0.12150389210917714" STUDY_ID="STD-Dupont-2000" TOTAL_1="111" TOTAL_2="116" VAR="0.014763195797678558" WEIGHT="10.683424461834525"/>
<DICH_DATA CI_END="2.2426050933818775" CI_START="0.3101381342896954" EFFECT_SIZE="0.833976833976834" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.35075280418274624" LOG_CI_START="-0.5084448300433881" LOG_EFFECT_SIZE="-0.07884601293032092" ORDER="1338" O_E="0.0" SE="0.5046969434413138" STUDY_ID="STD-Felisart-1985" TOTAL_1="37" TOTAL_2="36" VAR="0.2547190047190047" WEIGHT="1.1744819060367413"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-26 07:22:20 +0000" MODIFIED_BY="[Empty name]" ORDER="2088" O_E="0.0" SE="0.0" STUDY_ID="STD-Figueroa_x002d_Damian-1996" TOTAL_1="14" TOTAL_2="42" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.2351123827516797" CI_START="1.0241323019972275" EFFECT_SIZE="1.5129609346476816" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="33" LOG_CI_END="0.34929936459630767" LOG_CI_START="0.010356064370122701" LOG_EFFECT_SIZE="0.1798277144832152" ORDER="1322" O_E="0.0" SE="0.19909697234925633" STUDY_ID="STD-Finer-1992" TOTAL_1="249" TOTAL_2="222" VAR="0.03963960439864054" WEIGHT="5.775130552746436"/>
<DICH_DATA CI_END="0.9647716490964461" CI_START="0.054435016991115005" EFFECT_SIZE="0.22916666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.01557546724981849" LOG_CI_START="-1.264121637184906" LOG_EFFECT_SIZE="-0.6398485522173621" ORDER="1306" O_E="0.0" SE="0.7334022006230878" STUDY_ID="STD-Gerecht-1989" TOTAL_1="24" TOTAL_2="22" VAR="0.537878787878788" WEIGHT="1.3816970282869705"/>
<DICH_DATA CI_END="1.5250057453009744" CI_START="0.16393380862356036" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.18327147984530298" LOG_CI_START="-0.7853314711732654" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="1311" O_E="0.0" SE="0.5689621680902419" STUDY_ID="STD-Gomez-1990a" TOTAL_1="39" TOTAL_2="39" VAR="0.3237179487179487" WEIGHT="1.3241263187750134"/>
<DICH_DATA CI_END="2.738907095287997" CI_START="0.22403502191321667" EFFECT_SIZE="0.7833333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4375773010790554" LOG_CI_START="-0.6496840859749078" LOG_EFFECT_SIZE="-0.10605339244792618" ORDER="1317" O_E="0.0" SE="0.6386627207861642" STUDY_ID="STD-Iakovlev-1998" TOTAL_1="48" TOTAL_2="47" VAR="0.40789007092198587" WEIGHT="0.8362903065947452"/>
<DICH_DATA CI_END="1.7324841139670482" CI_START="0.6765247652700485" EFFECT_SIZE="1.0826210826210827" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.23866926103386948" LOG_CI_START="-0.1697163007318973" LOG_EFFECT_SIZE="0.03447648015098611" ORDER="1304" O_E="0.0" SE="0.23988770052234512" STUDY_ID="STD-Jaspers-1998" TOTAL_1="39" TOTAL_2="40" VAR="0.057546108861898336" WEIGHT="2.941571758797656"/>
<DICH_DATA CI_END="5.083060192649951" CI_START="0.04918297059741634" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7061252525673394" LOG_CI_START="-1.3081852438953019" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="1327" O_E="0.0" SE="1.1832159566199232" STUDY_ID="STD-Limson-1988" TOTAL_1="20" TOTAL_2="20" VAR="1.4" WEIGHT="0.33103157969375335"/>
<DICH_DATA CI_END="1.443740947029279" CI_START="0.302483902944778" EFFECT_SIZE="0.6608391608391608" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.15948927400328056" LOG_CI_START="-0.5192977319148783" LOG_EFFECT_SIZE="-0.17990422895579886" ORDER="1332" O_E="0.0" SE="0.39872284732619595" STUDY_ID="STD-Martin-1991" TOTAL_1="52" TOTAL_2="42" VAR="0.15897990897990896" WEIGHT="2.014362378561988"/>
<DICH_DATA CI_END="2.8269604484714446" CI_START="0.273933793597545" EFFECT_SIZE="0.88" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4513197323909125" LOG_CI_START="-0.5623543880905753" LOG_EFFECT_SIZE="-0.05551732784983137" ORDER="1324" O_E="0.0" SE="0.5954371961386479" STUDY_ID="STD-Mergoni-1987" TOTAL_1="20" TOTAL_2="22" VAR="0.35454545454545455" WEIGHT="0.7881704278422699"/>
<DICH_DATA CI_END="2.2959022500989343" CI_START="1.0235755981308114" EFFECT_SIZE="1.5329805996472663" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="27" LOG_CI_END="0.360953393679618" LOG_CI_START="0.010119923831542766" LOG_EFFECT_SIZE="0.18553665875558034" ORDER="1318" O_E="0.0" SE="0.20608131684244352" STUDY_ID="STD-Mouton-1990" TOTAL_1="105" TOTAL_2="106" VAR="0.042469509151515594" WEIGHT="4.447746580245454"/>
<DICH_DATA CI_END="1.5555678848441312" CI_START="0.8293405993483007" EFFECT_SIZE="1.135823754789272" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="45" LOG_CI_END="0.19188896843083952" LOG_CI_START="-0.08126707374543639" LOG_EFFECT_SIZE="0.055310947342701575" ORDER="1314" O_E="0.0" SE="0.1604532113185603" STUDY_ID="STD-Mouton-1995" TOTAL_1="116" TOTAL_2="121" VAR="0.02574523302243857" WEIGHT="7.291075299583935"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1330" O_E="0.0" SE="0.0" STUDY_ID="STD-Naime-Libien-1992" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.621115240645157" CI_START="0.27929655653896834" EFFECT_SIZE="1.5517241379310345" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.935563450456867" LOG_CI_START="-0.5539344187040918" LOG_EFFECT_SIZE="0.1908145158763876" ORDER="1302" O_E="0.0" SE="0.874938421478512" STUDY_ID="STD-Rasmussen-1986" TOTAL_1="29" TOTAL_2="30" VAR="0.7655172413793103" WEIGHT="0.3254208749531813"/>
<DICH_DATA CI_END="1.3685982061742106" CI_START="0.6403134385245557" EFFECT_SIZE="0.9361259655377302" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="44" LOG_CI_END="0.13627596642958023" LOG_CI_START="-0.1936073833611911" LOG_EFFECT_SIZE="-0.028665708465805413" ORDER="1325" O_E="0.0" SE="0.19377511261601638" STUDY_ID="STD-Rubinstein-1995" TOTAL_1="306" TOTAL_2="274" VAR="0.03754879426934983" WEIGHT="7.684498601718439"/>
<DICH_DATA CI_END="2.001674334280597" CI_START="0.07993308264978286" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.30139342063094" LOG_CI_START="-1.097273437975015" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="1340" O_E="0.0" SE="0.8215838362577492" STUDY_ID="STD-Sage-1987" TOTAL_1="30" TOTAL_2="24" VAR="0.675" WEIGHT="0.7356257326527853"/>
<DICH_DATA CI_END="1.9181275274905478" CI_START="0.4380719038410852" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.2828774780402053" LOG_CI_START="-0.3584545998190049" LOG_EFFECT_SIZE="-0.0377885608893998" ORDER="1335" O_E="0.0" SE="0.3767216371794855" STUDY_ID="STD-Sandberg-1997" TOTAL_1="36" TOTAL_2="33" VAR="0.14191919191919192" WEIGHT="1.7271212853587132"/>
<DICH_DATA CI_END="13.867772482168174" CI_START="0.07210963413813187" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1420067079086855" LOG_CI_START="-1.1420067079086855" LOG_EFFECT_SIZE="0.0" ORDER="1321" O_E="0.0" SE="1.3416407864998738" STUDY_ID="STD-Sculier-1982" TOTAL_1="10" TOTAL_2="10" VAR="1.7999999999999998" WEIGHT="0.16551578984687668"/>
<DICH_DATA CI_END="6.0103718932243595" CI_START="0.42729663795385037" EFFECT_SIZE="1.6025641025641026" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7789013449109462" LOG_CI_START="-0.36927052427579415" LOG_EFFECT_SIZE="0.20481541031757602" ORDER="1305" O_E="0.0" SE="0.6744418395027068" STUDY_ID="STD-Sexton-1998" TOTAL_1="26" TOTAL_2="25" VAR="0.4548717948717949" WEIGHT="0.5062835924727992"/>
<DICH_DATA CI_END="2.0202621121596076" CI_START="0.6929291607905105" EFFECT_SIZE="1.1831730769230768" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="20" LOG_CI_END="0.30540771918906967" LOG_CI_START="-0.1593111617089878" LOG_EFFECT_SIZE="0.07304827874004094" ORDER="1310" O_E="0.0" SE="0.2729781710350797" STUDY_ID="STD-Sieger-1997" TOTAL_1="104" TOTAL_2="107" VAR="0.07451708186165723" WEIGHT="3.263249695559275"/>
<DICH_DATA CI_END="3.1536383867094995" CI_START="0.03685235718662263" EFFECT_SIZE="0.3409090909090909" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4988118932857775" LOG_CI_START="-1.4335347281467898" LOG_EFFECT_SIZE="-0.46736141743050624" ORDER="1316" O_E="0.0" SE="1.1350699706995329" STUDY_ID="STD-Speich-1998" TOTAL_1="44" TOTAL_2="45" VAR="1.2883838383838384" WEIGHT="0.49096818561320726"/>
<DICH_DATA CI_END="1.251881881030492" CI_START="0.694001663962801" EFFECT_SIZE="0.9320987654320988" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="54" LOG_CI_END="0.09756335376524766" LOG_CI_START="-0.15863948826417065" LOG_EFFECT_SIZE="-0.03053806724946149" ORDER="1303" O_E="0.0" SE="0.150494817632602" STUDY_ID="STD-Stille-1992" TOTAL_1="186" TOTAL_2="151" VAR="0.022648690134270136" WEIGHT="9.866116280249432"/>
<DICH_DATA CI_END="5.2873353901832045" CI_START="0.5149096471267479" EFFECT_SIZE="1.65" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7232368597688349" LOG_CI_START="-0.28826897134102236" LOG_EFFECT_SIZE="0.21748394421390627" ORDER="1328" O_E="0.0" SE="0.5941635322285466" STUDY_ID="STD-Sukoh-1994" TOTAL_1="30" TOTAL_2="33" VAR="0.353030303030303" WEIGHT="0.6305363422738158"/>
<DICH_DATA CI_END="2.080637573472772" CI_START="0.4539788295078965" EFFECT_SIZE="0.9718875502008032" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.3181964369877807" LOG_CI_START="-0.34296439921839084" LOG_EFFECT_SIZE="-0.012383981115305072" ORDER="1333" O_E="0.0" SE="0.3883691479864274" STUDY_ID="STD-Takamoto-1994" TOTAL_1="83" TOTAL_2="88" VAR="0.15083059510770355" WEIGHT="1.9281137624267741"/>
<DICH_DATA CI_END="2.443242450332741" CI_START="0.26150168899896936" EFFECT_SIZE="0.7993197278911565" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.3879665654659089" LOG_CI_START="-0.582525501746751" LOG_EFFECT_SIZE="-0.09727946814042103" ORDER="1337" O_E="0.0" SE="0.5700718442939273" STUDY_ID="STD-Thompson--1990" TOTAL_1="49" TOTAL_2="47" VAR="0.3249819076566797" WEIGHT="1.0137842128121197"/>
<DICH_DATA CI_END="5.012515118574269" CI_START="0.46777446192858985" EFFECT_SIZE="1.53125" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7000556955341694" LOG_CI_START="-0.3299634921169539" LOG_EFFECT_SIZE="0.1850461017086077" ORDER="1319" O_E="0.0" SE="0.6050383695034791" STUDY_ID="STD-Thompson-1993" TOTAL_1="80" TOTAL_2="70" VAR="0.36607142857142855" WEIGHT="0.7062007033466738"/>
<DICH_DATA CI_END="1.3240668079819158" CI_START="0.02312949755660538" EFFECT_SIZE="0.175" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.12190989870330167" LOG_CI_START="-1.6358338013307128" LOG_EFFECT_SIZE="-0.7569619513137056" ORDER="1312" O_E="0.0" SE="1.0325073503716227" STUDY_ID="STD-Trujillo-1992" TOTAL_1="16" TOTAL_2="14" VAR="1.0660714285714286" WEIGHT="0.8827508791833423"/>
<DICH_DATA CI_END="4.3236885819537445" CI_START="0.04426920356819715" EFFECT_SIZE="0.4375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6358544059081014" LOG_CI_START="-1.3538982911914372" LOG_EFFECT_SIZE="-0.3590219426416679" ORDER="1329" O_E="0.0" SE="1.1687905837109693" STUDY_ID="STD-Vergnon-1985" TOTAL_1="16" TOTAL_2="14" VAR="1.3660714285714286" WEIGHT="0.3531003516733369"/>
<DICH_DATA CI_END="1.3409029994187545" CI_START="0.504953660215931" EFFECT_SIZE="0.8228571428571428" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="25" LOG_CI_END="0.12739736223574416" LOG_CI_START="-0.29674847541783367" LOG_EFFECT_SIZE="-0.0846755565910448" ORDER="1334" O_E="0.0" SE="0.24914536459346923" STUDY_ID="STD-Warren-1983" TOTAL_1="56" TOTAL_2="64" VAR="0.06207341269841271" WEIGHT="3.8620350964271224"/>
<DICH_DATA CI_END="1.0224835386236688" CI_START="0.42119412805383905" EFFECT_SIZE="0.65625" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="20" LOG_CI_END="0.009656324853019642" LOG_CI_START="-0.375517692024993" LOG_EFFECT_SIZE="-0.18293068358598671" ORDER="1307" O_E="0.0" SE="0.2262531241562781" STUDY_ID="STD-Yellin-1993" TOTAL_1="56" TOTAL_2="35" VAR="0.05119047619047619" WEIGHT="4.0742348270000415"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.260865347037326" CI_END="1.517572559797943" CI_START="0.5188543357890523" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8873551163573993" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.1811494651947366" LOG_CI_START="-0.2849545497473565" LOG_EFFECT_SIZE="-0.05190254227630993" METHOD="MH" MODIFIED="2013-08-13 04:51:49 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.5853622127647531" P_Q="1.0" P_Z="0.6624742734292606" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="20" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1602" TOTAL_2="1496" WEIGHT="100.0" Z="0.4364996237171363">
<NAME>Adverse events requiring treatment discontinuation</NAME>
<GROUP_LABEL_1>Monotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours monotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.3224772866353254" CI_START="0.17925819623807865" EFFECT_SIZE="0.7717391304347826" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5214620206688972" LOG_CI_START="-0.7465209779218573" LOG_EFFECT_SIZE="-0.11252947862648" ORDER="1354" O_E="0.0" SE="0.7448194899892802" STUDY_ID="STD-Alvarez_x002d_Lerma-2001a" TOTAL_1="69" TOTAL_2="71" VAR="0.5547560726678914" WEIGHT="13.5125970715607"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1342" O_E="0.0" SE="0.0" STUDY_ID="STD-Bergeron-1988" TOTAL_1="36" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="21.41699363837319" CI_START="0.1797424702744359" EFFECT_SIZE="1.9620253164556962" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3307585076770039" LOG_CI_START="-0.7453492939173038" LOG_EFFECT_SIZE="0.29270460687985006" ORDER="1345" O_E="0.0" SE="1.219515999555858" STUDY_ID="STD-Cometta-1994" TOTAL_1="158" TOTAL_2="155" VAR="1.4872192731727236" WEIGHT="5.0404102597264195"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-26 07:22:48 +0000" MODIFIED_BY="[Empty name]" ORDER="2089" O_E="0.0" SE="0.0" STUDY_ID="STD-Figueroa_x002d_Damian-1996" TOTAL_1="14" TOTAL_2="42" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="17.6035402100311" CI_START="0.08180172753997735" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2456000166249395" LOG_CI_START="-1.0872375245296901" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="1351" O_E="0.0" SE="1.3703203194062976" STUDY_ID="STD-Holloway--1985" TOTAL_1="15" TOTAL_2="18" VAR="1.8777777777777778" WEIGHT="3.9920566595659164"/>
<DICH_DATA CI_END="3.9753171590223544" CI_START="0.009655583473830243" EFFECT_SIZE="0.19591836734693877" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5993717832864616" LOG_CI_START="-2.0152214772643524" LOG_EFFECT_SIZE="-0.7079248469889453" ORDER="1356" O_E="0.0" SE="1.5358250236929207" STUDY_ID="STD-Iakovlev-1998" TOTAL_1="48" TOTAL_2="47" VAR="2.3587585034013605" WEIGHT="3.178025758954574"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1357" O_E="0.0" SE="0.0" STUDY_ID="STD-Landau-1990" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.4946728673697534" CI_START="0.029055996899912635" EFFECT_SIZE="0.2692307692307692" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.3970136035823028" LOG_CI_START="-1.536764219495425" LOG_EFFECT_SIZE="-0.5698753079565612" ORDER="1343" O_E="0.0" SE="1.1359106656304625" STUDY_ID="STD-Martin-1991" TOTAL_1="52" TOTAL_2="42" VAR="1.2902930402930404" WEIGHT="5.809684349890155"/>
<DICH_DATA CI_END="103.88534653485917" CI_START="0.24521189902138602" EFFECT_SIZE="5.047169811320755" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0165542928135864" LOG_CI_START="-0.6104584593006701" LOG_EFFECT_SIZE="0.7030479167564582" ORDER="1347" O_E="0.0" SE="1.543120294514762" STUDY_ID="STD-Mouton-1990" TOTAL_1="105" TOTAL_2="106" VAR="2.3812202433433254" WEIGHT="3.1480478565215435"/>
<DICH_DATA CI_END="13.176253819034695" CI_START="0.516110657640581" EFFECT_SIZE="2.6077586206896552" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.1197919522169835" LOG_CI_START="-0.287257172693845" LOG_EFFECT_SIZE="0.41626738976156924" ORDER="1352" O_E="0.0" SE="0.8265076209781191" STUDY_ID="STD-Mouton-1995" TOTAL_1="116" TOTAL_2="121" VAR="0.6831148475349103" WEIGHT="10.973550509132469"/>
<DICH_DATA CI_END="60.548014681990736" CI_START="0.17084039507787313" EFFECT_SIZE="3.2162162162162162" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.7820999075650876" LOG_CI_START="-0.7674094329140158" LOG_EFFECT_SIZE="0.5073452373255357" ORDER="1341" O_E="0.0" SE="1.4975944068721978" STUDY_ID="STD-Muller-1987" TOTAL_1="73" TOTAL_2="33" VAR="2.2427890074948897" WEIGHT="3.342354210722492"/>
<DICH_DATA CI_END="8.12688689988809" CI_START="0.014598698956949398" EFFECT_SIZE="0.34444444444444444" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9099242158133338" LOG_CI_START="-1.835685847023438" LOG_EFFECT_SIZE="-0.4628808156050522" ORDER="1358" O_E="0.0" SE="1.6127849418993234" STUDY_ID="STD-Rasmussen-1986" TOTAL_1="29" TOTAL_2="30" VAR="2.6010752688172043" WEIGHT="2.8819601542601396"/>
<DICH_DATA CI_END="2.852579431346386" CI_START="0.031230433807530537" EFFECT_SIZE="0.2984749455337691" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4552377463821487" LOG_CI_START="-1.5054219831438576" LOG_EFFECT_SIZE="-0.5250921183808545" ORDER="1353" O_E="0.0" SE="1.1517012305457643" STUDY_ID="STD-Rubinstein-1995" TOTAL_1="306" TOTAL_2="274" VAR="1.3264157244406278" WEIGHT="5.651467443303974"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1348" O_E="0.0" SE="0.0" STUDY_ID="STD-Sexton-1998" TOTAL_1="26" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.012129623805599" CI_START="0.5284609500769639" EFFECT_SIZE="2.0576923076923075" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.9037479668881525" LOG_CI_START="-0.2769870987873316" LOG_EFFECT_SIZE="0.31338043405041044" ORDER="1346" O_E="0.0" SE="0.693569622310617" STUDY_ID="STD-Sieger-1997" TOTAL_1="104" TOTAL_2="107" VAR="0.481038820992092" WEIGHT="15.583347862658048"/>
<DICH_DATA CI_END="1.382916648565291" CI_START="0.06277631653026368" EFFECT_SIZE="0.29464285714285715" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.14079600501239828" LOG_CI_START="-1.2022041705969866" LOG_EFFECT_SIZE="-0.5307040827922941" ORDER="1359" O_E="0.0" SE="0.7888849511110388" STUDY_ID="STD-Smith-1984" TOTAL_1="96" TOTAL_2="99" VAR="0.6223394660894661" WEIGHT="12.045187058545034"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1355" O_E="0.0" SE="0.0" STUDY_ID="STD-Speich-1998" TOTAL_1="44" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.194125111840123" CI_START="0.20612588721809247" EFFECT_SIZE="1.217741935483871" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8569779862916825" LOG_CI_START="-0.6858674620298139" LOG_EFFECT_SIZE="0.08555526213093438" ORDER="1349" O_E="0.0" SE="0.9062750535521875" STUDY_ID="STD-Stille-1992" TOTAL_1="186" TOTAL_2="151" VAR="0.8213344726910203" WEIGHT="9.12684847916115"/>
<DICH_DATA CI_END="7.664308673807271" CI_START="0.013360630992062122" EFFECT_SIZE="0.32" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.884472987280259" LOG_CI_START="-1.8741730306404472" LOG_EFFECT_SIZE="-0.494850021680094" ORDER="1344" O_E="0.0" SE="1.6204423264446448" STUDY_ID="STD-Thompson--1990" TOTAL_1="49" TOTAL_2="47" VAR="2.625833333333333" WEIGHT="2.8547871594907006"/>
<DICH_DATA CI_END="5.028634439307753" CI_START="0.008813790339070766" EFFECT_SIZE="0.21052631578947367" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7014500653759611" LOG_CI_START="-2.054837284625694" LOG_EFFECT_SIZE="-0.6766936096248666" ORDER="1350" O_E="0.0" SE="1.6190568332334" STUDY_ID="STD-Yellin-1993" TOTAL_1="56" TOTAL_2="35" VAR="2.621345029239766" WEIGHT="2.8596751665066718"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="28.6092994049071" CI_END="0.38666103199365504" CI_START="0.2338831507252349" CI_STUDY="95" CI_TOTAL="95" DF="36" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3007216327857823" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="228" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="-0.41266959426488176" LOG_CI_START="-0.6310010642559665" LOG_EFFECT_SIZE="-0.5218353292604242" METHOD="MH" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.8047900709564724" P_Q="0.4465481764292841" P_Z="7.319322860383598E-21" Q="2.6630209480866336" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="46" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2709" TOTAL_2="2560" WEIGHT="99.99999999999999" Z="9.369042870941103">
<NAME>Any nephrotoxicity</NAME>
<GROUP_LABEL_1>Monotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours monotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.952927192550341" CI_END="0.5292071737877307" CI_START="0.057790349308513934" DF="3" EFFECT_SIZE="0.1748801516175132" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="18" I2="0.0" ID="CMP-001.14.01" LOG_CI_END="-0.2763742772673994" LOG_CI_START="-1.2381446804721599" LOG_EFFECT_SIZE="-0.7572594788697796" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5822343882981181" P_Z="0.002026000200499922" STUDIES="5" TAU2="0.0" TOTAL_1="448" TOTAL_2="417" WEIGHT="8.339795496653792" Z="3.0863942175612">
<NAME>Once-daily aminoglycoside</NAME>
<DICH_DATA CI_END="1.990570314222907" CI_START="0.0845538190506886" EFFECT_SIZE="0.41025641025641024" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.29897752306036335" LOG_CI_START="-1.0728667718015121" LOG_EFFECT_SIZE="-0.3869446243705744" ORDER="1361" O_E="0.0" SE="0.8058281295406449" STUDY_ID="STD-Jaspers-1998" TOTAL_1="39" TOTAL_2="40" VAR="0.6493589743589743" WEIGHT="2.0607473904499662"/>
<DICH_DATA CI_END="0.8062504567208701" CI_START="0.0027568393630107895" EFFECT_SIZE="0.04714555117435282" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="9" LOG_CI_END="-0.09353002633956264" LOG_CI_START="-2.5595885388599426" LOG_EFFECT_SIZE="-1.3265592825997528" ORDER="1364" O_E="0.0" SE="1.4485749774409833" STUDY_ID="STD-Rubinstein-1995" TOTAL_1="306" TOTAL_2="274" VAR="2.0983694652681453" WEIGHT="4.183658572345923"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1360" O_E="0.0" SE="0.0" STUDY_ID="STD-Sandberg-1997" TOTAL_1="33" TOTAL_2="33" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.8230354467494423" CI_START="0.009702213656709344" EFFECT_SIZE="0.1925925925925926" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5824083247666914" LOG_CI_START="-2.0131291658150676" LOG_EFFECT_SIZE="-0.7153604205241881" ORDER="1363" O_E="0.0" SE="1.5246315700855155" STUDY_ID="STD-Sexton-1998" TOTAL_1="26" TOTAL_2="25" VAR="2.3245014245014244" WEIGHT="1.0632738712699028"/>
<DICH_DATA CI_END="4.141121877590242" CI_START="0.010093286819300256" EFFECT_SIZE="0.20444444444444446" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6171180124357271" LOG_CI_START="-1.995967385295304" LOG_EFFECT_SIZE="-0.6894246864297884" ORDER="1362" O_E="0.0" SE="1.534939297608539" STUDY_ID="STD-Speich-1998" TOTAL_1="44" TOTAL_2="45" VAR="2.356038647342995" WEIGHT="1.0321156625880008"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.1672286360352646" CI_END="0.7687116375914448" CI_START="0.2361016606642751" DF="5" EFFECT_SIZE="0.42602123680316045" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="34" I2="0.0" ID="CMP-001.14.02" LOG_CI_END="-0.11423654405953529" LOG_CI_START="-0.6269009582207454" LOG_EFFECT_SIZE="-0.3705687511401404" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6742219876804794" P_Z="0.00460502457973993" STUDIES="7" TAU2="0.0" TOTAL_1="562" TOTAL_2="565" WEIGHT="14.668167716972356" Z="2.8334379604599267">
<NAME>Twice-daily aminoglycoside</NAME>
<DICH_DATA CI_END="4.208982487380191" CI_START="0.010054298746507522" EFFECT_SIZE="0.2057142857142857" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6241771187511183" LOG_CI_START="-1.9976482145891328" LOG_EFFECT_SIZE="-0.6867355479190071" ORDER="1368" O_E="0.0" SE="1.5400731790487738" STUDY_ID="STD-Alvarez_x002d_Lerma-2001a" TOTAL_1="69" TOTAL_2="71" VAR="2.371825396825397" WEIGHT="1.0288852536284139"/>
<DICH_DATA CI_END="1.2984097733913758" CI_START="0.2420256243870941" EFFECT_SIZE="0.5605786618444847" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.11341177585234768" LOG_CI_START="-0.6161386507931988" LOG_EFFECT_SIZE="-0.25136343747042555" ORDER="1365" O_E="0.0" SE="0.4285415319444488" STUDY_ID="STD-Cometta-1994" TOTAL_1="158" TOTAL_2="155" VAR="0.183647844601295" WEIGHT="5.900081674225455"/>
<DICH_DATA CI_END="5.068588898914366" CI_START="0.21546808548768276" EFFECT_SIZE="1.045045045045045" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7048870680682959" LOG_CI_START="-0.6666170471877737" LOG_EFFECT_SIZE="0.019135010440261037" ORDER="1371" O_E="0.0" SE="0.8056283063562782" STUDY_ID="STD-Dupont-2000" TOTAL_1="111" TOTAL_2="116" VAR="0.6490369680024852" WEIGHT="1.224716629403982"/>
<DICH_DATA CI_END="2.676976013183765" CI_START="0.007623588394067975" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.42764447974554265" LOG_CI_START="-2.1178405597740566" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="1366" O_E="0.0" SE="1.495230512567974" STUDY_ID="STD-Gomez-1990a" TOTAL_1="39" TOTAL_2="39" VAR="2.2357142857142858" WEIGHT="1.4610170601523478"/>
<DICH_DATA CI_END="1.0971293303495158" CI_START="0.05351512909856754" EFFECT_SIZE="0.2423076923076923" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.04025782552045248" LOG_CI_START="-1.271523422554925" LOG_EFFECT_SIZE="-0.6156327985172363" ORDER="1369" O_E="0.0" SE="0.7705467985413792" STUDY_ID="STD-McCormick-1997" TOTAL_1="65" TOTAL_2="63" VAR="0.5937423687423689" WEIGHT="3.3916467467822358"/>
<DICH_DATA CI_END="2.2206730679800337" CI_START="0.02868326096405346" EFFECT_SIZE="0.2523809523809524" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.34648462553480447" LOG_CI_START="-1.542371475801065" LOG_EFFECT_SIZE="-0.5979434251331303" ORDER="1367" O_E="0.0" SE="1.109523423913186" STUDY_ID="STD-Mouton-1990" TOTAL_1="105" TOTAL_2="106" VAR="1.2310422282120395" WEIGHT="1.6618203527799216"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1370" O_E="0.0" SE="0.0" STUDY_ID="STD-Naime-Libien-1992" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.5450115990918" CI_END="0.3867134971035584" CI_START="0.19640001380003352" DF="19" EFFECT_SIZE="0.2755912483512459" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="133" I2="0.0" ID="CMP-001.14.03" LOG_CI_END="-0.41261066988374123" LOG_CI_START="-0.7068584860333961" LOG_EFFECT_SIZE="-0.5597345779585686" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9041425819913129" P_Z="8.871287374103347E-14" STUDIES="24" TAU2="0.0" TOTAL_1="1121" TOTAL_2="1017" WEIGHT="58.02906462053903" Z="7.456705222529545">
<NAME>Thrice-daily aminoglycoside</NAME>
<DICH_DATA CI_END="2.3188622704311976" CI_START="0.006887124624202542" EFFECT_SIZE="0.12637362637362637" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.36527495434386836" LOG_CI_START="-2.1619620582788324" LOG_EFFECT_SIZE="-0.898343551967482" ORDER="1381" O_E="0.0" SE="1.484511531239546" STUDY_ID="STD-Arich-1987" TOTAL_1="25" TOTAL_2="22" VAR="2.203774486383182" WEIGHT="1.550467084243308"/>
<DICH_DATA CI_END="2.3600964430835227" CI_START="0.028479922381409672" EFFECT_SIZE="0.25925925925925924" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.37292975036128917" LOG_CI_START="-1.5454611986507503" LOG_EFFECT_SIZE="-0.5862657241447305" ORDER="1388" O_E="0.0" SE="1.126872339638022" STUDY_ID="STD-Bergeron-1988" TOTAL_1="36" TOTAL_2="28" VAR="1.2698412698412698" WEIGHT="1.408837879432621"/>
<DICH_DATA CI_END="7.02081776524327" CI_START="0.013079297544116708" EFFECT_SIZE="0.30303030303030304" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8463877004842707" LOG_CI_START="-1.8834155802400456" LOG_EFFECT_SIZE="-0.5185139398778875" ORDER="1390" O_E="0.0" SE="1.6034999598416337" STUDY_ID="STD-Cone-1985" TOTAL_1="21" TOTAL_2="19" VAR="2.5712121212121213" WEIGHT="0.6559668433337071"/>
<DICH_DATA CI_END="2.994016851312268" CI_START="0.009548632027969623" EFFECT_SIZE="0.16908212560386474" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.47625424036619707" LOG_CI_START="-2.0200588425794814" LOG_EFFECT_SIZE="-0.7719023011066422" ORDER="1373" O_E="0.0" SE="1.4663466618713423" STUDY_ID="STD-Coppens-1983" TOTAL_1="22" TOTAL_2="34" VAR="2.1501725327812284" WEIGHT="1.4898055736528868"/>
<DICH_DATA CI_END="0.7547183429948776" CI_START="0.012699864608560358" EFFECT_SIZE="0.0979020979020979" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="10" LOG_CI_END="-0.1222150946029461" LOG_CI_START="-1.8962009089707015" LOG_EFFECT_SIZE="-1.0092080017868237" ORDER="1377" O_E="0.0" SE="1.0420480487310246" STUDY_ID="STD-D_x0027_Antonio-1992" TOTAL_1="143" TOTAL_2="140" VAR="1.0858641358641359" WEIGHT="4.2185853528881525"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-26 07:23:39 +0000" MODIFIED_BY="[Empty name]" ORDER="2090" O_E="0.0" SE="0.0" STUDY_ID="STD-Figueroa_x002d_Damian-1996" TOTAL_1="14" TOTAL_2="42" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.8858476959129982" CI_START="0.003306121059743696" EFFECT_SIZE="0.05411764705882353" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="-0.052640940088548714" LOG_CI_START="-2.4806812479768885" LOG_EFFECT_SIZE="-1.2666610940327188" ORDER="1383" O_E="0.0" SE="1.4262428958469746" STUDY_ID="STD-Gerecht-1989" TOTAL_1="24" TOTAL_2="22" VAR="2.034168797953964" WEIGHT="3.6960253009806414"/>
<DICH_DATA CI_END="1.9555598690228826" CI_START="0.026530875822946026" EFFECT_SIZE="0.22777777777777777" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.29127111631896857" LOG_CI_START="-1.5762484130861099" LOG_EFFECT_SIZE="-0.6424886483835706" ORDER="1372" O_E="0.0" SE="1.096990215943305" STUDY_ID="STD-Hoepelman-1988" TOTAL_1="45" TOTAL_2="41" VAR="1.2033875338753388" WEIGHT="1.747395819451313"/>
<DICH_DATA CI_END="1.0516882325536607" CI_START="0.2018256423254164" EFFECT_SIZE="0.4607142857142857" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="16" LOG_CI_END="0.02188701458127291" LOG_CI_START="-0.6950236566672134" LOG_EFFECT_SIZE="-0.3365683210429703" ORDER="1389" O_E="0.0" SE="0.4211168770564173" STUDY_ID="STD-Korzeniowski-1982" TOTAL_1="35" TOTAL_2="43" VAR="0.1773394241417497" WEIGHT="5.993916144214761"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1385" O_E="0.0" SE="0.0" STUDY_ID="STD-Landau-1990" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.2684210344329139" CI_START="0.00434216508183644" EFFECT_SIZE="0.07421383647798742" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.10326343539100134" LOG_CI_START="-2.3622936694196537" LOG_EFFECT_SIZE="-1.129515117014326" ORDER="1378" O_E="0.0" SE="1.4482804480702824" STUDY_ID="STD-Mandell-1987" TOTAL_1="52" TOTAL_2="58" VAR="2.0975162562626584" WEIGHT="2.9630320480130523"/>
<DICH_DATA CI_END="2.1831168673058925" CI_START="0.006153356921746856" EFFECT_SIZE="0.11590296495956873" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.33907698512165774" LOG_CI_START="-2.210887893192576" LOG_EFFECT_SIZE="-0.9359054540354593" ORDER="1376" O_E="0.0" SE="1.4978619920515024" STUDY_ID="STD-Martin-1991" TOTAL_1="52" TOTAL_2="42" VAR="2.243590547232495" WEIGHT="1.6132063372515508"/>
<DICH_DATA CI_END="2.4058101411544586" CI_START="0.021235418139744923" EFFECT_SIZE="0.22602739726027396" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.3812613512239414" LOG_CI_START="-1.6729391830370408" LOG_EFFECT_SIZE="-0.6458389159065496" ORDER="1394" O_E="0.0" SE="1.2066475622815402" STUDY_ID="STD-Muller-1987" TOTAL_1="73" TOTAL_2="33" VAR="1.4559983395599834" WEIGHT="1.1499110015215244"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1386" O_E="0.0" SE="0.0" STUDY_ID="STD-Rasmussen-1986" TOTAL_1="29" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.2076625197390016" CI_START="0.1463550203828213" EFFECT_SIZE="0.5684210526315789" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.34393268453853787" LOG_CI_START="-0.8345923754702964" LOG_EFFECT_SIZE="-0.24532984546587927" ORDER="1384" O_E="0.0" SE="0.6922714540423225" STUDY_ID="STD-Ribera-1996" TOTAL_1="38" TOTAL_2="36" VAR="0.47923976608187135" WEIGHT="2.1435771538914756"/>
<DICH_DATA CI_END="2.9393068058151286" CI_START="0.09677262811820089" EFFECT_SIZE="0.5333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.4682449202401029" LOG_CI_START="-1.0142474643675783" LOG_EFFECT_SIZE="-0.27300127206373764" ORDER="1375" O_E="0.0" SE="0.8708233651742088" STUDY_ID="STD-Sage-1987" TOTAL_1="30" TOTAL_2="24" VAR="0.7583333333333333" WEIGHT="1.3914448191927122"/>
<DICH_DATA CI_END="7.3225436971144395" CI_START="0.015173840636129785" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8646619720038995" LOG_CI_START="-1.8189044814432243" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="1380" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Sculier-1982" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="0.6261501686367205"/>
<DICH_DATA CI_END="3.443121843215392" CI_START="0.008894544368316791" EFFECT_SIZE="0.175" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5369523915399373" LOG_CI_START="-2.0508762941673484" LOG_EFFECT_SIZE="-0.7569619513137056" ORDER="1387" O_E="0.0" SE="1.5201033799430503" STUDY_ID="STD-Sieger-1997" TOTAL_1="23" TOTAL_2="20" VAR="2.310714285714286" WEIGHT="1.1131558553541696"/>
<DICH_DATA CI_END="0.41533652243946584" CI_START="0.09215310013225975" EFFECT_SIZE="0.19563882063882063" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="37" LOG_CI_END="-0.3815998777114116" LOG_CI_START="-1.0354900500522146" LOG_EFFECT_SIZE="-0.7085449638818132" ORDER="1391" O_E="0.0" SE="0.3840983240415435" STUDY_ID="STD-Smith-1984" TOTAL_1="88" TOTAL_2="91" VAR="0.14753152253152255" WEIGHT="15.186182116060797"/>
<DICH_DATA CI_END="0.8773908213481598" CI_START="0.18779106633935538" EFFECT_SIZE="0.40591397849462363" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="18" LOG_CI_END="-0.05680691319377717" LOG_CI_START="-0.726325071983679" LOG_EFFECT_SIZE="-0.3915659925887281" ORDER="1374" O_E="0.0" SE="0.3932782806415246" STUDY_ID="STD-Stille-1992" TOTAL_1="186" TOTAL_2="151" VAR="0.15466780602435376" WEIGHT="8.294167218974245"/>
<DICH_DATA CI_END="3.0438269085566985" CI_START="0.1700223954049172" EFFECT_SIZE="0.7193877551020408" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4834199520420146" LOG_CI_START="-0.769493869444207" LOG_EFFECT_SIZE="-0.14303695870109617" ORDER="1379" O_E="0.0" SE="0.7359677807644478" STUDY_ID="STD-Thompson--1990" TOTAL_1="49" TOTAL_2="47" VAR="0.5416485743233462" WEIGHT="1.7045199035110723"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1382" O_E="0.0" SE="0.0" STUDY_ID="STD-Thompson-1993" TOTAL_1="80" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.690017380199802" CI_START="0.012930488128094391" EFFECT_SIZE="0.29411764705882354" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8254272460361436" LOG_CI_START="-1.8883850801206539" LOG_EFFECT_SIZE="-0.5314789170422551" ORDER="1392" O_E="0.0" SE="1.5941067939721714" STUDY_ID="STD-Vergnon-1985" TOTAL_1="16" TOTAL_2="14" VAR="2.541176470588235" WEIGHT="0.6652845541765156"/>
<DICH_DATA CI_END="13.867772482168174" CI_START="0.07210963413813187" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1420067079086855" LOG_CI_START="-1.1420067079086855" LOG_EFFECT_SIZE="0.0" ORDER="1393" O_E="0.0" SE="1.3416407864998738" STUDY_ID="STD-Wiecek-1986" TOTAL_1="10" TOTAL_2="10" VAR="1.7999999999999998" WEIGHT="0.41743344575781366"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.605230092753189" CI_END="0.5829208408634602" CI_START="0.193726855832125" DF="6" EFFECT_SIZE="0.3360467552283412" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="43" I2="37.53403154259895" ID="CMP-001.14.04" LOG_CI_END="-0.234390417299876" LOG_CI_START="-0.7128101700334304" LOG_EFFECT_SIZE="-0.4736002936666531" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.14229166973587537" P_Z="1.0426776216497682E-4" STUDIES="10" TAU2="0.0" TOTAL_1="578" TOTAL_2="561" WEIGHT="18.96297216583481" Z="3.880439774279958">
<NAME>Non-specified aminoglycoside regimen</NAME>
<DICH_DATA CI_END="0.9768154688994591" CI_START="0.003560524098123729" EFFECT_SIZE="0.05897435897435897" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="-0.010187471499207736" LOG_CI_START="-2.448486070518605" LOG_EFFECT_SIZE="-1.2293367710089063" ORDER="1402" O_E="0.0" SE="1.432268666836718" STUDY_ID="STD-Carbon-1987" TOTAL_1="25" TOTAL_2="22" VAR="2.0513935340022296" WEIGHT="3.32242946623566"/>
<DICH_DATA CI_END="2.2426050933818775" CI_START="0.3101381342896954" EFFECT_SIZE="0.833976833976834" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.35075280418274624" LOG_CI_START="-0.5084448300433881" LOG_EFFECT_SIZE="-0.07884601293032092" ORDER="1396" O_E="0.0" SE="0.5046969434413138" STUDY_ID="STD-Felisart-1985" TOTAL_1="37" TOTAL_2="36" VAR="0.2547190047190047" WEIGHT="2.962061984966404"/>
<DICH_DATA CI_END="0.5991545807947252" CI_START="0.002124764527897619" EFFECT_SIZE="0.03568" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="12" LOG_CI_END="-0.2224611159658793" LOG_CI_START="-2.67268919262595" LOG_EFFECT_SIZE="-1.4475751542959145" ORDER="1404" O_E="0.0" SE="1.439276101054716" STUDY_ID="STD-Finer-1992" TOTAL_1="249" TOTAL_2="222" VAR="2.071515695067265" WEIGHT="5.515769632106418"/>
<DICH_DATA CI_END="3.2434255287479843" CI_START="0.2098475805802554" EFFECT_SIZE="0.825" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5110039306845867" LOG_CI_START="-0.6780960335847365" LOG_EFFECT_SIZE="-0.08354605145007493" ORDER="1399" O_E="0.0" SE="0.6984832051515539" STUDY_ID="STD-Mergoni-1987" TOTAL_1="20" TOTAL_2="22" VAR="0.48787878787878775" WEIGHT="1.5902226505059567"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1403" O_E="0.0" SE="0.0" STUDY_ID="STD-Rapp-1984" TOTAL_1="17" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1400" O_E="0.0" SE="0.0" STUDY_ID="STD-Sukoh-1994" TOTAL_1="30" TOTAL_2="33" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.8865399477882656" CI_START="0.007936842988585205" EFFECT_SIZE="0.15136054421768708" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4603775722223018" LOG_CI_START="-2.1003522110847532" LOG_EFFECT_SIZE="-0.8199873194312257" ORDER="1395" O_E="0.0" SE="1.5041853505314244" STUDY_ID="STD-Takamoto-1994" TOTAL_1="83" TOTAL_2="88" VAR="2.262573568753344" WEIGHT="1.4187911335583492"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1401" O_E="0.0" SE="0.0" STUDY_ID="STD-Trujillo-1992" TOTAL_1="16" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.4442151962890595" CI_START="0.01304246918175915" EFFECT_SIZE="0.3115942028985507" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8718189191618472" LOG_CI_START="-1.8846401808051472" LOG_EFFECT_SIZE="-0.5064106308216499" ORDER="1397" O_E="0.0" SE="1.619157720013216" STUDY_ID="STD-Verzasconi-1995" TOTAL_1="45" TOTAL_2="42" VAR="2.6216717222783954" WEIGHT="0.6472563540963853"/>
<DICH_DATA CI_END="1.5596519084190728" CI_START="0.16542120373273106" EFFECT_SIZE="0.5079365079365079" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.1930276809688949" LOG_CI_START="-0.7814088232362463" LOG_EFFECT_SIZE="-0.29419057113367575" ORDER="1398" O_E="0.0" SE="0.5723888261085888" STUDY_ID="STD-Warren-1983" TOTAL_1="56" TOTAL_2="64" VAR="0.32762896825396826" WEIGHT="3.506440944365635"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Monotherapy versus combination therapy (subgroup analyses)</NAME>
<DICH_OUTCOME CHI2="1.1727228383878072" CI_END="1.8226075690031154" CI_START="0.766843278831717" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1822243290669727" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.260693169498028" LOG_CI_START="-0.11529338454280946" LOG_EFFECT_SIZE="0.07269989247760926" METHOD="MH" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9782105863418536" P_Q="0.43869307254772205" P_Z="0.44848198380839" Q="0.5996989628803224" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="220" TOTAL_2="210" WEIGHT="200.0" Z="0.7579482266303185">
<NAME>All-cause mortality (Gram-negative infection)</NAME>
<GROUP_LABEL_1>Monotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours monotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.21500362600540032" CI_END="4.070637621404868" CI_START="0.07708520110311938" DF="1" EFFECT_SIZE="0.5601659751037344" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.6096624420922072" LOG_CI_START="-1.1130289902519315" LOG_EFFECT_SIZE="-0.25168327407986224" MODIFIED="2011-12-11 14:38:14 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6428735788774751" P_Z="0.566849836387763" STUDIES="3" TAU2="0.0" TOTAL_1="57" TOTAL_2="60" WEIGHT="100.0" Z="0.5726970523518686">
<NAME>Same BL</NAME>
<DICH_DATA CI_END="13.251516091767591" CI_START="0.0584385963566154" EFFECT_SIZE="0.88" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1222655682820444" LOG_CI_START="-1.2333002239817072" LOG_EFFECT_SIZE="-0.05551732784983137" ORDER="1029" O_E="0.0" SE="1.3836710066144533" STUDY_ID="STD-Carbon-1987" TOTAL_1="25" TOTAL_2="22" VAR="1.9145454545454546" WEIGHT="41.49377593360996"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1030" O_E="0.0" SE="0.0" STUDY_ID="STD-Sandberg-1997" TOTAL_1="22" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.3225436971144395" CI_START="0.015173840636129785" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8646619720038995" LOG_CI_START="-1.8189044814432243" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="1028" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Sculier-1982" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="58.50622406639005"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.514491956425209" CI_END="1.9489248301361195" CI_START="0.8022755351521736" DF="4" EFFECT_SIZE="1.250429810532688" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="22" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.28979508873965604" LOG_CI_START="-0.09567645111099152" LOG_EFFECT_SIZE="0.09705931881433223" MODIFIED="2011-12-11 14:38:14 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9720749495830497" P_Z="0.3236361290942398" STUDIES="5" TAU2="0.0" TOTAL_1="163" TOTAL_2="150" WEIGHT="99.99999999999999" Z="0.987013304867013">
<NAME>Different BL</NAME>
<DICH_DATA CI_END="3.6745949117762566" CI_START="0.5395054550493839" EFFECT_SIZE="1.408" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.5652094693312208" LOG_CI_START="-0.2680041597190341" LOG_EFFECT_SIZE="0.1486026548060934" ORDER="1032" O_E="0.0" SE="0.48943381017810217" STUDY_ID="STD-Arich-1987" TOTAL_1="25" TOTAL_2="22" VAR="0.23954545454545456" WEIGHT="22.74788970641841"/>
<DICH_DATA CI_END="1.9171115225660975" CI_START="0.61566991069799" EFFECT_SIZE="1.0864197530864197" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.2826473774718505" LOG_CI_START="-0.2106520709288128" LOG_EFFECT_SIZE="0.035997653271518854" ORDER="1035" O_E="0.0" SE="0.2897665378622012" STUDY_ID="STD-Brown-1984" TOTAL_1="18" TOTAL_2="16" VAR="0.08396464646464646" WEIGHT="40.75351346462818"/>
<DICH_DATA CI_END="3.6075179132023756" CI_START="0.39916641708972667" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.557208496268825" LOG_CI_START="-0.39884600417357535" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="1033" O_E="0.0" SE="0.5615911461059686" STUDY_ID="STD-Gomez-1990a" TOTAL_1="39" TOTAL_2="39" VAR="0.3153846153846154" WEIGHT="21.383016324033303"/>
<DICH_DATA CI_END="5.208499115067838" CI_START="0.34132246900739327" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7167125947102104" LOG_CI_START="-0.46683512149361067" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="1031" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-Landau-1990" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="12.829809794419983"/>
<DICH_DATA CI_END="62.81596587827642" CI_START="0.10868675140106104" EFFECT_SIZE="2.6129032258064515" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.798070042010585" LOG_CI_START="-0.9638233919218309" LOG_EFFECT_SIZE="0.41712332504437705" ORDER="1034" O_E="0.0" SE="1.6223498746848917" STUDY_ID="STD-Stille-1992" TOTAL_1="61" TOTAL_2="53" VAR="2.6320191158900834" WEIGHT="2.2857707105001115"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4281374218712704" CI_END="2.640055132699705" CI_START="0.6970709550460426" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3565786938932771" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.42161299640666483" LOG_CI_START="-0.15672301269603225" LOG_EFFECT_SIZE="0.13244499185531627" METHOD="MH" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9343705682302169" P_Q="0.8202331257468407" P_Z="0.3693431288810254" Q="0.05164035636818642" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="103" TOTAL_2="107" WEIGHT="200.0" Z="0.8977044828036116">
<NAME>All-cause mortality (Gram-negative bacteraemia)</NAME>
<GROUP_LABEL_1>Monotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours monotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.33396706524072034" CI_END="8.746194823426617" CI_START="0.29911188827597385" DF="1" EFFECT_SIZE="1.6174334140435838" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.9418191471223479" LOG_CI_START="-0.5241663254840586" LOG_EFFECT_SIZE="0.20882641081914471" MODIFIED="2011-12-11 14:38:14 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5633325809135827" P_Z="0.576581427332457" STUDIES="3" TAU2="0.0" TOTAL_1="39" TOTAL_2="46" WEIGHT="100.0" Z="0.5583851298316072">
<NAME>Same BL</NAME>
<DICH_DATA CI_END="13.251516091767591" CI_START="0.0584385963566154" EFFECT_SIZE="0.88" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1222655682820444" LOG_CI_START="-1.2333002239817072" LOG_EFFECT_SIZE="-0.05551732784983137" ORDER="1036" O_E="0.0" SE="1.3836710066144533" STUDY_ID="STD-Carbon-1987" TOTAL_1="25" TOTAL_2="22" VAR="1.9145454545454546" WEIGHT="54.479418886198545"/>
<DICH_DATA CI_END="24.375123737009112" CI_START="0.2564089547783724" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3869468290131945" LOG_CI_START="-0.5910668116691193" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="1038" O_E="0.0" SE="1.161895003862225" STUDY_ID="STD-Piccart-1984" TOTAL_1="12" TOTAL_2="15" VAR="1.35" WEIGHT="45.52058111380145"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1037" O_E="0.0" SE="0.0" STUDY_ID="STD-Sandberg-1997" TOTAL_1="2" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.046248629717739395" CI_END="2.6968835158381994" CI_START="0.6336257959827707" DF="1" EFFECT_SIZE="1.307216494845361" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="10" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="0.43086218875129884" LOG_CI_START="-0.19816715019236053" LOG_EFFECT_SIZE="0.11634751927946911" MODIFIED="2011-12-11 14:38:14 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8297246388178788" P_Z="0.4684250948441451" STUDIES="2" TAU2="0.0" TOTAL_1="64" TOTAL_2="61" WEIGHT="100.0" Z="0.7250439156344782">
<NAME>Different BL</NAME>
<DICH_DATA CI_END="3.6745949117762566" CI_START="0.5395054550493839" EFFECT_SIZE="1.408" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.5652094693312208" LOG_CI_START="-0.2680041597190341" LOG_EFFECT_SIZE="0.1486026548060934" ORDER="1039" O_E="0.0" SE="0.48943381017810217" STUDY_ID="STD-Arich-1987" TOTAL_1="25" TOTAL_2="22" VAR="0.23954545454545456" WEIGHT="51.54639175257732"/>
<DICH_DATA CI_END="3.6075179132023756" CI_START="0.39916641708972667" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.557208496268825" LOG_CI_START="-0.39884600417357535" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="1040" O_E="0.0" SE="0.5615911461059686" STUDY_ID="STD-Gomez-1990a" TOTAL_1="39" TOTAL_2="39" VAR="0.3153846153846154" WEIGHT="48.453608247422686"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.365888205526819" CI_END="0.9423273971194268" CI_START="0.5649016727320146" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7296042234622615" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="109" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-0.025798182069969467" LOG_CI_START="-0.24802713927109335" LOG_EFFECT_SIZE="-0.13691266067053143" METHOD="MH" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6714017864018555" P_Q="0.6271685600502064" P_Z="0.015734269566165682" Q="0.23592003613794477" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="977" TOTAL_2="882" WEIGHT="200.0" Z="2.4150217624333794">
<NAME>All-cause mortality (non&#8211;urinary tract infection)</NAME>
<GROUP_LABEL_1>Monotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours monotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.1557624404413704" CI_END="1.3139604083996974" CI_START="0.49634247982954915" DF="2" EFFECT_SIZE="0.8075731344608691" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="30" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.11858227947598017" LOG_CI_START="-0.30421855380515933" LOG_EFFECT_SIZE="-0.09281813716458959" MODIFIED="2011-12-26 07:02:51 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5610861104051064" P_Z="0.38948704438365" STUDIES="4" TAU2="0.0" TOTAL_1="201" TOTAL_2="200" WEIGHT="100.0" Z="0.8605480010193229">
<NAME>Same BL</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1042" O_E="0.0" SE="0.0" STUDY_ID="STD-Cardozo-2001" TOTAL_1="56" TOTAL_2="48" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.0276339895692987" CI_START="0.09260930658282401" EFFECT_SIZE="0.43333333333333335" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3069895627637647" LOG_CI_START="-1.033345367589416" LOG_EFFECT_SIZE="-0.36317790241282566" MODIFIED="2011-12-26 07:02:51 +0000" MODIFIED_BY="[Empty name]" ORDER="2077" O_E="0.0" SE="0.7873193728543677" STUDY_ID="STD-Damas-2006" TOTAL_1="24" TOTAL_2="26" VAR="0.6198717948717949" WEIGHT="16.122874772495226"/>
<DICH_DATA CI_END="1.5452478612798557" CI_START="0.5411130099195283" EFFECT_SIZE="0.9144144144144144" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.18899815117342472" LOG_CI_START="-0.26671202424827617" LOG_EFFECT_SIZE="-0.03885693653742572" ORDER="1043" O_E="0.0" SE="0.26768641284445654" STUDY_ID="STD-Dupont-2000" TOTAL_1="111" TOTAL_2="116" VAR="0.07165601562153284" WEIGHT="78.83872686110001"/>
<DICH_DATA CI_END="7.3225436971144395" CI_START="0.015173840636129785" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8646619720038995" LOG_CI_START="-1.8189044814432243" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="1041" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Sculier-1982" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="5.038398366404758"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.200434903851178" CI_END="0.9468252989493171" CI_START="0.5186964116036958" DF="9" EFFECT_SIZE="0.7007958939524456" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="79" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="-0.023730146341500027" LOG_CI_START="-0.285086756490904" LOG_EFFECT_SIZE="-0.154408451416202" MODIFIED="2011-12-11 14:38:14 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5140805478173688" P_Z="0.02056493423741092" STUDIES="13" TAU2="0.0" TOTAL_1="776" TOTAL_2="682" WEIGHT="100.0" Z="2.3158779378976337">
<NAME>Different BL</NAME>
<DICH_DATA CI_END="1.4524039103370738" CI_START="0.4665638439939939" EFFECT_SIZE="0.8231884057971014" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" LOG_CI_END="0.16208740950244066" LOG_CI_START="-0.33108891955491365" LOG_EFFECT_SIZE="-0.08450075502623647" ORDER="1047" O_E="0.0" SE="0.2896942169504909" STUDY_ID="STD-Alvarez_x002d_Lerma-2001a" TOTAL_1="69" TOTAL_2="71" VAR="0.08392273933455809" WEIGHT="24.4668971999811"/>
<DICH_DATA CI_END="6.44336151838637" CI_START="0.011476281328463182" EFFECT_SIZE="0.2719298245614035" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8091124990377422" LOG_CI_START="-1.9401988140421422" LOG_EFFECT_SIZE="-0.5655431575021999" ORDER="1051" O_E="0.0" SE="1.6149590746136118" STUDY_ID="STD-Bergeron-1988" TOTAL_1="37" TOTAL_2="30" VAR="2.6080928126768534" WEIGHT="2.0504709058585293"/>
<DICH_DATA CI_END="1.9171115225660975" CI_START="0.61566991069799" EFFECT_SIZE="1.0864197530864197" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.2826473774718505" LOG_CI_START="-0.2106520709288128" LOG_EFFECT_SIZE="0.035997653271518854" ORDER="1048" O_E="0.0" SE="0.2897665378622012" STUDY_ID="STD-Brown-1984" TOTAL_1="18" TOTAL_2="16" VAR="0.08396464646464646" WEIGHT="11.826709899735109"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1046" O_E="0.0" SE="0.0" STUDY_ID="STD-Havig-1973" TOTAL_1="24" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="12.12734418453573" CI_START="0.4875119785752522" EFFECT_SIZE="2.4315068493150687" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0837657033986128" LOG_CI_START="-0.3120147088572987" LOG_EFFECT_SIZE="0.385875497270657" ORDER="1056" O_E="0.0" SE="0.8198883233835935" STUDY_ID="STD-Koehler-1990" TOTAL_1="73" TOTAL_2="71" VAR="0.6722168628207601" WEIGHT="2.5166232828482973"/>
<DICH_DATA CI_END="2.4141748889384615" CI_START="0.15597444431311783" EFFECT_SIZE="0.6136363636363636" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.38276872829228675" LOG_CI_START="-0.806946552946687" LOG_EFFECT_SIZE="-0.21208891232720012" ORDER="1054" O_E="0.0" SE="0.6988446453853949" STUDY_ID="STD-Mouton-1990" TOTAL_1="44" TOTAL_2="45" VAR="0.4883838383838384" WEIGHT="6.135649191983536"/>
<DICH_DATA CI_END="1.0856025424423192" CI_START="0.3115021565079405" EFFECT_SIZE="0.5815217391304348" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="23" LOG_CI_END="0.035670851755012306" LOG_CI_START="-0.5065389424036659" LOG_EFFECT_SIZE="-0.2354340453243268" ORDER="1052" O_E="0.0" SE="0.3184967170705754" STUDY_ID="STD-Sieger-1997" TOTAL_1="104" TOTAL_2="107" VAR="0.10144015878473417" WEIGHT="28.138864394291062"/>
<DICH_DATA CI_END="2.0547857500489064" CI_START="0.1821387243679367" EFFECT_SIZE="0.611764705882353" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.31276654522799235" LOG_CI_START="-0.7395977093869794" LOG_EFFECT_SIZE="-0.21341558207949354" ORDER="1045" O_E="0.0" SE="0.618163972447909" STUDY_ID="STD-Smith-1984" TOTAL_1="34" TOTAL_2="26" VAR="0.38212669683257916" WEIGHT="7.032755475356886"/>
<DICH_DATA CI_END="1.3587073697477343" CI_START="0.02138411310119719" EFFECT_SIZE="0.17045454545454544" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.13312593106030254" LOG_CI_START="-1.6699087572492775" LOG_EFFECT_SIZE="-0.7683914130944874" ORDER="1050" O_E="0.0" SE="1.0591115010786976" STUDY_ID="STD-Speich-1998" TOTAL_1="44" TOTAL_2="45" VAR="1.121717171717172" WEIGHT="7.362779030380243"/>
<DICH_DATA CI_END="1.7442519140738586" CI_START="0.06801883050914526" EFFECT_SIZE="0.34444444444444444" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.24160920822922846" LOG_CI_START="-1.1673708394393327" LOG_EFFECT_SIZE="-0.4628808156050522" ORDER="1053" O_E="0.0" SE="0.8276418545642331" STUDY_ID="STD-Stille-1992" TOTAL_1="144" TOTAL_2="124" VAR="0.6849910394265233" WEIGHT="6.668459976633396"/>
<DICH_DATA CI_END="3.6573286525107553" CI_START="0.1118039247724491" EFFECT_SIZE="0.6394557823129252" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5631639883825202" LOG_CI_START="-0.9515429506794751" LOG_EFFECT_SIZE="-0.19418948114847742" ORDER="1055" O_E="0.0" SE="0.8897463539252893" STUDY_ID="STD-Thompson--1990" TOTAL_1="49" TOTAL_2="47" VAR="0.7916485743233462" WEIGHT="3.8007906429318465"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1044" O_E="0.0" SE="0.0" STUDY_ID="STD-Thompson-1993" TOTAL_1="80" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1049" O_E="0.0" SE="0.0" STUDY_ID="STD-Yellin-1993" TOTAL_1="56" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.017169597409872412" CI_END="1.5820121487772982" CI_START="0.12098911512653905" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.19920981426069936" LOG_CI_START="-0.9172536995440354" LOG_EFFECT_SIZE="-0.3590219426416679" METHOD="MH" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8957493571967419" P_Q="1.0" P_Z="0.20747683625278024" Q="0.0" RANDOM="NO" SCALE="833.81" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="90" TOTAL_2="98" WEIGHT="100.0" Z="1.2605339422858088">
<NAME>All-cause mortality (Gram-positive infection)</NAME>
<GROUP_LABEL_1>Monotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1437" O_E="0.0" SE="0.0" STUDY_ID="STD-Abrams-1979" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.9188136720990658" CI_START="0.08938497437295481" EFFECT_SIZE="0.41414141414141414" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.28303280427792576" LOG_CI_START="-1.0487354800335547" LOG_EFFECT_SIZE="-0.38285133787781445" ORDER="1439" O_E="0.0" SE="0.7822872825638911" STUDY_ID="STD-Korzeniowski-1982" TOTAL_1="33" TOTAL_2="41" VAR="0.6119733924611973" WEIGHT="72.79411764705883"/>
<DICH_DATA CI_END="5.320030029638535" CI_START="0.04699221594750772" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7259140837366838" LOG_CI_START="-1.3279740750646463" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="1438" O_E="0.0" SE="1.2064640713902572" STUDY_ID="STD-Ribera-1996" TOTAL_1="45" TOTAL_2="45" VAR="1.4555555555555557" WEIGHT="27.205882352941174"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="29.41477936627866" CI_END="1.17965511415578" CI_START="0.801098684881814" CI_STUDY="95" CI_TOTAL="95" DF="26" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9721214741812371" ESTIMABLE="YES" EVENTS_1="154" EVENTS_2="168" I2="11.609059934657843" I2_Q="70.95220556158623" ID="CMP-002.05" LOG_CI_END="0.07175505483819963" LOG_CI_START="-0.09631398121948309" LOG_EFFECT_SIZE="-0.012279463190641732" METHOD="MH" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.2925606406475545" P_Q="0.06353565733180644" P_Z="0.7745734187183793" Q="3.4426021642371802" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="28" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="923" TOTAL_2="912" WEIGHT="200.0" Z="0.2863978537353304">
<NAME>Clinical failure (Gram-negative infection)</NAME>
<GROUP_LABEL_1>Monotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours monotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.53610270359904" CI_END="1.6841473015290016" CI_START="0.9046787192074317" DF="9" EFFECT_SIZE="1.2343468814332175" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="55" I2="5.621821830806294" ID="CMP-002.05.01" LOG_CI_END="0.22638007376904612" LOG_CI_START="-0.04350562548907629" LOG_EFFECT_SIZE="0.09143722413998491" NO="1" P_CHI2="0.389327170856137" P_Z="0.18415469945350615" STUDIES="10" TAU2="0.0" TOTAL_1="212" TOTAL_2="220" WEIGHT="100.0" Z="1.328070858539892">
<NAME>Same BL</NAME>
<DICH_DATA CI_END="2.6312143240480275" CI_START="0.1655509382184593" EFFECT_SIZE="0.66" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4201562247335235" LOG_CI_START="-0.781068353649786" LOG_EFFECT_SIZE="-0.1804560644581313" ORDER="283" O_E="0.0" SE="0.7056052634999174" STUDY_ID="STD-Carbon-1987" TOTAL_1="25" TOTAL_2="22" VAR="0.49787878787878775" WEIGHT="8.151623416991328"/>
<DICH_DATA CI_END="2.8586014481972484" CI_START="0.4947072732284088" EFFECT_SIZE="1.1891891891891893" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.45615360939285426" LOG_CI_START="-0.3056517045544694" LOG_EFFECT_SIZE="0.07525095241919245" ORDER="284" O_E="0.0" SE="0.4474882124097798" STUDY_ID="STD-Cometta-1994" TOTAL_1="37" TOTAL_2="44" VAR="0.20024570024570024" WEIGHT="14.000664811997943"/>
<DICH_DATA CI_END="3.721369763776578" CI_START="0.28267535349952144" EFFECT_SIZE="1.0256410256410255" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.5707028246545354" LOG_CI_START="-0.548712056051609" LOG_EFFECT_SIZE="0.010995384301463145" ORDER="285" O_E="0.0" SE="0.6575498421198159" STUDY_ID="STD-D_x0027_Antonio-1992" TOTAL_1="26" TOTAL_2="16" VAR="0.4323717948717949" WEIGHT="7.11520272540243"/>
<DICH_DATA CI_END="7.689843930627566" CI_START="1.0748755208254848" EFFECT_SIZE="2.875" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.8859175256590314" LOG_CI_START="0.0313581723922671" LOG_EFFECT_SIZE="0.4586378490256493" ORDER="286" O_E="0.0" SE="0.5019723942459189" STUDY_ID="STD-Klastersky-1973" TOTAL_1="22" TOTAL_2="23" VAR="0.2519762845849802" WEIGHT="7.4922476561502505"/>
<DICH_DATA CI_END="1.414121690015944" CI_START="0.3607922042599464" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.15048678359696982" LOG_CI_START="-0.4427428549534459" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="287" O_E="0.0" SE="0.3484660262185848" STUDY_ID="STD-Mergoni-1987" TOTAL_1="24" TOTAL_2="30" VAR="0.12142857142857144" WEIGHT="23.838969815023525"/>
<DICH_DATA CI_END="3.557194299009407" CI_START="0.39263928182527985" EFFECT_SIZE="1.1818181818181819" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5511075876156435" LOG_CI_START="-0.40600625331842" LOG_EFFECT_SIZE="0.07255066714861175" ORDER="288" O_E="0.0" SE="0.5622134079545916" STUDY_ID="STD-Piccart-1984" TOTAL_1="22" TOTAL_2="26" VAR="0.31608391608391606" WEIGHT="8.779977722051074"/>
<DICH_DATA CI_END="153.41589019728076" CI_START="0.6140442957244899" EFFECT_SIZE="9.705882352941176" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.1858703444082224" LOG_CI_START="-0.21180029873695772" LOG_EFFECT_SIZE="0.9870350228356323" ORDER="289" O_E="0.0" SE="1.4084036044445776" STUDY_ID="STD-Sage-1987" TOTAL_1="16" TOTAL_2="10" VAR="1.983600713012478" WEIGHT="1.1630619839600125"/>
<DICH_DATA CI_END="2.523907854293063" CI_START="0.22286867527402432" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.40207349514318896" LOG_CI_START="-0.6519509683597887" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="290" O_E="0.0" SE="0.6191391873668903" STUDY_ID="STD-Sculier-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.3833333333333333" WEIGHT="7.662526011971847"/>
<DICH_DATA CI_END="9.662229021563036" CI_START="0.47523575817198604" EFFECT_SIZE="2.142857142857143" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9850773272534075" LOG_CI_START="-0.3230908891705587" LOG_EFFECT_SIZE="0.3309932190414244" ORDER="291" O_E="0.0" SE="0.7684244858645451" STUDY_ID="STD-Sukoh-1994" TOTAL_1="7" TOTAL_2="10" VAR="0.5904761904761905" WEIGHT="3.1551577696354665"/>
<DICH_DATA CI_END="2.2148644112287212" CI_START="0.5932091053892072" EFFECT_SIZE="1.1462450592885376" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.3453471448897647" LOG_CI_START="-0.2267921914434884" LOG_EFFECT_SIZE="0.059277476723138184" ORDER="292" O_E="0.0" SE="0.3360774782975438" STUDY_ID="STD-Takamoto-1994" TOTAL_1="23" TOTAL_2="29" VAR="0.11294807141883605" WEIGHT="18.640568086816128"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="18.61807846268975" CI_END="1.0858680297086978" CI_START="0.6606463510439795" DF="16" EFFECT_SIZE="0.8469797822512453" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="113" I2="14.062022930756923" ID="CMP-002.05.02" LOG_CI_END="0.03577704675194847" LOG_CI_START="-0.1800309594117068" LOG_EFFECT_SIZE="-0.07212695632987913" NO="2" P_CHI2="0.2889648195031791" P_Z="0.19015823965859469" STUDIES="18" TAU2="0.0" TOTAL_1="711" TOTAL_2="692" WEIGHT="100.0" Z="1.3101111421589529">
<NAME>Different BL</NAME>
<DICH_DATA CI_END="1.1559664322985748" CI_START="0.311427728298442" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" LOG_CI_END="0.06294522294336519" LOG_CI_START="-0.5066427221760781" LOG_EFFECT_SIZE="-0.2218487496163564" ORDER="293" O_E="0.0" SE="0.33457877846896167" STUDY_ID="STD-Alvarez_x002d_Lerma-2001a" TOTAL_1="55" TOTAL_2="51" VAR="0.11194295900178251" WEIGHT="16.127793926789327"/>
<DICH_DATA CI_END="1.9601526210417917" CI_START="0.14222565988347913" EFFECT_SIZE="0.528" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.2922898876298273" LOG_CI_START="-0.8470220425622028" LOG_EFFECT_SIZE="-0.27736607746618774" ORDER="294" O_E="0.0" SE="0.6692374674798086" STUDY_ID="STD-Arich-1987" TOTAL_1="25" TOTAL_2="22" VAR="0.4478787878787879" WEIGHT="4.862743646147652"/>
<DICH_DATA CI_END="1.423999570845346" CI_START="0.3356573471587424" EFFECT_SIZE="0.691358024691358" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.1535098584163388" LOG_CI_START="-0.4741038421612374" LOG_EFFECT_SIZE="-0.16029699187244936" ORDER="295" O_E="0.0" SE="0.368663394457191" STUDY_ID="STD-Brown-1984" TOTAL_1="18" TOTAL_2="16" VAR="0.1359126984126984" WEIGHT="8.711748263945465"/>
<DICH_DATA CI_END="3.2695645121039627" CI_START="0.5890277485306519" EFFECT_SIZE="1.3877551020408163" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.5144899108911242" LOG_CI_START="-0.22986424553567888" LOG_EFFECT_SIZE="0.14231283267772266" ORDER="296" O_E="0.0" SE="0.4372373160976031" STUDY_ID="STD-Duff-1982" TOTAL_1="7" TOTAL_2="17" VAR="0.19117647058823528" WEIGHT="3.732966205692681"/>
<DICH_DATA CI_END="3.6075179132023756" CI_START="0.39916641708972667" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.557208496268825" LOG_CI_START="-0.39884600417357535" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="297" O_E="0.0" SE="0.5615911461059686" STUDY_ID="STD-Gomez-1990a" TOTAL_1="39" TOTAL_2="39" VAR="0.3153846153846154" WEIGHT="4.570979027378793"/>
<DICH_DATA CI_END="22.503489331122083" CI_START="0.11734291340979042" EFFECT_SIZE="1.625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.3522498638784313" LOG_CI_START="-0.9305431332486448" LOG_EFFECT_SIZE="0.21085336531489318" ORDER="298" O_E="0.0" SE="1.3409239065200245" STUDY_ID="STD-Holloway--1985" TOTAL_1="8" TOTAL_2="13" VAR="1.7980769230769231" WEIGHT="0.6965301375053399"/>
<DICH_DATA CI_END="19.91371461525375" CI_START="0.20086659256109013" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2991522789342274" LOG_CI_START="-0.6970922876062648" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="299" O_E="0.0" SE="1.1726039399558574" STUDY_ID="STD-Koehler-1990" TOTAL_1="16" TOTAL_2="16" VAR="1.375" WEIGHT="0.9141958054757586"/>
<DICH_DATA CI_END="5.208499115067838" CI_START="0.34132246900739327" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7167125947102104" LOG_CI_START="-0.46683512149361067" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="300" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-Landau-1990" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="2.742587416427276"/>
<DICH_DATA CI_END="3.410572268034031" CI_START="0.1181984080578936" EFFECT_SIZE="0.6349206349206349" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5328272564110385" LOG_CI_START="-0.9273883726622772" LOG_EFFECT_SIZE="-0.19728055812561934" ORDER="301" O_E="0.0" SE="0.8577378887016042" STUDY_ID="STD-Limson-1988" TOTAL_1="21" TOTAL_2="20" VAR="0.7357142857142855" WEIGHT="2.8094797924376973"/>
<DICH_DATA CI_END="60.93381569300773" CI_START="0.11670221256022738" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7848583746209683" LOG_CI_START="-0.9329209100764063" LOG_EFFECT_SIZE="0.4259687322722811" ORDER="302" O_E="0.0" SE="1.596437005055668" STUDY_ID="STD-Moreno-1997" TOTAL_1="17" TOTAL_2="15" VAR="2.548611111111111" WEIGHT="0.48398601466363694"/>
<DICH_DATA CI_END="3.287260222126143" CI_START="0.679225707512685" EFFECT_SIZE="1.4942528735632183" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.5168340845380388" LOG_CI_START="-0.16798588516160237" LOG_EFFECT_SIZE="0.17442409968821823" ORDER="303" O_E="0.0" SE="0.40226664011509106" STUDY_ID="STD-Mouton-1995" TOTAL_1="58" TOTAL_2="65" VAR="0.1618184497494842" WEIGHT="7.759515617208878"/>
<DICH_DATA CI_END="4.377285339896797" CI_START="0.6432863044205839" EFFECT_SIZE="1.6780487804878048" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" LOG_CI_END="0.6412048576717277" LOG_CI_START="-0.19159569464017606" LOG_EFFECT_SIZE="0.2248045815157758" ORDER="304" O_E="0.0" SE="0.4891911668572319" STUDY_ID="STD-Rubinstein-1995" TOTAL_1="205" TOTAL_2="172" VAR="0.2393079977311401" WEIGHT="5.965309499921396"/>
<DICH_DATA CI_END="0.8858243896865517" CI_START="0.15091212454909164" EFFECT_SIZE="0.365625" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="16" LOG_CI_END="-0.05265236631761506" LOG_CI_START="-0.8212758668298736" LOG_EFFECT_SIZE="-0.43696411657374434" ORDER="305" O_E="0.0" SE="0.4514932489485904" STUDY_ID="STD-Sieger-1997" TOTAL_1="80" TOTAL_2="78" VAR="0.20384615384615382" WEIGHT="14.812286468467988"/>
<DICH_DATA CI_END="0.8059793060859012" CI_START="0.08298558115906324" EFFECT_SIZE="0.25862068965517243" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="16" LOG_CI_END="-0.09367610877565026" LOG_CI_START="-1.0809973602388616" LOG_EFFECT_SIZE="-0.587336734507256" ORDER="306" O_E="0.0" SE="0.5799573904285069" STUDY_ID="STD-Smith-1984" TOTAL_1="29" TOTAL_2="40" VAR="0.3363505747126436" WEIGHT="12.295271122920347"/>
<DICH_DATA CI_END="2.533189924858837" CI_START="0.2980055258118481" EFFECT_SIZE="0.8688524590163934" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.40366775205901057" LOG_CI_START="-0.5257756828789665" LOG_EFFECT_SIZE="-0.061053965409978005" ORDER="307" O_E="0.0" SE="0.5459596745017717" STUDY_ID="STD-Stille-1992" TOTAL_1="61" TOTAL_2="53" VAR="0.2980719661820806" WEIGHT="5.870099382528556"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="308" O_E="0.0" SE="0.0" STUDY_ID="STD-Trujillo-1992" TOTAL_1="5" TOTAL_2="1" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.2933242212101583" CI_START="0.6360975128924929" EFFECT_SIZE="1.4473684210526316" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.5176344882433843" LOG_CI_START="-0.19647630248851689" LOG_EFFECT_SIZE="0.16057909287743372" ORDER="309" O_E="0.0" SE="0.4194722133813431" STUDY_ID="STD-Warren-1983" TOTAL_1="38" TOTAL_2="44" VAR="0.17595693779904306" WEIGHT="6.778427435722699"/>
<DICH_DATA CI_END="15.283894463332386" CI_START="0.08077574103880536" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1842340301842182" LOG_CI_START="-1.092719049062868" LOG_EFFECT_SIZE="0.04575749056067514" ORDER="310" O_E="0.0" SE="1.3374935098492586" STUDY_ID="STD-Wiecek-1986" TOTAL_1="9" TOTAL_2="10" VAR="1.7888888888888888" WEIGHT="0.8660802367665081"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.922682542815625" CI_END="1.4860917215388818" CI_START="0.8349990928497042" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1139502858639705" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="55" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.1720456148948803" LOG_CI_START="-0.07831399633745388" LOG_EFFECT_SIZE="0.04686580927871322" METHOD="MH" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.8245750289599263" P_Q="0.5620949478827297" P_Z="0.4630786470945819" Q="0.3360901854185715" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="18" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="222" TOTAL_2="204" WEIGHT="200.0" Z="0.7337868743322111">
<NAME>Clinical failure (<I>Pseudomonas aeruginosa</I> infection)</NAME>
<GROUP_LABEL_1>Monotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours monotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.2108563135586954" CI_END="1.510632164161637" CI_START="0.6836810236986852" DF="5" EFFECT_SIZE="1.0162630291544548" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="30" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="0.17915872739491207" LOG_CI_START="-0.16514647424259765" LOG_EFFECT_SIZE="0.007006126576157202" NO="1" P_CHI2="0.9438316220068468" P_Z="0.9364241451214272" STUDIES="6" TAU2="0.0" TOTAL_1="56" TOTAL_2="68" WEIGHT="100.0" Z="0.07976502065660955">
<NAME>Same BL</NAME>
<DICH_DATA CI_END="2.2392765551326286" CI_START="0.3528476440210511" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.35010773312840454" LOG_CI_START="-0.45241277802316715" LOG_EFFECT_SIZE="-0.05115252244738131" ORDER="322" O_E="0.0" SE="0.4714045207910317" STUDY_ID="STD-Cometta-1994" TOTAL_1="9" TOTAL_2="12" VAR="0.2222222222222222" WEIGHT="19.634632759646536"/>
<DICH_DATA CI_END="14.630590273864367" CI_START="0.17497585210715014" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.1652618481697905" LOG_CI_START="-0.7570218828579409" LOG_EFFECT_SIZE="0.2041199826559248" ORDER="323" O_E="0.0" SE="1.1291589790636214" STUDY_ID="STD-D_x0027_Antonio-1992" TOTAL_1="10" TOTAL_2="8" VAR="1.275" WEIGHT="4.242050287577955"/>
<DICH_DATA CI_END="1.8191408322069051" CI_START="0.49611332120181423" EFFECT_SIZE="0.95" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.25986632208864097" LOG_CI_START="-0.3044191115109454" LOG_EFFECT_SIZE="-0.022276394711152253" ORDER="324" O_E="0.0" SE="0.33146405695434245" STUDY_ID="STD-Mergoni-1987" TOTAL_1="16" TOTAL_2="19" VAR="0.10986842105263159" WEIGHT="34.90601379492717"/>
<DICH_DATA CI_END="4.656955069562792" CI_START="0.08387991598911279" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6681020478672214" LOG_CI_START="-1.076342013179071" LOG_EFFECT_SIZE="-0.2041199826559248" ORDER="325" O_E="0.0" SE="1.02469507659596" STUDY_ID="STD-Sculier-1982" TOTAL_1="4" TOTAL_2="5" VAR="1.05" WEIGHT="6.787280460124727"/>
<DICH_DATA CI_END="6.866791466838105" CI_START="0.4718360846760789" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8367538587854034" LOG_CI_START="-0.32620884857879123" LOG_EFFECT_SIZE="0.25527250510330607" ORDER="326" O_E="0.0" SE="0.6831300510639732" STUDY_ID="STD-Sukoh-1994" TOTAL_1="5" TOTAL_2="6" VAR="0.4666666666666667" WEIGHT="6.941536834218471"/>
<DICH_DATA CI_END="2.0759843992857436" CI_START="0.48169918827138425" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.3172240855301905" LOG_CI_START="-0.31722408553019055" LOG_EFFECT_SIZE="0.0" ORDER="327" O_E="0.0" SE="0.372677996249965" STUDY_ID="STD-Takamoto-1994" TOTAL_1="12" TOTAL_2="18" VAR="0.13888888888888892" WEIGHT="27.488485863505147"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.02477045589658" CI_END="1.8208300121008187" CI_START="0.796055299966913" DF="9" EFFECT_SIZE="1.203944093997589" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="25" I2="0.274471866266636" ID="CMP-002.06.02" LOG_CI_END="0.2602694030972032" LOG_CI_START="-0.09905676186499623" LOG_EFFECT_SIZE="0.08060632061610348" NO="2" P_CHI2="0.434990954452563" P_Z="0.37921530271871695" STUDIES="12" TAU2="0.0" TOTAL_1="166" TOTAL_2="136" WEIGHT="100.0" Z="0.8793430634280204">
<NAME>Different BL</NAME>
<DICH_DATA CI_END="2.157311311183563" CI_START="0.399684965952425" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.33391282056551425" LOG_CI_START="-0.39828218730831677" LOG_EFFECT_SIZE="-0.03218468337140124" ORDER="328" O_E="0.0" SE="0.43009497204883124" STUDY_ID="STD-Alvarez_x002d_Lerma-2001a" TOTAL_1="14" TOTAL_2="13" VAR="0.18498168498168494" WEIGHT="21.88459709262243"/>
<DICH_DATA CI_END="1.602818118675055" CI_START="0.6239011078977786" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.2048842431667764" LOG_CI_START="-0.2048842431667764" LOG_EFFECT_SIZE="0.0" ORDER="329" O_E="0.0" SE="0.24070003725904968" STUDY_ID="STD-Brown-1984" TOTAL_1="4" TOTAL_2="3" VAR="0.0579365079365079" WEIGHT="13.677873182889018"/>
<DICH_DATA CI_END="3.9897518484988193" CI_START="0.11139651319709787" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.600945884614294" LOG_CI_START="-0.9531284027256566" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="330" O_E="0.0" SE="0.9128709291752769" STUDY_ID="STD-Iakovlev-1998" TOTAL_1="15" TOTAL_2="10" VAR="0.8333333333333334" WEIGHT="8.441201735725793"/>
<DICH_DATA CI_END="34.917922510254485" CI_START="0.715964702443513" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.5430483968556332" LOG_CI_START="-0.14510838818359573" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="331" O_E="0.0" SE="0.9916316520429012" STUDY_ID="STD-Klastersky-1973" TOTAL_1="12" TOTAL_2="10" VAR="0.9833333333333335" WEIGHT="3.8369098798753605"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="332" O_E="0.0" SE="0.0" STUDY_ID="STD-Koehler-1990" TOTAL_1="6" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="13.016206486842576" CI_START="0.07682729995185997" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1144844295558007" LOG_CI_START="-1.1144844295558007" LOG_EFFECT_SIZE="0.0" ORDER="333" O_E="0.0" SE="1.3093073414159544" STUDY_ID="STD-Limson-1988" TOTAL_1="7" TOTAL_2="7" VAR="1.7142857142857144" WEIGHT="3.5171673898857474"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="334" O_E="0.0" SE="0.0" STUDY_ID="STD-Moreno-1997" TOTAL_1="4" TOTAL_2="8" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="28.87412364389806" CI_START="0.5975744262447549" EFFECT_SIZE="4.153846153846154" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.4605088118648786" LOG_CI_START="-0.22360799683261498" LOG_EFFECT_SIZE="0.6184504075161318" ORDER="335" O_E="0.0" SE="0.9892585499415604" STUDY_ID="STD-Mouton-1995" TOTAL_1="13" TOTAL_2="9" VAR="0.9786324786324787" WEIGHT="4.156652369864974"/>
<DICH_DATA CI_END="6.441804076309738" CI_START="0.05588496572317828" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.8090075118727597" LOG_CI_START="-1.2527050111054725" LOG_EFFECT_SIZE="-0.2218487496163564" ORDER="336" O_E="0.0" SE="1.2110601416389968" STUDY_ID="STD-Rapp-1984" TOTAL_1="5" TOTAL_2="3" VAR="1.4666666666666668" WEIGHT="4.396459237357185"/>
<DICH_DATA CI_END="5.572546124884582" CI_START="0.5722295408133795" EFFECT_SIZE="1.7857142857142858" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7460536718943029" LOG_CI_START="-0.24242972590670378" LOG_EFFECT_SIZE="0.2518119729937996" ORDER="337" O_E="0.0" SE="0.580640040940045" STUDY_ID="STD-Rubinstein-1995" TOTAL_1="56" TOTAL_2="50" VAR="0.33714285714285713" WEIGHT="14.865009345932215"/>
<DICH_DATA CI_END="2.180121527093581" CI_START="0.16512840936896409" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.3384807032720784" LOG_CI_START="-0.7821782025047912" LOG_EFFECT_SIZE="-0.2218487496163564" ORDER="338" O_E="0.0" SE="0.6582805886043833" STUDY_ID="STD-Sieger-1997" TOTAL_1="15" TOTAL_2="12" VAR="0.4333333333333333" WEIGHT="15.631855066158877"/>
<DICH_DATA CI_END="2.162391456152008" CI_START="0.025177885479314994" EFFECT_SIZE="0.23333333333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.33493431674849017" LOG_CI_START="-1.5989807461593013" LOG_EFFECT_SIZE="-0.6320232147054056" ORDER="339" O_E="0.0" SE="1.13599128098599" STUDY_ID="STD-Stille-1992" TOTAL_1="15" TOTAL_2="7" VAR="1.2904761904761906" WEIGHT="9.592274699688401"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.901963811993184" CI_END="1.4598975637020932" CI_START="0.5018661658841885" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8559633128112661" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="0.16432238381206465" LOG_CI_START="-0.2994120819929673" LOG_EFFECT_SIZE="-0.06754484909045133" METHOD="MH" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.9177456938536144" P_Q="0.5298343423342626" P_Z="0.5680309812292891" Q="0.39471001249052484" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="145" TOTAL_2="154" WEIGHT="200.0" Z="0.5709537734214326">
<NAME>Clinical failure (Gram-negative bacteraemia)</NAME>
<GROUP_LABEL_1>Monotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours monotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.198862644511566" CI_END="2.5594806325577157" CI_START="0.44800589873076135" DF="3" EFFECT_SIZE="1.0708232445520582" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" I2="0.0" ID="CMP-002.07.01" LOG_CI_END="0.4081518476174086" LOG_CI_START="-0.3487162677666891" LOG_EFFECT_SIZE="0.029717789925359762" NO="1" P_CHI2="0.7532771727834184" P_Z="0.8776785904035901" STUDIES="4" TAU2="0.0" TOTAL_1="49" TOTAL_2="52" WEIGHT="99.99999999999999" Z="0.15391267453319432">
<NAME>Same BL</NAME>
<DICH_DATA CI_END="2.6312143240480275" CI_START="0.1655509382184593" EFFECT_SIZE="0.66" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4201562247335235" LOG_CI_START="-0.781068353649786" LOG_EFFECT_SIZE="-0.1804560644581313" ORDER="311" O_E="0.0" SE="0.7056052634999174" STUDY_ID="STD-Carbon-1987" TOTAL_1="25" TOTAL_2="22" VAR="0.49787878787878775" WEIGHT="54.479418886198545"/>
<DICH_DATA CI_END="7.018713210418516" CI_START="0.2226191544171713" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8462574971953312" LOG_CI_START="-0.6524374711792184" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="312" O_E="0.0" SE="0.8803408430829505" STUDY_ID="STD-Cometta-1994" TOTAL_1="8" TOTAL_2="10" VAR="0.775" WEIGHT="22.760290556900724"/>
<DICH_DATA CI_END="18.62782027825117" CI_START="0.3355196639564512" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2701620391951838" LOG_CI_START="-0.47428202185110857" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="313" O_E="0.0" SE="1.02469507659596" STUDY_ID="STD-Klastersky-1973" TOTAL_1="4" TOTAL_2="5" VAR="1.05" WEIGHT="11.380145278450362"/>
<DICH_DATA CI_END="17.97501583773661" CI_START="0.08692620991853033" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2546692817107525" LOG_CI_START="-1.0608492556946398" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="314" O_E="0.0" SE="1.3601470508735443" STUDY_ID="STD-Piccart-1984" TOTAL_1="12" TOTAL_2="15" VAR="1.85" WEIGHT="11.380145278450362"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.2898247595576793" CI_END="1.482182852220621" CI_START="0.3809972013898975" DF="5" EFFECT_SIZE="0.7514702380295262" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" I2="0.0" ID="CMP-002.07.02" LOG_CI_END="0.1709017844880003" LOG_CI_START="-0.41907821441726373" LOG_EFFECT_SIZE="-0.12408821496463167" NO="2" P_CHI2="0.8077602969227685" P_Z="0.40967636100269467" STUDIES="7" TAU2="0.0" TOTAL_1="96" TOTAL_2="102" WEIGHT="100.0" Z="0.8244633129523953">
<NAME>Different BL</NAME>
<DICH_DATA CI_END="1.9601526210417917" CI_START="0.14222565988347913" EFFECT_SIZE="0.528" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.2922898876298273" LOG_CI_START="-0.8470220425622028" LOG_EFFECT_SIZE="-0.27736607746618774" ORDER="315" O_E="0.0" SE="0.6692374674798086" STUDY_ID="STD-Arich-1987" TOTAL_1="25" TOTAL_2="22" VAR="0.4478787878787879" WEIGHT="33.11879712528841"/>
<DICH_DATA CI_END="3.6075179132023756" CI_START="0.39916641708972667" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.557208496268825" LOG_CI_START="-0.39884600417357535" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="316" O_E="0.0" SE="0.5615911461059686" STUDY_ID="STD-Gomez-1990a" TOTAL_1="39" TOTAL_2="39" VAR="0.3153846153846154" WEIGHT="31.131669297771104"/>
<DICH_DATA CI_END="22.503489331122083" CI_START="0.11734291340979042" EFFECT_SIZE="1.625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.3522498638784313" LOG_CI_START="-0.9305431332486448" LOG_EFFECT_SIZE="0.21085336531489318" ORDER="317" O_E="0.0" SE="1.3409239065200245" STUDY_ID="STD-Holloway--1985" TOTAL_1="8" TOTAL_2="13" VAR="1.7980769230769231" WEIGHT="4.743873416803216"/>
<DICH_DATA CI_END="5.179278712462457" CI_START="0.058405816097928845" EFFECT_SIZE="0.55" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7142692823304204" LOG_CI_START="-1.2335439033419326" LOG_EFFECT_SIZE="-0.2596373105057561" ORDER="318" O_E="0.0" SE="1.1441551070947107" STUDY_ID="STD-Limson-1988" TOTAL_1="10" TOTAL_2="11" VAR="1.309090909090909" WEIGHT="11.859683542008039"/>
<DICH_DATA CI_END="3.501784576367324" CI_START="0.011422747210079708" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.5442894255359413" LOG_CI_START="-1.9422294342079789" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="319" O_E="0.0" SE="1.4605934866804429" STUDY_ID="STD-Mandell-1987" TOTAL_1="4" TOTAL_2="2" VAR="2.133333333333333" WEIGHT="11.674375986664165"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="320" O_E="0.0" SE="0.0" STUDY_ID="STD-Mouton-1995" TOTAL_1="9" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.103990012502697" CI_START="0.03519149091707779" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8515023421964996" LOG_CI_START="-1.453562333524462" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="321" O_E="0.0" SE="1.35400640077266" STUDY_ID="STD-Rapp-1984" TOTAL_1="1" TOTAL_2="2" VAR="1.8333333333333333" WEIGHT="7.471600631465065"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="18.498847930739213" CI_END="1.0204496674736305" CI_START="0.5759470996819412" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7666322627915152" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="82" I2="0.0" I2_Q="80.13532440453673" ID="CMP-002.08" LOG_CI_END="0.008791588495947912" LOG_CI_START="-0.2396174043741466" LOG_EFFECT_SIZE="-0.11541290793909936" METHOD="MH" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.6172542216351959" P_Q="0.024853578403174814" P_Z="0.06857167215950538" Q="5.034061569212747" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="22" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="383" TOTAL_2="382" WEIGHT="200.00000000000003" Z="1.8212315125802685">
<NAME>Clinical failure (bacteraemia)</NAME>
<GROUP_LABEL_1>Monotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours monotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.539410807772122" CI_END="2.6632891183884873" CI_START="0.768214674403538" DF="4" EFFECT_SIZE="1.4303767975345858" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="13" I2="11.882837456538931" ID="CMP-002.08.01" LOG_CI_END="0.42541831465717317" LOG_CI_START="-0.114517401217168" LOG_EFFECT_SIZE="0.1554504567200026" NO="1" P_CHI2="0.3379000570846763" P_Z="0.2590798047674615" STUDIES="5" TAU2="0.0" TOTAL_1="72" TOTAL_2="69" WEIGHT="100.00000000000001" Z="1.128568781778514">
<NAME>Same BL</NAME>
<DICH_DATA CI_END="2.6312143240480275" CI_START="0.1655509382184593" EFFECT_SIZE="0.66" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4201562247335235" LOG_CI_START="-0.781068353649786" LOG_EFFECT_SIZE="-0.1804560644581313" ORDER="340" O_E="0.0" SE="0.7056052634999174" STUDY_ID="STD-Carbon-1987" TOTAL_1="25" TOTAL_2="22" VAR="0.49787878787878775" WEIGHT="31.354056888857844"/>
<DICH_DATA CI_END="3.4009632556583522" CI_START="0.44123528753312335" EFFECT_SIZE="1.225" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.5316019397977548" LOG_CI_START="-0.3553297623966522" LOG_EFFECT_SIZE="0.0881360887005513" ORDER="341" O_E="0.0" SE="0.5209880722517277" STUDY_ID="STD-D_x0027_Antonio-1992" TOTAL_1="20" TOTAL_2="14" VAR="0.27142857142857146" WEIGHT="34.67389820650162"/>
<DICH_DATA CI_END="18.62782027825117" CI_START="0.3355196639564512" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2701620391951838" LOG_CI_START="-0.47428202185110857" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="342" O_E="0.0" SE="1.02469507659596" STUDY_ID="STD-Klastersky-1973" TOTAL_1="4" TOTAL_2="5" VAR="1.05" WEIGHT="6.549514105672527"/>
<DICH_DATA CI_END="3.4711718799517923" CI_START="0.16204901959732748" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.5404761189051974" LOG_CI_START="-0.7903535921217972" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="343" O_E="0.0" SE="0.7817359599705715" STUDY_ID="STD-Piccart-1984" TOTAL_1="12" TOTAL_2="18" VAR="0.611111111111111" WEIGHT="23.5782507804211"/>
<DICH_DATA CI_END="187.83722728790315" CI_START="0.7560106507896145" EFFECT_SIZE="11.916666666666666" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.2737816688858175" LOG_CI_START="-0.12147208605094371" LOG_EFFECT_SIZE="1.076154791417437" ORDER="344" O_E="0.0" SE="1.406983912347163" STUDY_ID="STD-Sage-1987" TOTAL_1="11" TOTAL_2="10" VAR="1.9796037296037294" WEIGHT="3.844280018546918"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.915219347263728" CI_END="0.8880596898955426" CI_START="0.46096094741464866" DF="16" EFFECT_SIZE="0.6398131258539547" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="69" I2="0.0" ID="CMP-002.08.02" LOG_CI_END="-0.05155784264364201" LOG_CI_START="-0.33633586645577623" LOG_EFFECT_SIZE="-0.1939468545497091" NO="2" P_CHI2="0.7497951141730879" P_Z="0.00759303110005367" STUDIES="17" TAU2="0.0" TOTAL_1="311" TOTAL_2="313" WEIGHT="100.00000000000001" Z="2.6696501699374537">
<NAME>Different BL</NAME>
<DICH_DATA CI_END="1.9601526210417917" CI_START="0.14222565988347913" EFFECT_SIZE="0.528" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.2922898876298273" LOG_CI_START="-0.8470220425622028" LOG_EFFECT_SIZE="-0.27736607746618774" ORDER="345" O_E="0.0" SE="0.6692374674798086" STUDY_ID="STD-Arich-1987" TOTAL_1="25" TOTAL_2="22" VAR="0.4478787878787879" WEIGHT="7.488375093881765"/>
<DICH_DATA CI_END="2.3171613985625013" CI_START="0.007672222482562756" EFFECT_SIZE="0.13333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.364956285004416" LOG_CI_START="-2.115078811787816" LOG_EFFECT_SIZE="-0.8750612633917001" ORDER="346" O_E="0.0" SE="1.456784892227477" STUDY_ID="STD-Bergeron-1988" TOTAL_1="8" TOTAL_2="5" VAR="2.1222222222222222" WEIGHT="4.223443552949315"/>
<DICH_DATA CI_END="4.473446635382062" CI_START="0.05588532073293601" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6506422609265902" LOG_CI_START="-1.2527022522545526" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="347" O_E="0.0" SE="1.118033988749895" STUDY_ID="STD-Cone-1985" TOTAL_1="8" TOTAL_2="8" VAR="1.25" WEIGHT="2.8156290352995437"/>
<DICH_DATA CI_END="0.9529077241445654" CI_START="0.1679071288289048" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="-0.020949152703870377" LOG_CI_START="-0.7749308646402048" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="348" O_E="0.0" SE="0.44289258986107016" STUDY_ID="STD-Felisart-1985" TOTAL_1="13" TOTAL_2="13" VAR="0.19615384615384612" WEIGHT="14.078145176497719"/>
<DICH_DATA CI_END="1.7685874605893872" CI_START="0.10822549309278337" EFFECT_SIZE="0.4375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.2476265415113309" LOG_CI_START="-0.9656704267946667" LOG_EFFECT_SIZE="-0.3590219426416679" ORDER="349" O_E="0.0" SE="0.7126966450997984" STUDY_ID="STD-Finer-1992" TOTAL_1="36" TOTAL_2="21" VAR="0.5079365079365079" WEIGHT="7.113168089177794"/>
<DICH_DATA CI_END="3.6075179132023756" CI_START="0.39916641708972667" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.557208496268825" LOG_CI_START="-0.39884600417357535" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="350" O_E="0.0" SE="0.5615911461059686" STUDY_ID="STD-Gomez-1990a" TOTAL_1="39" TOTAL_2="39" VAR="0.3153846153846154" WEIGHT="7.039072588248859"/>
<DICH_DATA CI_END="4.8810775965295745" CI_START="0.1926443893676355" EFFECT_SIZE="0.9696969696969697" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6885157118722021" LOG_CI_START="-0.715243634988165" LOG_EFFECT_SIZE="-0.01336396155798149" ORDER="351" O_E="0.0" SE="0.8245751890666141" STUDY_ID="STD-Holloway--1985" TOTAL_1="11" TOTAL_2="16" VAR="0.6799242424242423" WEIGHT="3.4413243764772203"/>
<DICH_DATA CI_END="5.179278712462457" CI_START="0.058405816097928845" EFFECT_SIZE="0.55" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7142692823304204" LOG_CI_START="-1.2335439033419326" LOG_EFFECT_SIZE="-0.2596373105057561" ORDER="352" O_E="0.0" SE="1.1441551070947107" STUDY_ID="STD-Limson-1988" TOTAL_1="10" TOTAL_2="11" VAR="1.309090909090909" WEIGHT="2.6815514621900416"/>
<DICH_DATA CI_END="3.501784576367324" CI_START="0.011422747210079708" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.5442894255359413" LOG_CI_START="-1.9422294342079789" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="353" O_E="0.0" SE="1.4605934866804429" STUDY_ID="STD-Mandell-1987" TOTAL_1="4" TOTAL_2="2" VAR="2.133333333333333" WEIGHT="2.639652220593322"/>
<DICH_DATA CI_END="5.686850282451908" CI_START="0.06330393488832708" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7548717947440117" LOG_CI_START="-1.1985692939767243" LOG_EFFECT_SIZE="-0.2218487496163564" ORDER="354" O_E="0.0" SE="1.1474609652039003" STUDY_ID="STD-Martin-1991" TOTAL_1="10" TOTAL_2="12" VAR="1.3166666666666667" WEIGHT="2.5596627593632215"/>
<DICH_DATA CI_END="12.459310421453043" CI_START="0.1805878434592849" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="1.0954940063323635" LOG_CI_START="-0.7433114882210011" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="355" O_E="0.0" SE="1.0801234497346435" STUDY_ID="STD-McCormick-1997" TOTAL_1="4" TOTAL_2="12" VAR="1.1666666666666667" WEIGHT="1.4078145176497718"/>
<DICH_DATA CI_END="3.304556943671362" CI_START="0.4028863685630486" EFFECT_SIZE="1.1538461538461537" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5191132399737891" LOG_CI_START="-0.3948174264761003" LOG_EFFECT_SIZE="0.062147906748844434" ORDER="356" O_E="0.0" SE="0.5368473975024265" STUDY_ID="STD-Mouton-1990" TOTAL_1="26" TOTAL_2="25" VAR="0.2882051282051283" WEIGHT="7.177093619390993"/>
<DICH_DATA CI_END="27.808224609160423" CI_START="0.2886835779920059" EFFECT_SIZE="2.8333333333333335" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.4441732626125385" LOG_CI_START="-0.5395779206232778" LOG_EFFECT_SIZE="0.4522976709946303" ORDER="357" O_E="0.0" SE="1.1652652647594461" STUDY_ID="STD-Mouton-1995" TOTAL_1="12" TOTAL_2="17" VAR="1.357843137254902" WEIGHT="1.1650878766756732"/>
<DICH_DATA CI_END="9.72717937879812" CI_START="0.03172985336133252" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.987986924768654" LOG_CI_START="-1.4985319349752662" LOG_EFFECT_SIZE="-0.25527250510330607" ORDER="358" O_E="0.0" SE="1.4605934866804429" STUDY_ID="STD-Rapp-1984" TOTAL_1="2" TOTAL_2="4" VAR="2.133333333333333" WEIGHT="1.5837913323559933"/>
<DICH_DATA CI_END="0.8917799233247932" CI_START="0.1321442820700447" EFFECT_SIZE="0.34328358208955223" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="15" LOG_CI_END="-0.04974230916448317" LOG_CI_START="-0.8789516242019841" LOG_EFFECT_SIZE="-0.46434696668323355" ORDER="359" O_E="0.0" SE="0.48708165630533645" STUDY_ID="STD-Rubinstein-1995" TOTAL_1="67" TOTAL_2="69" VAR="0.2372485399091499" WEIGHT="20.806670444676776"/>
<DICH_DATA CI_END="5.221518216003353" CI_START="0.014109587736753347" EFFECT_SIZE="0.2714285714285714" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.7177967974402164" LOG_CI_START="-1.850485675563072" LOG_EFFECT_SIZE="-0.566344439061428" ORDER="360" O_E="0.0" SE="1.508621837845409" STUDY_ID="STD-Stille-1992" TOTAL_1="13" TOTAL_2="18" VAR="2.2759398496240597" WEIGHT="2.9862732192570918"/>
<DICH_DATA CI_END="2.314006229767166" CI_START="0.4875014871725447" EFFECT_SIZE="1.062111801242236" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.3643645238248327" LOG_CI_START="-0.31202405510422454" LOG_EFFECT_SIZE="0.026170234360304082" ORDER="361" O_E="0.0" SE="0.39731399944039264" STUDY_ID="STD-Warren-1983" TOTAL_1="23" TOTAL_2="19" VAR="0.15785841415132032" WEIGHT="10.793244635314919"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.131765708119707" CI_END="1.7038576807582202" CI_START="0.8392872659859075" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="1.195836968199535" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="42" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="0.23143331634461337" LOG_CI_START="-0.07608936613270258" LOG_EFFECT_SIZE="0.07767197510595542" METHOD="MH" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.9630601730759331" P_Q="0.820868438054712" P_Z="0.3221406093225837" Q="0.051269706589290955" RANDOM="NO" SCALE="131.85" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="418" TOTAL_2="374" WEIGHT="200.0" Z="0.9900685867423368">
<NAME>Clinical failure (urinary tract infection)</NAME>
<GROUP_LABEL_1>Monotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours monotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7324273348845465" CI_END="2.1311488494326003" CI_START="0.58874913109213" DF="2" EFFECT_SIZE="1.1201392919326756" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" I2="0.0" ID="CMP-002.09.01" LOG_CI_END="0.3286137839373944" LOG_CI_START="-0.23006972081790378" LOG_EFFECT_SIZE="0.04927203155974528" NO="1" P_CHI2="0.6933547653926675" P_Z="0.7295602112247492" STUDIES="4" TAU2="0.0" TOTAL_1="40" TOTAL_2="44" WEIGHT="100.0" Z="0.3457106088876552">
<NAME>Same BL</NAME>
<DICH_DATA CI_END="14.030767893963262" CI_START="0.37235950558103126" EFFECT_SIZE="2.2857142857142856" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.1470814403073957" LOG_CI_START="-0.42903755502405977" LOG_EFFECT_SIZE="0.3590219426416679" ORDER="362" O_E="0.0" SE="0.9258200997725515" STUDY_ID="STD-D_x0027_Antonio-1992" TOTAL_1="7" TOTAL_2="4" VAR="0.8571428571428572" WEIGHT="10.621009866511898"/>
<DICH_DATA CI_END="5.459616783460526" CI_START="0.18316303866407257" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.7371621601645829" LOG_CI_START="-0.7371621601645829" LOG_EFFECT_SIZE="0.0" ORDER="363" O_E="0.0" SE="0.8660254037844386" STUDY_ID="STD-Klastersky-1973" TOTAL_1="4" TOTAL_2="2" VAR="0.75" WEIGHT="11.126772241107702"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="364" O_E="0.0" SE="0.0" STUDY_ID="STD-Sage-1987" TOTAL_1="3" TOTAL_2="3" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.0855643415267795" CI_START="0.45957924110915704" EFFECT_SIZE="0.9790209790209791" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.3192235927620454" LOG_CI_START="-0.33763959633569307" LOG_EFFECT_SIZE="-0.009208001786823765" ORDER="365" O_E="0.0" SE="0.38584468880123757" STUDY_ID="STD-Sandberg-1997" TOTAL_1="26" TOTAL_2="35" VAR="0.14887612387612387" WEIGHT="78.2522178923804"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.445078020787015" CI_END="1.8674625703869565" CI_START="0.8026006040446576" DF="11" EFFECT_SIZE="1.2242657338271623" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="29" I2="0.0" ID="CMP-002.09.02" LOG_CI_END="0.27125190599624066" LOG_CI_START="-0.09550051774800251" LOG_EFFECT_SIZE="0.08787569412411908" NO="2" P_CHI2="0.9077135538854004" P_Z="0.3476105641248073" STUDIES="13" TAU2="0.0" TOTAL_1="378" TOTAL_2="330" WEIGHT="99.99999999999999" Z="0.9392341233433223">
<NAME>Different BL</NAME>
<DICH_DATA CI_END="2.1844236592731727" CI_START="0.20346073553896832" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.3393368716888767" LOG_CI_START="-0.6915193898002392" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="366" O_E="0.0" SE="0.6055300708194984" STUDY_ID="STD-Felisart-1985" TOTAL_1="4" TOTAL_2="1" VAR="0.3666666666666667" WEIGHT="6.715821368322695"/>
<DICH_DATA CI_END="7.136685127407792" CI_START="0.3152724212756815" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8534965359826647" LOG_CI_START="-0.5013140178713021" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="367" O_E="0.0" SE="0.7958224257542215" STUDY_ID="STD-Iakovlev-1998" TOTAL_1="10" TOTAL_2="10" VAR="0.6333333333333333" WEIGHT="6.268099943767849"/>
<DICH_DATA CI_END="4.7686051853042395" CI_START="0.32766394769172147" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.6783913666901538" LOG_CI_START="-0.4845713406740409" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="368" O_E="0.0" SE="0.6831300510639732" STUDY_ID="STD-Jaspers-1998" TOTAL_1="6" TOTAL_2="5" VAR="0.4666666666666666" WEIGHT="6.837927211383108"/>
<DICH_DATA CI_END="5.208499115067838" CI_START="0.34132246900739327" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7167125947102104" LOG_CI_START="-0.46683512149361067" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="369" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-Landau-1990" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="9.402149915651773"/>
<DICH_DATA CI_END="2.418331250224626" CI_START="0.4558928806372554" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.38351578796049896" LOG_CI_START="-0.3411371898206228" LOG_EFFECT_SIZE="0.021189299069938092" ORDER="370" O_E="0.0" SE="0.42566474623872275" STUDY_ID="STD-Martin-1991" TOTAL_1="50" TOTAL_2="42" VAR="0.1811904761904762" WEIGHT="27.25260845116456"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="371" O_E="0.0" SE="0.0" STUDY_ID="STD-Moreno-1997" TOTAL_1="16" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="149.6811672810001" CI_START="0.3906804691116402" EFFECT_SIZE="7.647058823529412" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.175167161328675" LOG_CI_START="-0.4081782994715495" LOG_EFFECT_SIZE="0.8834944309285628" ORDER="372" O_E="0.0" SE="1.5174699114403214" STUDY_ID="STD-Mouton-1995" TOTAL_1="16" TOTAL_2="25" VAR="2.302714932126697" WEIGHT="1.239043012140156"/>
<DICH_DATA CI_END="15.773173963622442" CI_START="0.06784649559762428" EFFECT_SIZE="1.0344827586206897" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1979190932141035" LOG_CI_START="-1.1684725795726907" LOG_EFFECT_SIZE="0.014723256820706378" ORDER="373" O_E="0.0" SE="1.3900301824226613" STUDY_ID="STD-Rasmussen-1986" TOTAL_1="29" TOTAL_2="30" VAR="1.9321839080459768" WEIGHT="3.0809304808350446"/>
<DICH_DATA CI_END="16.650348347325306" CI_START="0.0699161002243967" EFFECT_SIZE="1.0789473684210527" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2214233239527656" LOG_CI_START="-1.1554228037469152" LOG_EFFECT_SIZE="0.033000260102925345" ORDER="374" O_E="0.0" SE="1.3961711809888775" STUDY_ID="STD-Rubinstein-1995" TOTAL_1="38" TOTAL_2="41" VAR="1.9492939666238767" WEIGHT="3.0150354159895985"/>
<DICH_DATA CI_END="9.452341278992531" CI_START="0.22879302534196783" EFFECT_SIZE="1.4705882352941178" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9755393935472478" LOG_CI_START="-0.6405572189597206" LOG_EFFECT_SIZE="0.16749108729376372" ORDER="375" O_E="0.0" SE="0.9493031499938444" STUDY_ID="STD-Smith-1984" TOTAL_1="17" TOTAL_2="25" VAR="0.9011764705882352" WEIGHT="5.074176144954926"/>
<DICH_DATA CI_END="1.8491276278552056" CI_START="0.26498982148049377" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.26696688744925967" LOG_CI_START="-0.5767708074207462" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="376" O_E="0.0" SE="0.4956156985355898" STUDY_ID="STD-Verzasconi-1995" TOTAL_1="45" TOTAL_2="42" VAR="0.24563492063492062" WEIGHT="25.936965284556617"/>
<DICH_DATA CI_END="13.867772482168174" CI_START="0.07210963413813187" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1420067079086855" LOG_CI_START="-1.1420067079086855" LOG_EFFECT_SIZE="0.0" ORDER="377" O_E="0.0" SE="1.3416407864998738" STUDY_ID="STD-Wiecek-1986" TOTAL_1="10" TOTAL_2="10" VAR="1.7999999999999998" WEIGHT="3.1340499718839245"/>
<DICH_DATA CI_END="121.21138446425599" CI_START="0.3974297533358782" EFFECT_SIZE="6.940677966101695" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.08354341172641" LOG_CI_START="-0.40073962281782394" LOG_EFFECT_SIZE="0.841401894454293" ORDER="378" O_E="0.0" SE="1.459280151890634" STUDY_ID="STD-Wing-1998" TOTAL_1="117" TOTAL_2="62" VAR="2.1294985617019515" WEIGHT="2.043192799349741"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="65.99371573788925" CI_END="0.9215107686708043" CI_START="0.7404806406892019" CI_STUDY="95" CI_TOTAL="95" DF="41" EFFECT_MEASURE="RR" EFFECT_SIZE="0.826051381202983" ESTIMABLE="YES" EVENTS_1="434" EVENTS_2="508" I2="37.8728723764519" I2_Q="95.54376891120474" ID="CMP-002.10" LOG_CI_END="-0.03549958529896979" LOG_CI_START="-0.13048629129774617" LOG_EFFECT_SIZE="-0.08299293829835801" METHOD="MH" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.007952212066388742" P_Q="2.1676056032315927E-6" P_Z="6.148739439176931E-4" Q="22.44048793866176" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="44" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2266" TOTAL_2="2114" WEIGHT="200.00000000000003" Z="3.424967069350358">
<NAME>Clinical failure (non&#8211;urinary tract infection)</NAME>
<GROUP_LABEL_1>Monotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours monotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.266341266914104" CI_END="1.4179630380336454" CI_START="0.9875959277892541" DF="9" EFFECT_SIZE="1.1833742105174117" ESTIMABLE="YES" EVENTS_1="175" EVENTS_2="149" I2="0.0" ID="CMP-002.10.01" LOG_CI_END="0.15166491026365952" LOG_CI_START="-0.005420709487677476" LOG_EFFECT_SIZE="0.073122100387991" NO="1" P_CHI2="0.5075445682080061" P_Z="0.06804704751931845" STUDIES="10" TAU2="0.0" TOTAL_1="626" TOTAL_2="622" WEIGHT="100.00000000000001" Z="1.824695137101051">
<NAME>Same BL</NAME>
<DICH_DATA CI_END="1.9847833295834896" CI_START="0.37016326497723917" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.2977131035916891" LOG_CI_START="-0.4316066828529156" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="379" O_E="0.0" SE="0.4284060527487281" STUDY_ID="STD-Cardozo-2001" TOTAL_1="56" TOTAL_2="48" VAR="0.18353174603174602" WEIGHT="6.548376761663198"/>
<DICH_DATA CI_END="2.4021466963986886" CI_START="0.7671113991103266" EFFECT_SIZE="1.3574660633484164" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="17" LOG_CI_END="0.38059952575260503" LOG_CI_START="-0.11514156368350148" LOG_EFFECT_SIZE="0.13272898103455175" ORDER="380" O_E="0.0" SE="0.2912007698927386" STUDY_ID="STD-Cometta-1994" TOTAL_1="130" TOTAL_2="125" VAR="0.08479788838612368" WEIGHT="11.710853679588151"/>
<DICH_DATA CI_END="1.6585052588891667" CI_START="0.721305558778421" EFFECT_SIZE="1.09375" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="32" LOG_CI_END="0.21971685294499468" LOG_CI_START="-0.14188072088425532" LOG_EFFECT_SIZE="0.03891806603036966" ORDER="381" O_E="0.0" SE="0.2124042048041596" STUDY_ID="STD-D_x0027_Antonio-1992" TOTAL_1="136" TOTAL_2="136" VAR="0.04511554621848739" WEIGHT="21.62003756231659"/>
<DICH_DATA CI_END="1.3667256675620698" CI_START="0.8230512110018743" EFFECT_SIZE="1.0606060606060606" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="55" LOG_CI_END="0.13568135069047074" LOG_CI_START="-0.08457314174569446" LOG_EFFECT_SIZE="0.025554104472388137" ORDER="382" O_E="0.0" SE="0.12937857913432477" STUDY_ID="STD-Dupont-2000" TOTAL_1="99" TOTAL_2="105" VAR="0.016738816738816734" WEIGHT="36.06651486728365"/>
<DICH_DATA CI_END="9.552732247274859" CI_START="0.9421388318056817" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.9801276051130026" LOG_CI_START="-0.025885095673677708" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="383" O_E="0.0" SE="0.5909368402852788" STUDY_ID="STD-Klastersky-1973" TOTAL_1="21" TOTAL_2="21" VAR="0.3492063492063492" WEIGHT="2.0268785214671805"/>
<DICH_DATA CI_END="2.9094577025383535" CI_START="0.6391239613516574" EFFECT_SIZE="1.3636363636363635" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.46381204783713936" LOG_CI_START="-0.19441490004222706" LOG_EFFECT_SIZE="0.13469857389745618" ORDER="384" O_E="0.0" SE="0.3866457674602807" STUDY_ID="STD-Kljucar-1990" TOTAL_1="44" TOTAL_2="45" VAR="0.14949494949494946" WEIGHT="6.012313816486917"/>
<DICH_DATA CI_END="16.604395372873423" CI_START="1.027468396787" EFFECT_SIZE="4.130434782608695" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.2202230659623783" LOG_CI_START="0.011768472580131379" LOG_EFFECT_SIZE="0.6159957692712549" ORDER="385" O_E="0.0" SE="0.7098522100994448" STUDY_ID="STD-Sage-1987" TOTAL_1="23" TOTAL_2="19" VAR="0.5038901601830663" WEIGHT="1.4799430474204809"/>
<DICH_DATA CI_END="2.523907854293063" CI_START="0.22286867527402432" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.40207349514318896" LOG_CI_START="-0.6519509683597887" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="386" O_E="0.0" SE="0.6191391873668903" STUDY_ID="STD-Sculier-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.3833333333333333" WEIGHT="2.7025046952895737"/>
<DICH_DATA CI_END="3.8827994475086087" CI_START="0.44874838980365256" EFFECT_SIZE="1.32" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5891449591554481" LOG_CI_START="-0.3479970967437483" LOG_EFFECT_SIZE="0.12057393120584989" ORDER="387" O_E="0.0" SE="0.5504818825631803" STUDY_ID="STD-Sukoh-1994" TOTAL_1="30" TOTAL_2="33" VAR="0.3030303030303031" WEIGHT="3.21726749439235"/>
<DICH_DATA CI_END="1.9693429049207163" CI_START="0.46703880711684953" EFFECT_SIZE="0.9590409590409591" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.2943213427246578" LOG_CI_START="-0.33064703160415826" LOG_EFFECT_SIZE="-0.018162844439750202" ORDER="388" O_E="0.0" SE="0.36710951672409314" STUDY_ID="STD-Takamoto-1994" TOTAL_1="77" TOTAL_2="80" VAR="0.13476939726939724" WEIGHT="8.61530955409192"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="38.829445415527964" CI_END="0.7835767807094727" CI_START="0.59350968476864" DF="31" EFFECT_SIZE="0.6819533767867895" ESTIMABLE="YES" EVENTS_1="259" EVENTS_2="359" I2="20.163680762736195" ID="CMP-002.10.02" LOG_CI_END="-0.10591844169102656" LOG_CI_START="-0.2265721899237758" LOG_EFFECT_SIZE="-0.16624531580740118" MODIFIED="2011-12-26 07:24:33 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.15761905995535996" P_Z="6.621297478061507E-8" STUDIES="34" TAU2="0.0" TOTAL_1="1640" TOTAL_2="1492" WEIGHT="100.00000000000001" Z="5.40115556049591">
<NAME>Different BL</NAME>
<DICH_DATA CI_END="1.0874717249006474" CI_START="0.4601992930573304" EFFECT_SIZE="0.707427536231884" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="32" LOG_CI_END="0.03641797378367374" LOG_CI_START="-0.33705405281543327" LOG_EFFECT_SIZE="-0.1503180395158798" ORDER="389" O_E="0.0" SE="0.21937931714066283" STUDY_ID="STD-Alvarez_x002d_Lerma-2001a" TOTAL_1="69" TOTAL_2="71" VAR="0.048127284789103525" WEIGHT="8.594184980472289"/>
<DICH_DATA CI_END="17.69656322236463" CI_START="0.0749290767652106" EFFECT_SIZE="1.1515151515151516" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2478889319840376" LOG_CI_START="-1.1253496185061924" LOG_EFFECT_SIZE="0.06126965673892271" MODIFIED="2011-12-26 06:59:44 +0000" MODIFIED_BY="[Empty name]" ORDER="2071" O_E="0.0" SE="1.3940520722782508" STUDY_ID="STD-Banasal-2006" TOTAL_1="33" TOTAL_2="38" VAR="1.9433811802232854" WEIGHT="0.25327321015629445"/>
<DICH_DATA CI_END="1.5550666855189255" CI_START="0.06764100107599494" EFFECT_SIZE="0.32432432432432434" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.19174901749913703" LOG_CI_START="-1.1697899735378774" LOG_EFFECT_SIZE="-0.48902047801937015" ORDER="390" O_E="0.0" SE="0.7997747430618447" STUDY_ID="STD-Bergeron-1988" TOTAL_1="37" TOTAL_2="30" VAR="0.6396396396396397" WEIGHT="1.5046330237010077"/>
<DICH_DATA CI_END="1.423999570845346" CI_START="0.3356573471587424" EFFECT_SIZE="0.691358024691358" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.1535098584163388" LOG_CI_START="-0.4741038421612374" LOG_EFFECT_SIZE="-0.16029699187244936" ORDER="391" O_E="0.0" SE="0.368663394457191" STUDY_ID="STD-Brown-1984" TOTAL_1="18" TOTAL_2="16" VAR="0.1359126984126984" WEIGHT="2.5963890046503555"/>
<DICH_DATA CI_END="4.063240623267338" CI_START="0.04405205092094786" EFFECT_SIZE="0.4230769230769231" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6088725418102658" LOG_CI_START="-1.3560338674354517" LOG_EFFECT_SIZE="-0.37358066281259295" ORDER="392" O_E="0.0" SE="1.1541957512345262" STUDY_ID="STD-Cone-1985" TOTAL_1="13" TOTAL_2="11" VAR="1.3321678321678323" WEIGHT="0.5903312448844944"/>
<DICH_DATA CI_END="1.87491372144196" CI_START="0.5772378000241282" EFFECT_SIZE="1.0403225806451613" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.27298128744304856" LOG_CI_START="-0.23864523716902078" LOG_EFFECT_SIZE="0.01716802513701388" ORDER="393" O_E="0.0" SE="0.3005319531492715" STUDY_ID="STD-Duff-1982" TOTAL_1="31" TOTAL_2="43" VAR="0.09031945486371591" WEIGHT="3.6524444589942937"/>
<DICH_DATA CI_END="0.9159458776873503" CI_START="0.20822680422592182" EFFECT_SIZE="0.43672014260249553" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="17" LOG_CI_END="-0.03813018759433509" LOG_CI_START="-0.6814633661889229" LOG_EFFECT_SIZE="-0.359796776891629" ORDER="394" O_E="0.0" SE="0.3778970936570546" STUDY_ID="STD-Felisart-1985" TOTAL_1="33" TOTAL_2="35" VAR="0.14280621339444868" WEIGHT="4.495599480274227"/>
<DICH_DATA CI_END="6.586766671602955" CI_START="0.4918953655924044" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.8186722793470714" LOG_CI_START="-0.30812726914045924" LOG_EFFECT_SIZE="0.25527250510330607" MODIFIED="2011-12-26 07:24:33 +0000" MODIFIED_BY="[Empty name]" ORDER="2091" O_E="0.0" SE="0.6618876325292973" STUDY_ID="STD-Figueroa_x002d_Damian-1996" TOTAL_1="14" TOTAL_2="42" VAR="0.4380952380952381" WEIGHT="0.6811514364051858"/>
<DICH_DATA CI_END="2.1889881062026486" CI_START="0.5055279655753675" EFFECT_SIZE="1.051948051948052" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.3402434018490685" LOG_CI_START="-0.2962548144367327" LOG_EFFECT_SIZE="0.021994293706167886" ORDER="395" O_E="0.0" SE="0.37388220296326435" STUDY_ID="STD-Finer-1992" TOTAL_1="98" TOTAL_2="81" VAR="0.13978790169266359" WEIGHT="3.2817039036638675"/>
<DICH_DATA CI_END="0.5205513287712564" CI_START="0.09922728020675375" EFFECT_SIZE="0.22727272727272727" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="22" LOG_CI_END="-0.2835364405952395" LOG_CI_START="-1.0033689123771354" LOG_EFFECT_SIZE="-0.6434526764861874" MODIFIED="2011-12-26 07:10:10 +0000" MODIFIED_BY="[Empty name]" ORDER="2081" O_E="0.0" SE="0.42283315715288794" STUDY_ID="STD-Garc_x00ed_a-Ram_x00ed_rez-1999" TOTAL_1="30" TOTAL_2="30" VAR="0.17878787878787883" WEIGHT="5.994132640365636"/>
<DICH_DATA CI_END="0.7364746482815971" CI_START="0.10801855283463083" EFFECT_SIZE="0.28205128205128205" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.132842198313418" LOG_CI_START="-0.9665016454231303" LOG_EFFECT_SIZE="-0.5496719218682742" ORDER="396" O_E="0.0" SE="0.4896956859130625" STUDY_ID="STD-Gerecht-1989" TOTAL_1="24" TOTAL_2="22" VAR="0.23980186480186477" WEIGHT="3.6959869244942256"/>
<DICH_DATA CI_END="5.597705211534098" CI_START="0.052414831915982264" EFFECT_SIZE="0.5416666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7480100237523192" LOG_CI_START="-1.2805458025618577" LOG_EFFECT_SIZE="-0.2662678894047693" ORDER="397" O_E="0.0" SE="1.191583733890235" STUDY_ID="STD-Havig-1973" TOTAL_1="24" TOTAL_2="26" VAR="1.4198717948717947" WEIGHT="0.5231243031591827"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="398" O_E="0.0" SE="0.0" STUDY_ID="STD-Holloway--1985" TOTAL_1="4" TOTAL_2="2" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.2835271427327677" CI_START="0.020517701017078505" EFFECT_SIZE="0.16228070175438597" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.10840505712466061" LOG_CI_START="-1.6878713029915782" LOG_EFFECT_SIZE="-0.7897331229334588" ORDER="399" O_E="0.0" SE="1.0551416256436648" STUDY_ID="STD-Iakovlev-1998" TOTAL_1="38" TOTAL_2="37" VAR="1.1133238501659555" WEIGHT="1.656560293337412"/>
<DICH_DATA CI_END="2.2606425302677775" CI_START="0.4012264063485572" EFFECT_SIZE="0.9523809523809523" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.35423189387745857" LOG_CI_START="-0.3966104920173347" LOG_EFFECT_SIZE="-0.021189299069938095" ORDER="400" O_E="0.0" SE="0.44104853420435436" STUDY_ID="STD-Jaspers-1998" TOTAL_1="30" TOTAL_2="25" VAR="0.19452380952380952" WEIGHT="2.080608023928568"/>
<DICH_DATA CI_END="5.237851475238857" CI_START="0.847816767848738" EFFECT_SIZE="2.1073059360730593" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" LOG_CI_END="0.7191531793891917" LOG_CI_START="-0.0716979983455667" LOG_EFFECT_SIZE="0.3237275905218125" ORDER="401" O_E="0.0" SE="0.4645498965778636" STUDY_ID="STD-Koehler-1990" TOTAL_1="73" TOTAL_2="71" VAR="0.21580660641050375" WEIGHT="1.6574684952526189"/>
<DICH_DATA CI_END="8.998765467178366" CI_START="0.020410963043505946" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9541829330429346" LOG_CI_START="-1.6901365036321232" LOG_EFFECT_SIZE="-0.36797678529459443" ORDER="402" O_E="0.0" SE="1.5532863266952466" STUDY_ID="STD-Limson-1988" TOTAL_1="6" TOTAL_2="8" VAR="2.4126984126984126" WEIGHT="0.3576045041127226"/>
<DICH_DATA CI_END="2.163966825485128" CI_START="0.34778413155082627" EFFECT_SIZE="0.8675213675213675" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.3352505985698439" LOG_CI_START="-0.4586902375637037" LOG_EFFECT_SIZE="-0.06171981949692991" ORDER="403" O_E="0.0" SE="0.46636477721536806" STUDY_ID="STD-Mandell-1987" TOTAL_1="52" TOTAL_2="58" VAR="0.2174961054271399" WEIGHT="2.3183917980918327"/>
<DICH_DATA CI_END="3.891173114395432" CI_START="0.4568745017282504" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.5900805525601674" LOG_CI_START="-0.3402030793435677" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="404" O_E="0.0" SE="0.5464532103585" STUDY_ID="STD-McCormick-1997" TOTAL_1="18" TOTAL_2="16" VAR="0.29861111111111105" WEIGHT="1.1539506687334913"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="405" O_E="0.0" SE="0.0" STUDY_ID="STD-Moreno-1997" TOTAL_1="3" TOTAL_2="2" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.3772712493103656" CI_START="0.22595258977237417" EFFECT_SIZE="0.5578512396694215" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.1390194816349722" LOG_CI_START="-0.6459826766058225" LOG_EFFECT_SIZE="-0.25348159748542515" ORDER="406" O_E="0.0" SE="0.4611141535739958" STUDY_ID="STD-Mouton-1990" TOTAL_1="44" TOTAL_2="45" VAR="0.2126262626262626" WEIGHT="2.9633914177088534"/>
<DICH_DATA CI_END="1.1319994076995852" CI_START="0.30477194573004535" EFFECT_SIZE="0.5873684210526315" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="20" LOG_CI_END="0.05384619961473577" LOG_CI_START="-0.5160250123172738" LOG_EFFECT_SIZE="-0.23108940635126904" ORDER="407" O_E="0.0" SE="0.3347451707968565" STUDY_ID="STD-Mouton-1995" TOTAL_1="95" TOTAL_2="93" VAR="0.11205432937181663" WEIGHT="5.507181826254694"/>
<DICH_DATA CI_END="4.167077593198385" CI_START="0.517985132006146" EFFECT_SIZE="1.4691780821917808" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" LOG_CI_END="0.6198315873265244" LOG_CI_START="-0.2856827058539126" LOG_EFFECT_SIZE="0.16707444073630595" ORDER="408" O_E="0.0" SE="0.5319035781822307" STUDY_ID="STD-Muller-1987" TOTAL_1="73" TOTAL_2="33" VAR="0.28292141648306035" WEIGHT="1.5011035428702963"/>
<DICH_DATA CI_END="3.7194272700246453" CI_START="0.133964145557945" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5704760708987405" LOG_CI_START="-0.8730114215600387" LOG_EFFECT_SIZE="-0.15126767533064908" ORDER="409" O_E="0.0" SE="0.8479116984486138" STUDY_ID="STD-Rapp-1984" TOTAL_1="17" TOTAL_2="18" VAR="0.718954248366013" WEIGHT="0.7940279601523309"/>
<DICH_DATA CI_END="0.8299663714522441" CI_START="0.37699991937657606" EFFECT_SIZE="0.559372197309417" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="50" LOG_CI_END="-0.08093950399572976" LOG_CI_START="-0.42365874267036596" LOG_EFFECT_SIZE="-0.2522991233330479" ORDER="410" O_E="0.0" SE="0.20131497728507333" STUDY_ID="STD-Rubinstein-1995" TOTAL_1="223" TOTAL_2="189" VAR="0.04052772007928959" WEIGHT="14.747259254209363"/>
<DICH_DATA CI_END="7.501364429912652" CI_START="0.014812120134843915" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.875140264790061" LOG_CI_START="-1.8293827742293858" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="411" O_E="0.0" SE="1.5886502207249786" STUDY_ID="STD-Sanfilippo-1989" TOTAL_1="13" TOTAL_2="13" VAR="2.5238095238095233" WEIGHT="0.40869086184311154"/>
<DICH_DATA CI_END="1.0498293637606162" CI_START="0.4907810203774489" EFFECT_SIZE="0.7177996422182469" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="43" LOG_CI_END="0.021118715832443468" LOG_CI_START="-0.30911224077943306" LOG_EFFECT_SIZE="-0.1439967624734948" ORDER="412" O_E="0.0" SE="0.19397929858341514" STUDY_ID="STD-Sieger-1997" TOTAL_1="104" TOTAL_2="107" VAR="0.03762796827891372" WEIGHT="11.549229283806602"/>
<DICH_DATA CI_END="0.7590542652452565" CI_START="0.2377776478891498" EFFECT_SIZE="0.42483660130718953" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="18" LOG_CI_END="-0.11972717502132989" LOG_CI_START="-0.6238289733281566" LOG_EFFECT_SIZE="-0.37177807417474323" ORDER="413" O_E="0.0" SE="0.296111891669576" STUDY_ID="STD-Smith-1984" TOTAL_1="34" TOTAL_2="26" VAR="0.08768225238813473" WEIGHT="5.558195721066316"/>
<DICH_DATA CI_END="1.856914576365029" CI_START="0.1839296107936143" EFFECT_SIZE="0.5844155844155844" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2687919253517288" LOG_CI_START="-0.7353483481460054" LOG_EFFECT_SIZE="-0.23327821139713822" ORDER="414" O_E="0.0" SE="0.5898369672270872" STUDY_ID="STD-Speich-1998" TOTAL_1="44" TOTAL_2="45" VAR="0.34790764790764794" WEIGHT="1.8857945385419976"/>
<DICH_DATA CI_END="1.3011380393179783" CI_START="0.3332605250065565" EFFECT_SIZE="0.6584967320261438" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="17" LOG_CI_END="0.11432337383591536" LOG_CI_START="-0.4772161258448188" LOG_EFFECT_SIZE="-0.18144637600445174" ORDER="415" O_E="0.0" SE="0.3474732302802116" STUDY_ID="STD-Stille-1992" TOTAL_1="144" TOTAL_2="124" VAR="0.12073764576136495" WEIGHT="4.977488705432522"/>
<DICH_DATA CI_END="1.9178966014943377" CI_START="0.47970955198178095" EFFECT_SIZE="0.9591836734693877" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.282825189585998" LOG_CI_START="-0.31902163377159043" LOG_EFFECT_SIZE="-0.01809822209279622" ORDER="416" O_E="0.0" SE="0.3535278032300708" STUDY_ID="STD-Thompson--1990" TOTAL_1="49" TOTAL_2="47" VAR="0.12498190765667969" WEIGHT="3.3376420383854106"/>
<DICH_DATA CI_END="51.50073659814336" CI_START="0.12437246551099736" EFFECT_SIZE="2.5308641975308643" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7118134406571388" LOG_CI_START="-0.9052757563029298" LOG_EFFECT_SIZE="0.40326884217710457" ORDER="417" O_E="0.0" SE="1.5372911490948016" STUDY_ID="STD-Thompson-1993" TOTAL_1="80" TOTAL_2="40" VAR="2.363264077085215" WEIGHT="0.18089595524203295"/>
<DICH_DATA CI_END="4.151262680181564" CI_START="0.5648224993551716" EFFECT_SIZE="1.53125" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.6181802151766247" LOG_CI_START="-0.24808801175940942" LOG_EFFECT_SIZE="0.1850461017086077" ORDER="418" O_E="0.0" SE="0.5088502445991073" STUDY_ID="STD-Vergnon-1985" TOTAL_1="16" TOTAL_2="14" VAR="0.2589285714285714" WEIGHT="1.1624984514648504"/>
<DICH_DATA CI_END="9.392068384176333" CI_START="0.039248271403202646" EFFECT_SIZE="0.6071428571428571" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.9727612460375162" LOG_CI_START="-1.406179465965407" LOG_EFFECT_SIZE="-0.21670910996394532" ORDER="419" O_E="0.0" SE="1.3974015501769614" STUDY_ID="STD-Yellin-1993" TOTAL_1="56" TOTAL_2="34" VAR="1.952731092436975" WEIGHT="0.33906204834391473"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.41896551098694135" CI_END="1.1948058753172206" CI_START="0.4020469556362946" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6930858999775185" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="0.07729734952932427" LOG_CI_START="-0.3957232220825653" LOG_EFFECT_SIZE="-0.15921293627662053" METHOD="MH" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.9362974090893291" P_Q="1.0" P_Z="0.18703549258463356" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="138" TOTAL_2="167" WEIGHT="100.0" Z="1.3193997880966721">
<NAME>Clinical failure (Gram-positive infection)</NAME>
<GROUP_LABEL_1>Monotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1444" O_E="0.0" SE="0.0" STUDY_ID="STD-Abrams-1979" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.5248479213118067" CI_START="0.1293268436046026" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.40223522446491633" LOG_CI_START="-0.8883113218375052" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="1440" O_E="0.0" SE="0.758073429606476" STUDY_ID="STD-Coppens-1983" TOTAL_1="22" TOTAL_2="44" VAR="0.5746753246753247" WEIGHT="17.997506591183143"/>
<DICH_DATA CI_END="1.9007156127572655" CI_START="0.14916575169326518" EFFECT_SIZE="0.5324675324675324" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.27891714208928725" LOG_CI_START="-0.8263308789947802" LOG_EFFECT_SIZE="-0.2737068684527464" ORDER="1442" O_E="0.0" SE="0.6492281586507218" STUDY_ID="STD-Korzeniowski-1982" TOTAL_1="33" TOTAL_2="41" VAR="0.42149720198500684" WEIGHT="24.07774530442069"/>
<DICH_DATA CI_END="1.5400316693721572" CI_START="0.4008663919406224" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.18752965180539463" LOG_CI_START="-0.3970003528454206" LOG_EFFECT_SIZE="-0.104735350520013" ORDER="1441" O_E="0.0" SE="0.34335581820207717" STUDY_ID="STD-Ribera-1996" TOTAL_1="45" TOTAL_2="45" VAR="0.11789321789321788" WEIGHT="53.99251977354943"/>
<DICH_DATA CI_END="14.55119169880151" CI_START="0.06353817832623988" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1628985621892929" LOG_CI_START="-1.1969652407868534" LOG_EFFECT_SIZE="-0.017033339298780342" ORDER="1443" O_E="0.0" SE="1.3861956793824102" STUDY_ID="STD-Sexton-1998" TOTAL_1="26" TOTAL_2="25" VAR="1.9215384615384614" WEIGHT="3.932228330846737"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9160990432943495" CI_END="1.392236233208207" CI_START="0.41054325235772793" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7560245969752369" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-002.12" LOG_CI_END="0.1437129321669184" LOG_CI_START="-0.3866410814903195" LOG_EFFECT_SIZE="-0.12146407466170057" METHOD="MH" MODIFIED="2013-08-12 05:10:04 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.3385014614415043" P_Q="1.0" P_Z="0.3693137208457863" Q="0.0" RANDOM="NO" SCALE="121.56333741221304" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="118" TOTAL_2="125" WEIGHT="100.0" Z="0.8977596308200141">
<NAME>Need for operation (endocarditis)</NAME>
<GROUP_LABEL_1>Monotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1451" O_E="0.0" SE="0.0" STUDY_ID="STD-Abrams-1979" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.2218240945060157" CI_START="0.4347815678360809" EFFECT_SIZE="0.9828571428571429" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.3467096721523534" LOG_CI_START="-0.3617288757098443" LOG_EFFECT_SIZE="-0.007509601778745516" ORDER="1453" O_E="0.0" SE="0.41614030984162426" STUDY_ID="STD-Korzeniowski-1982" TOTAL_1="35" TOTAL_2="43" VAR="0.17317275747508304" WEIGHT="49.44324414159881"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1450" O_E="0.0" SE="0.0" STUDY_ID="STD-Ribera-1996" TOTAL_1="45" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.374866961652013" CI_START="0.20755234057468164" EFFECT_SIZE="0.5341880341880342" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.13826067590028598" LOG_CI_START="-0.6828723647044589" LOG_EFFECT_SIZE="-0.27230584440208644" ORDER="1452" O_E="0.0" SE="0.4823376127253323" STUDY_ID="STD-Sexton-1998" TOTAL_1="26" TOTAL_2="25" VAR="0.23264957264957267" WEIGHT="50.556755858401196"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.45514657860389224" CI_END="1.692320232058131" CI_START="0.4726128854874077" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8943222842139811" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="19" I2="0.0" I2_Q="100.0" ID="CMP-002.13" LOG_CI_END="0.2284825465615132" LOG_CI_START="-0.3254944417815378" LOG_EFFECT_SIZE="-0.0485059476100123" METHOD="MH" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.7964642058659244" P_Q="0.0" P_Z="0.7314277476563282" Q="1.818786959599382E-33" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="135" TOTAL_2="165" WEIGHT="100.0" Z="0.34322692946494254">
<NAME>Bacteriological failure (Gram-positive infection)</NAME>
<GROUP_LABEL_1>Monotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1449" O_E="0.0" SE="0.0" STUDY_ID="STD-Abrams-1979" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.83287055353535" CI_START="0.48329280378274286" EFFECT_SIZE="0.9411764705882353" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="17" LOG_CI_END="0.26313179400179854" LOG_CI_START="-0.3157896714464969" LOG_EFFECT_SIZE="-0.026328938722349152" ORDER="1447" O_E="0.0" SE="0.34006133451180026" STUDY_ID="STD-Coppens-1983" TOTAL_1="22" TOTAL_2="44" VAR="0.11564171122994651" WEIGHT="82.57302264522481"/>
<DICH_DATA CI_END="19.11951674209537" CI_START="0.08073519948152638" EFFECT_SIZE="1.2424242424242424" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.281476911010496" LOG_CI_START="-1.0929370773267997" LOG_EFFECT_SIZE="0.09426991684184802" ORDER="1446" O_E="0.0" SE="1.3947425302881284" STUDY_ID="STD-Korzeniowski-1982" TOTAL_1="33" TOTAL_2="41" VAR="1.9453067257945307" WEIGHT="6.498194945848375"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1448" O_E="0.0" SE="0.0" STUDY_ID="STD-Ribera-1996" TOTAL_1="45" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.780254682310321" CI_START="0.014281166317568032" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8909938136107249" LOG_CI_START="-1.8452363230500497" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="1445" O_E="0.0" SE="1.6072751268321592" STUDY_ID="STD-Sexton-1998" TOTAL_1="23" TOTAL_2="23" VAR="2.5833333333333335" WEIGHT="10.928782408926814"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Monotherapy versus combination therapy (sensitivity analyses)</NAME>
<DICH_OUTCOME CHI2="33.39089293583769" CI_END="1.0241503968046566" CI_START="0.7578960648225566" CI_STUDY="95" CI_TOTAL="95" DF="31" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8810218814108473" ESTIMABLE="YES" EVENTS_1="273" EVENTS_2="302" I2="7.160314461886101" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.010363737602945844" LOG_CI_START="-0.12039034788900575" LOG_EFFECT_SIZE="-0.05501330514302996" METHOD="MH" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.35181051226161564" P_Q="0.44891511617915647" P_Z="0.09909326789455376" Q="3.6945778850209186" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="44" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2891" TOTAL_2="2686" WEIGHT="500.0" Z="1.6492654335835326">
<NAME>All-cause mortality by allocation concealment</NAME>
<GROUP_LABEL_1>Monotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours monotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.1342600608492543" CI_END="1.3116246672407688" CI_START="0.7050294170386711" DF="5" EFFECT_SIZE="0.9616308930760805" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="70" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.11780957569007902" LOG_CI_START="-0.15179276188656476" LOG_EFFECT_SIZE="-0.016991593098242847" MODIFIED="2013-08-13 05:03:43 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6792957478898825" P_Z="0.8048679112676145" STUDIES="6" TAU2="0.0" TOTAL_1="530" TOTAL_2="538" WEIGHT="100.0" Z="0.2470520902145207">
<NAME>A same BL</NAME>
<DICH_DATA CI_END="2.143933394780039" CI_START="0.7045398228271409" EFFECT_SIZE="1.229018492176387" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="19" LOG_CI_END="0.33121128907632275" LOG_CI_START="-0.15209445415818415" LOG_EFFECT_SIZE="0.08955841745906934" ORDER="646" O_E="0.0" SE="0.2838961859779625" STUDY_ID="STD-Cometta-1994" TOTAL_1="148" TOTAL_2="144" VAR="0.08059704441283387" WEIGHT="27.888376592402295"/>
<DICH_DATA CI_END="1.7629588148188347" CI_START="0.2702748393715548" EFFECT_SIZE="0.6902777777777778" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.24624216669192472" LOG_CI_START="-0.5681943820877975" LOG_EFFECT_SIZE="-0.16097610769793635" ORDER="647" O_E="0.0" SE="0.47840406027914484" STUDY_ID="STD-D_x0027_Antonio-1992" TOTAL_1="144" TOTAL_2="142" VAR="0.22887044489157166" WEIGHT="14.580997261453557"/>
<DICH_DATA CI_END="1.5452478612798557" CI_START="0.5411130099195283" EFFECT_SIZE="0.9144144144144144" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.18899815117342472" LOG_CI_START="-0.26671202424827617" LOG_EFFECT_SIZE="-0.03885693653742572" ORDER="648" O_E="0.0" SE="0.26768641284445654" STUDY_ID="STD-Dupont-2000" TOTAL_1="111" TOTAL_2="116" VAR="0.07165601562153284" WEIGHT="33.985927978128096"/>
<DICH_DATA CI_END="2.74230421376631" CI_START="0.5671952289593608" EFFECT_SIZE="1.2471655328798186" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.43811563099017203" LOG_CI_START="-0.2462674309373614" LOG_EFFECT_SIZE="0.0959241000264053" ORDER="649" O_E="0.0" SE="0.40200999832702655" STUDY_ID="STD-Kljucar-1990" TOTAL_1="49" TOTAL_2="50" VAR="0.1616120387548959" WEIGHT="12.900132299369327"/>
<DICH_DATA CI_END="1.9188136720990658" CI_START="0.08938497437295481" EFFECT_SIZE="0.41414141414141414" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.28303280427792576" LOG_CI_START="-1.0487354800335547" LOG_EFFECT_SIZE="-0.38285133787781445" ORDER="650" O_E="0.0" SE="0.7822872825638911" STUDY_ID="STD-Korzeniowski-1982" TOTAL_1="33" TOTAL_2="41" VAR="0.6119733924611973" WEIGHT="7.748617801441367"/>
<DICH_DATA CI_END="5.320030029638535" CI_START="0.04699221594750772" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7259140837366838" LOG_CI_START="-1.3279740750646463" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="651" O_E="0.0" SE="1.2064640713902572" STUDY_ID="STD-Ribera-1996" TOTAL_1="45" TOTAL_2="45" VAR="1.4555555555555557" WEIGHT="2.8959480672053592"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.6506244837058026" CI_END="2.295391311528688" CI_START="0.46792623436269465" DF="3" EFFECT_SIZE="1.0363753242877147" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" I2="17.822279081559877" ID="CMP-003.01.02" LOG_CI_END="0.3608567334249046" LOG_CI_START="-0.32982260533237406" LOG_EFFECT_SIZE="0.015517064046265237" MODIFIED="2013-08-13 05:03:44 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.30174582036207465" P_Z="0.9298237514105959" STUDIES="7" TAU2="0.0" TOTAL_1="186" TOTAL_2="177" WEIGHT="99.99999999999999" Z="0.08806658884918245">
<NAME>B same BL</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="652" O_E="0.0" SE="0.0" STUDY_ID="STD-Abrams-1979" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="13.251516091767591" CI_START="0.0584385963566154" EFFECT_SIZE="0.88" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1222655682820444" LOG_CI_START="-1.2333002239817072" LOG_EFFECT_SIZE="-0.05551732784983137" ORDER="653" O_E="0.0" SE="1.3836710066144533" STUDY_ID="STD-Carbon-1987" TOTAL_1="25" TOTAL_2="22" VAR="1.9145454545454546" WEIGHT="10.33129003374888"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="654" O_E="0.0" SE="0.0" STUDY_ID="STD-Cardozo-2001" TOTAL_1="56" TOTAL_2="48" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.0276339895692987" CI_START="0.09260930658282401" EFFECT_SIZE="0.43333333333333335" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3069895627637647" LOG_CI_START="-1.033345367589416" LOG_EFFECT_SIZE="-0.36317790241282566" MODIFIED="2011-12-26 06:40:47 +0000" MODIFIED_BY="[Empty name]" ORDER="1038" O_E="0.0" SE="0.7873193728543677" STUDY_ID="STD-Damas-2006" TOTAL_1="24" TOTAL_2="26" VAR="0.6198717948717949" WEIGHT="46.61478063227494"/>
<DICH_DATA CI_END="8.260092687698416" CI_START="0.7204087189498556" EFFECT_SIZE="2.4393939393939394" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9169849206291129" LOG_CI_START="-0.14242103964915054" LOG_EFFECT_SIZE="0.38728194048998105" ORDER="655" O_E="0.0" SE="0.6223003052115317" STUDY_ID="STD-Klastersky-1973" TOTAL_1="22" TOTAL_2="23" VAR="0.38725766986636545" WEIGHT="28.486810386390243"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="656" O_E="0.0" SE="0.0" STUDY_ID="STD-Sandberg-1997" TOTAL_1="37" TOTAL_2="36" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.3225436971144395" CI_START="0.015173840636129785" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8646619720038995" LOG_CI_START="-1.8189044814432243" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="657" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Sculier-1982" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="14.567118947585922"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="16.319589914718122" CI_END="1.1900883080320068" CI_START="0.7525635998832032" DF="9" EFFECT_SIZE="0.9463705095106659" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="126" I2="44.85155541878424" ID="CMP-003.01.03" LOG_CI_END="0.07557918850855538" LOG_CI_START="-0.12345679153325546" LOG_EFFECT_SIZE="-0.02393880151235005" MODIFIED="2011-12-26 07:00:26 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.06050038572162286" P_Z="0.6373091426569386" STUDIES="12" TAU2="0.0" TOTAL_1="1148" TOTAL_2="1006" WEIGHT="100.0" Z="0.4714643933966402">
<NAME>A different BL</NAME>
<DICH_DATA CI_END="1.4524039103370738" CI_START="0.4665638439939939" EFFECT_SIZE="0.8231884057971014" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" LOG_CI_END="0.16208740950244066" LOG_CI_START="-0.33108891955491365" LOG_EFFECT_SIZE="-0.08450075502623647" ORDER="658" O_E="0.0" SE="0.2896942169504909" STUDY_ID="STD-Alvarez_x002d_Lerma-2001a" TOTAL_1="69" TOTAL_2="71" VAR="0.08392273933455809" WEIGHT="15.238899367911664"/>
<DICH_DATA CI_END="3.6745949117762566" CI_START="0.5395054550493839" EFFECT_SIZE="1.408" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.5652094693312208" LOG_CI_START="-0.2680041597190341" LOG_EFFECT_SIZE="0.1486026548060934" ORDER="659" O_E="0.0" SE="0.48943381017810217" STUDY_ID="STD-Arich-1987" TOTAL_1="25" TOTAL_2="22" VAR="0.23954545454545456" WEIGHT="4.111636431366853"/>
<DICH_DATA CI_END="2.7893228503916" CI_START="1.0339269681475727" EFFECT_SIZE="1.6982214572576018" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="21" LOG_CI_END="0.44549878462417336" LOG_CI_START="0.01448986327371745" LOG_EFFECT_SIZE="0.2299943239489454" ORDER="660" O_E="0.0" SE="0.25317677392982757" STUDY_ID="STD-Finer-1992" TOTAL_1="249" TOTAL_2="222" VAR="0.064098478857515" WEIGHT="17.163279902879182"/>
<DICH_DATA CI_END="3.6075179132023756" CI_START="0.39916641708972667" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.557208496268825" LOG_CI_START="-0.39884600417357535" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="661" O_E="0.0" SE="0.5615911461059686" STUDY_ID="STD-Gomez-1990a" TOTAL_1="39" TOTAL_2="39" VAR="0.3153846153846154" WEIGHT="3.8649382454848418"/>
<DICH_DATA CI_END="2.357375570364182" CI_START="0.08803470554565483" EFFECT_SIZE="0.45555555555555555" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.37242877859690693" LOG_CI_START="-1.0553460840360858" LOG_EFFECT_SIZE="-0.34145865271958936" ORDER="662" O_E="0.0" SE="0.8386820219101747" STUDY_ID="STD-Hoepelman-1988" TOTAL_1="45" TOTAL_2="41" VAR="0.7033875338753387" WEIGHT="3.235762252033821"/>
<DICH_DATA CI_END="3.215975079542482" CI_START="0.1839927119135329" EFFECT_SIZE="0.7692307692307693" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5073126747595234" LOG_CI_START="-0.7351993793731969" LOG_EFFECT_SIZE="-0.11394335230683675" ORDER="663" O_E="0.0" SE="0.7298577311314224" STUDY_ID="STD-Jaspers-1998" TOTAL_1="39" TOTAL_2="40" VAR="0.5326923076923076" WEIGHT="3.0528119812437233"/>
<DICH_DATA CI_END="3.0420157098392417" CI_START="0.6443096245888809" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.4831614525436979" LOG_CI_START="-0.19090538118722192" LOG_EFFECT_SIZE="0.146128035678238" ORDER="664" O_E="0.0" SE="0.3959501948181826" STUDY_ID="STD-McCormick-1997" TOTAL_1="65" TOTAL_2="63" VAR="0.15677655677655677" WEIGHT="7.065590230026976"/>
<DICH_DATA CI_END="1.335567150499819" CI_START="0.5297708425076304" EFFECT_SIZE="0.8411566646860764" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="33" LOG_CI_END="0.1256657286422107" LOG_CI_START="-0.27591194805182445" LOG_EFFECT_SIZE="-0.07512310970480685" ORDER="665" O_E="0.0" SE="0.2358887151316354" STUDY_ID="STD-Rubinstein-1995" TOTAL_1="306" TOTAL_2="274" VAR="0.05564348592645383" WEIGHT="26.91596303648685"/>
<DICH_DATA CI_END="0.8257784681916034" CI_START="0.160892393837605" EFFECT_SIZE="0.364501679731243" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="19" LOG_CI_END="-0.08313644535025404" LOG_CI_START="-0.7934644866184174" LOG_EFFECT_SIZE="-0.4383004659843357" ORDER="666" O_E="0.0" SE="0.41725020762143167" STUDY_ID="STD-Smith-1984" TOTAL_1="94" TOTAL_2="93" VAR="0.17409773576012785" WEIGHT="14.765304184889684"/>
<DICH_DATA CI_END="1.3587073697477343" CI_START="0.02138411310119719" EFFECT_SIZE="0.17045454545454544" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.13312593106030254" LOG_CI_START="-1.6699087572492775" LOG_EFFECT_SIZE="-0.7683914130944874" ORDER="667" O_E="0.0" SE="1.0591115010786976" STUDY_ID="STD-Speich-1998" TOTAL_1="44" TOTAL_2="45" VAR="1.121717171717172" WEIGHT="4.585814367676397"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="668" O_E="0.0" SE="0.0" STUDY_ID="STD-Wing-1998" TOTAL_1="117" TOTAL_2="62" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="669" O_E="0.0" SE="0.0" STUDY_ID="STD-Yellin-1993" TOTAL_1="56" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.366301498267108" CI_END="0.9308357295005663" CI_START="0.5269769437493863" DF="10" EFFECT_SIZE="0.700377732273763" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="93" I2="0.0" ID="CMP-003.01.04" LOG_CI_END="-0.031126954965103443" LOG_CI_START="-0.2782083855871879" LOG_EFFECT_SIZE="-0.1546676702761457" MODIFIED="2011-12-26 14:20:27 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6904701943830818" P_Z="0.014135921532328078" STUDIES="17" TAU2="0.0" TOTAL_1="976" TOTAL_2="902" WEIGHT="100.00000000000001" Z="2.4537907405726873">
<NAME>B different BL</NAME>
<DICH_DATA CI_END="6.2314434482611825" CI_START="0.011113328418578669" EFFECT_SIZE="0.2631578947368421" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7945886580562603" LOG_CI_START="-1.9541558512898807" LOG_EFFECT_SIZE="-0.5797835966168102" ORDER="670" O_E="0.0" SE="1.6146261312946875" STUDY_ID="STD-Bergeron-1988" TOTAL_1="37" TOTAL_2="29" VAR="2.6070175438596492" WEIGHT="1.7837800778057866"/>
<DICH_DATA CI_END="1.9171115225660975" CI_START="0.61566991069799" EFFECT_SIZE="1.0864197530864197" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.2826473774718505" LOG_CI_START="-0.2106520709288128" LOG_EFFECT_SIZE="0.035997653271518854" ORDER="671" O_E="0.0" SE="0.2897665378622012" STUDY_ID="STD-Brown-1984" TOTAL_1="18" TOTAL_2="16" VAR="0.08396464646464646" WEIGHT="10.13938149489605"/>
<DICH_DATA CI_END="4.598004635829613" CI_START="0.04450811651697542" EFFECT_SIZE="0.4523809523809524" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6625694048006385" LOG_CI_START="-1.3515607836907813" LOG_EFFECT_SIZE="-0.3444956894450715" ORDER="672" O_E="0.0" SE="1.183110042825089" STUDY_ID="STD-Cone-1985" TOTAL_1="21" TOTAL_2="19" VAR="1.399749373433584" WEIGHT="2.234419255356722"/>
<DICH_DATA CI_END="1.418721045629022" CI_START="0.2702186076723028" EFFECT_SIZE="0.6191646191646192" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.15189701120549098" LOG_CI_START="-0.5682847480928428" LOG_EFFECT_SIZE="-0.20819386844367593" ORDER="674" O_E="0.0" SE="0.42303833036904465" STUDY_ID="STD-Felisart-1985" TOTAL_1="37" TOTAL_2="36" VAR="0.17896142896142897" WEIGHT="11.86443101017855"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="675" O_E="0.0" SE="0.0" STUDY_ID="STD-Havig-1973" TOTAL_1="24" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="12.12734418453573" CI_START="0.4875119785752522" EFFECT_SIZE="2.4315068493150687" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0837657033986128" LOG_CI_START="-0.3120147088572987" LOG_EFFECT_SIZE="0.385875497270657" ORDER="676" O_E="0.0" SE="0.8198883233835935" STUDY_ID="STD-Koehler-1990" TOTAL_1="73" TOTAL_2="71" VAR="0.6722168628207601" WEIGHT="2.1575741486910145"/>
<DICH_DATA CI_END="1.4042559079538888" CI_START="0.3940358551877818" EFFECT_SIZE="0.743859649122807" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="19" LOG_CI_END="0.14744625970600495" LOG_CI_START="-0.4044642578655225" LOG_EFFECT_SIZE="-0.12850899907975877" ORDER="677" O_E="0.0" SE="0.32419497002263836" STUDY_ID="STD-Mouton-1990" TOTAL_1="105" TOTAL_2="106" VAR="0.10510237858797938" WEIGHT="20.120362962927828"/>
<DICH_DATA CI_END="2.4364795063951146" CI_START="0.3419070889891188" EFFECT_SIZE="0.9127155172413793" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3867627628148112" LOG_CI_START="-0.46609189459112144" LOG_EFFECT_SIZE="-0.03966456588815514" ORDER="678" O_E="0.0" SE="0.5009710474588857" STUDY_ID="STD-Mouton-1995" TOTAL_1="116" TOTAL_2="121" VAR="0.2509719903920531" WEIGHT="8.332493747120909"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="679" O_E="0.0" SE="0.0" STUDY_ID="STD-Naime-Libien-1992" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="680" O_E="0.0" SE="0.0" STUDY_ID="STD-Rasmussen-1986" TOTAL_1="29" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.0856025424423192" CI_START="0.3115021565079405" EFFECT_SIZE="0.5815217391304348" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="23" LOG_CI_END="0.035670851755012306" LOG_CI_START="-0.5065389424036659" LOG_EFFECT_SIZE="-0.2354340453243268" ORDER="681" O_E="0.0" SE="0.3184967170705754" STUDY_ID="STD-Sieger-1997" TOTAL_1="104" TOTAL_2="107" VAR="0.10144015878473417" WEIGHT="24.124264765575624"/>
<DICH_DATA CI_END="1.596094261813414" CI_START="0.10323084411702192" EFFECT_SIZE="0.40591397849462363" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2030585362481443" LOG_CI_START="-0.9861905214256007" LOG_EFFECT_SIZE="-0.3915659925887281" ORDER="682" O_E="0.0" SE="0.6985707833553355" STUDY_ID="STD-Stille-1992" TOTAL_1="186" TOTAL_2="151" VAR="0.48800113935768713" WEIGHT="7.047087435292078"/>
<DICH_DATA CI_END="3.6573286525107553" CI_START="0.1118039247724491" EFFECT_SIZE="0.6394557823129252" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5631639883825202" LOG_CI_START="-0.9515429506794751" LOG_EFFECT_SIZE="-0.19418948114847742" ORDER="683" O_E="0.0" SE="0.8897463539252893" STUDY_ID="STD-Thompson--1990" TOTAL_1="49" TOTAL_2="47" VAR="0.7916485743233462" WEIGHT="3.258528080728553"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="684" O_E="0.0" SE="0.0" STUDY_ID="STD-Thompson-1993" TOTAL_1="80" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="685" O_E="0.0" SE="0.0" STUDY_ID="STD-Trujillo-1992" TOTAL_1="16" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.338273443885321" CI_START="0.1084417517334551" EFFECT_SIZE="0.38095238095238093" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.1265448600964545" LOG_CI_START="-0.964803475580406" LOG_EFFECT_SIZE="-0.4191293077419757" ORDER="686" O_E="0.0" SE="0.641063414637976" STUDY_ID="STD-Warren-1983" TOTAL_1="56" TOTAL_2="64" VAR="0.41096230158730157" WEIGHT="8.937677021426888"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="687" O_E="0.0" SE="0.0" STUDY_ID="STD-Wiecek-1986" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.208499115067839" CI_START="0.3413224690073932" DF="0" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-003.01.05" LOG_CI_END="0.7167125947102105" LOG_CI_START="-0.4668351214936107" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2013-08-13 05:03:38 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.6790213257374376" STUDIES="2" TAU2="0.0" TOTAL_1="51" TOTAL_2="63" WEIGHT="100.0" Z="0.41379898870766496">
<NAME>C different BL</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-26 14:20:27 +0000" MODIFIED_BY="[Empty name]" ORDER="3124" O_E="0.0" SE="0.0" STUDY_ID="STD-Duff-1982" TOTAL_1="31" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.208499115067838" CI_START="0.34132246900739327" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7167125947102104" LOG_CI_START="-0.46683512149361067" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="688" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-Landau-1990" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="33.3908929358377" CI_END="1.0241503968046566" CI_START="0.7578960648225567" CI_STUDY="95" CI_TOTAL="95" DF="31" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8810218814108474" ESTIMABLE="YES" EVENTS_1="273" EVENTS_2="302" I2="7.160314461886122" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.010363737602945844" LOG_CI_START="-0.12039034788900568" LOG_EFFECT_SIZE="-0.055013305143029906" METHOD="MH" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3518105122616153" P_Q="0.732149642603932" P_Z="0.09909326789455412" Q="2.0196228369001417" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="44" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2891" TOTAL_2="2686" WEIGHT="500.0" Z="1.6492654335835308">
<NAME>All-cause mortality by allocation generation</NAME>
<GROUP_LABEL_1>Monotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours monotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.134260060849254" CI_END="1.3116246672407688" CI_START="0.7050294170386712" DF="5" EFFECT_SIZE="0.9616308930760805" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="70" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.11780957569007902" LOG_CI_START="-0.15179276188656468" LOG_EFFECT_SIZE="-0.016991593098242847" MODIFIED="2013-08-13 05:03:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6792957478898825" P_Z="0.8048679112676145" STUDIES="6" TAU2="0.0" TOTAL_1="530" TOTAL_2="538" WEIGHT="100.0" Z="0.24705209021452076">
<NAME>A same BL</NAME>
<DICH_DATA CI_END="2.143933394780039" CI_START="0.7045398228271409" EFFECT_SIZE="1.229018492176387" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="19" LOG_CI_END="0.33121128907632275" LOG_CI_START="-0.15209445415818415" LOG_EFFECT_SIZE="0.08955841745906934" ORDER="689" O_E="0.0" SE="0.2838961859779625" STUDY_ID="STD-Cometta-1994" TOTAL_1="148" TOTAL_2="144" VAR="0.08059704441283387" WEIGHT="27.888376592402295"/>
<DICH_DATA CI_END="1.7629588148188347" CI_START="0.2702748393715548" EFFECT_SIZE="0.6902777777777778" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.24624216669192472" LOG_CI_START="-0.5681943820877975" LOG_EFFECT_SIZE="-0.16097610769793635" ORDER="690" O_E="0.0" SE="0.47840406027914484" STUDY_ID="STD-D_x0027_Antonio-1992" TOTAL_1="144" TOTAL_2="142" VAR="0.22887044489157166" WEIGHT="14.580997261453557"/>
<DICH_DATA CI_END="1.5452478612798557" CI_START="0.5411130099195283" EFFECT_SIZE="0.9144144144144144" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.18899815117342472" LOG_CI_START="-0.26671202424827617" LOG_EFFECT_SIZE="-0.03885693653742572" ORDER="691" O_E="0.0" SE="0.26768641284445654" STUDY_ID="STD-Dupont-2000" TOTAL_1="111" TOTAL_2="116" VAR="0.07165601562153284" WEIGHT="33.985927978128096"/>
<DICH_DATA CI_END="2.74230421376631" CI_START="0.5671952289593608" EFFECT_SIZE="1.2471655328798186" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.43811563099017203" LOG_CI_START="-0.2462674309373614" LOG_EFFECT_SIZE="0.0959241000264053" ORDER="692" O_E="0.0" SE="0.40200999832702655" STUDY_ID="STD-Kljucar-1990" TOTAL_1="49" TOTAL_2="50" VAR="0.1616120387548959" WEIGHT="12.900132299369327"/>
<DICH_DATA CI_END="1.9188136720990658" CI_START="0.08938497437295481" EFFECT_SIZE="0.41414141414141414" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.28303280427792576" LOG_CI_START="-1.0487354800335547" LOG_EFFECT_SIZE="-0.38285133787781445" ORDER="693" O_E="0.0" SE="0.7822872825638911" STUDY_ID="STD-Korzeniowski-1982" TOTAL_1="33" TOTAL_2="41" VAR="0.6119733924611973" WEIGHT="7.748617801441367"/>
<DICH_DATA CI_END="5.320030029638535" CI_START="0.04699221594750772" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7259140837366838" LOG_CI_START="-1.3279740750646463" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="694" O_E="0.0" SE="1.2064640713902572" STUDY_ID="STD-Ribera-1996" TOTAL_1="45" TOTAL_2="45" VAR="1.4555555555555557" WEIGHT="2.8959480672053592"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.650624483705803" CI_END="2.295391311528688" CI_START="0.4679262343626946" DF="3" EFFECT_SIZE="1.0363753242877147" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" I2="17.82227908155989" ID="CMP-003.02.02" LOG_CI_END="0.3608567334249046" LOG_CI_START="-0.3298226053323741" LOG_EFFECT_SIZE="0.015517064046265237" MODIFIED="2013-08-13 05:03:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.30174582036207476" P_Z="0.9298237514105959" STUDIES="7" TAU2="0.0" TOTAL_1="186" TOTAL_2="177" WEIGHT="99.99999999999999" Z="0.08806658884918245">
<NAME>B same BL</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="695" O_E="0.0" SE="0.0" STUDY_ID="STD-Abrams-1979" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="13.251516091767591" CI_START="0.0584385963566154" EFFECT_SIZE="0.88" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1222655682820444" LOG_CI_START="-1.2333002239817072" LOG_EFFECT_SIZE="-0.05551732784983137" ORDER="696" O_E="0.0" SE="1.3836710066144533" STUDY_ID="STD-Carbon-1987" TOTAL_1="25" TOTAL_2="22" VAR="1.9145454545454546" WEIGHT="10.33129003374888"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="697" O_E="0.0" SE="0.0" STUDY_ID="STD-Cardozo-2001" TOTAL_1="56" TOTAL_2="48" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.0276339895692987" CI_START="0.09260930658282401" EFFECT_SIZE="0.43333333333333335" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3069895627637647" LOG_CI_START="-1.033345367589416" LOG_EFFECT_SIZE="-0.36317790241282566" MODIFIED="2011-12-26 06:41:17 +0000" MODIFIED_BY="[Empty name]" ORDER="1039" O_E="0.0" SE="0.7873193728543677" STUDY_ID="STD-Damas-2006" TOTAL_1="24" TOTAL_2="26" VAR="0.6198717948717949" WEIGHT="46.61478063227494"/>
<DICH_DATA CI_END="8.260092687698416" CI_START="0.7204087189498556" EFFECT_SIZE="2.4393939393939394" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9169849206291129" LOG_CI_START="-0.14242103964915054" LOG_EFFECT_SIZE="0.38728194048998105" ORDER="698" O_E="0.0" SE="0.6223003052115317" STUDY_ID="STD-Klastersky-1973" TOTAL_1="22" TOTAL_2="23" VAR="0.38725766986636545" WEIGHT="28.486810386390243"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="699" O_E="0.0" SE="0.0" STUDY_ID="STD-Sandberg-1997" TOTAL_1="37" TOTAL_2="36" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.3225436971144395" CI_START="0.015173840636129785" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8646619720038995" LOG_CI_START="-1.8189044814432243" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="700" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Sculier-1982" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="14.567118947585922"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="20.541287077089176" CI_END="1.0887369041830943" CI_START="0.7246856478463592" DF="13" EFFECT_SIZE="0.8882522213550413" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="160" I2="36.712826459157895" ID="CMP-003.02.03" LOG_CI_END="0.036922944157879375" LOG_CI_START="-0.13985033965157276" LOG_EFFECT_SIZE="-0.05146369774684667" NO="3" P_CHI2="0.08251113050035275" P_Z="0.2537859780832278" STUDIES="19" TAU2="0.0" TOTAL_1="1582" TOTAL_2="1375" WEIGHT="100.0" Z="1.1412017915987962">
<NAME>A different BL</NAME>
<DICH_DATA CI_END="1.4524039103370738" CI_START="0.4665638439939939" EFFECT_SIZE="0.8231884057971014" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" LOG_CI_END="0.16208740950244066" LOG_CI_START="-0.33108891955491365" LOG_EFFECT_SIZE="-0.08450075502623647" ORDER="701" O_E="0.0" SE="0.2896942169504909" STUDY_ID="STD-Alvarez_x002d_Lerma-2001a" TOTAL_1="69" TOTAL_2="71" VAR="0.08392273933455809" WEIGHT="12.024728269558338"/>
<DICH_DATA CI_END="3.6745949117762566" CI_START="0.5395054550493839" EFFECT_SIZE="1.408" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.5652094693312208" LOG_CI_START="-0.2680041597190341" LOG_EFFECT_SIZE="0.1486026548060934" ORDER="702" O_E="0.0" SE="0.48943381017810217" STUDY_ID="STD-Arich-1987" TOTAL_1="25" TOTAL_2="22" VAR="0.23954545454545456" WEIGHT="3.244414812168839"/>
<DICH_DATA CI_END="1.9171115225660975" CI_START="0.61566991069799" EFFECT_SIZE="1.0864197530864197" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.2826473774718505" LOG_CI_START="-0.2106520709288128" LOG_EFFECT_SIZE="0.035997653271518854" ORDER="703" O_E="0.0" SE="0.2897665378622012" STUDY_ID="STD-Brown-1984" TOTAL_1="18" TOTAL_2="16" VAR="0.08396464646464646" WEIGHT="5.812464559965539"/>
<DICH_DATA CI_END="1.418721045629022" CI_START="0.2702186076723028" EFFECT_SIZE="0.6191646191646192" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.15189701120549098" LOG_CI_START="-0.5682847480928428" LOG_EFFECT_SIZE="-0.20819386844367593" ORDER="704" O_E="0.0" SE="0.42303833036904465" STUDY_ID="STD-Felisart-1985" TOTAL_1="37" TOTAL_2="36" VAR="0.17896142896142897" WEIGHT="6.801360103230435"/>
<DICH_DATA CI_END="2.7893228503916" CI_START="1.0339269681475727" EFFECT_SIZE="1.6982214572576018" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="21" LOG_CI_END="0.44549878462417336" LOG_CI_START="0.01448986327371745" LOG_EFFECT_SIZE="0.2299943239489454" ORDER="705" O_E="0.0" SE="0.25317677392982757" STUDY_ID="STD-Finer-1992" TOTAL_1="249" TOTAL_2="222" VAR="0.064098478857515" WEIGHT="13.54322067911763"/>
<DICH_DATA CI_END="3.6075179132023756" CI_START="0.39916641708972667" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.557208496268825" LOG_CI_START="-0.39884600417357535" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="706" O_E="0.0" SE="0.5615911461059686" STUDY_ID="STD-Gomez-1990a" TOTAL_1="39" TOTAL_2="39" VAR="0.3153846153846154" WEIGHT="3.049749923438709"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="707" O_E="0.0" SE="0.0" STUDY_ID="STD-Havig-1973" TOTAL_1="24" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.215975079542482" CI_START="0.1839927119135329" EFFECT_SIZE="0.7692307692307693" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5073126747595234" LOG_CI_START="-0.7351993793731969" LOG_EFFECT_SIZE="-0.11394335230683675" ORDER="708" O_E="0.0" SE="0.7298577311314224" STUDY_ID="STD-Jaspers-1998" TOTAL_1="39" TOTAL_2="40" VAR="0.5326923076923076" WEIGHT="2.408916395222474"/>
<DICH_DATA CI_END="3.0420157098392417" CI_START="0.6443096245888809" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.4831614525436979" LOG_CI_START="-0.19090538118722192" LOG_EFFECT_SIZE="0.146128035678238" ORDER="709" O_E="0.0" SE="0.3959501948181826" STUDY_ID="STD-McCormick-1997" TOTAL_1="65" TOTAL_2="63" VAR="0.15677655677655677" WEIGHT="5.575324078786389"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="710" O_E="0.0" SE="0.0" STUDY_ID="STD-Rasmussen-1986" TOTAL_1="29" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.335567150499819" CI_START="0.5297708425076304" EFFECT_SIZE="0.8411566646860764" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="33" LOG_CI_END="0.1256657286422107" LOG_CI_START="-0.27591194805182445" LOG_EFFECT_SIZE="-0.07512310970480685" ORDER="711" O_E="0.0" SE="0.2358887151316354" STUDY_ID="STD-Rubinstein-1995" TOTAL_1="306" TOTAL_2="274" VAR="0.05564348592645383" WEIGHT="21.238879121989022"/>
<DICH_DATA CI_END="0.8257784681916034" CI_START="0.160892393837605" EFFECT_SIZE="0.364501679731243" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="19" LOG_CI_END="-0.08313644535025404" LOG_CI_START="-0.7934644866184174" LOG_EFFECT_SIZE="-0.4383004659843357" ORDER="712" O_E="0.0" SE="0.41725020762143167" STUDY_ID="STD-Smith-1984" TOTAL_1="94" TOTAL_2="93" VAR="0.17409773576012785" WEIGHT="11.651023236923066"/>
<DICH_DATA CI_END="1.3587073697477343" CI_START="0.02138411310119719" EFFECT_SIZE="0.17045454545454544" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.13312593106030254" LOG_CI_START="-1.6699087572492775" LOG_EFFECT_SIZE="-0.7683914130944874" ORDER="713" O_E="0.0" SE="1.0591115010786976" STUDY_ID="STD-Speich-1998" TOTAL_1="44" TOTAL_2="45" VAR="1.121717171717172" WEIGHT="3.6185796844396365"/>
<DICH_DATA CI_END="1.596094261813414" CI_START="0.10323084411702192" EFFECT_SIZE="0.40591397849462363" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2030585362481443" LOG_CI_START="-0.9861905214256007" LOG_EFFECT_SIZE="-0.3915659925887281" ORDER="714" O_E="0.0" SE="0.6985707833553355" STUDY_ID="STD-Stille-1992" TOTAL_1="186" TOTAL_2="151" VAR="0.48800113935768713" WEIGHT="4.039787435676676"/>
<DICH_DATA CI_END="3.6573286525107553" CI_START="0.1118039247724491" EFFECT_SIZE="0.6394557823129252" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5631639883825202" LOG_CI_START="-0.9515429506794751" LOG_EFFECT_SIZE="-0.19418948114847742" ORDER="715" O_E="0.0" SE="0.8897463539252893" STUDY_ID="STD-Thompson--1990" TOTAL_1="49" TOTAL_2="47" VAR="0.7916485743233462" WEIGHT="1.8679718281062092"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="716" O_E="0.0" SE="0.0" STUDY_ID="STD-Thompson-1993" TOTAL_1="80" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.338273443885321" CI_START="0.1084417517334551" EFFECT_SIZE="0.38095238095238093" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.1265448600964545" LOG_CI_START="-0.964803475580406" LOG_EFFECT_SIZE="-0.4191293077419757" ORDER="717" O_E="0.0" SE="0.641063414637976" STUDY_ID="STD-Warren-1983" TOTAL_1="56" TOTAL_2="64" VAR="0.41096230158730157" WEIGHT="5.123579871377031"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="718" O_E="0.0" SE="0.0" STUDY_ID="STD-Wing-1998" TOTAL_1="117" TOTAL_2="62" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="719" O_E="0.0" SE="0.0" STUDY_ID="STD-Yellin-1993" TOTAL_1="56" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.725679469770737" CI_END="1.0370384931101888" CI_START="0.4965331811446985" DF="6" EFFECT_SIZE="0.7175820663544391" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="59" I2="0.0" ID="CMP-003.02.04" LOG_CI_END="0.015794876962891204" LOG_CI_START="-0.30405172419469584" LOG_EFFECT_SIZE="-0.1441284236159023" MODIFIED="2011-12-26 14:20:57 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.71374156017004" P_Z="0.07733086040749988" STUDIES="10" TAU2="0.0" TOTAL_1="542" TOTAL_2="533" WEIGHT="100.0" Z="1.7663875020921098">
<NAME>B different BL</NAME>
<DICH_DATA CI_END="6.2314434482611825" CI_START="0.011113328418578669" EFFECT_SIZE="0.2631578947368421" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7945886580562603" LOG_CI_START="-1.9541558512898807" LOG_EFFECT_SIZE="-0.5797835966168102" ORDER="720" O_E="0.0" SE="1.6146261312946875" STUDY_ID="STD-Bergeron-1988" TOTAL_1="37" TOTAL_2="29" VAR="2.6070175438596492" WEIGHT="2.822129307906475"/>
<DICH_DATA CI_END="4.598004635829613" CI_START="0.04450811651697542" EFFECT_SIZE="0.4523809523809524" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6625694048006385" LOG_CI_START="-1.3515607836907813" LOG_EFFECT_SIZE="-0.3444956894450715" ORDER="721" O_E="0.0" SE="1.183110042825089" STUDY_ID="STD-Cone-1985" TOTAL_1="21" TOTAL_2="19" VAR="1.399749373433584" WEIGHT="3.5350882909565318"/>
<DICH_DATA CI_END="2.357375570364182" CI_START="0.08803470554565483" EFFECT_SIZE="0.45555555555555555" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.37242877859690693" LOG_CI_START="-1.0553460840360858" LOG_EFFECT_SIZE="-0.34145865271958936" ORDER="723" O_E="0.0" SE="0.8386820219101747" STUDY_ID="STD-Hoepelman-1988" TOTAL_1="45" TOTAL_2="41" VAR="0.7033875338753387" WEIGHT="7.046687623169166"/>
<DICH_DATA CI_END="12.12734418453573" CI_START="0.4875119785752522" EFFECT_SIZE="2.4315068493150687" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0837657033986128" LOG_CI_START="-0.3120147088572987" LOG_EFFECT_SIZE="0.385875497270657" ORDER="724" O_E="0.0" SE="0.8198883233835935" STUDY_ID="STD-Koehler-1990" TOTAL_1="73" TOTAL_2="71" VAR="0.6722168628207601" WEIGHT="3.4135111804209894"/>
<DICH_DATA CI_END="1.4042559079538888" CI_START="0.3940358551877818" EFFECT_SIZE="0.743859649122807" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="19" LOG_CI_END="0.14744625970600495" LOG_CI_START="-0.4044642578655225" LOG_EFFECT_SIZE="-0.12850899907975877" ORDER="725" O_E="0.0" SE="0.32419497002263836" STUDY_ID="STD-Mouton-1990" TOTAL_1="105" TOTAL_2="106" VAR="0.10510237858797938" WEIGHT="31.832548591551703"/>
<DICH_DATA CI_END="2.4364795063951146" CI_START="0.3419070889891188" EFFECT_SIZE="0.9127155172413793" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3867627628148112" LOG_CI_START="-0.46609189459112144" LOG_EFFECT_SIZE="-0.03966456588815514" ORDER="726" O_E="0.0" SE="0.5009710474588857" STUDY_ID="STD-Mouton-1995" TOTAL_1="116" TOTAL_2="121" VAR="0.2509719903920531" WEIGHT="13.182889025548167"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="727" O_E="0.0" SE="0.0" STUDY_ID="STD-Naime-Libien-1992" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.0856025424423192" CI_START="0.3115021565079405" EFFECT_SIZE="0.5815217391304348" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="23" LOG_CI_END="0.035670851755012306" LOG_CI_START="-0.5065389424036659" LOG_EFFECT_SIZE="-0.2354340453243268" ORDER="728" O_E="0.0" SE="0.3184967170705754" STUDY_ID="STD-Sieger-1997" TOTAL_1="104" TOTAL_2="107" VAR="0.10144015878473417" WEIGHT="38.16714598044696"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="729" O_E="0.0" SE="0.0" STUDY_ID="STD-Trujillo-1992" TOTAL_1="16" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="730" O_E="0.0" SE="0.0" STUDY_ID="STD-Wiecek-1986" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.208499115067839" CI_START="0.3413224690073932" DF="0" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-003.02.05" LOG_CI_END="0.7167125947102105" LOG_CI_START="-0.4668351214936107" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2013-08-13 05:03:29 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.6790213257374376" STUDIES="2" TAU2="0.0" TOTAL_1="51" TOTAL_2="63" WEIGHT="100.0" Z="0.41379898870766496">
<NAME>C different BL</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-26 14:20:57 +0000" MODIFIED_BY="[Empty name]" ORDER="3125" O_E="0.0" SE="0.0" STUDY_ID="STD-Duff-1982" TOTAL_1="31" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.208499115067838" CI_START="0.34132246900739327" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7167125947102104" LOG_CI_START="-0.46683512149361067" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="731" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-Landau-1990" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="33.39089293583769" CI_END="1.0241503968046561" CI_START="0.7578960648225563" CI_STUDY="95" CI_TOTAL="95" DF="31" EFFECT_MEASURE="RR" EFFECT_SIZE="0.881021881410847" ESTIMABLE="YES" EVENTS_1="273" EVENTS_2="302" I2="7.160314461886101" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.010363737602945655" LOG_CI_START="-0.12039034788900588" LOG_EFFECT_SIZE="-0.05501330514303007" METHOD="MH" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.35181051226161564" P_Q="0.5192867753610799" P_Z="0.09909326789455312" Q="4.212198445887672" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="44" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2891" TOTAL_2="2686" WEIGHT="600.0" Z="1.6492654335835357">
<NAME>All-cause mortality by ITT versus per-protocol analysis</NAME>
<GROUP_LABEL_1>Monotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours monotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.4082367136145764" CI_END="1.1919727792467492" CI_START="0.2757159682284764" DF="3" EFFECT_SIZE="0.5732764855913814" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="18" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.076266337654289" LOG_CI_START="-0.5595380807832735" LOG_EFFECT_SIZE="-0.24163587156449223" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9385357903950353" P_Z="0.13628767438620537" STUDIES="5" TAU2="0.0" TOTAL_1="260" TOTAL_2="259" WEIGHT="100.0" Z="1.4897587745715215">
<NAME>ITT&#8212;same BL (type one studies)</NAME>
<DICH_DATA CI_END="1.7629588148188347" CI_START="0.2702748393715548" EFFECT_SIZE="0.6902777777777778" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.24624216669192472" LOG_CI_START="-0.5681943820877975" LOG_EFFECT_SIZE="-0.16097610769793635" ORDER="732" O_E="0.0" SE="0.47840406027914484" STUDY_ID="STD-D_x0027_Antonio-1992" TOTAL_1="144" TOTAL_2="142" VAR="0.22887044489157166" WEIGHT="54.81746545357646"/>
<DICH_DATA CI_END="2.0276339895692987" CI_START="0.09260930658282401" EFFECT_SIZE="0.43333333333333335" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3069895627637647" LOG_CI_START="-1.033345367589416" LOG_EFFECT_SIZE="-0.36317790241282566" MODIFIED="2011-12-26 06:43:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1040" O_E="0.0" SE="0.7873193728543677" STUDY_ID="STD-Damas-2006" TOTAL_1="24" TOTAL_2="26" VAR="0.6198717948717949" WEIGHT="26.129658532871446"/>
<DICH_DATA CI_END="5.320030029638535" CI_START="0.04699221594750772" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7259140837366838" LOG_CI_START="-1.3279740750646463" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="733" O_E="0.0" SE="1.2064640713902572" STUDY_ID="STD-Ribera-1996" TOTAL_1="45" TOTAL_2="45" VAR="1.4555555555555557" WEIGHT="10.887357722029769"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="734" O_E="0.0" SE="0.0" STUDY_ID="STD-Sandberg-1997" TOTAL_1="37" TOTAL_2="36" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.3225436971144395" CI_START="0.015173840636129785" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8646619720038995" LOG_CI_START="-1.8189044814432243" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="735" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Sculier-1982" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="8.165518291522327"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.925028792369379" CI_END="1.5065581656200184" CI_START="0.7958301283640108" DF="4" EFFECT_SIZE="1.0949723185237277" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="61" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="0.1779859036961746" LOG_CI_START="-0.09917962345231096" LOG_EFFECT_SIZE="0.03940314012193179" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="Dolores Matthews" NO="2" P_CHI2="0.41624734041545375" P_Z="0.5773394285093563" STUDIES="6" TAU2="0.0" TOTAL_1="375" TOTAL_2="386" WEIGHT="100.0" Z="0.5572751872233941">
<NAME>Per-protocol&#8212;same BL (type two and three studies)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="736" O_E="0.0" SE="0.0" STUDY_ID="STD-Abrams-1979" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.143933394780039" CI_START="0.7045398228271409" EFFECT_SIZE="1.229018492176387" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="19" LOG_CI_END="0.33121128907632275" LOG_CI_START="-0.15209445415818415" LOG_EFFECT_SIZE="0.08955841745906934" ORDER="737" O_E="0.0" SE="0.2838961859779625" STUDY_ID="STD-Cometta-1994" TOTAL_1="148" TOTAL_2="144" VAR="0.08059704441283387" WEIGHT="32.1404097187618"/>
<DICH_DATA CI_END="1.5452478612798557" CI_START="0.5411130099195283" EFFECT_SIZE="0.9144144144144144" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.18899815117342472" LOG_CI_START="-0.26671202424827617" LOG_EFFECT_SIZE="-0.03885693653742572" ORDER="738" O_E="0.0" SE="0.26768641284445654" STUDY_ID="STD-Dupont-2000" TOTAL_1="111" TOTAL_2="116" VAR="0.07165601562153284" WEIGHT="39.1676312269446"/>
<DICH_DATA CI_END="8.260092687698416" CI_START="0.7204087189498556" EFFECT_SIZE="2.4393939393939394" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9169849206291129" LOG_CI_START="-0.14242103964915054" LOG_EFFECT_SIZE="0.38728194048998105" ORDER="739" O_E="0.0" SE="0.6223003052115317" STUDY_ID="STD-Klastersky-1973" TOTAL_1="22" TOTAL_2="23" VAR="0.38725766986636545" WEIGHT="4.894973732416449"/>
<DICH_DATA CI_END="2.74230421376631" CI_START="0.5671952289593608" EFFECT_SIZE="1.2471655328798186" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.43811563099017203" LOG_CI_START="-0.2462674309373614" LOG_EFFECT_SIZE="0.0959241000264053" ORDER="740" O_E="0.0" SE="0.40200999832702655" STUDY_ID="STD-Kljucar-1990" TOTAL_1="49" TOTAL_2="50" VAR="0.1616120387548959" WEIGHT="14.866965674901197"/>
<DICH_DATA CI_END="1.9188136720990658" CI_START="0.08938497437295481" EFFECT_SIZE="0.41414141414141414" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.28303280427792576" LOG_CI_START="-1.0487354800335547" LOG_EFFECT_SIZE="-0.38285133787781445" ORDER="741" O_E="0.0" SE="0.7822872825638911" STUDY_ID="STD-Korzeniowski-1982" TOTAL_1="33" TOTAL_2="41" VAR="0.6119733924611973" WEIGHT="8.930019646975955"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.251516091767591" CI_START="0.0584385963566154" DF="0" EFFECT_SIZE="0.88" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-003.03.03" LOG_CI_END="1.1222655682820444" LOG_CI_START="-1.2333002239817072" LOG_EFFECT_SIZE="-0.05551732784983137" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.9263904769071222" STUDIES="2" TAU2="0.0" TOTAL_1="81" TOTAL_2="70" WEIGHT="100.0" Z="0.09238711434928869">
<NAME>Unknown&#8212;same BL (type four studies)</NAME>
<DICH_DATA CI_END="13.251516091767591" CI_START="0.0584385963566154" EFFECT_SIZE="0.88" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1222655682820444" LOG_CI_START="-1.2333002239817072" LOG_EFFECT_SIZE="-0.05551732784983137" ORDER="742" O_E="0.0" SE="1.3836710066144533" STUDY_ID="STD-Carbon-1987" TOTAL_1="25" TOTAL_2="22" VAR="1.9145454545454546" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="743" O_E="0.0" SE="0.0" STUDY_ID="STD-Cardozo-2001" TOTAL_1="56" TOTAL_2="48" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="15.605625526898189" CI_END="1.0747853228415796" CI_START="0.7094796170593956" DF="12" EFFECT_SIZE="0.8732343782002072" ESTIMABLE="YES" EVENTS_1="148" EVENTS_2="162" I2="23.104652361954066" ID="CMP-003.03.04" LOG_CI_END="0.031321727120607414" LOG_CI_START="-0.14906007705751148" LOG_EFFECT_SIZE="-0.05886917496845208" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.20997402327576475" P_Z="0.20079051506701506" STUDIES="15" TAU2="0.0" TOTAL_1="1560" TOTAL_2="1429" WEIGHT="100.0" Z="1.279302679818181">
<NAME>ITT&#8212;different BL (type one studies)</NAME>
<DICH_DATA CI_END="1.4524039103370738" CI_START="0.4665638439939939" EFFECT_SIZE="0.8231884057971014" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" LOG_CI_END="0.16208740950244066" LOG_CI_START="-0.33108891955491365" LOG_EFFECT_SIZE="-0.08450075502623647" ORDER="744" O_E="0.0" SE="0.2896942169504909" STUDY_ID="STD-Alvarez_x002d_Lerma-2001a" TOTAL_1="69" TOTAL_2="71" VAR="0.08392273933455809" WEIGHT="11.946418183225695"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="745" O_E="0.0" SE="0.0" STUDY_ID="STD-Duff-1982" TOTAL_1="31" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.418721045629022" CI_START="0.2702186076723028" EFFECT_SIZE="0.6191646191646192" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.15189701120549098" LOG_CI_START="-0.5682847480928428" LOG_EFFECT_SIZE="-0.20819386844367593" ORDER="746" O_E="0.0" SE="0.42303833036904465" STUDY_ID="STD-Felisart-1985" TOTAL_1="37" TOTAL_2="36" VAR="0.17896142896142897" WEIGHT="6.757066786581299"/>
<DICH_DATA CI_END="2.7893228503916" CI_START="1.0339269681475727" EFFECT_SIZE="1.6982214572576018" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="21" LOG_CI_END="0.44549878462417336" LOG_CI_START="0.01448986327371745" LOG_EFFECT_SIZE="0.2299943239489454" ORDER="747" O_E="0.0" SE="0.25317677392982757" STUDY_ID="STD-Finer-1992" TOTAL_1="249" TOTAL_2="222" VAR="0.064098478857515" WEIGHT="13.455021531758211"/>
<DICH_DATA CI_END="3.6075179132023756" CI_START="0.39916641708972667" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.557208496268825" LOG_CI_START="-0.39884600417357535" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="748" O_E="0.0" SE="0.5615911461059686" STUDY_ID="STD-Gomez-1990a" TOTAL_1="39" TOTAL_2="39" VAR="0.3153846153846154" WEIGHT="3.029888669658691"/>
<DICH_DATA CI_END="2.357375570364182" CI_START="0.08803470554565483" EFFECT_SIZE="0.45555555555555555" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.37242877859690693" LOG_CI_START="-1.0553460840360858" LOG_EFFECT_SIZE="-0.34145865271958936" ORDER="749" O_E="0.0" SE="0.8386820219101747" STUDY_ID="STD-Hoepelman-1988" TOTAL_1="45" TOTAL_2="41" VAR="0.7033875338753387" WEIGHT="2.5366509792491367"/>
<DICH_DATA CI_END="3.215975079542482" CI_START="0.1839927119135329" EFFECT_SIZE="0.7692307692307693" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5073126747595234" LOG_CI_START="-0.7351993793731969" LOG_EFFECT_SIZE="-0.11394335230683675" ORDER="750" O_E="0.0" SE="0.7298577311314224" STUDY_ID="STD-Jaspers-1998" TOTAL_1="39" TOTAL_2="40" VAR="0.5326923076923076" WEIGHT="2.3932285188190168"/>
<DICH_DATA CI_END="12.12734418453573" CI_START="0.4875119785752522" EFFECT_SIZE="2.4315068493150687" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0837657033986128" LOG_CI_START="-0.3120147088572987" LOG_EFFECT_SIZE="0.385875497270657" ORDER="751" O_E="0.0" SE="0.8198883233835935" STUDY_ID="STD-Koehler-1990" TOTAL_1="73" TOTAL_2="71" VAR="0.6722168628207601" WEIGHT="1.2287881826949134"/>
<DICH_DATA CI_END="1.4042559079538888" CI_START="0.3940358551877818" EFFECT_SIZE="0.743859649122807" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="19" LOG_CI_END="0.14744625970600495" LOG_CI_START="-0.4044642578655225" LOG_EFFECT_SIZE="-0.12850899907975877" ORDER="752" O_E="0.0" SE="0.32419497002263836" STUDY_ID="STD-Mouton-1990" TOTAL_1="105" TOTAL_2="106" VAR="0.10510237858797938" WEIGHT="11.459010229325285"/>
<DICH_DATA CI_END="2.4364795063951146" CI_START="0.3419070889891188" EFFECT_SIZE="0.9127155172413793" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3867627628148112" LOG_CI_START="-0.46609189459112144" LOG_EFFECT_SIZE="-0.03966456588815514" ORDER="753" O_E="0.0" SE="0.5009710474588857" STUDY_ID="STD-Mouton-1995" TOTAL_1="116" TOTAL_2="121" VAR="0.2509719903920531" WEIGHT="4.745547148427452"/>
<DICH_DATA CI_END="1.335567150499819" CI_START="0.5297708425076304" EFFECT_SIZE="0.8411566646860764" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="33" LOG_CI_END="0.1256657286422107" LOG_CI_START="-0.27591194805182445" LOG_EFFECT_SIZE="-0.07512310970480685" ORDER="754" O_E="0.0" SE="0.2358887151316354" STUDY_ID="STD-Rubinstein-1995" TOTAL_1="306" TOTAL_2="274" VAR="0.05564348592645383" WEIGHT="21.100562611181697"/>
<DICH_DATA CI_END="1.0856025424423192" CI_START="0.3115021565079405" EFFECT_SIZE="0.5815217391304348" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="23" LOG_CI_END="0.035670851755012306" LOG_CI_START="-0.5065389424036659" LOG_EFFECT_SIZE="-0.2354340453243268" ORDER="755" O_E="0.0" SE="0.3184967170705754" STUDY_ID="STD-Sieger-1997" TOTAL_1="104" TOTAL_2="107" VAR="0.10144015878473417" WEIGHT="13.739324545637135"/>
<DICH_DATA CI_END="1.3587073697477343" CI_START="0.02138411310119719" EFFECT_SIZE="0.17045454545454544" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.13312593106030254" LOG_CI_START="-1.6699087572492775" LOG_EFFECT_SIZE="-0.7683914130944874" ORDER="756" O_E="0.0" SE="1.0591115010786976" STUDY_ID="STD-Speich-1998" TOTAL_1="44" TOTAL_2="45" VAR="1.121717171717172" WEIGHT="3.595013972089413"/>
<DICH_DATA CI_END="1.596094261813414" CI_START="0.10323084411702192" EFFECT_SIZE="0.40591397849462363" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2030585362481443" LOG_CI_START="-0.9861905214256007" LOG_EFFECT_SIZE="-0.3915659925887281" ORDER="757" O_E="0.0" SE="0.6985707833553355" STUDY_ID="STD-Stille-1992" TOTAL_1="186" TOTAL_2="151" VAR="0.48800113935768713" WEIGHT="4.013478641352046"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="758" O_E="0.0" SE="0.0" STUDY_ID="STD-Wing-1998" TOTAL_1="117" TOTAL_2="62" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.443230864597513" CI_END="1.0688617569793113" CI_START="0.5360239199534245" DF="7" EFFECT_SIZE="0.7569250087454866" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="57" I2="32.970935041473076" ID="CMP-003.03.05" LOG_CI_END="0.02892153863866709" LOG_CI_START="-0.2708158295759086" LOG_EFFECT_SIZE="-0.12094714546862075" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.1648161526400268" P_Z="0.11371083177378906" STUDIES="12" TAU2="0.0" TOTAL_1="554" TOTAL_2="483" WEIGHT="99.99999999999999" Z="1.5817317044147992">
<NAME>Per-protocol&#8212;different BL (type two and three studies)</NAME>
<DICH_DATA CI_END="3.6745949117762566" CI_START="0.5395054550493839" EFFECT_SIZE="1.408" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.5652094693312208" LOG_CI_START="-0.2680041597190341" LOG_EFFECT_SIZE="0.1486026548060934" ORDER="759" O_E="0.0" SE="0.48943381017810217" STUDY_ID="STD-Arich-1987" TOTAL_1="25" TOTAL_2="22" VAR="0.23954545454545456" WEIGHT="9.119099554752038"/>
<DICH_DATA CI_END="6.2314434482611825" CI_START="0.011113328418578669" EFFECT_SIZE="0.2631578947368421" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7945886580562603" LOG_CI_START="-1.9541558512898807" LOG_EFFECT_SIZE="-0.5797835966168102" ORDER="760" O_E="0.0" SE="1.6146261312946875" STUDY_ID="STD-Bergeron-1988" TOTAL_1="37" TOTAL_2="29" VAR="2.6070175438596492" WEIGHT="2.874125612609496"/>
<DICH_DATA CI_END="1.9171115225660975" CI_START="0.61566991069799" EFFECT_SIZE="1.0864197530864197" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.2826473774718505" LOG_CI_START="-0.2106520709288128" LOG_EFFECT_SIZE="0.035997653271518854" ORDER="761" O_E="0.0" SE="0.2897665378622012" STUDY_ID="STD-Brown-1984" TOTAL_1="18" TOTAL_2="16" VAR="0.08396464646464646" WEIGHT="16.33713506114871"/>
<DICH_DATA CI_END="4.598004635829613" CI_START="0.04450811651697542" EFFECT_SIZE="0.4523809523809524" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6625694048006385" LOG_CI_START="-1.3515607836907813" LOG_EFFECT_SIZE="-0.3444956894450715" ORDER="762" O_E="0.0" SE="1.183110042825089" STUDY_ID="STD-Cone-1985" TOTAL_1="21" TOTAL_2="19" VAR="1.399749373433584" WEIGHT="3.600220504216105"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="763" O_E="0.0" SE="0.0" STUDY_ID="STD-Havig-1973" TOTAL_1="24" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.0420157098392417" CI_START="0.6443096245888809" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.4831614525436979" LOG_CI_START="-0.19090538118722192" LOG_EFFECT_SIZE="0.146128035678238" ORDER="764" O_E="0.0" SE="0.3959501948181826" STUDY_ID="STD-McCormick-1997" TOTAL_1="65" TOTAL_2="63" VAR="0.15677655677655677" WEIGHT="15.670602641119208"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="765" O_E="0.0" SE="0.0" STUDY_ID="STD-Rasmussen-1986" TOTAL_1="29" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.8257784681916034" CI_START="0.160892393837605" EFFECT_SIZE="0.364501679731243" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="19" LOG_CI_END="-0.08313644535025404" LOG_CI_START="-0.7934644866184174" LOG_EFFECT_SIZE="-0.4383004659843357" ORDER="766" O_E="0.0" SE="0.41725020762143167" STUDY_ID="STD-Smith-1984" TOTAL_1="94" TOTAL_2="93" VAR="0.17409773576012785" WEIGHT="32.747613040641525"/>
<DICH_DATA CI_END="3.6573286525107553" CI_START="0.1118039247724491" EFFECT_SIZE="0.6394557823129252" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5631639883825202" LOG_CI_START="-0.9515429506794751" LOG_EFFECT_SIZE="-0.19418948114847742" ORDER="767" O_E="0.0" SE="0.8897463539252893" STUDY_ID="STD-Thompson--1990" TOTAL_1="49" TOTAL_2="47" VAR="0.7916485743233462" WEIGHT="5.250321568648486"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="768" O_E="0.0" SE="0.0" STUDY_ID="STD-Thompson-1993" TOTAL_1="80" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.338273443885321" CI_START="0.1084417517334551" EFFECT_SIZE="0.38095238095238093" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.1265448600964545" LOG_CI_START="-0.964803475580406" LOG_EFFECT_SIZE="-0.4191293077419757" ORDER="769" O_E="0.0" SE="0.641063414637976" STUDY_ID="STD-Warren-1983" TOTAL_1="56" TOTAL_2="64" VAR="0.41096230158730157" WEIGHT="14.40088201686442"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="770" O_E="0.0" SE="0.0" STUDY_ID="STD-Yellin-1993" TOTAL_1="56" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.208499115067839" CI_START="0.3413224690073932" DF="0" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-003.03.06" LOG_CI_END="0.7167125947102105" LOG_CI_START="-0.4668351214936107" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.6790213257374376" STUDIES="4" TAU2="0.0" TOTAL_1="61" TOTAL_2="59" WEIGHT="100.0" Z="0.41379898870766496">
<NAME>Unknown&#8212;different BL (type four studies)</NAME>
<DICH_DATA CI_END="5.208499115067838" CI_START="0.34132246900739327" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7167125947102104" LOG_CI_START="-0.46683512149361067" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="771" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-Landau-1990" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="772" O_E="0.0" SE="0.0" STUDY_ID="STD-Naime-Libien-1992" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="773" O_E="0.0" SE="0.0" STUDY_ID="STD-Trujillo-1992" TOTAL_1="16" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="774" O_E="0.0" SE="0.0" STUDY_ID="STD-Wiecek-1986" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="80.3008592760863" CI_END="0.93307983023589" CI_START="0.7797855402900833" CI_STUDY="95" CI_TOTAL="95" DF="63" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8529959903506421" ESTIMABLE="YES" EVENTS_1="655" EVENTS_2="756" I2="21.545048747988325" I2_Q="77.7243128958774" ID="CMP-003.04" LOG_CI_END="-0.03008119832446029" LOG_CI_START="-0.10802482227761744" LOG_EFFECT_SIZE="-0.06905301030103886" METHOD="MH" MODIFIED="2013-08-13 06:58:39 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.06978359872616458" P_Q="0.0012583242408121809" P_Z="5.150538685185325E-4" Q="17.956797387676154" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="66" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="3491" TOTAL_2="3312" WEIGHT="500.0" Z="3.4728026835254053">
<NAME>Clinical failure by allocation concealment</NAME>
<GROUP_LABEL_1>Monotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours monotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.7740593149560393" CI_END="1.3244100928057625" CI_START="0.9321935164372213" DF="7" EFFECT_SIZE="1.11112848114768" ESTIMABLE="YES" EVENTS_1="171" EVENTS_2="160" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="0.12202248167920628" LOG_CI_START="-0.030493921984134705" LOG_EFFECT_SIZE="0.045764279847535796" NO="1" P_CHI2="0.8054025859543303" P_Z="0.23950742404109038" STUDIES="8" TAU2="0.0" TOTAL_1="559" TOTAL_2="579" WEIGHT="99.99999999999999" Z="1.1762189262943115">
<NAME>A same BL</NAME>
<DICH_DATA CI_END="2.155845445955638" CI_START="0.8606766127447515" EFFECT_SIZE="1.3621621621621622" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="25" LOG_CI_END="0.3336176227602601" LOG_CI_START="-0.06515999800319945" LOG_EFFECT_SIZE="0.13422881237853032" ORDER="775" O_E="0.0" SE="0.23424394841751486" STUDY_ID="STD-Cometta-1994" TOTAL_1="148" TOTAL_2="144" VAR="0.05487022737022737" WEIGHT="16.21416942647189"/>
<DICH_DATA CI_END="1.7738115910050403" CI_START="0.8274562460098094" EFFECT_SIZE="1.2115079365079364" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="35" LOG_CI_END="0.24890748847637187" LOG_CI_START="-0.08225496144213654" LOG_EFFECT_SIZE="0.08332626351711768" ORDER="776" O_E="0.0" SE="0.1945264623626969" STUDY_ID="STD-D_x0027_Antonio-1992" TOTAL_1="144" TOTAL_2="142" VAR="0.03784054455934573" WEIGHT="22.549677623842516"/>
<DICH_DATA CI_END="1.3667256675620698" CI_START="0.8230512110018743" EFFECT_SIZE="1.0606060606060606" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="55" LOG_CI_END="0.13568135069047074" LOG_CI_START="-0.08457314174569446" LOG_EFFECT_SIZE="0.025554104472388137" ORDER="777" O_E="0.0" SE="0.12937857913432477" STUDY_ID="STD-Dupont-2000" TOTAL_1="99" TOTAL_2="105" VAR="0.016738816738816734" WEIGHT="34.15415545565013"/>
<DICH_DATA CI_END="2.9094577025383535" CI_START="0.6391239613516574" EFFECT_SIZE="1.3636363636363635" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.46381204783713936" LOG_CI_START="-0.19441490004222706" LOG_EFFECT_SIZE="0.13469857389745618" ORDER="778" O_E="0.0" SE="0.3866457674602807" STUDY_ID="STD-Kljucar-1990" TOTAL_1="44" TOTAL_2="45" VAR="0.14949494949494946" WEIGHT="5.693522135201329"/>
<DICH_DATA CI_END="1.9007156127572655" CI_START="0.14916575169326518" EFFECT_SIZE="0.5324675324675324" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.27891714208928725" LOG_CI_START="-0.8263308789947802" LOG_EFFECT_SIZE="-0.2737068684527464" ORDER="779" O_E="0.0" SE="0.6492281586507218" STUDY_ID="STD-Korzeniowski-1982" TOTAL_1="33" TOTAL_2="41" VAR="0.42149720198500684" WEIGHT="3.9944417682775084"/>
<DICH_DATA CI_END="3.826396404729478" CI_START="0.31622442424010855" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.582789959802314" LOG_CI_START="-0.5000045894858638" LOG_EFFECT_SIZE="0.04139268515822508" ORDER="780" O_E="0.0" SE="0.6360388781713383" STUDY_ID="STD-Mergoni-1987" TOTAL_1="20" TOTAL_2="22" VAR="0.40454545454545454" WEIGHT="2.4373423282006645"/>
<DICH_DATA CI_END="1.5400316693721572" CI_START="0.4008663919406224" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.18752965180539463" LOG_CI_START="-0.3970003528454206" LOG_EFFECT_SIZE="-0.104735350520013" ORDER="781" O_E="0.0" SE="0.34335581820207717" STUDY_ID="STD-Ribera-1996" TOTAL_1="45" TOTAL_2="45" VAR="0.11789321789321788" WEIGHT="8.957233056137444"/>
<DICH_DATA CI_END="2.0855643415267795" CI_START="0.45957924110915704" EFFECT_SIZE="0.9790209790209791" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.3192235927620454" LOG_CI_START="-0.33763959633569307" LOG_EFFECT_SIZE="-0.009208001786823765" ORDER="782" O_E="0.0" SE="0.38584468880123757" STUDY_ID="STD-Sandberg-1997" TOTAL_1="26" TOTAL_2="35" VAR="0.14887612387612387" WEIGHT="5.999458206218522"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.923182782978333" CI_END="1.504837368764996" CI_START="0.793622079119483" DF="10" EFFECT_SIZE="1.0928275990914433" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="61" I2="8.45159145754601" ID="CMP-003.04.02" LOG_CI_END="0.17748956726250345" LOG_CI_START="-0.10038625831056701" LOG_EFFECT_SIZE="0.03855165447596823" NO="2" P_CHI2="0.36353412643943095" P_Z="0.5865522771358911" STUDIES="12" TAU2="0.0" TOTAL_1="360" TOTAL_2="372" WEIGHT="100.00000000000001" Z="0.5438389911141143">
<NAME>B same BL</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="783" O_E="0.0" SE="0.0" STUDY_ID="STD-Abrams-1979" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="11.697696457498267" CI_START="0.0593659142180342" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0681003477040096" LOG_CI_START="-1.226462839799259" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="784" O_E="0.0" SE="1.347837774610382" STUDY_ID="STD-Biglino-1991" TOTAL_1="12" TOTAL_2="10" VAR="1.8166666666666667" WEIGHT="1.8431667553543538"/>
<DICH_DATA CI_END="2.6312143240480275" CI_START="0.1655509382184593" EFFECT_SIZE="0.66" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4201562247335235" LOG_CI_START="-0.781068353649786" LOG_EFFECT_SIZE="-0.1804560644581313" ORDER="785" O_E="0.0" SE="0.7056052634999174" STUDY_ID="STD-Carbon-1987" TOTAL_1="25" TOTAL_2="22" VAR="0.49787878787878775" WEIGHT="7.189657556346771"/>
<DICH_DATA CI_END="1.9847833295834896" CI_START="0.37016326497723917" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.2977131035916891" LOG_CI_START="-0.4316066828529156" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="786" O_E="0.0" SE="0.4284060527487281" STUDY_ID="STD-Cardozo-2001" TOTAL_1="56" TOTAL_2="48" VAR="0.18353174603174602" WEIGHT="16.375827711032912"/>
<DICH_DATA CI_END="2.5248479213118067" CI_START="0.1293268436046026" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.40223522446491633" LOG_CI_START="-0.8883113218375052" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="787" O_E="0.0" SE="0.758073429606476" STUDY_ID="STD-Coppens-1983" TOTAL_1="22" TOTAL_2="44" VAR="0.5746753246753247" WEIGHT="7.884657786793626"/>
<DICH_DATA CI_END="7.689843930627566" CI_START="1.0748755208254848" EFFECT_SIZE="2.875" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.8859175256590314" LOG_CI_START="0.0313581723922671" LOG_EFFECT_SIZE="0.4586378490256493" ORDER="788" O_E="0.0" SE="0.5019723942459189" STUDY_ID="STD-Klastersky-1973" TOTAL_1="22" TOTAL_2="23" VAR="0.2519762845849802" WEIGHT="6.608094145122276"/>
<DICH_DATA CI_END="1.5195651886332249" CI_START="0.279337797304769" EFFECT_SIZE="0.6515151515151515" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.18171933584499625" LOG_CI_START="-0.5538702957695606" LOG_EFFECT_SIZE="-0.18607547996228216" ORDER="789" O_E="0.0" SE="0.4320889908377921" STUDY_ID="STD-Piccart-1984" TOTAL_1="42" TOTAL_2="43" VAR="0.1867008960032216" WEIGHT="18.366614609236915"/>
<DICH_DATA CI_END="17.294732547204912" CI_START="1.0349630001602124" EFFECT_SIZE="4.230769230769231" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.2379138502953821" LOG_CI_START="0.014924824079431976" LOG_EFFECT_SIZE="0.626419337187407" ORDER="790" O_E="0.0" SE="0.7183898078925648" STUDY_ID="STD-Sage-1987" TOTAL_1="26" TOTAL_2="22" VAR="0.5160839160839161" WEIGHT="3.660733972439897"/>
<DICH_DATA CI_END="2.523907854293063" CI_START="0.22286867527402432" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.40207349514318896" LOG_CI_START="-0.6519509683597887" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="791" O_E="0.0" SE="0.6191391873668903" STUDY_ID="STD-Sculier-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.3833333333333333" WEIGHT="6.758278102965964"/>
<DICH_DATA CI_END="14.55119169880151" CI_START="0.06353817832623988" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1628985621892929" LOG_CI_START="-1.1969652407868534" LOG_EFFECT_SIZE="-0.017033339298780342" ORDER="792" O_E="0.0" SE="1.3861956793824102" STUDY_ID="STD-Sexton-1998" TOTAL_1="26" TOTAL_2="25" VAR="1.9215384615384614" WEIGHT="1.7226983399717164"/>
<DICH_DATA CI_END="3.8827994475086087" CI_START="0.44874838980365256" EFFECT_SIZE="1.32" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5891449591554481" LOG_CI_START="-0.3479970967437483" LOG_EFFECT_SIZE="0.12057393120584989" ORDER="793" O_E="0.0" SE="0.5504818825631803" STUDY_ID="STD-Sukoh-1994" TOTAL_1="30" TOTAL_2="33" VAR="0.3030303030303031" WEIGHT="8.045569170197577"/>
<DICH_DATA CI_END="1.9693429049207163" CI_START="0.46703880711684953" EFFECT_SIZE="0.9590409590409591" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.2943213427246578" LOG_CI_START="-0.33064703160415826" LOG_EFFECT_SIZE="-0.018162844439750202" ORDER="794" O_E="0.0" SE="0.36710951672409314" STUDY_ID="STD-Takamoto-1994" TOTAL_1="77" TOTAL_2="80" VAR="0.13476939726939724" WEIGHT="21.544701850537994"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.8638120398082" CI_END="0.8569411264132021" CI_START="0.6014667925394692" DF="13" EFFECT_SIZE="0.7179287086465539" ESTIMABLE="YES" EVENTS_1="163" EVENTS_2="215" I2="0.0" ID="CMP-003.04.03" LOG_CI_END="-0.06704901396030123" LOG_CI_START="-0.22078834540639614" LOG_EFFECT_SIZE="-0.1439186796833487" MODIFIED="2011-12-26 07:00:53 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5388418892123136" P_Z="2.429982503041069E-4" STUDIES="14" TAU2="0.0" TOTAL_1="1113" TOTAL_2="986" WEIGHT="100.0" Z="3.669528496431936">
<NAME>A different BL</NAME>
<DICH_DATA CI_END="1.0074864919644275" CI_START="0.2658612783365917" EFFECT_SIZE="0.5175438596491229" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="20" LOG_CI_END="0.0032392319797593778" LOG_CI_START="-0.575344911368416" LOG_EFFECT_SIZE="-0.2860528396943284" ORDER="795" O_E="0.0" SE="0.33986318984041847" STUDY_ID="STD-Alvarez_x002d_Lerma-2001a" TOTAL_1="57" TOTAL_2="59" VAR="0.11550698780850434" WEIGHT="8.914132725023492"/>
<DICH_DATA CI_END="1.9601526210417917" CI_START="0.14222565988347913" EFFECT_SIZE="0.528" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.2922898876298273" LOG_CI_START="-0.8470220425622028" LOG_EFFECT_SIZE="-0.27736607746618774" ORDER="796" O_E="0.0" SE="0.6692374674798086" STUDY_ID="STD-Arich-1987" TOTAL_1="25" TOTAL_2="22" VAR="0.4478787878787879" WEIGHT="2.4123726112885526"/>
<DICH_DATA CI_END="17.69656322236463" CI_START="0.0749290767652106" EFFECT_SIZE="1.1515151515151516" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2478889319840376" LOG_CI_START="-1.1253496185061924" LOG_EFFECT_SIZE="0.06126965673892271" MODIFIED="2011-12-26 07:00:53 +0000" MODIFIED_BY="[Empty name]" ORDER="2073" O_E="0.0" SE="1.3940520722782508" STUDY_ID="STD-Banasal-2006" TOTAL_1="33" TOTAL_2="38" VAR="1.9433811802232854" WEIGHT="0.4215875966319487"/>
<DICH_DATA CI_END="1.668340822997299" CI_START="0.5604233296704261" EFFECT_SIZE="0.9669421487603306" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" LOG_CI_END="0.22228477677345543" LOG_CI_START="-0.25148379391403236" LOG_EFFECT_SIZE="-0.014599508570288439" ORDER="797" O_E="0.0" SE="0.278294003614078" STUDY_ID="STD-Finer-1992" TOTAL_1="220" TOTAL_2="195" VAR="0.07744755244755246" WEIGHT="10.578631741993638"/>
<DICH_DATA CI_END="3.6075179132023756" CI_START="0.39916641708972667" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.557208496268825" LOG_CI_START="-0.39884600417357535" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="798" O_E="0.0" SE="0.5615911461059686" STUDY_ID="STD-Gomez-1990a" TOTAL_1="39" TOTAL_2="39" VAR="0.3153846153846154" WEIGHT="2.2676302546112397"/>
<DICH_DATA CI_END="1.2138694205384808" CI_START="0.2589786629232571" EFFECT_SIZE="0.5606837606837607" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.08417197093223315" LOG_CI_START="-0.5867360156732359" LOG_EFFECT_SIZE="-0.25128202237050135" ORDER="799" O_E="0.0" SE="0.39409467238014734" STUDY_ID="STD-Hoepelman-1988" TOTAL_1="45" TOTAL_2="41" VAR="0.15531061079841568" WEIGHT="6.170063716035233"/>
<DICH_DATA CI_END="1.5219304663112376" CI_START="0.4423600838070252" EFFECT_SIZE="0.8205128205128205" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="15" LOG_CI_END="0.1823948109186749" LOG_CI_START="-0.3542240683318614" LOG_EFFECT_SIZE="-0.08591462870659325" ORDER="800" O_E="0.0" SE="0.3152125859780576" STUDY_ID="STD-Jaspers-1998" TOTAL_1="39" TOTAL_2="40" VAR="0.09935897435897437" WEIGHT="6.716778222519368"/>
<DICH_DATA CI_END="3.5393716644310933" CI_START="0.7008659262685055" EFFECT_SIZE="1.575" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.5489261696836956" LOG_CI_START="-0.15436505343245688" LOG_EFFECT_SIZE="0.19728055812561932" ORDER="801" O_E="0.0" SE="0.41311674580612884" STUDY_ID="STD-McCormick-1997" TOTAL_1="65" TOTAL_2="63" VAR="0.17066544566544567" WEIGHT="3.6848991637432644"/>
<DICH_DATA CI_END="0.867426039722828" CI_START="0.4210317967449039" EFFECT_SIZE="0.604329334095093" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="59" LOG_CI_END="-0.061767544674934186" LOG_CI_START="-0.37568510456955584" LOG_EFFECT_SIZE="-0.21872632462224503" ORDER="802" O_E="0.0" SE="0.1843967285990835" STUDY_ID="STD-Rubinstein-1995" TOTAL_1="267" TOTAL_2="238" VAR="0.03400215351804405" WEIGHT="28.294637149220478"/>
<DICH_DATA CI_END="7.501364429912652" CI_START="0.014812120134843915" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.875140264790061" LOG_CI_START="-1.8293827742293858" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="803" O_E="0.0" SE="1.5886502207249786" STUDY_ID="STD-Sanfilippo-1989" TOTAL_1="13" TOTAL_2="13" VAR="2.5238095238095233" WEIGHT="0.6802890763833719"/>
<DICH_DATA CI_END="0.8499294497951944" CI_START="0.45564346622766727" EFFECT_SIZE="0.6223060344827587" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="58" LOG_CI_END="-0.07061712232836635" LOG_CI_START="-0.34137485298099385" LOG_EFFECT_SIZE="-0.2059959876546801" ORDER="804" O_E="0.0" SE="0.15904443125773576" STUDY_ID="STD-Smith-1984" TOTAL_1="96" TOTAL_2="99" VAR="0.025295131114096633" WEIGHT="25.89982616959053"/>
<DICH_DATA CI_END="1.8956893891166395" CI_START="0.18946365936729576" EFFECT_SIZE="0.5993031358885017" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2777671791816151" LOG_CI_START="-0.7224740788345019" LOG_EFFECT_SIZE="-0.22235344982644345" ORDER="805" O_E="0.0" SE="0.5875466662327474" STUDY_ID="STD-Speich-1998" TOTAL_1="41" TOTAL_2="43" VAR="0.34521108500121545" WEIGHT="3.0990946813020273"/>
<DICH_DATA CI_END="121.21138446425599" CI_START="0.3974297533358782" EFFECT_SIZE="6.940677966101695" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.08354341172641" LOG_CI_START="-0.40073962281782394" LOG_EFFECT_SIZE="0.841401894454293" ORDER="806" O_E="0.0" SE="1.459280151890634" STUDY_ID="STD-Wing-1998" TOTAL_1="117" TOTAL_2="62" VAR="2.1294985617019515" WEIGHT="0.2956689171758301"/>
<DICH_DATA CI_END="9.392068384176333" CI_START="0.039248271403202646" EFFECT_SIZE="0.6071428571428571" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.9727612460375162" LOG_CI_START="-1.406179465965407" LOG_EFFECT_SIZE="-0.21670910996394532" ORDER="807" O_E="0.0" SE="1.3974015501769614" STUDY_ID="STD-Yellin-1993" TOTAL_1="56" TOTAL_2="34" VAR="1.952731092436975" WEIGHT="0.5643879744810196"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="27.469165404748495" CI_END="0.9307450693543616" CI_START="0.6885966725742235" DF="27" EFFECT_SIZE="0.8005672724838796" ESTIMABLE="YES" EVENTS_1="235" EVENTS_2="279" I2="1.7079710935352685" ID="CMP-003.04.04" LOG_CI_END="-0.031169255789521656" LOG_CI_START="-0.1620350802170919" LOG_EFFECT_SIZE="-0.09660216800330677" MODIFIED="2011-12-26 07:25:29 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.43871526016144236" P_Z="0.003808512278865706" STUDIES="29" TAU2="0.0" TOTAL_1="1378" TOTAL_2="1282" WEIGHT="100.00000000000001" Z="2.893601456960374">
<NAME>B different BL</NAME>
<DICH_DATA CI_END="2.3225990308636475" CI_START="0.007117290597831311" EFFECT_SIZE="0.12857142857142856" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3659742404872978" LOG_CI_START="-2.147685301637162" LOG_EFFECT_SIZE="-0.890855530574932" ORDER="808" O_E="0.0" SE="1.4765360578593163" STUDY_ID="STD-Aguilar-1992" TOTAL_1="19" TOTAL_2="17" VAR="2.1801587301587304" WEIGHT="1.2924452892597484"/>
<DICH_DATA CI_END="1.5550666855189255" CI_START="0.06764100107599494" EFFECT_SIZE="0.32432432432432434" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.19174901749913703" LOG_CI_START="-1.1697899735378774" LOG_EFFECT_SIZE="-0.48902047801937015" ORDER="809" O_E="0.0" SE="0.7997747430618447" STUDY_ID="STD-Bergeron-1988" TOTAL_1="37" TOTAL_2="30" VAR="0.6396396396396397" WEIGHT="1.9372900604469152"/>
<DICH_DATA CI_END="1.423999570845346" CI_START="0.3356573471587424" EFFECT_SIZE="0.691358024691358" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.1535098584163388" LOG_CI_START="-0.4741038421612374" LOG_EFFECT_SIZE="-0.16029699187244936" ORDER="810" O_E="0.0" SE="0.368663394457191" STUDY_ID="STD-Brown-1984" TOTAL_1="18" TOTAL_2="16" VAR="0.1359126984126984" WEIGHT="3.342980336421433"/>
<DICH_DATA CI_END="2.6498175935704897" CI_START="0.17377014357166556" EFFECT_SIZE="0.6785714285714286" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4232159792831023" LOG_CI_START="-0.7600248400618829" LOG_EFFECT_SIZE="-0.16840443038939024" ORDER="811" O_E="0.0" SE="0.6950415144197627" STUDY_ID="STD-Cone-1985" TOTAL_1="21" TOTAL_2="19" VAR="0.48308270676691717" WEIGHT="1.4733876297561133"/>
<DICH_DATA CI_END="0.9370474331203014" CI_START="0.2525689662751385" EFFECT_SIZE="0.4864864864864865" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="18" LOG_CI_END="-0.028238424671436866" LOG_CI_START="-0.5976200132559408" LOG_EFFECT_SIZE="-0.3129292189636889" ORDER="812" O_E="0.0" SE="0.3344575636188571" STUDY_ID="STD-Felisart-1985" TOTAL_1="37" TOTAL_2="36" VAR="0.11186186186186185" WEIGHT="6.401018665476656"/>
<DICH_DATA CI_END="6.586766671602955" CI_START="0.4918953655924044" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.8186722793470714" LOG_CI_START="-0.30812726914045924" LOG_EFFECT_SIZE="0.25527250510330607" MODIFIED="2011-12-26 07:25:29 +0000" MODIFIED_BY="[Empty name]" ORDER="2093" O_E="0.0" SE="0.6618876325292973" STUDY_ID="STD-Figueroa_x002d_Damian-1996" TOTAL_1="14" TOTAL_2="42" VAR="0.4380952380952381" WEIGHT="0.8770164462834007"/>
<DICH_DATA CI_END="0.7364746482815971" CI_START="0.10801855283463083" EFFECT_SIZE="0.28205128205128205" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.132842198313418" LOG_CI_START="-0.9665016454231303" LOG_EFFECT_SIZE="-0.5496719218682742" ORDER="813" O_E="0.0" SE="0.4896956859130625" STUDY_ID="STD-Gerecht-1989" TOTAL_1="24" TOTAL_2="22" VAR="0.23980186480186477" WEIGHT="4.758767499833409"/>
<DICH_DATA CI_END="5.597705211534098" CI_START="0.052414831915982264" EFFECT_SIZE="0.5416666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7480100237523192" LOG_CI_START="-1.2805458025618577" LOG_EFFECT_SIZE="-0.2662678894047693" ORDER="814" O_E="0.0" SE="1.191583733890235" STUDY_ID="STD-Havig-1973" TOTAL_1="24" TOTAL_2="26" VAR="1.4198717948717947" WEIGHT="0.6735486307456517"/>
<DICH_DATA CI_END="4.177208504264446" CI_START="0.15321236642763564" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6208861535010605" LOG_CI_START="-0.8147061795171733" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="815" O_E="0.0" SE="0.8432740427115678" STUDY_ID="STD-Holloway--1985" TOTAL_1="15" TOTAL_2="18" VAR="0.711111111111111" WEIGHT="0.9567452141273461"/>
<DICH_DATA CI_END="1.1620638386085749" CI_START="0.1320089074981098" EFFECT_SIZE="0.39166666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.0652299869130772" LOG_CI_START="-0.879396763136892" LOG_EFFECT_SIZE="-0.40708338811190736" ORDER="816" O_E="0.0" SE="0.5548784289571779" STUDY_ID="STD-Iakovlev-1998" TOTAL_1="48" TOTAL_2="47" VAR="0.30789007092198584" WEIGHT="3.544992793398167"/>
<DICH_DATA CI_END="5.427988616422285" CI_START="0.8925326758770527" EFFECT_SIZE="2.201058201058201" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" LOG_CI_END="0.734638928186268" LOG_CI_START="-0.04937587527927091" LOG_EFFECT_SIZE="0.3426315264534986" ORDER="817" O_E="0.0" SE="0.46053417649152567" STUDY_ID="STD-Koehler-1990" TOTAL_1="63" TOTAL_2="64" VAR="0.2120917277167277" WEIGHT="2.0882659319377983"/>
<DICH_DATA CI_END="3.5713646359076354" CI_START="0.12444667228203433" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5528341938718855" LOG_CI_START="-0.905016711983248" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="818" O_E="0.0" SE="0.8563488385776752" STUDY_ID="STD-Limson-1988" TOTAL_1="20" TOTAL_2="20" VAR="0.7333333333333332" WEIGHT="1.0524197355400808"/>
<DICH_DATA CI_END="2.163966825485128" CI_START="0.34778413155082627" EFFECT_SIZE="0.8675213675213675" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.3352505985698439" LOG_CI_START="-0.4586902375637037" LOG_EFFECT_SIZE="-0.06171981949692991" ORDER="819" O_E="0.0" SE="0.46636477721536806" STUDY_ID="STD-Mandell-1987" TOTAL_1="52" TOTAL_2="58" VAR="0.2174961054271399" WEIGHT="2.9850450680773206"/>
<DICH_DATA CI_END="2.3294358192549933" CI_START="0.4375837344074471" EFFECT_SIZE="1.0096153846153846" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.3672507492434021" LOG_CI_START="-0.35893882970108676" LOG_EFFECT_SIZE="0.0041559597711577035" ORDER="820" O_E="0.0" SE="0.42656735336838303" STUDY_ID="STD-Martin-1991" TOTAL_1="52" TOTAL_2="42" VAR="0.18195970695970695" WEIGHT="3.105011418331019"/>
<DICH_DATA CI_END="66.16971022291247" CI_START="0.11902984959483541" EFFECT_SIZE="2.806451612903226" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8206592327414395" LOG_CI_START="-0.9243441151727481" LOG_EFFECT_SIZE="0.4481575587843459" ORDER="821" O_E="0.0" SE="1.6124285545505104" STUDY_ID="STD-Moreno-1997" TOTAL_1="30" TOTAL_2="28" VAR="2.599925843529848" WEIGHT="0.18125006556523615"/>
<DICH_DATA CI_END="1.2852729000490246" CI_START="0.6522740256592976" EFFECT_SIZE="0.9156146179401994" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="43" LOG_CI_END="0.10899535054827328" LOG_CI_START="-0.18556991526478353" LOG_EFFECT_SIZE="-0.03828728235825513" ORDER="822" O_E="0.0" SE="0.17302909526017163" STUDY_ID="STD-Mouton-1990" TOTAL_1="105" TOTAL_2="106" VAR="0.029939067806553546" WEIGHT="15.013191488036224"/>
<DICH_DATA CI_END="1.399873218217452" CI_START="0.39557189898178535" EFFECT_SIZE="0.7441441441441441" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="20" LOG_CI_END="0.146088704876939" LOG_CI_START="-0.4027745678094895" LOG_EFFECT_SIZE="-0.12834293146627523" ORDER="823" O_E="0.0" SE="0.3224050032930258" STUDY_ID="STD-Mouton-1995" TOTAL_1="111" TOTAL_2="118" VAR="0.10394498614837597" WEIGHT="6.801664666372575"/>
<DICH_DATA CI_END="3.6159719739665412" CI_START="0.5787047677624713" EFFECT_SIZE="1.4465753424657535" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="5" LOG_CI_END="0.558225055763821" LOG_CI_START="-0.2375429396091458" LOG_EFFECT_SIZE="0.16034105807733756" ORDER="824" O_E="0.0" SE="0.46743805959718704" STUDY_ID="STD-Muller-1987" TOTAL_1="73" TOTAL_2="33" VAR="0.2184983395599834" WEIGHT="2.4159320973089904"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="825" O_E="0.0" SE="0.0" STUDY_ID="STD-Naime-Libien-1992" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.7194272700246453" CI_START="0.133964145557945" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5704760708987405" LOG_CI_START="-0.8730114215600387" LOG_EFFECT_SIZE="-0.15126767533064908" ORDER="826" O_E="0.0" SE="0.8479116984486138" STUDY_ID="STD-Rapp-1984" TOTAL_1="17" TOTAL_2="18" VAR="0.718954248366013" WEIGHT="1.0223506002389355"/>
<DICH_DATA CI_END="15.773173963622442" CI_START="0.06784649559762428" EFFECT_SIZE="1.0344827586206897" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1979190932141035" LOG_CI_START="-1.1684725795726907" LOG_EFFECT_SIZE="0.014723256820706378" ORDER="827" O_E="0.0" SE="1.3900301824226613" STUDY_ID="STD-Rasmussen-1986" TOTAL_1="29" TOTAL_2="30" VAR="1.9321839080459768" WEIGHT="0.3448607043012694"/>
<DICH_DATA CI_END="1.0107859270454354" CI_START="0.47251247521932604" EFFECT_SIZE="0.6910925844668714" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="43" LOG_CI_END="0.004659186701519816" LOG_CI_START="-0.3255867208110324" LOG_EFFECT_SIZE="-0.1604637670547563" ORDER="828" O_E="0.0" SE="0.19398808081648017" STUDY_ID="STD-Sieger-1997" TOTAL_1="106" TOTAL_2="105" VAR="0.03763137549886124" WEIGHT="15.15617426411276"/>
<DICH_DATA CI_END="1.1619390455620113" CI_START="0.406109665538784" EFFECT_SIZE="0.6869313482216708" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="26" LOG_CI_END="0.06518334589389115" LOG_CI_START="-0.39135667404060837" LOG_EFFECT_SIZE="-0.16308666407335862" ORDER="829" O_E="0.0" SE="0.268173867619071" STUDY_ID="STD-Stille-1992" TOTAL_1="186" TOTAL_2="151" VAR="0.07191722327377102" WEIGHT="10.068252900241012"/>
<DICH_DATA CI_END="1.8887018010491008" CI_START="0.5591992858596423" EFFECT_SIZE="1.0276967930029155" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.27616339445866245" LOG_CI_START="-0.25243339188936836" LOG_EFFECT_SIZE="0.011865001284647039" ORDER="830" O_E="0.0" SE="0.3105003688971257" STUDY_ID="STD-Thompson--1990" TOTAL_1="49" TOTAL_2="47" VAR="0.09641047908525113" WEIGHT="5.013610684586774"/>
<DICH_DATA CI_END="51.50073659814336" CI_START="0.12437246551099736" EFFECT_SIZE="2.5308641975308643" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7118134406571388" LOG_CI_START="-0.9052757563029298" LOG_EFFECT_SIZE="0.40326884217710457" ORDER="831" O_E="0.0" SE="1.5372911490948016" STUDY_ID="STD-Thompson-1993" TOTAL_1="80" TOTAL_2="40" VAR="2.363264077085215" WEIGHT="0.23291256442280475"/>
<DICH_DATA CI_END="3.3916425334872047" CI_START="0.009181943027495709" EFFECT_SIZE="0.17647058823529413" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.530410072972988" LOG_CI_START="-2.037065406290211" LOG_EFFECT_SIZE="-0.7533276666586115" ORDER="832" O_E="0.0" SE="1.5081478057277968" STUDY_ID="STD-Trujillo-1992" TOTAL_1="16" TOTAL_2="14" VAR="2.2745098039215685" WEIGHT="0.9318299741761132"/>
<DICH_DATA CI_END="4.151262680181564" CI_START="0.5648224993551716" EFFECT_SIZE="1.53125" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.6181802151766247" LOG_CI_START="-0.24808801175940942" LOG_EFFECT_SIZE="0.1850461017086077" ORDER="833" O_E="0.0" SE="0.5088502445991073" STUDY_ID="STD-Vergnon-1985" TOTAL_1="16" TOTAL_2="14" VAR="0.2589285714285714" WEIGHT="1.496774734990337"/>
<DICH_DATA CI_END="1.8491276278552056" CI_START="0.26498982148049377" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.26696688744925967" LOG_CI_START="-0.5767708074207462" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="834" O_E="0.0" SE="0.4956156985355898" STUDY_ID="STD-Verzasconi-1995" TOTAL_1="45" TOTAL_2="42" VAR="0.24563492063492062" WEIGHT="2.9032268566622923"/>
<DICH_DATA CI_END="2.4878692263738946" CI_START="0.6161416373272557" EFFECT_SIZE="1.2380952380952381" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.3958275481422332" LOG_CI_START="-0.21031944166843577" LOG_EFFECT_SIZE="0.09275405323689871" ORDER="835" O_E="0.0" SE="0.3560537422907775" STUDY_ID="STD-Warren-1983" TOTAL_1="56" TOTAL_2="64" VAR="0.1267742673992674" WEIGHT="3.9290336793496348"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.963817374426515" CI_END="0.9181576520215244" CI_START="0.3887854170473806" DF="2" EFFECT_SIZE="0.5974665728360309" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="41" I2="79.92737196154087" ID="CMP-003.04.05" LOG_CI_END="-0.03708274197459236" LOG_CI_START="-0.41029003339244197" LOG_EFFECT_SIZE="-0.22368638768351715" MODIFIED="2011-12-26 07:10:45 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.006860971736829757" P_Z="0.01880080956694559" STUDIES="3" TAU2="0.0" TOTAL_1="81" TOTAL_2="93" WEIGHT="100.0" Z="2.3494571181927832">
<NAME>C different BL</NAME>
<DICH_DATA CI_END="1.87491372144196" CI_START="0.5772378000241282" EFFECT_SIZE="1.0403225806451613" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.27298128744304856" LOG_CI_START="-0.23864523716902078" LOG_EFFECT_SIZE="0.01716802513701388" ORDER="836" O_E="0.0" SE="0.3005319531492715" STUDY_ID="STD-Duff-1982" TOTAL_1="31" TOTAL_2="43" VAR="0.09031945486371591" WEIGHT="34.90499648135116"/>
<DICH_DATA CI_END="0.5205513287712564" CI_START="0.09922728020675375" EFFECT_SIZE="0.22727272727272727" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="22" LOG_CI_END="-0.2835364405952395" LOG_CI_START="-1.0033689123771354" LOG_EFFECT_SIZE="-0.6434526764861874" MODIFIED="2011-12-26 07:10:45 +0000" MODIFIED_BY="[Empty name]" ORDER="2082" O_E="0.0" SE="0.42283315715288794" STUDY_ID="STD-Garc_x00ed_a-Ram_x00ed_rez-1999" TOTAL_1="30" TOTAL_2="30" VAR="0.17878787878787883" WEIGHT="57.28360309641098"/>
<DICH_DATA CI_END="5.208499115067838" CI_START="0.34132246900739327" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7167125947102104" LOG_CI_START="-0.46683512149361067" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="837" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-Landau-1990" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="7.8114004222378615"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="80.30085927608633" CI_END="0.9330798302358899" CI_START="0.7797855402900833" CI_STUDY="95" CI_TOTAL="95" DF="63" EFFECT_MEASURE="RR" EFFECT_SIZE="0.852995990350642" ESTIMABLE="YES" EVENTS_1="655" EVENTS_2="756" I2="21.545048747988353" I2_Q="76.48331428913431" ID="CMP-003.05" LOG_CI_END="-0.03008119832446034" LOG_CI_START="-0.10802482227761744" LOG_EFFECT_SIZE="-0.06905301030103891" METHOD="MH" MODIFIED="2013-08-13 06:58:46 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.06978359872616424" P_Q="0.0019250185302435163" P_Z="5.150538685185286E-4" Q="17.009199549542966" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="66" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="3491" TOTAL_2="3312" WEIGHT="500.0" Z="3.4728026835254076">
<NAME>Clinical failure by allocation generation</NAME>
<GROUP_LABEL_1>Monotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours monotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.6299699584523815" CI_END="1.2880244335401163" CI_START="0.9142137167848509" DF="8" EFFECT_SIZE="1.085140361748844" ESTIMABLE="YES" EVENTS_1="181" EVENTS_2="176" I2="0.0" ID="CMP-003.05.01" LOG_CI_END="0.10992410157270457" LOG_CI_START="-0.0389522668803351" LOG_EFFECT_SIZE="0.03548591734618477" NO="1" P_CHI2="0.7962936145095688" P_Z="0.3501247595619297" STUDIES="9" TAU2="0.0" TOTAL_1="638" TOTAL_2="681" WEIGHT="100.00000000000001" Z="0.93434734712549">
<NAME>A same BL</NAME>
<DICH_DATA CI_END="2.155845445955638" CI_START="0.8606766127447515" EFFECT_SIZE="1.3621621621621622" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="25" LOG_CI_END="0.3336176227602601" LOG_CI_START="-0.06515999800319945" LOG_EFFECT_SIZE="0.13422881237853032" ORDER="838" O_E="0.0" SE="0.23424394841751486" STUDY_ID="STD-Cometta-1994" TOTAL_1="148" TOTAL_2="144" VAR="0.05487022737022737" WEIGHT="14.91549229067757"/>
<DICH_DATA CI_END="2.5248479213118067" CI_START="0.1293268436046026" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.40223522446491633" LOG_CI_START="-0.8883113218375052" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="839" O_E="0.0" SE="0.758073429606476" STUDY_ID="STD-Coppens-1983" TOTAL_1="22" TOTAL_2="44" VAR="0.5746753246753247" WEIGHT="2.7466005623554013"/>
<DICH_DATA CI_END="1.7738115910050403" CI_START="0.8274562460098094" EFFECT_SIZE="1.2115079365079364" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="35" LOG_CI_END="0.24890748847637187" LOG_CI_START="-0.08225496144213654" LOG_EFFECT_SIZE="0.08332626351711768" ORDER="840" O_E="0.0" SE="0.1945264623626969" STUDY_ID="STD-D_x0027_Antonio-1992" TOTAL_1="144" TOTAL_2="142" VAR="0.03784054455934573" WEIGHT="20.74355669471212"/>
<DICH_DATA CI_END="1.3667256675620698" CI_START="0.8230512110018743" EFFECT_SIZE="1.0606060606060606" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="55" LOG_CI_END="0.13568135069047074" LOG_CI_START="-0.08457314174569446" LOG_EFFECT_SIZE="0.025554104472388137" ORDER="841" O_E="0.0" SE="0.12937857913432477" STUDY_ID="STD-Dupont-2000" TOTAL_1="99" TOTAL_2="105" VAR="0.016738816738816734" WEIGHT="31.418571558876383"/>
<DICH_DATA CI_END="2.9094577025383535" CI_START="0.6391239613516574" EFFECT_SIZE="1.3636363636363635" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.46381204783713936" LOG_CI_START="-0.19441490004222706" LOG_EFFECT_SIZE="0.13469857389745618" ORDER="842" O_E="0.0" SE="0.3866457674602807" STUDY_ID="STD-Kljucar-1990" TOTAL_1="44" TOTAL_2="45" VAR="0.14949494949494946" WEIGHT="5.237498343624746"/>
<DICH_DATA CI_END="1.9007156127572655" CI_START="0.14916575169326518" EFFECT_SIZE="0.5324675324675324" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.27891714208928725" LOG_CI_START="-0.8263308789947802" LOG_EFFECT_SIZE="-0.2737068684527464" ORDER="843" O_E="0.0" SE="0.6492281586507218" STUDY_ID="STD-Korzeniowski-1982" TOTAL_1="33" TOTAL_2="41" VAR="0.42149720198500684" WEIGHT="3.674506157745739"/>
<DICH_DATA CI_END="1.5400316693721572" CI_START="0.4008663919406224" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.18752965180539463" LOG_CI_START="-0.3970003528454206" LOG_EFFECT_SIZE="-0.104735350520013" ORDER="844" O_E="0.0" SE="0.34335581820207717" STUDY_ID="STD-Ribera-1996" TOTAL_1="45" TOTAL_2="45" VAR="0.11789321789321788" WEIGHT="8.239801687066203"/>
<DICH_DATA CI_END="2.0855643415267795" CI_START="0.45957924110915704" EFFECT_SIZE="0.9790209790209791" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.3192235927620454" LOG_CI_START="-0.33763959633569307" LOG_EFFECT_SIZE="-0.009208001786823765" ORDER="845" O_E="0.0" SE="0.38584468880123757" STUDY_ID="STD-Sandberg-1997" TOTAL_1="26" TOTAL_2="35" VAR="0.14887612387612387" WEIGHT="5.518930403983452"/>
<DICH_DATA CI_END="1.9693429049207163" CI_START="0.46703880711684953" EFFECT_SIZE="0.9590409590409591" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.2943213427246578" LOG_CI_START="-0.33064703160415826" LOG_EFFECT_SIZE="-0.018162844439750202" ORDER="846" O_E="0.0" SE="0.36710951672409314" STUDY_ID="STD-Takamoto-1994" TOTAL_1="77" TOTAL_2="80" VAR="0.13476939726939724" WEIGHT="7.505042300958388"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.11904923713921" CI_END="1.687373983944103" CI_START="0.8311321456946092" DF="9" EFFECT_SIZE="1.1842426946638613" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="45" I2="11.058837751594734" ID="CMP-003.05.02" LOG_CI_END="0.22721134883861754" LOG_CI_START="-0.0803299201588894" LOG_EFFECT_SIZE="0.07344071433986407" NO="2" P_CHI2="0.3409340042003276" P_Z="0.3492335523438329" STUDIES="11" TAU2="0.0" TOTAL_1="281" TOTAL_2="270" WEIGHT="99.99999999999997" Z="0.936077005692493">
<NAME>B same BL</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="847" O_E="0.0" SE="0.0" STUDY_ID="STD-Abrams-1979" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="11.697696457498267" CI_START="0.0593659142180342" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0681003477040096" LOG_CI_START="-1.226462839799259" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="848" O_E="0.0" SE="1.347837774610382" STUDY_ID="STD-Biglino-1991" TOTAL_1="12" TOTAL_2="10" VAR="1.8166666666666667" WEIGHT="2.393502493020838"/>
<DICH_DATA CI_END="2.6312143240480275" CI_START="0.1655509382184593" EFFECT_SIZE="0.66" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4201562247335235" LOG_CI_START="-0.781068353649786" LOG_EFFECT_SIZE="-0.1804560644581313" ORDER="849" O_E="0.0" SE="0.7056052634999174" STUDY_ID="STD-Carbon-1987" TOTAL_1="25" TOTAL_2="22" VAR="0.49787878787878775" WEIGHT="9.336357242279867"/>
<DICH_DATA CI_END="1.9847833295834896" CI_START="0.37016326497723917" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.2977131035916891" LOG_CI_START="-0.4316066828529156" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="850" O_E="0.0" SE="0.4284060527487281" STUDY_ID="STD-Cardozo-2001" TOTAL_1="56" TOTAL_2="48" VAR="0.18353174603174602" WEIGHT="21.265349072608217"/>
<DICH_DATA CI_END="7.689843930627566" CI_START="1.0748755208254848" EFFECT_SIZE="2.875" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.8859175256590314" LOG_CI_START="0.0313581723922671" LOG_EFFECT_SIZE="0.4586378490256493" ORDER="851" O_E="0.0" SE="0.5019723942459189" STUDY_ID="STD-Klastersky-1973" TOTAL_1="22" TOTAL_2="23" VAR="0.2519762845849802" WEIGHT="8.581149678682117"/>
<DICH_DATA CI_END="3.826396404729478" CI_START="0.31622442424010855" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.582789959802314" LOG_CI_START="-0.5000045894858638" LOG_EFFECT_SIZE="0.04139268515822508" ORDER="852" O_E="0.0" SE="0.6360388781713383" STUDY_ID="STD-Mergoni-1987" TOTAL_1="20" TOTAL_2="22" VAR="0.40454545454545454" WEIGHT="8.358262674041024"/>
<DICH_DATA CI_END="1.5195651886332249" CI_START="0.279337797304769" EFFECT_SIZE="0.6515151515151515" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.18171933584499625" LOG_CI_START="-0.5538702957695606" LOG_EFFECT_SIZE="-0.18607547996228216" ORDER="853" O_E="0.0" SE="0.4320889908377921" STUDY_ID="STD-Piccart-1984" TOTAL_1="42" TOTAL_2="43" VAR="0.1867008960032216" WEIGHT="23.85054837163118"/>
<DICH_DATA CI_END="17.294732547204912" CI_START="1.0349630001602124" EFFECT_SIZE="4.230769230769231" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.2379138502953821" LOG_CI_START="0.014924824079431976" LOG_EFFECT_SIZE="0.626419337187407" ORDER="854" O_E="0.0" SE="0.7183898078925648" STUDY_ID="STD-Sage-1987" TOTAL_1="26" TOTAL_2="22" VAR="0.5160839160839161" WEIGHT="4.753761895860832"/>
<DICH_DATA CI_END="2.523907854293063" CI_START="0.22286867527402432" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.40207349514318896" LOG_CI_START="-0.6519509683597887" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="855" O_E="0.0" SE="0.6191391873668903" STUDY_ID="STD-Sculier-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.3833333333333333" WEIGHT="8.776175807743074"/>
<DICH_DATA CI_END="14.55119169880151" CI_START="0.06353817832623988" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1628985621892929" LOG_CI_START="-1.1969652407868534" LOG_EFFECT_SIZE="-0.017033339298780342" ORDER="856" O_E="0.0" SE="1.3861956793824102" STUDY_ID="STD-Sexton-1998" TOTAL_1="26" TOTAL_2="25" VAR="1.9215384615384614" WEIGHT="2.237064421581568"/>
<DICH_DATA CI_END="3.8827994475086087" CI_START="0.44874838980365256" EFFECT_SIZE="1.32" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5891449591554481" LOG_CI_START="-0.3479970967437483" LOG_EFFECT_SIZE="0.12057393120584989" ORDER="857" O_E="0.0" SE="0.5504818825631803" STUDY_ID="STD-Sukoh-1994" TOTAL_1="30" TOTAL_2="33" VAR="0.3030303030303031" WEIGHT="10.44782834255128"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="26.1076660434516" CI_END="0.8776876868402467" CI_START="0.6609946850999966" DF="25" EFFECT_SIZE="0.7616737465471114" ESTIMABLE="YES" EVENTS_1="269" EVENTS_2="323" I2="4.242685047403651" ID="CMP-003.05.03" LOG_CI_END="-0.05665999435714524" LOG_CI_START="-0.17980203255826793" LOG_EFFECT_SIZE="-0.11823101345770658" MODIFIED="2011-12-26 07:01:14 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.40187103250909684" P_Z="1.6748644085736028E-4" STUDIES="26" TAU2="0.0" TOTAL_1="1764" TOTAL_2="1524" WEIGHT="100.0" Z="3.7635974134893386">
<NAME>A different BL</NAME>
<DICH_DATA CI_END="1.0074864919644275" CI_START="0.2658612783365917" EFFECT_SIZE="0.5175438596491229" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="20" LOG_CI_END="0.0032392319797593778" LOG_CI_START="-0.575344911368416" LOG_EFFECT_SIZE="-0.2860528396943284" ORDER="858" O_E="0.0" SE="0.33986318984041847" STUDY_ID="STD-Alvarez_x002d_Lerma-2001a" TOTAL_1="57" TOTAL_2="59" VAR="0.11550698780850434" WEIGHT="5.875922250133554"/>
<DICH_DATA CI_END="1.9601526210417917" CI_START="0.14222565988347913" EFFECT_SIZE="0.528" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.2922898876298273" LOG_CI_START="-0.8470220425622028" LOG_EFFECT_SIZE="-0.27736607746618774" ORDER="859" O_E="0.0" SE="0.6692374674798086" STUDY_ID="STD-Arich-1987" TOTAL_1="25" TOTAL_2="22" VAR="0.4478787878787879" WEIGHT="1.5901618631380465"/>
<DICH_DATA CI_END="17.69656322236463" CI_START="0.0749290767652106" EFFECT_SIZE="1.1515151515151516" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2478889319840376" LOG_CI_START="-1.1253496185061924" LOG_EFFECT_SIZE="0.06126965673892271" MODIFIED="2011-12-26 07:01:14 +0000" MODIFIED_BY="[Empty name]" ORDER="2074" O_E="0.0" SE="1.3940520722782508" STUDY_ID="STD-Banasal-2006" TOTAL_1="33" TOTAL_2="38" VAR="1.9433811802232854" WEIGHT="0.2778975830678434"/>
<DICH_DATA CI_END="1.423999570845346" CI_START="0.3356573471587424" EFFECT_SIZE="0.691358024691358" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.1535098584163388" LOG_CI_START="-0.4741038421612374" LOG_EFFECT_SIZE="-0.16029699187244936" ORDER="860" O_E="0.0" SE="0.368663394457191" STUDY_ID="STD-Brown-1984" TOTAL_1="18" TOTAL_2="16" VAR="0.1359126984126984" WEIGHT="2.8488217472783735"/>
<DICH_DATA CI_END="0.9370474331203014" CI_START="0.2525689662751385" EFFECT_SIZE="0.4864864864864865" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="18" LOG_CI_END="-0.028238424671436866" LOG_CI_START="-0.5976200132559408" LOG_EFFECT_SIZE="-0.3129292189636889" ORDER="861" O_E="0.0" SE="0.3344575636188571" STUDY_ID="STD-Felisart-1985" TOTAL_1="37" TOTAL_2="36" VAR="0.11186186186186185" WEIGHT="5.454821549583248"/>
<DICH_DATA CI_END="1.668340822997299" CI_START="0.5604233296704261" EFFECT_SIZE="0.9669421487603306" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" LOG_CI_END="0.22228477677345543" LOG_CI_START="-0.25148379391403236" LOG_EFFECT_SIZE="-0.014599508570288439" ORDER="862" O_E="0.0" SE="0.278294003614078" STUDY_ID="STD-Finer-1992" TOTAL_1="220" TOTAL_2="195" VAR="0.07744755244755246" WEIGHT="6.973108831356971"/>
<DICH_DATA CI_END="0.7364746482815971" CI_START="0.10801855283463083" EFFECT_SIZE="0.28205128205128205" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.132842198313418" LOG_CI_START="-0.9665016454231303" LOG_EFFECT_SIZE="-0.5496719218682742" ORDER="863" O_E="0.0" SE="0.4896956859130625" STUDY_ID="STD-Gerecht-1989" TOTAL_1="24" TOTAL_2="22" VAR="0.23980186480186477" WEIGHT="4.055327575835881"/>
<DICH_DATA CI_END="3.6075179132023756" CI_START="0.39916641708972667" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.557208496268825" LOG_CI_START="-0.39884600417357535" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="864" O_E="0.0" SE="0.5615911461059686" STUDY_ID="STD-Gomez-1990a" TOTAL_1="39" TOTAL_2="39" VAR="0.3153846153846154" WEIGHT="1.494752151349764"/>
<DICH_DATA CI_END="5.597705211534098" CI_START="0.052414831915982264" EFFECT_SIZE="0.5416666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7480100237523192" LOG_CI_START="-1.2805458025618577" LOG_EFFECT_SIZE="-0.2662678894047693" ORDER="865" O_E="0.0" SE="1.191583733890235" STUDY_ID="STD-Havig-1973" TOTAL_1="24" TOTAL_2="26" VAR="1.4198717948717947" WEIGHT="0.5739848261183093"/>
<DICH_DATA CI_END="1.5219304663112376" CI_START="0.4423600838070252" EFFECT_SIZE="0.8205128205128205" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="15" LOG_CI_END="0.1823948109186749" LOG_CI_START="-0.3542240683318614" LOG_EFFECT_SIZE="-0.08591462870659325" ORDER="866" O_E="0.0" SE="0.3152125859780576" STUDY_ID="STD-Jaspers-1998" TOTAL_1="39" TOTAL_2="40" VAR="0.09935897435897437" WEIGHT="4.427493714124617"/>
<DICH_DATA CI_END="2.163966825485128" CI_START="0.34778413155082627" EFFECT_SIZE="0.8675213675213675" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.3352505985698439" LOG_CI_START="-0.4586902375637037" LOG_EFFECT_SIZE="-0.06171981949692991" ORDER="867" O_E="0.0" SE="0.46636477721536806" STUDY_ID="STD-Mandell-1987" TOTAL_1="52" TOTAL_2="58" VAR="0.2174961054271399" WEIGHT="2.5437963884788712"/>
<DICH_DATA CI_END="2.3294358192549933" CI_START="0.4375837344074471" EFFECT_SIZE="1.0096153846153846" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.3672507492434021" LOG_CI_START="-0.35893882970108676" LOG_EFFECT_SIZE="0.0041559597711577035" ORDER="868" O_E="0.0" SE="0.42656735336838303" STUDY_ID="STD-Martin-1991" TOTAL_1="52" TOTAL_2="42" VAR="0.18195970695970695" WEIGHT="2.64602934026171"/>
<DICH_DATA CI_END="3.5393716644310933" CI_START="0.7008659262685055" EFFECT_SIZE="1.575" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.5489261696836956" LOG_CI_START="-0.15436505343245688" LOG_EFFECT_SIZE="0.19728055812561932" ORDER="869" O_E="0.0" SE="0.41311674580612884" STUDY_ID="STD-McCormick-1997" TOTAL_1="65" TOTAL_2="63" VAR="0.17066544566544567" WEIGHT="2.4289722459433665"/>
<DICH_DATA CI_END="3.6159719739665412" CI_START="0.5787047677624713" EFFECT_SIZE="1.4465753424657535" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="5" LOG_CI_END="0.558225055763821" LOG_CI_START="-0.2375429396091458" LOG_EFFECT_SIZE="0.16034105807733756" ORDER="870" O_E="0.0" SE="0.46743805959718704" STUDY_ID="STD-Muller-1987" TOTAL_1="73" TOTAL_2="33" VAR="0.2184983395599834" WEIGHT="2.0588095669534483"/>
<DICH_DATA CI_END="15.773173963622442" CI_START="0.06784649559762428" EFFECT_SIZE="1.0344827586206897" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1979190932141035" LOG_CI_START="-1.1684725795726907" LOG_EFFECT_SIZE="0.014723256820706378" ORDER="871" O_E="0.0" SE="1.3900301824226613" STUDY_ID="STD-Rasmussen-1986" TOTAL_1="29" TOTAL_2="30" VAR="1.9321839080459768" WEIGHT="0.29388347382469937"/>
<DICH_DATA CI_END="0.867426039722828" CI_START="0.4210317967449039" EFFECT_SIZE="0.604329334095093" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="59" LOG_CI_END="-0.061767544674934186" LOG_CI_START="-0.37568510456955584" LOG_EFFECT_SIZE="-0.21872632462224503" ORDER="872" O_E="0.0" SE="0.1843967285990835" STUDY_ID="STD-Rubinstein-1995" TOTAL_1="267" TOTAL_2="238" VAR="0.03400215351804405" WEIGHT="18.650954962544816"/>
<DICH_DATA CI_END="7.501364429912652" CI_START="0.014812120134843915" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.875140264790061" LOG_CI_START="-1.8293827742293858" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="873" O_E="0.0" SE="1.5886502207249786" STUDY_ID="STD-Sanfilippo-1989" TOTAL_1="13" TOTAL_2="13" VAR="2.5238095238095233" WEIGHT="0.44842564540492913"/>
<DICH_DATA CI_END="0.8499294497951944" CI_START="0.45564346622766727" EFFECT_SIZE="0.6223060344827587" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="58" LOG_CI_END="-0.07061712232836635" LOG_CI_START="-0.34137485298099385" LOG_EFFECT_SIZE="-0.2059959876546801" ORDER="874" O_E="0.0" SE="0.15904443125773576" STUDY_ID="STD-Smith-1984" TOTAL_1="96" TOTAL_2="99" VAR="0.025295131114096633" WEIGHT="17.072369187108688"/>
<DICH_DATA CI_END="1.8956893891166395" CI_START="0.18946365936729576" EFFECT_SIZE="0.5993031358885017" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2777671791816151" LOG_CI_START="-0.7224740788345019" LOG_EFFECT_SIZE="-0.22235344982644345" ORDER="875" O_E="0.0" SE="0.5875466662327474" STUDY_ID="STD-Speich-1998" TOTAL_1="41" TOTAL_2="43" VAR="0.34521108500121545" WEIGHT="2.0428279401780105"/>
<DICH_DATA CI_END="1.1619390455620113" CI_START="0.406109665538784" EFFECT_SIZE="0.6869313482216708" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="26" LOG_CI_END="0.06518334589389115" LOG_CI_START="-0.39135667404060837" LOG_EFFECT_SIZE="-0.16308666407335862" ORDER="876" O_E="0.0" SE="0.268173867619071" STUDY_ID="STD-Stille-1992" TOTAL_1="186" TOTAL_2="151" VAR="0.07191722327377102" WEIGHT="8.579966058074135"/>
<DICH_DATA CI_END="1.8887018010491008" CI_START="0.5591992858596423" EFFECT_SIZE="1.0276967930029155" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.27616339445866245" LOG_CI_START="-0.25243339188936836" LOG_EFFECT_SIZE="0.011865001284647039" ORDER="877" O_E="0.0" SE="0.3105003688971257" STUDY_ID="STD-Thompson--1990" TOTAL_1="49" TOTAL_2="47" VAR="0.09641047908525113" WEIGHT="4.272499899274742"/>
<DICH_DATA CI_END="51.50073659814336" CI_START="0.12437246551099736" EFFECT_SIZE="2.5308641975308643" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7118134406571388" LOG_CI_START="-0.9052757563029298" LOG_EFFECT_SIZE="0.40326884217710457" ORDER="878" O_E="0.0" SE="1.5372911490948016" STUDY_ID="STD-Thompson-1993" TOTAL_1="80" TOTAL_2="40" VAR="2.363264077085215" WEIGHT="0.19848348239234567"/>
<DICH_DATA CI_END="4.151262680181564" CI_START="0.5648224993551716" EFFECT_SIZE="1.53125" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.6181802151766247" LOG_CI_START="-0.24808801175940942" LOG_EFFECT_SIZE="0.1850461017086077" ORDER="879" O_E="0.0" SE="0.5088502445991073" STUDY_ID="STD-Vergnon-1985" TOTAL_1="16" TOTAL_2="14" VAR="0.2589285714285714" WEIGHT="1.2755218358184652"/>
<DICH_DATA CI_END="2.4878692263738946" CI_START="0.6161416373272557" EFFECT_SIZE="1.2380952380952381" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.3958275481422332" LOG_CI_START="-0.21031944166843577" LOG_EFFECT_SIZE="0.09275405323689871" ORDER="880" O_E="0.0" SE="0.3560537422907775" STUDY_ID="STD-Warren-1983" TOTAL_1="56" TOTAL_2="64" VAR="0.1267742673992674" WEIGHT="3.348244819023471"/>
<DICH_DATA CI_END="121.21138446425599" CI_START="0.3974297533358782" EFFECT_SIZE="6.940677966101695" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.08354341172641" LOG_CI_START="-0.40073962281782394" LOG_EFFECT_SIZE="0.841401894454293" ORDER="881" O_E="0.0" SE="1.459280151890634" STUDY_ID="STD-Wing-1998" TOTAL_1="117" TOTAL_2="62" VAR="2.1294985617019515" WEIGHT="0.19489586061798025"/>
<DICH_DATA CI_END="9.392068384176333" CI_START="0.039248271403202646" EFFECT_SIZE="0.6071428571428571" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.9727612460375162" LOG_CI_START="-1.406179465965407" LOG_EFFECT_SIZE="-0.21670910996394532" ORDER="882" O_E="0.0" SE="1.3974015501769614" STUDY_ID="STD-Yellin-1993" TOTAL_1="56" TOTAL_2="34" VAR="1.952731092436975" WEIGHT="0.37202720211371904"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="14.649393095597825" CI_END="0.9359581257806742" CI_START="0.6336335390945107" DF="15" EFFECT_SIZE="0.7701002919637635" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="171" I2="0.0" ID="CMP-003.05.04" LOG_CI_END="-0.028743580908466234" LOG_CI_START="-0.19816184300604373" LOG_EFFECT_SIZE="-0.11345271195725497" MODIFIED="2011-12-26 07:25:56 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.4769544155633625" P_Z="0.008664367885319858" STUDIES="17" TAU2="0.0" TOTAL_1="727" TOTAL_2="744" WEIGHT="99.99999999999999" Z="2.6250207814851163">
<NAME>B different BL</NAME>
<DICH_DATA CI_END="2.3225990308636475" CI_START="0.007117290597831311" EFFECT_SIZE="0.12857142857142856" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3659742404872978" LOG_CI_START="-2.147685301637162" LOG_EFFECT_SIZE="-0.890855530574932" ORDER="883" O_E="0.0" SE="1.4765360578593163" STUDY_ID="STD-Aguilar-1992" TOTAL_1="19" TOTAL_2="17" VAR="2.1801587301587304" WEIGHT="2.1539012981765175"/>
<DICH_DATA CI_END="1.5550666855189255" CI_START="0.06764100107599494" EFFECT_SIZE="0.32432432432432434" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.19174901749913703" LOG_CI_START="-1.1697899735378774" LOG_EFFECT_SIZE="-0.48902047801937015" ORDER="884" O_E="0.0" SE="0.7997747430618447" STUDY_ID="STD-Bergeron-1988" TOTAL_1="37" TOTAL_2="30" VAR="0.6396396396396397" WEIGHT="3.228555677224077"/>
<DICH_DATA CI_END="2.6498175935704897" CI_START="0.17377014357166556" EFFECT_SIZE="0.6785714285714286" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4232159792831023" LOG_CI_START="-0.7600248400618829" LOG_EFFECT_SIZE="-0.16840443038939024" ORDER="885" O_E="0.0" SE="0.6950415144197627" STUDY_ID="STD-Cone-1985" TOTAL_1="21" TOTAL_2="19" VAR="0.48308270676691717" WEIGHT="2.4554474799212302"/>
<DICH_DATA CI_END="6.586766671602955" CI_START="0.4918953655924044" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.8186722793470714" LOG_CI_START="-0.30812726914045924" LOG_EFFECT_SIZE="0.25527250510330607" MODIFIED="2011-12-26 07:25:56 +0000" MODIFIED_BY="[Empty name]" ORDER="2094" O_E="0.0" SE="0.6618876325292973" STUDY_ID="STD-Figueroa_x002d_Damian-1996" TOTAL_1="14" TOTAL_2="42" VAR="0.4380952380952381" WEIGHT="1.4615758809054942"/>
<DICH_DATA CI_END="1.2138694205384808" CI_START="0.2589786629232571" EFFECT_SIZE="0.5606837606837607" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.08417197093223315" LOG_CI_START="-0.5867360156732359" LOG_EFFECT_SIZE="-0.25128202237050135" ORDER="886" O_E="0.0" SE="0.39409467238014734" STUDY_ID="STD-Hoepelman-1988" TOTAL_1="45" TOTAL_2="41" VAR="0.15531061079841568" WEIGHT="7.953692003067107"/>
<DICH_DATA CI_END="4.177208504264446" CI_START="0.15321236642763564" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6208861535010605" LOG_CI_START="-0.8147061795171733" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="887" O_E="0.0" SE="0.8432740427115678" STUDY_ID="STD-Holloway--1985" TOTAL_1="15" TOTAL_2="18" VAR="0.711111111111111" WEIGHT="1.594446415533266"/>
<DICH_DATA CI_END="1.1620638386085749" CI_START="0.1320089074981098" EFFECT_SIZE="0.39166666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.0652299869130772" LOG_CI_START="-0.879396763136892" LOG_EFFECT_SIZE="-0.40708338811190736" ORDER="888" O_E="0.0" SE="0.5548784289571779" STUDY_ID="STD-Iakovlev-1998" TOTAL_1="48" TOTAL_2="47" VAR="0.30789007092198584" WEIGHT="5.907843560712734"/>
<DICH_DATA CI_END="5.427988616422285" CI_START="0.8925326758770527" EFFECT_SIZE="2.201058201058201" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" LOG_CI_END="0.734638928186268" LOG_CI_START="-0.04937587527927091" LOG_EFFECT_SIZE="0.3426315264534986" ORDER="889" O_E="0.0" SE="0.46053417649152567" STUDY_ID="STD-Koehler-1990" TOTAL_1="63" TOTAL_2="64" VAR="0.2120917277167277" WEIGHT="3.480161782565523"/>
<DICH_DATA CI_END="3.5713646359076354" CI_START="0.12444667228203433" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5528341938718855" LOG_CI_START="-0.905016711983248" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="890" O_E="0.0" SE="0.8563488385776752" STUDY_ID="STD-Limson-1988" TOTAL_1="20" TOTAL_2="20" VAR="0.7333333333333332" WEIGHT="1.7538910570865929"/>
<DICH_DATA CI_END="66.16971022291247" CI_START="0.11902984959483541" EFFECT_SIZE="2.806451612903226" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8206592327414395" LOG_CI_START="-0.9243441151727481" LOG_EFFECT_SIZE="0.4481575587843459" ORDER="891" O_E="0.0" SE="1.6124285545505104" STUDY_ID="STD-Moreno-1997" TOTAL_1="30" TOTAL_2="28" VAR="2.599925843529848" WEIGHT="0.3020590153871355"/>
<DICH_DATA CI_END="1.2852729000490246" CI_START="0.6522740256592976" EFFECT_SIZE="0.9156146179401994" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="43" LOG_CI_END="0.10899535054827328" LOG_CI_START="-0.18556991526478353" LOG_EFFECT_SIZE="-0.03828728235825513" ORDER="892" O_E="0.0" SE="0.17302909526017163" STUDY_ID="STD-Mouton-1990" TOTAL_1="105" TOTAL_2="106" VAR="0.029939067806553546" WEIGHT="25.019962473131017"/>
<DICH_DATA CI_END="1.399873218217452" CI_START="0.39557189898178535" EFFECT_SIZE="0.7441441441441441" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="20" LOG_CI_END="0.146088704876939" LOG_CI_START="-0.4027745678094895" LOG_EFFECT_SIZE="-0.12834293146627523" ORDER="893" O_E="0.0" SE="0.3224050032930258" STUDY_ID="STD-Mouton-1995" TOTAL_1="111" TOTAL_2="118" VAR="0.10394498614837597" WEIGHT="11.335191111301997"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="894" O_E="0.0" SE="0.0" STUDY_ID="STD-Naime-Libien-1992" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.7194272700246453" CI_START="0.133964145557945" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5704760708987405" LOG_CI_START="-0.8730114215600387" LOG_EFFECT_SIZE="-0.15126767533064908" ORDER="895" O_E="0.0" SE="0.8479116984486138" STUDY_ID="STD-Rapp-1984" TOTAL_1="17" TOTAL_2="18" VAR="0.718954248366013" WEIGHT="1.7037798840269758"/>
<DICH_DATA CI_END="1.0107859270454354" CI_START="0.47251247521932604" EFFECT_SIZE="0.6910925844668714" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="43" LOG_CI_END="0.004659186701519816" LOG_CI_START="-0.3255867208110324" LOG_EFFECT_SIZE="-0.1604637670547563" ORDER="896" O_E="0.0" SE="0.19398808081648017" STUDY_ID="STD-Sieger-1997" TOTAL_1="106" TOTAL_2="105" VAR="0.03763137549886124" WEIGHT="25.25824783001798"/>
<DICH_DATA CI_END="3.3916425334872047" CI_START="0.009181943027495709" EFFECT_SIZE="0.17647058823529413" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.530410072972988" LOG_CI_START="-2.037065406290211" LOG_EFFECT_SIZE="-0.7533276666586115" ORDER="897" O_E="0.0" SE="1.5081478057277968" STUDY_ID="STD-Trujillo-1992" TOTAL_1="16" TOTAL_2="14" VAR="2.2745098039215685" WEIGHT="1.5529243734620874"/>
<DICH_DATA CI_END="1.8491276278552056" CI_START="0.26498982148049377" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.26696688744925967" LOG_CI_START="-0.5767708074207462" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="898" O_E="0.0" SE="0.4956156985355898" STUDY_ID="STD-Verzasconi-1995" TOTAL_1="45" TOTAL_2="42" VAR="0.24563492063492062" WEIGHT="4.838320157480257"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.963817374426515" CI_END="0.9181576520215244" CI_START="0.3887854170473806" DF="2" EFFECT_SIZE="0.5974665728360309" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="41" I2="79.92737196154087" ID="CMP-003.05.05" LOG_CI_END="-0.03708274197459236" LOG_CI_START="-0.41029003339244197" LOG_EFFECT_SIZE="-0.22368638768351715" MODIFIED="2011-12-26 07:11:12 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.006860971736829757" P_Z="0.01880080956694559" STUDIES="3" TAU2="0.0" TOTAL_1="81" TOTAL_2="93" WEIGHT="100.0" Z="2.3494571181927832">
<NAME>C different BL</NAME>
<DICH_DATA CI_END="1.87491372144196" CI_START="0.5772378000241282" EFFECT_SIZE="1.0403225806451613" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.27298128744304856" LOG_CI_START="-0.23864523716902078" LOG_EFFECT_SIZE="0.01716802513701388" ORDER="899" O_E="0.0" SE="0.3005319531492715" STUDY_ID="STD-Duff-1982" TOTAL_1="31" TOTAL_2="43" VAR="0.09031945486371591" WEIGHT="34.90499648135116"/>
<DICH_DATA CI_END="0.5205513287712564" CI_START="0.09922728020675375" EFFECT_SIZE="0.22727272727272727" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="22" LOG_CI_END="-0.2835364405952395" LOG_CI_START="-1.0033689123771354" LOG_EFFECT_SIZE="-0.6434526764861874" MODIFIED="2011-12-26 07:11:12 +0000" MODIFIED_BY="[Empty name]" ORDER="2083" O_E="0.0" SE="0.42283315715288794" STUDY_ID="STD-Garc_x00ed_a-Ram_x00ed_rez-1999" TOTAL_1="30" TOTAL_2="30" VAR="0.17878787878787883" WEIGHT="57.28360309641098"/>
<DICH_DATA CI_END="5.208499115067838" CI_START="0.34132246900739327" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7167125947102104" LOG_CI_START="-0.46683512149361067" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="900" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-Landau-1990" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="7.8114004222378615"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="80.30085927608633" CI_END="0.9330798302358896" CI_START="0.7797855402900831" CI_STUDY="95" CI_TOTAL="95" DF="63" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8529959903506418" ESTIMABLE="YES" EVENTS_1="655" EVENTS_2="756" I2="21.545048747988353" I2_Q="84.9640100849861" ID="CMP-003.06" LOG_CI_END="-0.030081198324460497" LOG_CI_START="-0.10802482227761756" LOG_EFFECT_SIZE="-0.06905301030103903" METHOD="MH" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.06978359872616424" P_Q="1.736654979257457E-4" P_Z="5.150538685185158E-4" Q="19.952128306526784" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="66" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="3491" TOTAL_2="3312" WEIGHT="400.0" Z="3.472802683525414">
<NAME>Clinical failure by blinding</NAME>
<GROUP_LABEL_1>Monotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours monotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="14.631249669210002" CI_END="1.3521266825287357" CI_START="0.9295206251376087" DF="17" EFFECT_SIZE="1.1210841356514467" ESTIMABLE="YES" EVENTS_1="181" EVENTS_2="166" I2="0.0" ID="CMP-003.06.01" LOG_CI_END="0.13101738313355415" LOG_CI_START="-0.031740969222826564" LOG_EFFECT_SIZE="0.049638206955363806" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6220233771086597" P_Z="0.23189035310378314" STUDIES="19" TAU2="0.0" TOTAL_1="820" TOTAL_2="846" WEIGHT="99.99999999999999" Z="1.19550359758658">
<NAME>Non-blinded&#8212;same BL</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-08-13 06:58:55 +0100" MODIFIED_BY="[Empty name]" ORDER="901" O_E="0.0" SE="0.0" STUDY_ID="STD-Abrams-1979" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="11.697696457498267" CI_START="0.0593659142180342" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0681003477040096" LOG_CI_START="-1.226462839799259" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2013-08-13 06:58:55 +0100" MODIFIED_BY="[Empty name]" ORDER="902" O_E="0.0" SE="1.347837774610382" STUDY_ID="STD-Biglino-1991" TOTAL_1="12" TOTAL_2="10" VAR="1.8166666666666667" WEIGHT="0.6729745093457054"/>
<DICH_DATA CI_END="2.6312143240480275" CI_START="0.1655509382184593" EFFECT_SIZE="0.66" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4201562247335235" LOG_CI_START="-0.781068353649786" LOG_EFFECT_SIZE="-0.1804560644581313" MODIFIED="2013-08-13 06:58:57 +0100" MODIFIED_BY="[Empty name]" ORDER="903" O_E="0.0" SE="0.7056052634999174" STUDY_ID="STD-Carbon-1987" TOTAL_1="25" TOTAL_2="22" VAR="0.49787878787878775" WEIGHT="2.6250778733343116"/>
<DICH_DATA CI_END="1.9847833295834896" CI_START="0.37016326497723917" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.2977131035916891" LOG_CI_START="-0.4316066828529156" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2013-08-13 06:58:57 +0100" MODIFIED_BY="[Empty name]" ORDER="904" O_E="0.0" SE="0.4284060527487281" STUDY_ID="STD-Cardozo-2001" TOTAL_1="56" TOTAL_2="48" VAR="0.18353174603174602" WEIGHT="5.9791196791868435"/>
<DICH_DATA CI_END="2.155845445955638" CI_START="0.8606766127447515" EFFECT_SIZE="1.3621621621621622" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="25" LOG_CI_END="0.3336176227602601" LOG_CI_START="-0.06515999800319945" LOG_EFFECT_SIZE="0.13422881237853032" MODIFIED="2013-08-13 06:58:57 +0100" MODIFIED_BY="[Empty name]" ORDER="905" O_E="0.0" SE="0.23424394841751486" STUDY_ID="STD-Cometta-1994" TOTAL_1="148" TOTAL_2="144" VAR="0.05487022737022737" WEIGHT="15.633597334686193"/>
<DICH_DATA CI_END="2.5248479213118067" CI_START="0.1293268436046026" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.40223522446491633" LOG_CI_START="-0.8883113218375052" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2013-08-13 06:58:58 +0100" MODIFIED_BY="[Empty name]" ORDER="906" O_E="0.0" SE="0.758073429606476" STUDY_ID="STD-Coppens-1983" TOTAL_1="22" TOTAL_2="44" VAR="0.5746753246753247" WEIGHT="2.878835401089962"/>
<DICH_DATA CI_END="1.7738115910050403" CI_START="0.8274562460098094" EFFECT_SIZE="1.2115079365079364" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="35" LOG_CI_END="0.24890748847637187" LOG_CI_START="-0.08225496144213654" LOG_EFFECT_SIZE="0.08332626351711768" MODIFIED="2013-08-13 06:58:58 +0100" MODIFIED_BY="[Empty name]" ORDER="907" O_E="0.0" SE="0.1945264623626969" STUDY_ID="STD-D_x0027_Antonio-1992" TOTAL_1="144" TOTAL_2="142" VAR="0.03784054455934573" WEIGHT="21.742253378861253"/>
<DICH_DATA CI_END="7.689843930627566" CI_START="1.0748755208254848" EFFECT_SIZE="2.875" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.8859175256590314" LOG_CI_START="0.0313581723922671" LOG_EFFECT_SIZE="0.4586378490256493" MODIFIED="2013-08-13 06:58:59 +0100" MODIFIED_BY="[Empty name]" ORDER="908" O_E="0.0" SE="0.5019723942459189" STUDY_ID="STD-Klastersky-1973" TOTAL_1="22" TOTAL_2="23" VAR="0.2519762845849802" WEIGHT="2.412738240913492"/>
<DICH_DATA CI_END="2.9094577025383535" CI_START="0.6391239613516574" EFFECT_SIZE="1.3636363636363635" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.46381204783713936" LOG_CI_START="-0.19441490004222706" LOG_EFFECT_SIZE="0.13469857389745618" MODIFIED="2013-08-13 06:58:59 +0100" MODIFIED_BY="[Empty name]" ORDER="909" O_E="0.0" SE="0.3866457674602807" STUDY_ID="STD-Kljucar-1990" TOTAL_1="44" TOTAL_2="45" VAR="0.14949494949494946" WEIGHT="5.489657233539125"/>
<DICH_DATA CI_END="1.9007156127572655" CI_START="0.14916575169326518" EFFECT_SIZE="0.5324675324675324" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.27891714208928725" LOG_CI_START="-0.8263308789947802" LOG_EFFECT_SIZE="-0.2737068684527464" MODIFIED="2013-08-13 06:58:59 +0100" MODIFIED_BY="[Empty name]" ORDER="910" O_E="0.0" SE="0.6492281586507218" STUDY_ID="STD-Korzeniowski-1982" TOTAL_1="33" TOTAL_2="41" VAR="0.42149720198500684" WEIGHT="3.851414928485219"/>
<DICH_DATA CI_END="3.826396404729478" CI_START="0.31622442424010855" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.582789959802314" LOG_CI_START="-0.5000045894858638" LOG_EFFECT_SIZE="0.04139268515822508" MODIFIED="2013-08-13 06:59:00 +0100" MODIFIED_BY="[Empty name]" ORDER="911" O_E="0.0" SE="0.6360388781713383" STUDY_ID="STD-Mergoni-1987" TOTAL_1="20" TOTAL_2="22" VAR="0.40454545454545454" WEIGHT="2.350069715175479"/>
<DICH_DATA CI_END="1.5195651886332249" CI_START="0.279337797304769" EFFECT_SIZE="0.6515151515151515" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.18171933584499625" LOG_CI_START="-0.5538702957695606" LOG_EFFECT_SIZE="-0.18607547996228216" MODIFIED="2013-08-13 06:59:01 +0100" MODIFIED_BY="[Empty name]" ORDER="912" O_E="0.0" SE="0.4320889908377921" STUDY_ID="STD-Piccart-1984" TOTAL_1="42" TOTAL_2="43" VAR="0.1867008960032216" WEIGHT="6.705993051950735"/>
<DICH_DATA CI_END="1.5400316693721572" CI_START="0.4008663919406224" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.18752965180539463" LOG_CI_START="-0.3970003528454206" LOG_EFFECT_SIZE="-0.104735350520013" MODIFIED="2013-08-13 06:59:01 +0100" MODIFIED_BY="[Empty name]" ORDER="913" O_E="0.0" SE="0.34335581820207717" STUDY_ID="STD-Ribera-1996" TOTAL_1="45" TOTAL_2="45" VAR="0.11789321789321788" WEIGHT="8.636506203269885"/>
<DICH_DATA CI_END="17.294732547204912" CI_START="1.0349630001602124" EFFECT_SIZE="4.230769230769231" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.2379138502953821" LOG_CI_START="0.014924824079431976" LOG_EFFECT_SIZE="0.626419337187407" MODIFIED="2013-08-13 06:59:02 +0100" MODIFIED_BY="[Empty name]" ORDER="914" O_E="0.0" SE="0.7183898078925648" STUDY_ID="STD-Sage-1987" TOTAL_1="26" TOTAL_2="22" VAR="0.5160839160839161" WEIGHT="1.3366021505060537"/>
<DICH_DATA CI_END="2.0855643415267795" CI_START="0.45957924110915704" EFFECT_SIZE="0.9790209790209791" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.3192235927620454" LOG_CI_START="-0.33763959633569307" LOG_EFFECT_SIZE="-0.009208001786823765" MODIFIED="2013-08-13 06:59:02 +0100" MODIFIED_BY="[Empty name]" ORDER="915" O_E="0.0" SE="0.38584468880123757" STUDY_ID="STD-Sandberg-1997" TOTAL_1="26" TOTAL_2="35" VAR="0.14887612387612387" WEIGHT="5.784638815304889"/>
<DICH_DATA CI_END="2.523907854293063" CI_START="0.22286867527402432" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.40207349514318896" LOG_CI_START="-0.6519509683597887" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2013-08-13 06:59:03 +0100" MODIFIED_BY="[Empty name]" ORDER="916" O_E="0.0" SE="0.6191391873668903" STUDY_ID="STD-Sculier-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.3833333333333333" WEIGHT="2.467573200934253"/>
<DICH_DATA CI_END="14.55119169880151" CI_START="0.06353817832623988" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1628985621892929" LOG_CI_START="-1.1969652407868534" LOG_EFFECT_SIZE="-0.017033339298780342" MODIFIED="2013-08-13 06:59:03 +0100" MODIFIED_BY="[Empty name]" ORDER="917" O_E="0.0" SE="1.3861956793824102" STUDY_ID="STD-Sexton-1998" TOTAL_1="26" TOTAL_2="25" VAR="1.9215384615384614" WEIGHT="0.6289892472969664"/>
<DICH_DATA CI_END="3.8827994475086087" CI_START="0.44874838980365256" EFFECT_SIZE="1.32" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5891449591554481" LOG_CI_START="-0.3479970967437483" LOG_EFFECT_SIZE="0.12057393120584989" MODIFIED="2013-08-13 06:59:03 +0100" MODIFIED_BY="[Empty name]" ORDER="918" O_E="0.0" SE="0.5504818825631803" STUDY_ID="STD-Sukoh-1994" TOTAL_1="30" TOTAL_2="33" VAR="0.3030303030303031" WEIGHT="2.9375871439693486"/>
<DICH_DATA CI_END="1.9693429049207163" CI_START="0.46703880711684953" EFFECT_SIZE="0.9590409590409591" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.2943213427246578" LOG_CI_START="-0.33064703160415826" LOG_EFFECT_SIZE="-0.018162844439750202" MODIFIED="2013-08-13 06:59:04 +0100" MODIFIED_BY="[Empty name]" ORDER="919" O_E="0.0" SE="0.36710951672409314" STUDY_ID="STD-Takamoto-1994" TOTAL_1="77" TOTAL_2="80" VAR="0.13476939726939724" WEIGHT="7.866371892150277"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3667256675620698" CI_START="0.8230512110018743" DF="0" EFFECT_SIZE="1.0606060606060606" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="55" I2="0.0" ID="CMP-003.06.02" LOG_CI_END="0.13568135069047074" LOG_CI_START="-0.08457314174569446" LOG_EFFECT_SIZE="0.025554104472388137" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6492580130508385" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="105" WEIGHT="100.0" Z="0.45479321551246443">
<NAME>Any blinding&#8212;same BL</NAME>
<DICH_DATA CI_END="1.3667256675620698" CI_START="0.8230512110018743" EFFECT_SIZE="1.0606060606060606" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="55" LOG_CI_END="0.13568135069047074" LOG_CI_START="-0.08457314174569446" LOG_EFFECT_SIZE="0.025554104472388137" MODIFIED="2013-08-13 06:59:08 +0100" MODIFIED_BY="[Empty name]" ORDER="920" O_E="0.0" SE="0.12937857913432477" STUDY_ID="STD-Dupont-2000" TOTAL_1="99" TOTAL_2="105" VAR="0.016738816738816734" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="46.43381900236545" CI_END="0.9077187139606654" CI_START="0.7026449872346945" DF="38" EFFECT_SIZE="0.7986263232473526" ESTIMABLE="YES" EVENTS_1="330" EVENTS_2="399" I2="18.163095742643556" ID="CMP-003.06.03" LOG_CI_END="-0.042048710840733916" LOG_CI_START="-0.15326404770893165" LOG_EFFECT_SIZE="-0.09765637927483281" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.1637546163486021" P_Z="5.773768370998209E-4" STUDIES="40" TAU2="0.0" TOTAL_1="2077" TOTAL_2="1919" WEIGHT="100.0" Z="3.442025023330899">
<NAME>Non-blinded&#8212;different BL</NAME>
<DICH_DATA CI_END="2.3225990308636475" CI_START="0.007117290597831311" EFFECT_SIZE="0.12857142857142856" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3659742404872978" LOG_CI_START="-2.147685301637162" LOG_EFFECT_SIZE="-0.890855530574932" ORDER="921" O_E="0.0" SE="1.4765360578593163" STUDY_ID="STD-Aguilar-1992" TOTAL_1="19" TOTAL_2="17" VAR="2.1801587301587304" WEIGHT="0.9121325577448653"/>
<DICH_DATA CI_END="1.0074864919644275" CI_START="0.2658612783365917" EFFECT_SIZE="0.5175438596491229" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="20" LOG_CI_END="0.0032392319797593778" LOG_CI_START="-0.575344911368416" LOG_EFFECT_SIZE="-0.2860528396943284" ORDER="922" O_E="0.0" SE="0.33986318984041847" STUDY_ID="STD-Alvarez_x002d_Lerma-2001a" TOTAL_1="57" TOTAL_2="59" VAR="0.11550698780850434" WEIGHT="4.8662047292497"/>
<DICH_DATA CI_END="1.9601526210417917" CI_START="0.14222565988347913" EFFECT_SIZE="0.528" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.2922898876298273" LOG_CI_START="-0.8470220425622028" LOG_EFFECT_SIZE="-0.27736607746618774" ORDER="923" O_E="0.0" SE="0.6692374674798086" STUDY_ID="STD-Arich-1987" TOTAL_1="25" TOTAL_2="22" VAR="0.4478787878787879" WEIGHT="1.316908707990307"/>
<DICH_DATA CI_END="17.69656322236463" CI_START="0.0749290767652106" EFFECT_SIZE="1.1515151515151516" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2478889319840376" LOG_CI_START="-1.1253496185061924" LOG_EFFECT_SIZE="0.06126965673892271" MODIFIED="2011-12-26 07:01:42 +0000" MODIFIED_BY="[Empty name]" ORDER="2075" O_E="0.0" SE="1.3940520722782508" STUDY_ID="STD-Banasal-2006" TOTAL_1="33" TOTAL_2="38" VAR="1.9433811802232854" WEIGHT="0.23014370772878492"/>
<DICH_DATA CI_END="1.5550666855189255" CI_START="0.06764100107599494" EFFECT_SIZE="0.32432432432432434" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.19174901749913703" LOG_CI_START="-1.1697899735378774" LOG_EFFECT_SIZE="-0.48902047801937015" ORDER="924" O_E="0.0" SE="0.7997747430618447" STUDY_ID="STD-Bergeron-1988" TOTAL_1="37" TOTAL_2="30" VAR="0.6396396396396397" WEIGHT="1.3672264138478474"/>
<DICH_DATA CI_END="2.6498175935704897" CI_START="0.17377014357166556" EFFECT_SIZE="0.6785714285714286" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4232159792831023" LOG_CI_START="-0.7600248400618829" LOG_EFFECT_SIZE="-0.16840443038939024" ORDER="925" O_E="0.0" SE="0.6950415144197627" STUDY_ID="STD-Cone-1985" TOTAL_1="21" TOTAL_2="19" VAR="0.48308270676691717" WEIGHT="1.0398311158291464"/>
<DICH_DATA CI_END="1.87491372144196" CI_START="0.5772378000241282" EFFECT_SIZE="1.0403225806451613" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.27298128744304856" LOG_CI_START="-0.23864523716902078" LOG_EFFECT_SIZE="0.01716802513701388" ORDER="926" O_E="0.0" SE="0.3005319531492715" STUDY_ID="STD-Duff-1982" TOTAL_1="31" TOTAL_2="43" VAR="0.09031945486371591" WEIGHT="3.318894681153518"/>
<DICH_DATA CI_END="0.9370474331203014" CI_START="0.2525689662751385" EFFECT_SIZE="0.4864864864864865" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="18" LOG_CI_END="-0.028238424671436866" LOG_CI_START="-0.5976200132559408" LOG_EFFECT_SIZE="-0.3129292189636889" ORDER="927" O_E="0.0" SE="0.3344575636188571" STUDY_ID="STD-Felisart-1985" TOTAL_1="37" TOTAL_2="36" VAR="0.11186186186186185" WEIGHT="4.517465904384942"/>
<DICH_DATA CI_END="6.586766671602955" CI_START="0.4918953655924044" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.8186722793470714" LOG_CI_START="-0.30812726914045924" LOG_EFFECT_SIZE="0.25527250510330607" MODIFIED="2011-12-26 07:26:23 +0000" MODIFIED_BY="[Empty name]" ORDER="2095" O_E="0.0" SE="0.6618876325292973" STUDY_ID="STD-Figueroa_x002d_Damian-1996" TOTAL_1="14" TOTAL_2="42" VAR="0.4380952380952381" WEIGHT="0.6189470927554444"/>
<DICH_DATA CI_END="1.668340822997299" CI_START="0.5604233296704261" EFFECT_SIZE="0.9669421487603306" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" LOG_CI_END="0.22228477677345543" LOG_CI_START="-0.25148379391403236" LOG_EFFECT_SIZE="-0.014599508570288439" ORDER="928" O_E="0.0" SE="0.278294003614078" STUDY_ID="STD-Finer-1992" TOTAL_1="220" TOTAL_2="195" VAR="0.07744755244755246" WEIGHT="5.774850947347182"/>
<DICH_DATA CI_END="0.5205513287712564" CI_START="0.09922728020675375" EFFECT_SIZE="0.22727272727272727" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="22" LOG_CI_END="-0.2835364405952395" LOG_CI_START="-1.0033689123771354" LOG_EFFECT_SIZE="-0.6434526764861874" MODIFIED="2011-12-26 07:11:41 +0000" MODIFIED_BY="[Empty name]" ORDER="2084" O_E="0.0" SE="0.42283315715288794" STUDY_ID="STD-Garc_x00ed_a-Ram_x00ed_rez-1999" TOTAL_1="30" TOTAL_2="30" VAR="0.17878787878787883" WEIGHT="5.44673441624791"/>
<DICH_DATA CI_END="0.7364746482815971" CI_START="0.10801855283463083" EFFECT_SIZE="0.28205128205128205" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.132842198313418" LOG_CI_START="-0.9665016454231303" LOG_EFFECT_SIZE="-0.5496719218682742" ORDER="929" O_E="0.0" SE="0.4896956859130625" STUDY_ID="STD-Gerecht-1989" TOTAL_1="24" TOTAL_2="22" VAR="0.23980186480186477" WEIGHT="3.3584607467773675"/>
<DICH_DATA CI_END="3.6075179132023756" CI_START="0.39916641708972667" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.557208496268825" LOG_CI_START="-0.39884600417357535" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="930" O_E="0.0" SE="0.5615911461059686" STUDY_ID="STD-Gomez-1990a" TOTAL_1="39" TOTAL_2="39" VAR="0.3153846153846154" WEIGHT="1.2378941855108887"/>
<DICH_DATA CI_END="5.597705211534098" CI_START="0.052414831915982264" EFFECT_SIZE="0.5416666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7480100237523192" LOG_CI_START="-1.2805458025618577" LOG_EFFECT_SIZE="-0.2662678894047693" ORDER="931" O_E="0.0" SE="1.191583733890235" STUDY_ID="STD-Havig-1973" TOTAL_1="24" TOTAL_2="26" VAR="1.4198717948717947" WEIGHT="0.4753513672361812"/>
<DICH_DATA CI_END="1.2138694205384808" CI_START="0.2589786629232571" EFFECT_SIZE="0.5606837606837607" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.08417197093223315" LOG_CI_START="-0.5867360156732359" LOG_EFFECT_SIZE="-0.25128202237050135" ORDER="932" O_E="0.0" SE="0.39409467238014734" STUDY_ID="STD-Hoepelman-1988" TOTAL_1="45" TOTAL_2="41" VAR="0.15531061079841568" WEIGHT="3.368223714064511"/>
<DICH_DATA CI_END="4.177208504264446" CI_START="0.15321236642763564" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6208861535010605" LOG_CI_START="-0.8147061795171733" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="933" O_E="0.0" SE="0.8432740427115678" STUDY_ID="STD-Holloway--1985" TOTAL_1="15" TOTAL_2="18" VAR="0.711111111111111" WEIGHT="0.6752150102786665"/>
<DICH_DATA CI_END="1.1620638386085749" CI_START="0.1320089074981098" EFFECT_SIZE="0.39166666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.0652299869130772" LOG_CI_START="-0.879396763136892" LOG_EFFECT_SIZE="-0.40708338811190736" ORDER="934" O_E="0.0" SE="0.5548784289571779" STUDY_ID="STD-Iakovlev-1998" TOTAL_1="48" TOTAL_2="47" VAR="0.30789007092198584" WEIGHT="2.501849301243059"/>
<DICH_DATA CI_END="1.5219304663112376" CI_START="0.4423600838070252" EFFECT_SIZE="0.8205128205128205" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="15" LOG_CI_END="0.1823948109186749" LOG_CI_START="-0.3542240683318614" LOG_EFFECT_SIZE="-0.08591462870659325" ORDER="935" O_E="0.0" SE="0.3152125859780576" STUDY_ID="STD-Jaspers-1998" TOTAL_1="39" TOTAL_2="40" VAR="0.09935897435897437" WEIGHT="3.6666739165765567"/>
<DICH_DATA CI_END="5.427988616422285" CI_START="0.8925326758770527" EFFECT_SIZE="2.201058201058201" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" LOG_CI_END="0.734638928186268" LOG_CI_START="-0.04937587527927091" LOG_EFFECT_SIZE="0.3426315264534986" ORDER="936" O_E="0.0" SE="0.46053417649152567" STUDY_ID="STD-Koehler-1990" TOTAL_1="63" TOTAL_2="64" VAR="0.2120917277167277" WEIGHT="1.4737763846397351"/>
<DICH_DATA CI_END="5.208499115067838" CI_START="0.34132246900739327" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7167125947102104" LOG_CI_START="-0.46683512149361067" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="937" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-Landau-1990" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="0.7427365113065332"/>
<DICH_DATA CI_END="3.5713646359076354" CI_START="0.12444667228203433" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5528341938718855" LOG_CI_START="-0.905016711983248" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="938" O_E="0.0" SE="0.8563488385776752" STUDY_ID="STD-Limson-1988" TOTAL_1="20" TOTAL_2="20" VAR="0.7333333333333332" WEIGHT="0.7427365113065332"/>
<DICH_DATA CI_END="2.163966825485128" CI_START="0.34778413155082627" EFFECT_SIZE="0.8675213675213675" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.3352505985698439" LOG_CI_START="-0.4586902375637037" LOG_EFFECT_SIZE="-0.06171981949692991" ORDER="939" O_E="0.0" SE="0.46636477721536806" STUDY_ID="STD-Mandell-1987" TOTAL_1="52" TOTAL_2="58" VAR="0.2174961054271399" WEIGHT="2.10667083206944"/>
<DICH_DATA CI_END="2.3294358192549933" CI_START="0.4375837344074471" EFFECT_SIZE="1.0096153846153846" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.3672507492434021" LOG_CI_START="-0.35893882970108676" LOG_EFFECT_SIZE="0.0041559597711577035" ORDER="940" O_E="0.0" SE="0.42656735336838303" STUDY_ID="STD-Martin-1991" TOTAL_1="52" TOTAL_2="42" VAR="0.18195970695970695" WEIGHT="2.191336090095871"/>
<DICH_DATA CI_END="3.5393716644310933" CI_START="0.7008659262685055" EFFECT_SIZE="1.575" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.5489261696836956" LOG_CI_START="-0.15436505343245688" LOG_EFFECT_SIZE="0.19728055812561932" ORDER="941" O_E="0.0" SE="0.41311674580612884" STUDY_ID="STD-McCormick-1997" TOTAL_1="65" TOTAL_2="63" VAR="0.17066544566544567" WEIGHT="2.011578051455194"/>
<DICH_DATA CI_END="66.16971022291247" CI_START="0.11902984959483541" EFFECT_SIZE="2.806451612903226" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8206592327414395" LOG_CI_START="-0.9243441151727481" LOG_EFFECT_SIZE="0.4481575587843459" ORDER="942" O_E="0.0" SE="1.6124285545505104" STUDY_ID="STD-Moreno-1997" TOTAL_1="30" TOTAL_2="28" VAR="2.599925843529848" WEIGHT="0.12791573250279184"/>
<DICH_DATA CI_END="1.2852729000490246" CI_START="0.6522740256592976" EFFECT_SIZE="0.9156146179401994" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="43" LOG_CI_END="0.10899535054827328" LOG_CI_START="-0.18556991526478353" LOG_EFFECT_SIZE="-0.03828728235825513" ORDER="943" O_E="0.0" SE="0.17302909526017163" STUDY_ID="STD-Mouton-1990" TOTAL_1="105" TOTAL_2="106" VAR="0.029939067806553546" WEIGHT="10.59543554043917"/>
<DICH_DATA CI_END="1.399873218217452" CI_START="0.39557189898178535" EFFECT_SIZE="0.7441441441441441" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="20" LOG_CI_END="0.146088704876939" LOG_CI_START="-0.4027745678094895" LOG_EFFECT_SIZE="-0.12834293146627523" ORDER="944" O_E="0.0" SE="0.3224050032930258" STUDY_ID="STD-Mouton-1995" TOTAL_1="111" TOTAL_2="118" VAR="0.10394498614837597" WEIGHT="4.800218501020389"/>
<DICH_DATA CI_END="3.6159719739665412" CI_START="0.5787047677624713" EFFECT_SIZE="1.4465753424657535" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="5" LOG_CI_END="0.558225055763821" LOG_CI_START="-0.2375429396091458" LOG_EFFECT_SIZE="0.16034105807733756" ORDER="945" O_E="0.0" SE="0.46743805959718704" STUDY_ID="STD-Muller-1987" TOTAL_1="73" TOTAL_2="33" VAR="0.2184983395599834" WEIGHT="1.7050240668357521"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="946" O_E="0.0" SE="0.0" STUDY_ID="STD-Naime-Libien-1992" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.7194272700246453" CI_START="0.133964145557945" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5704760708987405" LOG_CI_START="-0.8730114215600387" LOG_EFFECT_SIZE="-0.15126767533064908" ORDER="947" O_E="0.0" SE="0.8479116984486138" STUDY_ID="STD-Rapp-1984" TOTAL_1="17" TOTAL_2="18" VAR="0.718954248366013" WEIGHT="0.7215154681263465"/>
<DICH_DATA CI_END="15.773173963622442" CI_START="0.06784649559762428" EFFECT_SIZE="1.0344827586206897" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1979190932141035" LOG_CI_START="-1.1684725795726907" LOG_EFFECT_SIZE="0.014723256820706378" ORDER="948" O_E="0.0" SE="1.3900301824226613" STUDY_ID="STD-Rasmussen-1986" TOTAL_1="29" TOTAL_2="30" VAR="1.9321839080459768" WEIGHT="0.24338258562586965"/>
<DICH_DATA CI_END="1.0107859270454354" CI_START="0.47251247521932604" EFFECT_SIZE="0.6910925844668714" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="43" LOG_CI_END="0.004659186701519816" LOG_CI_START="-0.3255867208110324" LOG_EFFECT_SIZE="-0.1604637670547563" ORDER="949" O_E="0.0" SE="0.19398808081648017" STUDY_ID="STD-Sieger-1997" TOTAL_1="106" TOTAL_2="105" VAR="0.03763137549886124" WEIGHT="10.696344450348116"/>
<DICH_DATA CI_END="1.8956893891166395" CI_START="0.18946365936729576" EFFECT_SIZE="0.5993031358885017" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2777671791816151" LOG_CI_START="-0.7224740788345019" LOG_EFFECT_SIZE="-0.22235344982644345" ORDER="950" O_E="0.0" SE="0.5875466662327474" STUDY_ID="STD-Speich-1998" TOTAL_1="41" TOTAL_2="43" VAR="0.34521108500121545" WEIGHT="1.6917887201982145"/>
<DICH_DATA CI_END="1.1619390455620113" CI_START="0.406109665538784" EFFECT_SIZE="0.6869313482216708" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="26" LOG_CI_END="0.06518334589389115" LOG_CI_START="-0.39135667404060837" LOG_EFFECT_SIZE="-0.16308666407335862" ORDER="951" O_E="0.0" SE="0.268173867619071" STUDY_ID="STD-Stille-1992" TOTAL_1="186" TOTAL_2="151" VAR="0.07191722327377102" WEIGHT="7.105586090362799"/>
<DICH_DATA CI_END="1.8887018010491008" CI_START="0.5591992858596423" EFFECT_SIZE="1.0276967930029155" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.27616339445866245" LOG_CI_START="-0.25243339188936836" LOG_EFFECT_SIZE="0.011865001284647039" ORDER="952" O_E="0.0" SE="0.3105003688971257" STUDY_ID="STD-Thompson--1990" TOTAL_1="49" TOTAL_2="47" VAR="0.09641047908525113" WEIGHT="3.53831421358529"/>
<DICH_DATA CI_END="51.50073659814336" CI_START="0.12437246551099736" EFFECT_SIZE="2.5308641975308643" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7118134406571388" LOG_CI_START="-0.9052757563029298" LOG_EFFECT_SIZE="0.40326884217710457" ORDER="953" O_E="0.0" SE="1.5372911490948016" STUDY_ID="STD-Thompson-1993" TOTAL_1="80" TOTAL_2="40" VAR="2.363264077085215" WEIGHT="0.16437611315800324"/>
<DICH_DATA CI_END="3.3916425334872047" CI_START="0.009181943027495709" EFFECT_SIZE="0.17647058823529413" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.530410072972988" LOG_CI_START="-2.037065406290211" LOG_EFFECT_SIZE="-0.7533276666586115" ORDER="954" O_E="0.0" SE="1.5081478057277968" STUDY_ID="STD-Trujillo-1992" TOTAL_1="16" TOTAL_2="14" VAR="2.2745098039215685" WEIGHT="0.6576312860526596"/>
<DICH_DATA CI_END="4.151262680181564" CI_START="0.5648224993551716" EFFECT_SIZE="1.53125" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.6181802151766247" LOG_CI_START="-0.24808801175940942" LOG_EFFECT_SIZE="0.1850461017086077" ORDER="955" O_E="0.0" SE="0.5088502445991073" STUDY_ID="STD-Vergnon-1985" TOTAL_1="16" TOTAL_2="14" VAR="0.2589285714285714" WEIGHT="1.0563363716359584"/>
<DICH_DATA CI_END="2.4878692263738946" CI_START="0.6161416373272557" EFFECT_SIZE="1.2380952380952381" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.3958275481422332" LOG_CI_START="-0.21031944166843577" LOG_EFFECT_SIZE="0.09275405323689871" ORDER="956" O_E="0.0" SE="0.3560537422907775" STUDY_ID="STD-Warren-1983" TOTAL_1="56" TOTAL_2="64" VAR="0.1267742673992674" WEIGHT="2.7728829755443907"/>
<DICH_DATA CI_END="121.21138446425599" CI_START="0.3974297533358782" EFFECT_SIZE="6.940677966101695" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.08354341172641" LOG_CI_START="-0.40073962281782394" LOG_EFFECT_SIZE="0.841401894454293" ORDER="957" O_E="0.0" SE="1.459280151890634" STUDY_ID="STD-Wing-1998" TOTAL_1="117" TOTAL_2="62" VAR="2.1294985617019515" WEIGHT="0.16140498772407166"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.3194428885071679" CI_END="0.7741530070117604" CI_START="0.497115821476483" DF="5" EFFECT_SIZE="0.6203577258559296" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="136" I2="0.0" ID="CMP-003.06.04" LOG_CI_END="-0.11117319495829348" LOG_CI_START="-0.3035424145504234" LOG_EFFECT_SIZE="-0.20735780475435844" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="Dolores Matthews" NO="4" P_CHI2="0.997261341271779" P_Z="2.38567619993536E-5" STUDIES="6" TAU2="0.0" TOTAL_1="495" TOTAL_2="442" WEIGHT="99.99999999999999" Z="4.225351956966174">
<NAME>Any blinding&#8212;different BL</NAME>
<DICH_DATA CI_END="1.423999570845346" CI_START="0.3356573471587424" EFFECT_SIZE="0.691358024691358" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.1535098584163388" LOG_CI_START="-0.4741038421612374" LOG_EFFECT_SIZE="-0.16029699187244936" ORDER="958" O_E="0.0" SE="0.368663394457191" STUDY_ID="STD-Brown-1984" TOTAL_1="18" TOTAL_2="16" VAR="0.1359126984126984" WEIGHT="6.804509794557648"/>
<DICH_DATA CI_END="0.867426039722828" CI_START="0.4210317967449039" EFFECT_SIZE="0.604329334095093" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="59" LOG_CI_END="-0.061767544674934186" LOG_CI_START="-0.37568510456955584" LOG_EFFECT_SIZE="-0.21872632462224503" ORDER="959" O_E="0.0" SE="0.1843967285990835" STUDY_ID="STD-Rubinstein-1995" TOTAL_1="267" TOTAL_2="238" VAR="0.03400215351804405" WEIGHT="44.54845440636432"/>
<DICH_DATA CI_END="7.501364429912652" CI_START="0.014812120134843915" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.875140264790061" LOG_CI_START="-1.8293827742293858" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="960" O_E="0.0" SE="1.5886502207249786" STUDY_ID="STD-Sanfilippo-1989" TOTAL_1="13" TOTAL_2="13" VAR="2.5238095238095233" WEIGHT="1.0710802454396298"/>
<DICH_DATA CI_END="0.8499294497951944" CI_START="0.45564346622766727" EFFECT_SIZE="0.6223060344827587" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="58" LOG_CI_END="-0.07061712232836635" LOG_CI_START="-0.34137485298099385" LOG_EFFECT_SIZE="-0.2059959876546801" ORDER="961" O_E="0.0" SE="0.15904443125773576" STUDY_ID="STD-Smith-1984" TOTAL_1="96" TOTAL_2="99" VAR="0.025295131114096633" WEIGHT="40.77794739560929"/>
<DICH_DATA CI_END="1.8491276278552056" CI_START="0.26498982148049377" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.26696688744925967" LOG_CI_START="-0.5767708074207462" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="962" O_E="0.0" SE="0.4956156985355898" STUDY_ID="STD-Verzasconi-1995" TOTAL_1="45" TOTAL_2="42" VAR="0.24563492063492062" WEIGHT="5.909408250701406"/>
<DICH_DATA CI_END="9.392068384176333" CI_START="0.039248271403202646" EFFECT_SIZE="0.6071428571428571" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.9727612460375162" LOG_CI_START="-1.406179465965407" LOG_EFFECT_SIZE="-0.21670910996394532" ORDER="963" O_E="0.0" SE="1.3974015501769614" STUDY_ID="STD-Yellin-1993" TOTAL_1="56" TOTAL_2="34" VAR="1.952731092436975" WEIGHT="0.8885999073276929"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="113.22080374435428" CI_END="0.9567176352679557" CI_START="0.8236271566757882" CI_STUDY="95" CI_TOTAL="95" DF="63" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8876816015201229" ESTIMABLE="YES" EVENTS_1="880" EVENTS_2="966" I2="44.35651583762806" I2_Q="77.29654441469788" ID="CMP-003.07" LOG_CI_END="-0.019216220571745456" LOG_CI_START="-0.08426934223855767" LOG_EFFECT_SIZE="-0.05174278140515155" METHOD="MH" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0705634612029336E-4" P_Q="6.67609134471503E-5" P_Z="0.0018215553798860652" Q="30.832310851092178" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="66" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="3491" TOTAL_2="3312" WEIGHT="800.0" Z="3.117882291135729">
<NAME>Clinical failure by ITT versus per-protocol analysis</NAME>
<GROUP_LABEL_1>Monotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours monotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.004324546539085481" CI_END="1.4016545477122664" CI_START="0.43158870535703553" DF="1" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="18" I2="0.0" ID="CMP-003.07.01" LOG_CI_END="0.14664099044320386" LOG_CI_START="-0.36492992929333995" LOG_EFFECT_SIZE="-0.10914446942506803" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="Dolores Matthews" NO="1" P_CHI2="0.9475678800171772" P_Z="0.4029733002804543" STUDIES="2" TAU2="0.0" TOTAL_1="55" TOTAL_2="55" WEIGHT="100.0" Z="0.8363228671990727">
<NAME>ITT&#8212;same BL (type one)</NAME>
<DICH_DATA CI_END="1.5400316693721572" CI_START="0.4008663919406224" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.18752965180539463" LOG_CI_START="-0.3970003528454206" LOG_EFFECT_SIZE="-0.104735350520013" ORDER="964" O_E="0.0" SE="0.34335581820207717" STUDY_ID="STD-Ribera-1996" TOTAL_1="45" TOTAL_2="45" VAR="0.11789321789321788" WEIGHT="77.77777777777777"/>
<DICH_DATA CI_END="2.523907854293063" CI_START="0.22286867527402432" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.40207349514318896" LOG_CI_START="-0.6519509683597887" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="965" O_E="0.0" SE="0.6191391873668903" STUDY_ID="STD-Sculier-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.3833333333333333" WEIGHT="22.22222222222222"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.289497310047965" CI_END="1.5981274055639132" CI_START="1.0901095220172243" DF="8" EFFECT_SIZE="1.3198992015308988" ESTIMABLE="YES" EVENTS_1="158" EVENTS_2="124" I2="34.90376540089111" ID="CMP-003.07.02" LOG_CI_END="0.20361139908795284" LOG_CI_START="0.03747013318673131" LOG_EFFECT_SIZE="0.12054076613734208" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="Dolores Matthews" NO="2" P_CHI2="0.13874723633139008" P_Z="0.0044546536860656126" STUDIES="9" TAU2="0.0" TOTAL_1="444" TOTAL_2="458" WEIGHT="100.00000000000001" Z="2.8440322639472413">
<NAME>ITT assuming failure for dropouts&#8212;same BL (type two)</NAME>
<DICH_DATA CI_END="1.7667853181572402" CI_START="0.8372165363758395" EFFECT_SIZE="1.2162162162162162" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="36" LOG_CI_END="0.24718378164941232" LOG_CI_START="-0.0771622022327149" LOG_EFFECT_SIZE="0.08501078970834869" ORDER="966" O_E="0.0" SE="0.19052243647087552" STUDY_ID="STD-Cometta-1994" TOTAL_1="148" TOTAL_2="144" VAR="0.0362987987987988" WEIGHT="30.04813968925259"/>
<DICH_DATA CI_END="5.20030949600783" CI_START="1.144286276830267" EFFECT_SIZE="2.4393939393939394" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.7160291914056685" LOG_CI_START="0.0585346895742936" LOG_EFFECT_SIZE="0.38728194048998105" ORDER="967" O_E="0.0" SE="0.386215525026024" STUDY_ID="STD-Klastersky-1973" TOTAL_1="22" TOTAL_2="23" VAR="0.1491624317711274" WEIGHT="4.830561795889856"/>
<DICH_DATA CI_END="2.3051691630626916" CI_START="0.7500769369561273" EFFECT_SIZE="1.3149350649350648" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="14" LOG_CI_END="0.36270280126100685" LOG_CI_START="-0.12489418783255832" LOG_EFFECT_SIZE="0.11890430671422426" ORDER="968" O_E="0.0" SE="0.28641688503758295" STUDY_ID="STD-Kljucar-1990" TOTAL_1="44" TOTAL_2="45" VAR="0.08203463203463202" WEIGHT="11.397954799290671"/>
<DICH_DATA CI_END="1.8622005008641942" CI_START="0.25583996344864274" EFFECT_SIZE="0.6902356902356902" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.27002643912172664" LOG_CI_START="-0.5920316156446428" LOG_EFFECT_SIZE="-0.16100258826145808" ORDER="969" O_E="0.0" SE="0.5063771686259579" STUDY_ID="STD-Korzeniowski-1982" TOTAL_1="33" TOTAL_2="41" VAR="0.2564178369056418" WEIGHT="6.609383538295241"/>
<DICH_DATA CI_END="1.8274168662818542" CI_START="0.708134384230615" EFFECT_SIZE="1.1375661375661377" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="18" LOG_CI_END="0.26183762894793894" LOG_CI_START="-0.14988431746321645" LOG_EFFECT_SIZE="0.05597665574236123" ORDER="970" O_E="0.0" SE="0.24184750937841676" STUDY_ID="STD-Piccart-1984" TOTAL_1="42" TOTAL_2="43" VAR="0.058490217792543375" WEIGHT="14.646676675238226"/>
<DICH_DATA CI_END="4.223260101205608" CI_START="1.120984909915798" EFFECT_SIZE="2.1758241758241756" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="7" LOG_CI_END="0.6256478294807369" LOG_CI_START="0.049599766400137954" LOG_EFFECT_SIZE="0.33762379794043745" ORDER="971" O_E="0.0" SE="0.3383734837374443" STUDY_ID="STD-Sage-1987" TOTAL_1="26" TOTAL_2="22" VAR="0.11449661449661448" WEIGHT="6.244050048664444"/>
<DICH_DATA CI_END="3.5657354039450406" CI_START="1.2740456501917312" EFFECT_SIZE="2.1314102564102564" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="12" LOG_CI_END="0.5521491131326469" LOG_CI_START="0.10518498943667662" LOG_EFFECT_SIZE="0.3286670512846618" ORDER="972" O_E="0.0" SE="0.26254893876710816" STUDY_ID="STD-Sandberg-1997" TOTAL_1="26" TOTAL_2="35" VAR="0.0689319452477347" WEIGHT="8.422887185083653"/>
<DICH_DATA CI_END="14.55119169880151" CI_START="0.06353817832623988" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1628985621892929" LOG_CI_START="-1.1969652407868534" LOG_EFFECT_SIZE="-0.017033339298780342" ORDER="973" O_E="0.0" SE="1.3861956793824102" STUDY_ID="STD-Sexton-1998" TOTAL_1="26" TOTAL_2="25" VAR="1.9215384615384614" WEIGHT="0.8395361409969"/>
<DICH_DATA CI_END="1.537813142666863" CI_START="0.515705040436859" EFFECT_SIZE="0.8905380333951762" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="21" LOG_CI_END="0.1869035682100425" LOG_CI_START="-0.2875986238323455" LOG_EFFECT_SIZE="-0.050347527811151496" ORDER="974" O_E="0.0" SE="0.2787249364294307" STUDY_ID="STD-Takamoto-1994" TOTAL_1="77" TOTAL_2="80" VAR="0.07768759018759018" WEIGHT="16.960810127288426"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0363704338950683" CI_END="1.328189645637696" CI_START="0.9105252235283876" DF="2" EFFECT_SIZE="1.0997045848692062" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="108" I2="0.0" ID="CMP-003.07.03" LOG_CI_END="0.12326009022300255" LOG_CI_START="-0.04070801880101002" LOG_EFFECT_SIZE="0.04127603571099627" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="Dolores Matthews" NO="3" P_CHI2="0.5956005348391581" P_Z="0.32375459269602613" STUDIES="4" TAU2="0.0" TOTAL_1="277" TOTAL_2="303" WEIGHT="100.0" Z="0.9867716826117006">
<NAME>Per-protocol&#8212;same BL (type three studies)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="975" O_E="0.0" SE="0.0" STUDY_ID="STD-Abrams-1979" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.5248479213118067" CI_START="0.1293268436046026" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.40223522446491633" LOG_CI_START="-0.8883113218375052" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="976" O_E="0.0" SE="0.758073429606476" STUDY_ID="STD-Coppens-1983" TOTAL_1="22" TOTAL_2="44" VAR="0.5746753246753247" WEIGHT="4.488463643497241"/>
<DICH_DATA CI_END="1.7738115910050403" CI_START="0.8274562460098094" EFFECT_SIZE="1.2115079365079364" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="35" LOG_CI_END="0.24890748847637187" LOG_CI_START="-0.08225496144213654" LOG_EFFECT_SIZE="0.08332626351711768" ORDER="977" O_E="0.0" SE="0.1945264623626969" STUDY_ID="STD-D_x0027_Antonio-1992" TOTAL_1="144" TOTAL_2="142" VAR="0.03784054455934573" WEIGHT="33.89888625858056"/>
<DICH_DATA CI_END="1.3155515393719734" CI_START="0.8811748152727908" EFFECT_SIZE="1.076675849403122" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="66" LOG_CI_END="0.11910786711300905" LOG_CI_START="-0.05493792385031729" LOG_EFFECT_SIZE="0.03208497163134591" ORDER="978" O_E="0.0" SE="0.10223535915241792" STUDY_ID="STD-Dupont-2000" TOTAL_1="99" TOTAL_2="105" VAR="0.010452068661023883" WEIGHT="61.612650097922206"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7433061664632128" CI_END="1.6104311041127688" CI_START="0.5640135232644566" DF="4" EFFECT_SIZE="0.9530503244872811" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="23" I2="0.0" ID="CMP-003.07.04" LOG_CI_END="0.20694214999168106" LOG_CI_START="-0.248710482880627" LOG_EFFECT_SIZE="-0.020884166444472937" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="Dolores Matthews" NO="4" P_CHI2="0.9458829644361452" P_Z="0.8574162651839289" STUDIES="5" TAU2="0.0" TOTAL_1="143" TOTAL_2="135" WEIGHT="100.0" Z="0.17966411746720976">
<NAME>Type four studies&#8212;same BL</NAME>
<DICH_DATA CI_END="11.697696457498267" CI_START="0.0593659142180342" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0681003477040096" LOG_CI_START="-1.226462839799259" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="979" O_E="0.0" SE="1.347837774610382" STUDY_ID="STD-Biglino-1991" TOTAL_1="12" TOTAL_2="10" VAR="1.8166666666666667" WEIGHT="4.62054523946279"/>
<DICH_DATA CI_END="2.6312143240480275" CI_START="0.1655509382184593" EFFECT_SIZE="0.66" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4201562247335235" LOG_CI_START="-0.781068353649786" LOG_EFFECT_SIZE="-0.1804560644581313" ORDER="980" O_E="0.0" SE="0.7056052634999174" STUDY_ID="STD-Carbon-1987" TOTAL_1="25" TOTAL_2="22" VAR="0.49787878787878775" WEIGHT="18.02340341634422"/>
<DICH_DATA CI_END="1.9847833295834896" CI_START="0.37016326497723917" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.2977131035916891" LOG_CI_START="-0.4316066828529156" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="981" O_E="0.0" SE="0.4284060527487281" STUDY_ID="STD-Cardozo-2001" TOTAL_1="56" TOTAL_2="48" VAR="0.18353174603174602" WEIGHT="41.05176731984248"/>
<DICH_DATA CI_END="3.826396404729478" CI_START="0.31622442424010855" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.582789959802314" LOG_CI_START="-0.5000045894858638" LOG_EFFECT_SIZE="0.04139268515822508" ORDER="982" O_E="0.0" SE="0.6360388781713383" STUDY_ID="STD-Mergoni-1987" TOTAL_1="20" TOTAL_2="22" VAR="0.40454545454545454" WEIGHT="16.135237344155776"/>
<DICH_DATA CI_END="3.8827994475086087" CI_START="0.44874838980365256" EFFECT_SIZE="1.32" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5891449591554481" LOG_CI_START="-0.3479970967437483" LOG_EFFECT_SIZE="0.12057393120584989" ORDER="983" O_E="0.0" SE="0.5504818825631803" STUDY_ID="STD-Sukoh-1994" TOTAL_1="30" TOTAL_2="33" VAR="0.3030303030303031" WEIGHT="20.16904668019472"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="17.48769748113444" CI_END="0.8468183540857359" CI_START="0.5979965364353136" DF="12" EFFECT_SIZE="0.711613970304914" ESTIMABLE="YES" EVENTS_1="156" EVENTS_2="215" I2="31.380331727801874" ID="CMP-003.07.05" LOG_CI_END="-0.07220973757778905" LOG_CI_START="-0.2233013314152466" LOG_EFFECT_SIZE="-0.14775553449651782" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.13215426506915628" P_Z="1.263959755137605E-4" STUDIES="13" TAU2="0.0" TOTAL_1="833" TOTAL_2="756" WEIGHT="100.0" Z="3.83337707643992">
<NAME>ITT&#8212;different BL (type one)</NAME>
<DICH_DATA CI_END="17.69656322236463" CI_START="0.0749290767652106" EFFECT_SIZE="1.1515151515151516" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2478889319840376" LOG_CI_START="-1.1253496185061924" LOG_EFFECT_SIZE="0.06126965673892271" MODIFIED="2011-12-26 07:02:03 +0000" MODIFIED_BY="[Empty name]" ORDER="2076" O_E="0.0" SE="1.3940520722782508" STUDY_ID="STD-Banasal-2006" TOTAL_1="33" TOTAL_2="38" VAR="1.9433811802232854" WEIGHT="0.42962774974473406"/>
<DICH_DATA CI_END="1.87491372144196" CI_START="0.5772378000241282" EFFECT_SIZE="1.0403225806451613" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.27298128744304856" LOG_CI_START="-0.23864523716902078" LOG_EFFECT_SIZE="0.01716802513701388" ORDER="984" O_E="0.0" SE="0.3005319531492715" STUDY_ID="STD-Duff-1982" TOTAL_1="31" TOTAL_2="43" VAR="0.09031945486371591" WEIGHT="6.195647352584174"/>
<DICH_DATA CI_END="0.9370474331203014" CI_START="0.2525689662751385" EFFECT_SIZE="0.4864864864864865" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="18" LOG_CI_END="-0.028238424671436866" LOG_CI_START="-0.5976200132559408" LOG_EFFECT_SIZE="-0.3129292189636889" ORDER="985" O_E="0.0" SE="0.3344575636188571" STUDY_ID="STD-Felisart-1985" TOTAL_1="37" TOTAL_2="36" VAR="0.11186186186186185" WEIGHT="8.433116552274592"/>
<DICH_DATA CI_END="0.5205513287712564" CI_START="0.09922728020675375" EFFECT_SIZE="0.22727272727272727" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="22" LOG_CI_END="-0.2835364405952395" LOG_CI_START="-1.0033689123771354" LOG_EFFECT_SIZE="-0.6434526764861874" MODIFIED="2011-12-26 07:12:09 +0000" MODIFIED_BY="[Empty name]" ORDER="2085" O_E="0.0" SE="0.42283315715288794" STUDY_ID="STD-Garc_x00ed_a-Ram_x00ed_rez-1999" TOTAL_1="30" TOTAL_2="30" VAR="0.17878787878787883" WEIGHT="10.167856743958705"/>
<DICH_DATA CI_END="3.6075179132023756" CI_START="0.39916641708972667" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.557208496268825" LOG_CI_START="-0.39884600417357535" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="986" O_E="0.0" SE="0.5615911461059686" STUDY_ID="STD-Gomez-1990a" TOTAL_1="39" TOTAL_2="39" VAR="0.3153846153846154" WEIGHT="2.3108765327178875"/>
<DICH_DATA CI_END="1.2138694205384808" CI_START="0.2589786629232571" EFFECT_SIZE="0.5606837606837607" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.08417197093223315" LOG_CI_START="-0.5867360156732359" LOG_EFFECT_SIZE="-0.25128202237050135" ORDER="987" O_E="0.0" SE="0.39409467238014734" STUDY_ID="STD-Hoepelman-1988" TOTAL_1="45" TOTAL_2="41" VAR="0.15531061079841568" WEIGHT="6.287733821581229"/>
<DICH_DATA CI_END="1.1620638386085749" CI_START="0.1320089074981098" EFFECT_SIZE="0.39166666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.0652299869130772" LOG_CI_START="-0.879396763136892" LOG_EFFECT_SIZE="-0.40708338811190736" ORDER="988" O_E="0.0" SE="0.5548784289571779" STUDY_ID="STD-Iakovlev-1998" TOTAL_1="48" TOTAL_2="47" VAR="0.30789007092198584" WEIGHT="4.67040309770352"/>
<DICH_DATA CI_END="1.5219304663112376" CI_START="0.4423600838070252" EFFECT_SIZE="0.8205128205128205" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="15" LOG_CI_END="0.1823948109186749" LOG_CI_START="-0.3542240683318614" LOG_EFFECT_SIZE="-0.08591462870659325" ORDER="989" O_E="0.0" SE="0.3152125859780576" STUDY_ID="STD-Jaspers-1998" TOTAL_1="39" TOTAL_2="40" VAR="0.09935897435897437" WEIGHT="6.8448747931137435"/>
<DICH_DATA CI_END="1.2852729000490246" CI_START="0.6522740256592976" EFFECT_SIZE="0.9156146179401994" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="43" LOG_CI_END="0.10899535054827328" LOG_CI_START="-0.18556991526478353" LOG_EFFECT_SIZE="-0.03828728235825513" ORDER="990" O_E="0.0" SE="0.17302909526017163" STUDY_ID="STD-Mouton-1990" TOTAL_1="105" TOTAL_2="106" VAR="0.029939067806553546" WEIGHT="19.779350796627984"/>
<DICH_DATA CI_END="3.7194272700246453" CI_START="0.133964145557945" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5704760708987405" LOG_CI_START="-0.8730114215600387" LOG_EFFECT_SIZE="-0.15126767533064908" ORDER="991" O_E="0.0" SE="0.8479116984486138" STUDY_ID="STD-Rapp-1984" TOTAL_1="17" TOTAL_2="18" VAR="0.718954248366013" WEIGHT="1.3469108933555687"/>
<DICH_DATA CI_END="1.0107859270454354" CI_START="0.47251247521932604" EFFECT_SIZE="0.6910925844668714" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="43" LOG_CI_END="0.004659186701519816" LOG_CI_START="-0.3255867208110324" LOG_EFFECT_SIZE="-0.1604637670547563" ORDER="992" O_E="0.0" SE="0.19398808081648017" STUDY_ID="STD-Sieger-1997" TOTAL_1="106" TOTAL_2="105" VAR="0.03763137549886124" WEIGHT="19.967725566119682"/>
<DICH_DATA CI_END="1.1619390455620113" CI_START="0.406109665538784" EFFECT_SIZE="0.6869313482216708" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="26" LOG_CI_END="0.06518334589389115" LOG_CI_START="-0.39135667404060837" LOG_EFFECT_SIZE="-0.16308666407335862" ORDER="993" O_E="0.0" SE="0.268173867619071" STUDY_ID="STD-Stille-1992" TOTAL_1="186" TOTAL_2="151" VAR="0.07191722327377102" WEIGHT="13.264568441808551"/>
<DICH_DATA CI_END="121.21138446425599" CI_START="0.3974297533358782" EFFECT_SIZE="6.940677966101695" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.08354341172641" LOG_CI_START="-0.40073962281782394" LOG_EFFECT_SIZE="0.841401894454293" ORDER="994" O_E="0.0" SE="1.459280151890634" STUDY_ID="STD-Wing-1998" TOTAL_1="117" TOTAL_2="62" VAR="2.1294985617019515" WEIGHT="0.30130765840962515"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="29.566570112478693" CI_END="0.9416124266468996" CI_START="0.7263477005630498" DF="13" EFFECT_SIZE="0.8270054539823597" ESTIMABLE="YES" EVENTS_1="297" EVENTS_2="333" I2="56.03142349435623" ID="CMP-003.07.06" LOG_CI_END="-0.026127818655949882" LOG_CI_START="-0.13885543400042522" LOG_EFFECT_SIZE="-0.08249162632818756" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="Dolores Matthews" NO="6" P_CHI2="0.005435506574122839" P_Z="0.004123992745873396" STUDIES="14" TAU2="0.0" TOTAL_1="1071" TOTAL_2="994" WEIGHT="100.0" Z="2.8685183508107897">
<NAME>ITT assuming failure for dropouts&#8212;different BL (type two)</NAME>
<DICH_DATA CI_END="1.0644689749799745" CI_START="0.47573675829965395" EFFECT_SIZE="0.7116228070175439" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="32" LOG_CI_END="0.027133008008862106" LOG_CI_START="-0.322633291064956" LOG_EFFECT_SIZE="-0.14775014152804694" ORDER="995" O_E="0.0" SE="0.2054544554470644" STUDY_ID="STD-Alvarez_x002d_Lerma-2001a" TOTAL_1="57" TOTAL_2="59" VAR="0.04221153326304977" WEIGHT="9.143664513819639"/>
<DICH_DATA CI_END="0.6862922195333034" CI_START="0.0906908064950126" EFFECT_SIZE="0.2494802494802495" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.16349092466011797" LOG_CI_START="-1.042436735992296" LOG_EFFECT_SIZE="-0.6029638303262069" ORDER="996" O_E="0.0" SE="0.516297120428457" STUDY_ID="STD-Bergeron-1988" TOTAL_1="37" TOTAL_2="30" VAR="0.2665627165627166" WEIGHT="4.174685005998629"/>
<DICH_DATA CI_END="1.090184468639289" CI_START="0.38310035157614686" EFFECT_SIZE="0.6462585034013606" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.03749999054042055" LOG_CI_START="-0.4166874494590771" LOG_EFFECT_SIZE="-0.1895937294593283" ORDER="997" O_E="0.0" SE="0.2667919505197925" STUDY_ID="STD-Cone-1985" TOTAL_1="21" TOTAL_2="19" VAR="0.0711779448621554" WEIGHT="4.274061603334771"/>
<DICH_DATA CI_END="1.343210188701292" CI_START="0.6842888488632637" EFFECT_SIZE="0.9587198515769945" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="49" LOG_CI_END="0.12814397741227843" LOG_CI_START="-0.1647605371871041" LOG_EFFECT_SIZE="-0.018308279887412827" ORDER="998" O_E="0.0" SE="0.17205356177640826" STUDY_ID="STD-Finer-1992" TOTAL_1="220" TOTAL_2="195" VAR="0.029602428119948333" WEIGHT="15.105117312990357"/>
<DICH_DATA CI_END="2.897409958806917" CI_START="0.6491371097879041" EFFECT_SIZE="1.3714285714285714" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.4620099485179783" LOG_CI_START="-0.1876635624673551" LOG_EFFECT_SIZE="0.13717319302531158" ORDER="999" O_E="0.0" SE="0.3816214362885301" STUDY_ID="STD-Holloway--1985" TOTAL_1="15" TOTAL_2="18" VAR="0.14563492063492064" WEIGHT="1.850243118326741"/>
<DICH_DATA CI_END="3.2242134037451753" CI_START="1.0018992174222259" EFFECT_SIZE="1.7973137973137974" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="13" LOG_CI_END="0.5084237791013323" LOG_CI_START="8.240373807909483E-4" LOG_EFFECT_SIZE="0.25462390824106157" ORDER="1000" O_E="0.0" SE="0.2981666009458911" STUDY_ID="STD-Koehler-1990" TOTAL_1="63" TOTAL_2="64" VAR="0.08890332191962627" WEIGHT="3.750020304388214"/>
<DICH_DATA CI_END="1.2894238203166348" CI_START="0.5059367243154608" EFFECT_SIZE="0.8076923076923077" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="20" LOG_CI_END="0.11039568893737642" LOG_CI_START="-0.2959037954111738" LOG_EFFECT_SIZE="-0.09275405323689868" ORDER="1001" O_E="0.0" SE="0.23866232832122242" STUDY_ID="STD-Martin-1991" TOTAL_1="52" TOTAL_2="42" VAR="0.056959706959706966" WEIGHT="6.433672119652863"/>
<DICH_DATA CI_END="2.847075233319978" CI_START="0.41645510398510166" EFFECT_SIZE="1.0888888888888888" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.454398943432176" LOG_CI_START="-0.3804318109258361" LOG_EFFECT_SIZE="0.036983566253169946" ORDER="1002" O_E="0.0" SE="0.49038371758877813" STUDY_ID="STD-Moreno-1997" TOTAL_1="30" TOTAL_2="28" VAR="0.2404761904761905" WEIGHT="1.8046706277275602"/>
<DICH_DATA CI_END="0.7583856532762494" CI_START="0.31056383036213986" EFFECT_SIZE="0.48531139835487663" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="46" LOG_CI_END="-0.12010989133704239" LOG_CI_START="-0.5078491255193314" LOG_EFFECT_SIZE="-0.31397950842818684" ORDER="1003" O_E="0.0" SE="0.22775994549884046" STUDY_ID="STD-Mouton-1995" TOTAL_1="111" TOTAL_2="118" VAR="0.05187459277363478" WEIGHT="12.965783528875825"/>
<DICH_DATA CI_END="0.9441519250002142" CI_START="0.581964482678124" EFFECT_SIZE="0.741257638478218" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="95" LOG_CI_END="-0.024958117057352236" LOG_CI_START="-0.235103519555587" LOG_EFFECT_SIZE="-0.1300308183064696" ORDER="1004" O_E="0.0" SE="0.12344044966398218" STUDY_ID="STD-Rubinstein-1995" TOTAL_1="267" TOTAL_2="238" VAR="0.01523754461324612" WEIGHT="29.207670928426342"/>
<DICH_DATA CI_END="1.986913129488195" CI_START="0.3348893829732242" EFFECT_SIZE="0.8157181571815718" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.2981788795865887" LOG_CI_START="-0.47509862071702275" LOG_EFFECT_SIZE="-0.08845987056521701" ORDER="1005" O_E="0.0" SE="0.4542270314637016" STUDY_ID="STD-Speich-1998" TOTAL_1="41" TOTAL_2="43" VAR="0.20632219611232655" WEIGHT="2.5544683052000825"/>
<DICH_DATA CI_END="1.6560438534188335" CI_START="0.35212865568982327" EFFECT_SIZE="0.7636363636363637" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.21907183308028774" LOG_CI_START="-0.4532986312729745" LOG_EFFECT_SIZE="-0.11711339909634337" ORDER="1006" O_E="0.0" SE="0.3949537390485827" STUDY_ID="STD-Verzasconi-1995" TOTAL_1="45" TOTAL_2="42" VAR="0.15598845598845598" WEIGHT="3.308562817500527"/>
<DICH_DATA CI_END="2.9392970191590875" CI_START="0.7899832680117895" EFFECT_SIZE="1.5238095238095237" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.468243474219639" LOG_CI_START="-0.10238210704766565" LOG_EFFECT_SIZE="0.1829306835859867" ORDER="1007" O_E="0.0" SE="0.33518829107859727" STUDY_ID="STD-Warren-1983" TOTAL_1="56" TOTAL_2="64" VAR="0.11235119047619047" WEIGHT="3.256427888255064"/>
<DICH_DATA CI_END="4.134736117351773" CI_START="0.8023733429791869" EFFECT_SIZE="1.8214285714285714" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="6" LOG_CI_END="0.6164477977011545" LOG_CI_START="-0.09562350818972029" LOG_EFFECT_SIZE="0.2604121447557171" ORDER="1008" O_E="0.0" SE="0.41827420989011144" STUDY_ID="STD-Yellin-1993" TOTAL_1="56" TOTAL_2="34" VAR="0.174953314659197" WEIGHT="2.1709519255033762"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.868454216515936" CI_END="0.949473285307788" CI_START="0.6157821734461775" DF="11" EFFECT_SIZE="0.7646363339888527" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="127" I2="14.519647698772397" ID="CMP-003.07.07" LOG_CI_END="-0.022517250207249442" LOG_CI_START="-0.21057288783622818" LOG_EFFECT_SIZE="-0.1165450690217388" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="Dolores Matthews" NO="7" P_CHI2="0.30201027386811086" P_Z="0.0151269625612106" STUDIES="12" TAU2="0.0" TOTAL_1="555" TOTAL_2="476" WEIGHT="100.0" Z="2.4293250735615644">
<NAME>Per-protocol&#8212;different BL (type three studies)</NAME>
<DICH_DATA CI_END="1.9601526210417917" CI_START="0.14222565988347913" EFFECT_SIZE="0.528" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.2922898876298273" LOG_CI_START="-0.8470220425622028" LOG_EFFECT_SIZE="-0.27736607746618774" ORDER="1009" O_E="0.0" SE="0.6692374674798086" STUDY_ID="STD-Arich-1987" TOTAL_1="25" TOTAL_2="22" VAR="0.4478787878787879" WEIGHT="4.094771173955793"/>
<DICH_DATA CI_END="1.423999570845346" CI_START="0.3356573471587424" EFFECT_SIZE="0.691358024691358" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.1535098584163388" LOG_CI_START="-0.4741038421612374" LOG_EFFECT_SIZE="-0.16029699187244936" ORDER="1010" O_E="0.0" SE="0.368663394457191" STUDY_ID="STD-Brown-1984" TOTAL_1="18" TOTAL_2="16" VAR="0.1359126984126984" WEIGHT="7.335902992588096"/>
<DICH_DATA CI_END="0.7364746482815971" CI_START="0.10801855283463083" EFFECT_SIZE="0.28205128205128205" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.132842198313418" LOG_CI_START="-0.9665016454231303" LOG_EFFECT_SIZE="-0.5496719218682742" ORDER="1011" O_E="0.0" SE="0.4896956859130625" STUDY_ID="STD-Gerecht-1989" TOTAL_1="24" TOTAL_2="22" VAR="0.23980186480186477" WEIGHT="10.442734694763086"/>
<DICH_DATA CI_END="5.597705211534098" CI_START="0.052414831915982264" EFFECT_SIZE="0.5416666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7480100237523192" LOG_CI_START="-1.2805458025618577" LOG_EFFECT_SIZE="-0.2662678894047693" ORDER="1012" O_E="0.0" SE="1.191583733890235" STUDY_ID="STD-Havig-1973" TOTAL_1="24" TOTAL_2="26" VAR="1.4198717948717947" WEIGHT="1.478048602951083"/>
<DICH_DATA CI_END="3.5713646359076354" CI_START="0.12444667228203433" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5528341938718855" LOG_CI_START="-0.905016711983248" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="1013" O_E="0.0" SE="0.8563488385776752" STUDY_ID="STD-Limson-1988" TOTAL_1="20" TOTAL_2="20" VAR="0.7333333333333332" WEIGHT="2.3094509421110674"/>
<DICH_DATA CI_END="2.163966825485128" CI_START="0.34778413155082627" EFFECT_SIZE="0.8675213675213675" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.3352505985698439" LOG_CI_START="-0.4586902375637037" LOG_EFFECT_SIZE="-0.06171981949692991" ORDER="1014" O_E="0.0" SE="0.46636477721536806" STUDY_ID="STD-Mandell-1987" TOTAL_1="52" TOTAL_2="58" VAR="0.2174961054271399" WEIGHT="6.550442672169573"/>
<DICH_DATA CI_END="3.5393716644310933" CI_START="0.7008659262685055" EFFECT_SIZE="1.575" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.5489261696836956" LOG_CI_START="-0.15436505343245688" LOG_EFFECT_SIZE="0.19728055812561932" ORDER="1015" O_E="0.0" SE="0.41311674580612884" STUDY_ID="STD-McCormick-1997" TOTAL_1="65" TOTAL_2="63" VAR="0.17066544566544567" WEIGHT="6.254762968217474"/>
<DICH_DATA CI_END="3.6159719739665412" CI_START="0.5787047677624713" EFFECT_SIZE="1.4465753424657535" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="5" LOG_CI_END="0.558225055763821" LOG_CI_START="-0.2375429396091458" LOG_EFFECT_SIZE="0.16034105807733756" ORDER="1016" O_E="0.0" SE="0.46743805959718704" STUDY_ID="STD-Muller-1987" TOTAL_1="73" TOTAL_2="33" VAR="0.2184983395599834" WEIGHT="5.301569772770689"/>
<DICH_DATA CI_END="15.773173963622442" CI_START="0.06784649559762428" EFFECT_SIZE="1.0344827586206897" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1979190932141035" LOG_CI_START="-1.1684725795726907" LOG_EFFECT_SIZE="0.014723256820706378" ORDER="1017" O_E="0.0" SE="1.3900301824226613" STUDY_ID="STD-Rasmussen-1986" TOTAL_1="29" TOTAL_2="30" VAR="1.9321839080459768" WEIGHT="0.7567692352680334"/>
<DICH_DATA CI_END="0.8499294497951944" CI_START="0.45564346622766727" EFFECT_SIZE="0.6223060344827587" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="58" LOG_CI_END="-0.07061712232836635" LOG_CI_START="-0.34137485298099385" LOG_EFFECT_SIZE="-0.2059959876546801" ORDER="1018" O_E="0.0" SE="0.15904443125773576" STUDY_ID="STD-Smith-1984" TOTAL_1="96" TOTAL_2="99" VAR="0.025295131114096633" WEIGHT="43.962471267262984"/>
<DICH_DATA CI_END="1.8887018010491008" CI_START="0.5591992858596423" EFFECT_SIZE="1.0276967930029155" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.27616339445866245" LOG_CI_START="-0.25243339188936836" LOG_EFFECT_SIZE="0.011865001284647039" ORDER="1019" O_E="0.0" SE="0.3105003688971257" STUDY_ID="STD-Thompson--1990" TOTAL_1="49" TOTAL_2="47" VAR="0.09641047908525113" WEIGHT="11.00196768255689"/>
<DICH_DATA CI_END="51.50073659814336" CI_START="0.12437246551099736" EFFECT_SIZE="2.5308641975308643" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7118134406571388" LOG_CI_START="-0.9052757563029298" LOG_EFFECT_SIZE="0.40326884217710457" ORDER="1020" O_E="0.0" SE="1.5372911490948016" STUDY_ID="STD-Thompson-1993" TOTAL_1="80" TOTAL_2="40" VAR="2.363264077085215" WEIGHT="0.5111079953852362"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.625778279537627" CI_END="1.6916473979899864" CI_START="0.5176121517945182" DF="5" EFFECT_SIZE="0.935744222397977" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="18" I2="11.12340814805554" ID="CMP-003.07.08" LOG_CI_END="0.22830984507093882" LOG_CI_START="-0.28599553644415604" LOG_EFFECT_SIZE="-0.028842845686608574" MODIFIED="2013-12-20 15:49:50 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.34435097254935154" P_Z="0.8260003358774476" STUDIES="7" TAU2="0.0" TOTAL_1="113" TOTAL_2="135" WEIGHT="99.99999999999999" Z="0.2198341327514967">
<NAME>Type four studies&#8212;different BL</NAME>
<DICH_DATA CI_END="2.3225990308636475" CI_START="0.007117290597831311" EFFECT_SIZE="0.12857142857142856" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3659742404872978" LOG_CI_START="-2.147685301637162" LOG_EFFECT_SIZE="-0.890855530574932" ORDER="1021" O_E="0.0" SE="1.4765360578593163" STUDY_ID="STD-Aguilar-1992" TOTAL_1="19" TOTAL_2="17" VAR="2.1801587301587304" WEIGHT="20.924540874471436"/>
<DICH_DATA CI_END="6.586766671602955" CI_START="0.4918953655924044" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.8186722793470714" LOG_CI_START="-0.30812726914045924" LOG_EFFECT_SIZE="0.25527250510330607" MODIFIED="2011-12-26 07:33:01 +0000" MODIFIED_BY="[Empty name]" ORDER="2096" O_E="0.0" SE="0.6618876325292973" STUDY_ID="STD-Figueroa_x002d_Damian-1996" TOTAL_1="14" TOTAL_2="42" VAR="0.4380952380952381" WEIGHT="14.198795593391331"/>
<DICH_DATA CI_END="5.208499115067838" CI_START="0.34132246900739327" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7167125947102104" LOG_CI_START="-0.46683512149361067" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="1022" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-Landau-1990" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="17.038554712069597"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1023" O_E="0.0" SE="0.0" STUDY_ID="STD-Naime-Libien-1992" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.501364429912652" CI_START="0.014812120134843915" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.875140264790061" LOG_CI_START="-1.8293827742293858" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="1024" O_E="0.0" SE="1.5886502207249786" STUDY_ID="STD-Sanfilippo-1989" TOTAL_1="13" TOTAL_2="13" VAR="2.5238095238095233" WEIGHT="8.519277356034799"/>
<DICH_DATA CI_END="3.3916425334872047" CI_START="0.009181943027495709" EFFECT_SIZE="0.17647058823529413" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.530410072972988" LOG_CI_START="-2.037065406290211" LOG_EFFECT_SIZE="-0.7533276666586115" ORDER="1025" O_E="0.0" SE="1.5081478057277968" STUDY_ID="STD-Trujillo-1992" TOTAL_1="16" TOTAL_2="14" VAR="2.2745098039215685" WEIGHT="15.08622031797829"/>
<DICH_DATA CI_END="4.151262680181564" CI_START="0.5648224993551716" EFFECT_SIZE="1.53125" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.6181802151766247" LOG_CI_START="-0.24808801175940942" LOG_EFFECT_SIZE="0.1850461017086077" ORDER="1026" O_E="0.0" SE="0.5088502445991073" STUDY_ID="STD-Vergnon-1985" TOTAL_1="16" TOTAL_2="14" VAR="0.2589285714285714" WEIGHT="24.232611146054538"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-12-20 14:19:09 +0000" MODIFIED_BY="Karen Hovhannisyan">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-12-20 14:19:09 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZEAAAaSCAYAAADnEsJ3AACAAElEQVR42uy9AWTVX/z//yX5SJJI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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2012-03-21 07:48:06 +0000" MODIFIED_BY="Jane Cracknell" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2012-03-21 07:48:09 +0000" MODIFIED_BY="Jane Cracknell" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAWsAAAlrCAIAAACry3FIAACAAElEQVR42uy9v04kyba+nRISwsDA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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-04" MODIFIED="2013-12-20 14:19:09 +0000" MODIFIED_BY="Karen Hovhannisyan" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel mortality.</P>
<P>All-cause mortality.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-05" MODIFIED="2012-03-21 07:48:08 +0000" MODIFIED_BY="Karen Hovhannisyan" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel failure.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2014-01-06 14:37:26 +0000" MODIFIED_BY="Jane Cracknell">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2014-01-06 14:37:26 +0000" MODIFIED_BY="Jane Cracknell" NO="1">
<TITLE MODIFIED="2013-08-13 16:10:19 +0100" MODIFIED_BY="Jane Cracknell">Obtaining data on all-cause mortality</TITLE>
<DATE_SUBMITTED>
<DATE DAY="16" MONTH="6" YEAR="2013"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2014-01-06 14:37:26 +0000" MODIFIED_BY="Jane Cracknell">
<P>Thank you for taking on the large amount of data surrounding topic of aminoglycoside and beta-lactam combination therapy in the treatment of sepsis. With the large volume of studies spanning such a long time period this was no small task. With this in mind we still have some one question regarding the primary outcome analysis of all cause mortality between the two treatment arms.</P>
<P>The primary mortality analysis contained 43 of the total 64 studies included in the review and they were split into two separate subgroups, using either the same or a different beta-lactam agent as monotherapy as in combination therapy. Our concern is centered on the outstanding 21 studies not included in this analysis. We were wondering what attempts were made to collect mortality data from these remaining trials questioning whether the inclusion of those results would statistically alter the outcomes. We understand that a number of these studies were completed over 40 years ago and the data may be very difficult to obtain.</P>
<P>In the subgroup where a different beta-lactam was used the risk of mortality was non-significantly lowered in the monotherapy arm RR 0.85 (95% CI 0.71, 1.01). With the results being close to statistical significance we were wondering if the addition of data from the outstanding studies would actually make a statistical difference. If this were truly the case then your conclusion of &#8220;The addition of an aminoglycoside to beta-lactams for sepsis should be discouraged. All-cause fatality rates are unchanged. Combination treatment carries a significant risk of nephrotoxicity&#8221; would change and the call to avoid the use of these antibiotics would be much stronger.</P>
<P>We also pooled all of the data from both subgroups (same and different beta-lactams) and found that it did not change the results of the different beta-lactam group but greatly narrowed the confidence interval of the same beta-lactam group with a RR of 1.13 (0.97, 1.31) - increased risk of mortality in the combination group versus monotherapy. With this analysis we also found very little heterogeneity between same and different beta-lactam studies (<I>I<SUP>2</SUP> </I>= 8%).</P>
<P>We understand the beta-lactam agent selected, specifically in regards the spectrum of activity, greatly impacts the effects of empirical therapy but with this potentially increased risk of mortality that is consistent across this large number of studies leads us to believe that although statistically non-significant it seems plausible that the risk of mortality with combination therapy over beta-lactam monotherapy is real.</P>
<P>We also believe that the possibility of &#8220;emotional based medicine&#8221; is real in this patient population. As the majority of these studies were open-label despite being randomized, it is not unlikely that &#8220;sicker&#8221; patients would receive more drugs (i.e. combination therapy). If this were true then it is plausible that patients who were more likely to die received more antibiotics and were in the combination groups but with the effect remaining relatively consistent across this large number of studies, we feel that a true risk may actually exist.</P>
<P>After this long discussion, our question returns to whether or not mortality data are available from the remaining 21 studies and what attempts have been made to retrieve this information. A statistically significant increase in mortality, along with the increase in adverse events see with combination therapy would likely facilitate a rapid change in practice and removal of this therapeutic option. Just as an exercise we inserted the data provided by your review into Review Manager to test how many events it would take to make the difference in mortality. We understand this is not a truly scientific exercise but one based on curiosity.</P>
<P>What we found was that when we added two events (deaths) to the combination group in the most heavily weighted study (<A HREF="http://archie.cochrane.org/sections/documents/view?version=z1308140834172311675266682057354&amp;format=REVMAN_GRAPHS#STD-Felisart-1985">Felisart 1985</A>) the outcome of mortality became statistically significantly higher in the combination group. We also combined all of the data between the same different beta-lactam subgroups and found that only eight more deaths in the combination group made the entire analysis (all 43 studies) statistically significant for an increase in mortality in the combination group. On the flip side, it took 80 events in the monotherapy group to swing the analysis the other way and statistically favour combination therapy in the outcome of mortality.</P>
<P>Thank you for your time</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2014-01-06 14:28:00 +0000" MODIFIED_BY="Jane Cracknell">
<P>Dear Dr Amadio,</P>
<P>Thank you for your kind attention to our work and your input for the data analysis.</P>
<P>In response to your question regarding obtaining data on all-cause mortality, we mailed all authors of trials that did not report on this outcome asking for the data, as is routine in Cochrane reviews. We agree with you on the importance of the missing data on mortality and for this reason we made extra efforts to obtain the data. If we did not establish contact with the corresponding author, we tried to contact a second and third author. The data presented in our review are the result of this process and still we miss mortality data from a third of all randomized controlled trials (RCTs) that were conducted.</P>
<P>Selection bias should not occur in adequately conducted RCTs, those using appropriate allocation concealment. Allocation concealment is the procedure ensuring that no one is aware of the treatment assignment when the patient is recruited into the trial and before the patient is allocated to an intervention. We observed in our review that the advantage to combination therapy was larger in trials with unclear methods for allocation concealment (studies not reporting the methods for this procedure) compared to trials that used methods ensuring adequate allocation concealment. Therefore, it is possible that results were affected by selection of sicker patients to the combination therapy group. However the difference between trials with low and unclear risk of bias was not statistically significant and we have no actual data on whether bias could occur in the trials with unclear risk of bias. Most importantly to our view, the trials comparing different beta-lactams usually compared a new, broad-spectrum beta-lactam to an old, classical regimen; we believe that if selection bias crept in to some trials it would have worked in the opposite direction of recruiting the sicker patients to the novel monotherapy arm. The fact that most of the trials were open, might have led to a different type of bias, and dilution of effects, because physicians could add an aminoglycoside to failing patients in the monotherapy arm, while this could not occur in the combination therapy arm.</P>
<P>Methods exist to formally examine the possible effects of missing data in meta-analysis. We will consider adding such an analysis to an update of our review. More importantly, we will highlight the issue of missing data on all-cause mortality. Should your important correspondence result in any authors sending further data from their trials on mortality, these will be added to our review.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2013-12-20 14:15:22 +0000" MODIFIED_BY="Jane Cracknell">
<P>Anthony Amadio, BSc. Pharm, ACPR, RPh </P>
<P>Doctor of Pharmacy Student</P>
<P>Faculty of Pharmaceutical Sciences</P>
<P>University of British Columbia</P>
<P>Vancouver BC</P>
<P>Canada</P>
<P>Aaron M Tejani, BSc Pharm, PharmD<BR/>Researcher<BR/>Therapeutics Initiative, University of British Columbia<BR/>2176 Health Sciences Mall<BR/>Vancouver, BC, Canada<BR/>Canada<BR/>
</P>
<P>Reply</P>
<P>Mical Paul, corresponding author</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-11-28 12:36:34 +0000" MODIFIED_BY="Karen Hovhannisyan">Search strategy for CENTRAL, <I>T</I>
<I>he Cochrane Librar</I>y</TITLE>
<APPENDIX_BODY MODIFIED="2011-09-24 08:06:21 +0100" MODIFIED_BY="[Empty name]">
<P>#1 MeSH descriptor beta-Lactams, this term only<BR/>#2 MeSH descriptor Penicillins, this term only<BR/>#3 MeSH descriptor Cephalosporins, this term only<BR/>#4 MeSH descriptor Carbapenems, this term only<BR/>#5 MeSH descriptor Imipenem, this term only<BR/>#6 MeSH descriptor Ceftazidime, this term only<BR/>#7 MeSH descriptor Cefotaxime, this term only<BR/>#8 MeSH descriptor Amoxicillin-Potassium Clavulanate Combination, this term only<BR/>#9 beta-lactam*:ti,ab<BR/>#10 co?amoxiclav* or cephalosporin* or ceftazidim* or cefotaxim* or carbapenem* or imipenem* or meropenem*<BR/>#11 beta-lactam* near (combin* or mono*)<BR/>#12 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11)<BR/>#13 MeSH descriptor Aminoglycosides, this term only<BR/>#14 (aminoglycoside* or netilmicin* or gentamicin* or amikacin* or tobramycin* or streptomycin* or isepamicin* or sisomicin* or combinat*):ti,ab<BR/>#15 (#13 OR #14)<BR/>#16 (#12 OR ( #12 AND #15 ))<BR/>#17 MeSH descriptor Pneumonia, this term only<BR/>#18 MeSH descriptor Sepsis, this term only<BR/>#19 MeSH descriptor Shock, Septic, this term only<BR/>#20 MeSH descriptor Bacteremia explode all trees<BR/>#21 MeSH descriptor Infection, this term only<BR/>#22 MeSH descriptor Endocarditis, Bacterial explode all trees<BR/>#23 MeSH descriptor Endocarditis, this term only<BR/>#24 MeSH descriptor Staphylococcus, this term only<BR/>#25 MeSH descriptor Streptococcus, this term only<BR/>#26 (pneumonia* or infect* or sepsis* or septic* or bacter*):ti,ab<BR/>#27 (#17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26)<BR/>#28 (#16 AND #27)<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2012-02-11 10:23:29 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2012-02-11 10:23:29 +0000" MODIFIED_BY="Karen Hovhannisyan">Search strategy for MEDLINE (Ovid SP)</TITLE>
<APPENDIX_BODY MODIFIED="2011-09-24 08:06:21 +0100" MODIFIED_BY="[Empty name]">
<P>1. Beta-Lactams/ or Penicillins/ or Cephalosporins/ or Carbapenems/ or Imipenem/ or Ceftazidime/ or Cefotaxime/ or Amoxicillin-Potassium Clavulanate Combination/ or beta-lactam*.ti,ab. or (co?amoxiclav* or cephalosporin* or ceftazidim* or cefotaxim* or carbapenem* or imipenem* or meropenem*).mp. or (beta-lactam* adj5 (combin* or mono*)).mp. <BR/>2. Aminoglycosides/ or (aminoglycoside* or netilmicin* or gentamicin* or amikacin* or tobramycin* or streptomycin* or isepamicin* or sisomicin* or combinat*).ti,ab. or Drug-Therapy-Combination/ <BR/>3. 1 or (1 and 2) <BR/>4. pneumonia/ or exp Sepsis/ or Shock, Septic/ or exp Bacteremia/ or Infection/ or exp Endocarditis, Bacterial/ or Endocarditis/ or exp Endocarditis, Subacute Bacterial/ or Staphylococcus/ or Streptococcus/ or (pneumonia* or infect* or sepsis* or septic* or bacter*).ti,ab. <BR/>5. 3 and 4 <BR/>6. ((randomized controlled trial or controlled clinical trial).pt. or randomized.ab. or placebo.ab. or clinical trials as topic.sh. or randomly.ab. or trial.ti.) not (animals not (humans and animals)).sh. <BR/>7. 6 and 5</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2012-02-11 10:23:39 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2012-02-11 10:23:39 +0000" MODIFIED_BY="Karen Hovhannisyan">Search strategy for EMBASE (Ovid SP)</TITLE>
<APPENDIX_BODY MODIFIED="2011-09-24 08:06:21 +0100" MODIFIED_BY="[Empty name]">
<P>1. beta lactam/ or penicillin derivative/ or cephalosporin derivative/ or carbapenem derivative/ or imipenem/ or ceftazidime/ or cefotaxime/ or amoxicillin plus clavulanic acid/ or beta-lactam*.ti,ab. or (co?amoxiclav* or cephalosporin* or ceftazidim* or cefotaxim* or carbapenem* or imipenem* or meropenem*).mp. or (beta-lactam* adj5 (combin* or mono*)).mp. <BR/>2. aminoglycoside/ or (aminoglycoside* or netilmicin* or gentamicin* or amikacin* or tobramycin* or streptomycin* or isepamicin* or sisomicin* or combinat*).ti,ab. or drug combination/ <BR/>3. 1 or (1 and 2) <BR/>4. pneumonia/ or exp sepsis/ or septicemia/ or bacteremia/ or infection/ or exp bacterial endocarditis/ or endocarditis/ or Staphylococcus/ or Staphylococcus/ or (pneumonia* or infect* or sepsis* or septic* or bacter*).ti,ab. <BR/>5. 4 and 3 <BR/>6. (placebo.sh. or controlled study.ab. or random*.ti,ab. or trial*.ti,ab.) not (animals not (humans and animals)).sh. <BR/>7. 5 and 6</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2012-02-11 10:23:47 +0000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2012-02-11 10:23:47 +0000" MODIFIED_BY="Karen Hovhannisyan">Search strategy for LILACS (via BIREME)</TITLE>
<APPENDIX_BODY MODIFIED="2011-09-24 08:06:21 +0100" MODIFIED_BY="[Empty name]">
<P>(co?amoxiclav$ or cephalosporin$ or ceftazidim$ or cefotaxim$ or carbapenem$ or imipenem$ or meropenem$ or beta-lactam$) and (aminoglycoside$ or netilmicin$ or gentamicin$ or amikacin$ or tobramycin$ or streptomycin$ or isepamicin$ or sisomicin$ or combinat$ or pneumonia$ or infect$ or sepsis$ or septic$ or bacter$ or endocardit$ or Staphylococ$ or Streptococ$) and (trial$ or Random$ or placebo$ or ((single or double or triple) and (blind$ or mask$)) or (ensayo controlado) or (experimentação controlada) or multicenter or multicentre or prospective or (estudio anticipado) or (estudo em perspectiva))</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;69 randomized controlled trials included in the quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;84 of 159 studies fulfilled inclusion criteria&lt;br&gt;&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;159 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;3629 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;3629 records remaining after duplicates removed&lt;br&gt;&lt;/p&gt;" WIDTH="200">
<FLOWCHARTBOX TEXT="&lt;p&gt;6562 records identified through database searching&lt;br&gt;&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;3470 of records excluded based on abstract screening: reviews, non-randomized studies, irrelevant interventions, non-human studies&lt;br&gt;&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;72 full-text articles, representing 69 individual studies, excluded for the reasons:&lt;/p&gt;&lt;p&gt;-Inappropriate interventions or results for study intervention not provided separately (20 studies)&lt;/p&gt;&lt;p&gt;- Non-randomized, or allocation to monotherapy vs. combination therapy not randomized (18 studies)&lt;/p&gt;&lt;p&gt;- No sepsis in inclusion criteria, including prophylaxis studies (17 studies)&lt;/p&gt;&lt;p&gt;- Study population consisted of or included neutropenic patients and non-neutropenic patients could not be separate (7 studies)&lt;/p&gt;&lt;p&gt;- Study population consisted of neonates&lt;/p&gt;&lt;p&gt;- No relevant outcomes reported (2 studies)&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;- 14 secondary publications considered as part of a single study&lt;/p&gt;&lt;p&gt;- 1 ongoing study&lt;/p&gt;"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>